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  with	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  also	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  hallmark	  
of	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  constructed	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  compare	  the	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  profiles	  of	  patients	  with	  IBS	  against	  a	  
control	  group;	  to	  use	  cortical	  evoked	  potentials	  to	  observe	  the	  cortical	  representation	  of	  an	  
electrical	  rectal	  stimulus	  to	  see	  if	  changes	  in	  amplitude	  or	  latency	  might	  be	  suggestive	  of	  enhanced	  
afferent	  nerve	  transmission;	  and	  to	  use	  cytokine	  analysis	  of	  stimulated	  and	  un-­‐stimulated	  peripheral	  
blood	  mononuclear	  cells	  to	  study	  the	  inflammatory	  response.	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CLINICAL	  PRESENTATION	  OF	  IRRITABLE	  BOWEL	  SYNDROME	  
EPIDEMIOLOGY	  AND	  SOCIAL	  IMPACT	  OF	  IRRITABLE	  BOWEL	  SYNDROME	  
Irritable	  Bowel	  Syndrome	  (IBS)	  is	  a	  functional	  gastroenterological	  disorder	  (FGID)	  whose	  symptom	  
complex	  comprises	  recurrent	  abdominal	  pain	  or	  discomfort	  with	  disordered	  bowel	  habit.	  Symptoms	  
may	  be	  chronic	  and	  relapsing	  with	  only	  a	  minority	  of	  patients	  enjoying	  a	  return	  to	  a	  normal	  pre-­‐
morbid	  state.1	  Diagnosis	  has	  traditionally	  been	  secured	  by	  the	  exclusion	  of	  other	  viable	  organic	  
pathology,	  such	  as	  inflammatory	  bowel	  disease	  or	  coeliac	  disease,	  in	  the	  presence	  of	  
symptomatology	  consistent	  with	  the	  syndrome.	  As	  such	  no	  specific	  test	  or	  diagnostic	  process	  for	  IBS	  
exists.	  Therefore	  a	  physician	  is	  presented	  with	  a	  dilemma	  at	  the	  point	  of	  diagnosis	  because	  he	  has	  to	  
make	  a	  clinical	  judgement	  about	  whether	  a	  patient	  with	  a	  typical	  presentation	  should	  be	  subjected	  
to	  the	  full	  gamut	  of	  clinical	  investigation,	  for	  example	  colonoscopy,	  with	  all	  the	  concomitant	  risks	  
and	  associated	  costs	  of	  that	  process.	  From	  the	  perspective	  of	  the	  patient,	  the	  combination	  of	  
invasive	  testing	  with	  the	  subsequent	  negative	  findings	  and	  the	  lack	  of	  any	  cohesive	  system	  of	  patient	  
stratification	  is	  equally	  frustrating.2	  
EPIDEMIOLOGY	  
Prevalence	  
Irritable	  Bowel	  Syndrome	  is	  a	  common	  condition	  with	  10	  to	  20%	  prevalence	  in	  the	  United	  Kingdom.3	  
However	  the	  true	  prevalence	  of	  IBS	  may	  be	  masked	  by	  a	  population	  of	  patients	  who	  do	  not	  seek	  
health-­‐care	  services.	   	  
Age	  
Age	  distribution	  sees	  peak	  prevalence	  during	  the	  20	  to	  30	  year	  old	  age	  range.	  Prevalence	  of	  IBS	  
decreases	  with	  age.4	  However	  with	  increasing	  awareness	  of	  the	  syndrome,	  a	  discrete	  yet	  significant	  
elderly	  population	  has	  been	  identified.5,6	  Differential	  diagnoses	  must	  be	  excluded	  in	  this	  age	  range	  
before	  a	  diagnosis	  can	  be	  made.	  This	  is	  due	  to	  increasing	  medical	  co-­‐morbidity	  and	  polypharmacy	  
with	  increasing	  age.	  A	  community-­‐based	  survey	  performed	  by	  Talley	  in	  1995	  reported	  that	  23%	  of	  
IBS	  patients	  over	  60	  years	  of	  age	  had	  initial	  symptom	  onset	  within	  12	  months	  compared	  to	  just	  10%	  
of	  those	  of	  a	  younger	  age.	  Again,	  true	  prevalence	  in	  the	  elderly	  population	  cannot	  be	  reliably	  





Up	  to	  10%	  of	  the	  population	  will	  have	  symptoms	  consistent	  with	  IBS	  during	  a	  12-­‐month	  period.	  5%	  
of	  the	  population	  will	  seek	  primary	  health	  care	  services	  during	  this	  period	  of	  time.	  
Gender	  
Most	  population-­‐based	  studies	  report	  that	  females	  are	  more	  commonly	  affected	  than	  men	  by	  a	  
factor	  of	  between	  two	  and	  three	  times	  to	  one.4	  Some	  studies	  report	  an	  equal	  sex	  distribution.8	  
Composite	  scores	  for	  symptom	  severity	  and	  infringements	  on	  activities	  of	  daily	  living	  were	  studied	  
with	  regard	  to	  gender	  and	  medical	  point	  of	  entry	  in	  a	  study	  by	  van	  der	  Horst.9	  This	  showed	  that	  
symptom	  severity	  between	  the	  sexes	  was	  similar	  in	  outpatient	  gastroenterology	  clinics,	  but	  that	  
women	  felt	  that	  their	  symptoms	  were	  more	  serious	  and	  interfering	  than	  their	  male	  counterparts	  in	  
the	  primary	  care	  setting.	  With	  abdominal	  pain	  as	  the	  prominent	  IBS	  symptom,	  there	  seems	  to	  be	  an	  
equal	  distribution	  between	  sexes.	  However	  females	  are	  more	  predisposed	  to	  constipation,	  and	  
males	  are	  more	  predisposed	  to	  diarrhoea.10	  Corney	  concluded	  that	  women	  were	  more	  severely	  
affected	  by	  physical	  symptoms	  with	  the	  exception	  of	  diarrhoea,	  and	  were	  more	  likely	  to	  be	  in	  pain	  
longer	  and	  for	  more	  days	  in	  the	  month.11	  Differentiation	  between	  the	  sexes	  has	  also	  been	  noticed	  
with	  regard	  to	  extra-­‐gastrointestinal	  symptoms.	  Lee	  reported	  a	  constellation	  of	  extra-­‐colonic	  
symptoms	  that	  were	  more	  common	  in	  females.12	  These	  symptoms	  included	  abdominal	  distension,	  
bloating,	  nausea,	  alterations	  of	  taste	  and	  smell,	  unpleasant	  sensations	  on	  the	  tongue,	  muscle	  
stiffness	  in	  the	  morning,	  greater	  food	  sensitivity	  and	  side	  effects	  from	  medications.	  
Symptom	  severity	  is	  influenced	  by	  the	  menstrual	  cycle.	  IBS	  patients	  were	  compared	  to	  controls	  by	  
studying	  somatic	  and	  psychological	  symptom	  severity	  during	  the	  follicular	  and	  luteal	  phases	  of	  the	  
menstrual	  cycle13:	  IBS	  patients	  had	  higher	  severity	  scores	  regardless	  of	  oral	  contraceptive	  use	  or	  
predominant	  bowel	  pattern,	  with	  an	  amplification	  of	  pain	  severity	  noticed	  during	  the	  late	  luteal	  and	  
early	  menses	  phases	  of	  the	  cycle.	  
Whitehead	  approached	  this	  subject	  from	  a	  different	  angle-­‐	  he	  identified	  383	  females	  with	  a	  
diagnosis	  of	  dysmenorrhoea,	  and	  reported	  that	  61%	  had	  symptoms	  consistent	  with	  a	  diagnosis	  of	  
functional	  bowel	  disorder,	  defined	  as	  abdominal	  pain	  with	  altered	  bowel	  function.14	  Houghton	  
assessed	  rectal	  sensitivity	  using	  recto-­‐sigmoid	  distension	  during	  the	  menstrual	  cycle.15	  This	  study	  
documented	  increased	  rectal	  sensitivity	  in	  IBS	  patients	  during	  the	  menses,	  whereas	  rectal	  sensitivity	  
remained	  unchanged	  throughout	  the	  menstrual	  cycle	  in	  the	  control	  population.	  Houghton	  surmised	  
that	  female	  IBS	  patients	  responded	  differently	  to	  fluctuations	  in	  the	  sex	  hormonal	  environment	  





The	  lack	  of	  a	  reliable	  diagnostic	  marker	  for	  IBS	  has	  made	  the	  task	  of	  constructing	  reliable	  
epidemiological	  cross-­‐cultural	  studies	  extremely	  difficult.	  The	  methodology	  used	  for	  identifying	  
cases	  in	  such	  studies	  has	  significant	  variability.	  Diagnostic	  criteria	  has	  evolved	  over	  the	  course	  of	  
many	  years	  from	  being	  non-­‐specific	  to	  the	  adoption	  of	  the	  Manning	  criteria,	  and	  the	  later	  
incorporation	  of	  the	  Rome	  criteria,	  which	  is	  itself	  under	  continuous	  refinement	  and	  evolution.	  
Assessment	  of	  prevalence	  across	  different	  cultures	  can	  only	  be	  applicable	  if	  the	  methodology	  of	  the	  
studies	  under	  analysis	  is	  at	  least	  broadly	  similar.	  Furthermore,	  most	  of	  the	  epidemiological	  studies	  
have	  concentrated	  on	  the	  white	  Western	  population.	  Ethnic	  comparisons	  may	  be	  confounded	  by	  
factors	  such	  as	  a	  lack	  of	  uniformity	  of	  sampling	  sizes,	  composition	  of	  the	  study	  populations	  and	  
research	  methodology.	  A	  further	  consideration	  is	  whether	  to	  study	  ethnic	  populations	  in	  their	  native	  
or	  non-­‐native	  environments.	  
Western	  populations	  appear	  to	  have	  higher	  rates	  of	  prevalence	  of	  IBS	  than	  non-­‐Western	  
populations.	  This	  may	  reflect	  a	  true	  disparity	  in	  prevalence,	  either	  through	  cultural	  or	  biological	  
mechanisms,	  or	  may	  be	  secondary	  to	  intrinsic	  deficiencies	  of	  the	  research	  protocols	  and	  the	  
difficulties	  in	  assessing	  the	  target	  populations.	  There	  is	  now	  an	  impetus	  for	  the	  delivery	  of	  reliable	  
and	  robust	  cross-­‐cultural	  research	  competencies.	  Much	  work	  has	  been	  done	  recently	  in	  assessing	  
the	  validity	  of	  the	  Rome	  3	  criteria	  in	  different	  cultural	  contexts.	  
The	  relationship	  between	  culture	  and	  illness	  perception	  defines	  the	  subjective	  impact	  of	  the	  illness	  
on	  the	  individual.	  Illness	  beliefs,	  illness	  behaviour,	  the	  adoption	  of	  the	  sick	  role	  and	  psychological	  
coping	  mechanisms	  are	  influenced	  by	  one’s	  culture.	  This	  is	  in	  addition	  to	  any	  cultural	  physiological	  
differences	  that	  may	  be	  present.	  Cross-­‐cultural	  differences	  in	  epidemiological	  studies	  may	  also	  
reflect	  differences	  in	  socio-­‐economic	  status,	  literacy,	  schooling,	  political	  affiliation	  and	  healthcare	  
provision.	  Wigington	  demonstrated	  lower	  prevalence	  of	  IBS	  in	  African	  Americans	  compared	  to	  white	  
Americans	  (RR=-­‐2.5),	  but	  both	  groups	  shared	  the	  same	  quality	  of	  life	  disease	  burden.16	  Subsequent	  
research	  by	  the	  same	  group	  questioned	  whether	  race	  affected	  treatment	  outcome.	  They	  found	  that	  
Caucasian	  Americans	  with	  IBS	  were	  far	  more	  likely	  to	  be	  proposed	  for	  surgery	  (appendicectomy)	  for	  
flares	  of	  abdominal	  pain	  than	  African	  Americans	  (21.4%	  vs.	  1.9%	   	   	   	   (P	  <	  0.01).17	  This	  invites	  







Quality	  Of	  Life	  
Quality	  of	  life	  studies	  show	  that	  the	  psychosocial	  impact	  of	  IBS	  is	  considerable.20,21	  A	  study	  by	  Jones	  
compared	  quality	  of	  life	  scores	  between	  IBS	  patients,	  inflammatory	  bowel	  disease	  (IBD)	  patients	  and	  
control	  subjects.	  The	  results	  showed	  that	  impairment	  in	  quality	  of	  life	  was	  as	  significant	  in	  the	  IBS	  
group	  as	  the	  IBD	  group.	  Gralnek	  demonstrated	  that	  IBS	  patients	  scored	  significantly	  lower	  on	  all	  of	  
the	  SF-­‐36	  Health	  Survey	  scales	  (P	  <	  0.001)	  except	  physical	  functioning.	  Similarly,	  IBS	  patients	  had	  
significantly	  worse	  health-­‐related	  quality	  of	  life	  scores	  on	  selected	  SF-­‐36	  scales	  than	  patients	  with	  
diabetes	  mellitus	  and	  end	  stage	  renal	  disease.22	  However,	  it	  is	  important	  to	  note	  that	  quality	  of	  life	  
impairment	  is	  not	  entirely	  attributable	  to	  somatic	  or	  gastrointestinal	  symptomatology.	   	  
Recent	  studies	  suggest	  that	  the	  concomitant	  burden	  of	  psychosocial	  factors	  has	  a	  significant	  
negative	  impact	  on	  quality	  of	  life.	  Creed	  enrolled	  a	  cohort	  of	  257	  patients	  with	  refractory	  IBS	  to	  
assess	  the	  relationship	  between	  quality	  of	  life,	  physical	  symptoms	  and	  psychological	  factors.23	  The	  
results	  show	  that	  abdominal	  and	  psychological	  symptoms	  were	  independently	  associated	  with	  
impaired	  health-­‐related	  quality	  of	  life	  in	  patients	  with	  severe	  IBS.	  An	  interesting	  study	  by	  Simrén	  
sought	  to	  identify	  predictive	  factors	  for	  impaired	  quality	  of	  life	  in	  IBS	  patients.24	  He	  found	  that	  extra-­‐
colonic	  factors	  were	  the	  main	  determinants	  of	  impaired	  quality	  of	  life.	  These	  included	  factors	  such	  
as	  easy	  fatigueability,	  anergia,	  sexual	  dysfunction	  and	  feeling	  tense	  or	  nervous.	  As	  a	  consequence,	  
he	  proposed	  that	  physicians	  should	  turn	  their	  attention	  towards	  addressing	  patients’	  global	  
symptom	  severity	  and	  anxiety	  levels	  rather	  than	  obsessing	  with	  the	  vagaries	  of	  bowel	  dysfunction	  
and	  stool	  consistency.	  
Absenteeism	  
A	  large	  cross-­‐cultural	  population-­‐based	  study	  with	  41,894	  individuals	  in	  8	  different	  countries	  noted	  
that	  IBS	  patients	  reported	  having	  more	  sickness	  days	  off	  work	  in	  the	  previous	  12	  months	  than	  the	  
control	  population.25	  They	  spent	  3.9	  days	  in	  bed	  (compared	  to	  2.7	  days	  in	  the	  controls),	  5.5	  days	  off	  
work	  through	  illness	  (compared	  to	  3.1	  days	  in	  the	  controls),	  10.2	  days	  when	  work	  activities	  had	  to	  be	  
cut	  short	  (compared	  to	  4.8	  days	  in	  the	  controls)	  and	  8.4	  days	  consulting	  a	  doctor	  or	  nurse	  (compared	  
to	  5.2	  days	  in	  the	  controls).	  Of	  those	  who	  had	  formally	  diagnosed	  irritable	  bowel	  syndrome	  only	  10%	  
had	  informed	  their	  employer	  of	  their	  condition.	   	  
A	  study	  by	  Akehurst	  et	  al.	  published	  that	  45%	  of	  their	  population	  of	  IBS	  patients	  had	  taken	  time	  off	  
work	  with	  symptoms	  related	  to	  their	  condition.	  Of	  these,	  15%	  had	  taken	  more	  than	  1	  week	  off	  work	  





IBS	  is	  the	  most	  likely	  reason	  why	  a	  patient	  will	  present	  to	  a	  gastroenterological	  clinic.	  The	  majority	  of	  
IBS	  patients	  do	  not	  seek	  health	  care	  services.3	  Estimates	  suggest	  that	  up	  to	  3.9	  million	  people	  seek	  
medical	  consultation	  in	  England	  and	  Wales	  during	  a	  12	  month	  period.	  Women	  are	  more	  likely	  to	  
seek	  health	  care	  services	  than	  men.26	  With	  reference	  to	  the	  fact	  that	  functional	  gastrointestinal	  
disorders	  (FGIDs)	  are	  so	  common,	  the	  decision	  to	  seek	  health	  care	  may	  introduce	  bias	  into	  
research.27	  
Surgery	  
Irritable	  Bowel	  Syndrome	  is	  associated	  with	  an	  increased	  risk	  of	  surgery	  even	  if	  major	  confounding	  
variables	  such	  as	  age	  have	  been	  removed.	  A	  study	  published	  by	  Longstreth	  et	  al.	  examined	  a	  dataset	  
of	  89,000	  patients	  to	  investigate	  the	  propensity	  of	  IBS	  patients	  to	  undergo	  surgery.28	  Several	  
confounding	  variables	  were	  corrected	  for,	  yet	  despite	  this,	  IBS	  patients	  were	  two	  times	  more	  likely	  
to	  have	  an	  appendicectomy	  or	  hysterectomy,	  three	  times	  more	  likely	  to	  have	  a	  cholecystectomy	  and	  
50%	  more	  likely	  to	  have	  back	  surgery	  compared	  to	  non-­‐IBS	  controls.	  Data	  collected	  from	  a	  UK	  
sample	  showed	  that	  IBS	  patients	  were	  almost	  twice	  as	  likely	  to	  have	  cholecystectomies.29	  
Suicide	  
Feelings	  of	  hopelessness,	  the	  severity	  of	  one’s	  symptoms,	  and	  the	  ineffectiveness	  of	  treatment	  in	  
Irritable	  Bowel	  Syndrome	  can	  collude	  with	  fatal	  consequences.	  Peter	  Whorwell’s	  group	  sought	  to	  
compare	  suicidal	  ideation	  secondary	  to	  concurrent	  gastrointestinal	  symptomatology	  in	  IBS	  patients	  
in	  primary,	  secondary	  and	  tertiary	  care	  settings	  and	  to	  use	  an	  IBD	  population	  as	  a	  positive	  control.30	  
The	  data	  showed	  that	  38%	  of	  the	  tertiary	  care	  IBS	  patients	  had	  contemplated	  suicide	  because	  of	  
their	  symptoms	  compared	  with	  16%	  and	  4%	  of	  the	  secondary	  and	  primary	  care	  IBS	  patients.	  In	  
comparison,	  15%	  of	  the	  IBD	  patients	  acknowledged	  thoughts	  of	  suicide.	  Of	  the	  400	  patients	  studied	  
(100	  patients	  per	  group),	  5	  tertiary	  setting	  IBS	  patients	  and	  1	  IBD	  patient	  had	  previously	  attempted	  
suicide.	  Increasing	  scores	  for	  depression	  had	  a	  positive	  correlation	  with	  suicidal	  ideation.	  However	  
depression,	  anxiety	  and	  symptom	  severity	  could	  not	  account	  for	  all	  the	  observed	  differences.	   	  
Spiegel’s	  meta-­‐analysis	  was	  constructed	  to	  remove	  the	  variable	  of	  psychiatric	  comorbidity	  from	  
those	  patients	  with	  IBS	  (or	  recurrent	  abdominal	  pain)	  who	  expressed	  suicidal	  ideation.31	  IBS	  patients	  
were	  two	  to	  four	  times	  more	  likely	  to	  have	  suicidal	  behaviour	  compared	  to	  controls.	  After	  
adjustments	  for	  psychological	  comorbidity	  were	  made,	  chronic	  abdominal	  pain	  was	  an	  independent	  




Direct	  Costs	  of	  Irritable	  Bowel	  Syndrome	  
Maxion-­‐Bergemann	  et	  al.	  performed	  a	  systematic	  literature	  review	  on	  18	  original	  papers	  from	  the	  
UK	  and	  US	  that	  assessed	  the	  direct	  and	  indirect	  costs	  of	  Irritable	  Bowel	  Syndrome.32	  Total	  direct	  cost	  
estimates	  per	  patient	  per	  year	  ranged	  from	  US	  $348	  to	  $8750	  whilst	  indirect	  costs	  ranged	  from	  US	  
$355	  dollars	  to	  US	  3344	  dollars.	  Due	  to	  the	  different	  methodologies	  used	  in	  the	  individual	  papers,	  
comparison	  between	  US	  and	  UK	  costings	  proved	  impossible.	  However,	  the	  study	  concluded	  that	  IBS	  
patients	  had	  an	  increased	  economic	  burden	  of	  healthcare	  costs	  that	  was	  between	  1.1	  and	  6.0	  times	  
that	  of	  matched	  non-­‐IBS	  controls.	  An	  estimate	  of	  the	  total	  cost	  of	  IBS	  health	  care	  provision	  in	  the	  US	  
was	  $1.58	  billion	  in	  1998.33	  
Indirect	  Costs	  of	  Irritable	  Bowel	  Syndrome	  
Bentkover	  et	  al.	  analysed	  the	  indirect	  costs	  of	  Irritable	  Bowel	  Syndrome	  to	  the	  Canadian	  economy.34	  
An	  estimated	  annual	  figure	  of	  748	  Canadian	  dollars	  was	  calculated	  by	  multiplying	  the	  time	  lost	  at	  
work	  with	  the	  mean	  Canadian	  wage.	  Similar	  calculations	  were	  performed	  by	  Creed	  et	  al.	  who	  
determined	  that	  the	  annual	  cost	  to	  the	  American	  taxpayer	  was	  $335	  per	  IBS	  patient.23	  Sandler’s	  
review	  assessed	  indirect	  costs	  as	  being	  productivity	  losses	  caused	  by	  absence	  from	  paid	  employment	  
resulting	  from	  the	  consumption	  of	  health	  care.35	  It	  did	  not	  try	  to	  calculate	  other	  more	  intangible	  
costs	  such	  as	  diminished	  productivity	  in	  the	  workplace,	  absence	  from	  work,	  not	  receiving	  medical	  
care	  or	  the	  loss	  of	  future	  earnings	  due	  to	  disease	  severity.	  This	  study	  estimated	  that	  the	  cost	  to	  the	  





DIAGNOSIS	  OF	  IRRITABLE	  BOWEL	  SYNDROME	  
CLINICAL	  PRESENTATION	  
The	  Rome	  Committee	  
Irritable	  Bowel	  Syndrome	  is	  defined	  by	  the	  Rome	  criteria.	  The	  Rome	  criteria	  have	  been	  developed	  
over	  the	  years	  by	  a	  collective	  of	  international	  gastroenterologists	  who	  meet	  periodically	  to	  define	  
and	  then	  redefine	  the	  functional	  gastrointestinal	  disorders	  (FGIDs).	  The	  Rome	  committee	  was	  
founded	  in	  1989	  following	  on	  from	  initiatives	  by	  Professor	  Aldo	  Torsoli	  who	  invited	  investigators	  to	  
contribute	  to	  a	  consensus-­‐led	  approach	  to	  the	  development	  of	  diagnostic	  criteria	  for	  FGIDs.	  This	  
process	  saw	  its	  birth	  at	  the	  International	  Congress	  of	  Gastroenterology	  in	  Rome	  in	  1988-­‐	  this	  is	  
where	  the	  committee	  acquired	  its	  name	  and	  direction.	  Professor	  Torsoli	  encouraged	  the	  
implementation	  of	  a	  Delphi	  method	  of	  research	  communion.	  This	  is	  a	  process	  that	  favours	  
consensus-­‐led	  research	  by	  seeking	  unanimity	  and	  consistency	  of	  opinion	  from	  a	  panel	  of	  experts	  
rather	  than	  the	  individual.	  The	  infrastructure	  of	  the	  Rome	  Committee	  now	  demands	  a	  rigorous	  four	  
year	  13	  step	  cycle	  of	  evolution.	  The	  last	  Rome	  convention	  was	  in	  2006,	  in	  which	  they	  published	  the	  
Rome	  3	  criteria	  for	  IBS.36	  Ongoing	  research	  will	  see	  the	  publishing	  of	  the	  Rome	  4	  criteria	  in	  
approximately	  2014.	  
Manning	  Criteria	  
Manning	  et	  al.	  published	  their	  landmark	  paper	  in	  1978	  entitled	  “Towards	  positive	  diagnosis	  of	  the	  
irritable	  bowel”.	  They	  assessed	  a	  prospective	  cohort	  of	  109	  unselected	  and	  undiagnosed	  patients	  
who	  had	  been	  referred	  for	  specialist	  assessment	  of	  the	  symptoms	  of	  abdominal	  pain,	  constipation	  
and	  diarrhoea.	  A	  15	  point	  questionnaire	  had	  been	  devised	  to	  enquire	  about	  the	  various	  subtleties	  of	  
bowel	  dysfunction	  such	  as	  nocturnal	  bowel	  movements,	  mucus	  per	  rectum	  or	  pain	  easing	  after	  
bowel	  movement.	  The	  patients	  were	  reviewed	  between	  17	  and	  26	  months	  later	  by	  two	  independent	  
gastroenterologists	  who	  had	  been	  blinded	  to	  the	  results	  of	  the	  initial	  questionnaire.	  During	  the	  
intermission	  between	  questionnaire	  and	  later	  clinical	  review,	  the	  patients	  had	  been	  subjected	  to	  full	  
comprehensive	  investigation	  to	  establish	  each	  individual	  diagnosis.	  The	  questionnaire	  items	  were	  
compared	  to	  the	  underlying	  diagnosis,	  be	  it	  a	  functional	  or	  an	  organic	  cause.	  They	  found	  that	  of	  the	  
15	  questions,	  4	  questions	  clearly	  discriminated	  between	  functional	  and	  organic	  disease.	  The	  
questions	  favouring	  a	  functional	  diagnosis	  asked	  whether	  a	  patient	  became	  visibly	  distended,	  had	  
relief	  of	  pain	  with	  defaecation,	  or	  more	  frequent	  or	  loose	  stools	  with	  the	  onset	  of	  pain.	  The	  Manning	  





The	  patient	  should	  present	  with	  at	  least	  2	  of	  the	  following	  symptoms	  for	  an	  IBS	  diagnosis	  to	  be	  
made:	   	  
• Onset	  of	  pain	  associated	  with	  more	  frequent	  bowel	  movements	   	  
• Onset	  of	  pain	  associated	  with	  more	  loose	  bowel	  movements	   	  
• Relief	  of	  pain	  with	  defaecation	   	  
• Abdominal	  distension	   	  
• Sensation	  of	  incomplete	  evacuation	  with	  defaecation	   	  
• Passage	  of	  mucus	  
Kruis	  Criteria	  
Kruis	  combined	  elements	  of	  the	  clinical	  history,	  examination	  and	  basic	  investigation	  to	  create	  a	  
scoring	  system	  for	  the	  diagnosis	  of	  IBS.37	  The	  study	  also	  undertook	  to	  qualify	  the	  sensitivity	  and	  
specificity	  of	  the	  proposed	  scoring	  system,	  thus	  allowing	  the	  calculation	  of	  positive	  predictive	  values.	   	  
479	  unselected	  outpatients	  referred	  to	  a	  gastrointestinal	  clinic	  were	  examined	  clinically	  and	  by	  
investigation	  with	  upper	  and	  lower	  gastrointestinal	  endoscopy,	  abdominal	  ultrasound	  and	  routine	  
blood	  tests.	  Of	  the	  479	  subjects,	  108	  were	  diagnosed	  with	  IBS	  and	  209	  were	  diagnosed	  with	  organic	  
disease.	  A	  scoring	  system	  was	  devised.	  This	  incorporated	  a	  patient	  questionnaire	  and	  the	  results	  of	  
select	  clinical	  parameters	  and	  investigations.	  Logistic	  regression	  analysis	  computed	  a	  weighted	  
scoring	  system.	  Using	  the	  weighted	  score	  the	  specificity	  was	  99%	  with	  a	  sensitivity	  of	  67%	  for	  the	  
diagnosis	  of	  irritable	  bowel	  syndrome.	  It	  was	  thought	  that	  the	  scoring	  system	  was	  sufficiently	  
powered	  to	  discriminate	  IBS	  from	  organic	  pathologies.	  
Kruis	  Patient	  Questionnaire	   	  
• Did	  you	  come	  because	  of	  abdominal	  pain?	   	   	   	   	   	   YES	  /	  NO	  
• Do	  you	  suffer	  from	  flatulence?	   	   	   	   	   	   	   	   	   YES	  /	  NO	  
• Do	  you	  suffer	  irregular	  bowel	  movements?	   	   	   	   	   	   YES	  /	  NO	  
• Have	  you	  experienced	  this	  for	  >	  2	  years?	   	   	   	   	   	   	   	   	   	   YES	  /	  NO	   	  
• How	  can	  your	  abdominal	  pain	  be	  described:	  burning,	  cutting,	   	   	   	   	   	   	  	   YES	  /	  NO	   	   	   	   	   	   	   	   	   	   	   	   	   	  
very	  strong,	  terrible,	  feeling	  of	  pressure,	  dull,	  boring,	  not	  so	  bad?	   	   	   	   	  




• Have	  your	  stools	  any	  of	  the	  following	  properties?	  pencil-­‐like;	   	   	   YES	  /	  NO	   	   	   	   	  
rabbit	  pellets;	  hard	  in	  the	  first	  portion	  and	  looser	  in	  the	  second	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
portion;	  mucus?	   	   	   	   	  
If	  the	  patient	  answers	  yes	  in	  any	  of	  sections	  of	  each	  question,	  a	  scoring	  system	  is	  allocated	  as	  
follows:	   	  
• Question	  1:	   	   	   34	  points	   	  
• Question	  2:	   	   	   16	  points	  
• Question	  3:	   	   	   23	  points	  
• Question	  4:	   	   	   14	  points	  
• Question	  5:	   	   No	  score	   	  
Maximum	  score:	   87	  points	  
The	  patient	  questionnaire	  is	  then	  validated	  by	  the	  clinician-­‐	  he	  or	  she	  identifies	  markers	  or	  indicators	  
of	  disease	  and	  potential	  red	  flags,	  and	  then	  makes	  appropriate	  subtractions	  from	  the	  original	  total.	  
Kruis	  Clinician	  Questionnaire	  
• Abnormal	  physical	  findings,	  and/or	  history	  for	  alternative	  diagnosis	   	   YES	  /	  NO	  
• ESR	  >	  20	   	   	   	   	   	   	   	   	   	   	   	   	   	   YES	  /	  NO	  
• Leucocytosis	  >	  10,000	   	   	   	   	   	   	   	   YES	  /	  NO	  
• Haemoglobin:	  Females	  <	  12	  g/dl,	  Males	  <	  14	  g/dl	   	   	   	   	   	   	   YES	  /	  NO	  
• History	  of	  blood	  in	  stool	   	   	   	   	   	   	   	   	   	   	   YES	  /	  NO	  
• Fever	  (>	  38.5)	  in	  the	  last	  week	   	   	   	   	   	   	   	   	   	   YES	  /	  NO	  
• Underweight	   	   	   	   	   	   	   	   	   	   	   	   	   YES	  /	  NO	  
• Loss	  of	  weight	  >	  5	  kg	  in	  last	  6	  months	   	   	   	   	   	   	   	   YES	  /	  NO	  
If	  the	  clinician	  answers	  yes	  to	  questions	  1	  –	  5,	  a	  scoring	  system	  is	  allocated	  as	  follows:	   	  
• Question	  1:	  	   47	  points	   	  
• Question	  2:	  	   13	  points	  
• Question	  3:	  	   50	  points	  
• Question	  4:	  	   98	  points	  
• Question	  5:	  	   98	  points	  




This	  is	  then	  subtracted	  from	  the	  original	  patient	  score.	  Scores	  greater	  than	  44	  indicate	  positive	  IBS	  
cases.	  
Rome	  Criteria	  
The	  Rome	  criteria	  were	  published	  in	  1990	  following	  the	  proposals	  of	  the	  International	  Conference	  of	  
Gastroenterology	  in	  1998.	  It	  defined	  the	  symptom	  criteria	  required	  to	  make	  a	  diagnosis	  of	  IBS.	  It	  was	  
informed	  by	  the	  original	  Manning	  criteria38	  and	  the	  subsequent	  Kruis	  criteria.37	  
Rome	  1	  
The	  Rome	  Committee	  began	  in	  earnest	  in	  1990	  with	  the	  task	  of	  characterising	  the	  FGIDs	  including	  
IBS.	  They	  identified	  21	  distinct	  conditions	  that	  required	  symptom-­‐based	  definition.	  Owing	  to	  limited	  
systems	  of	  promotion,	  the	  Rome	  process	  was	  still	  a	  relatively	  unknown	  entity	  to	  both	  
gastroenterologists	  and	  general	  physicians	  alike.	  As	  a	  result	  there	  was	  little	  penetration	  of	  the	  Rome	  
criteria	  into	  the	  consciousness	  of	  the	  physician	  and	  investigator.	  The	  Rome	  1	  criteria	  was	  significant	  
in	  that	  it	  introduced	  abdominal	  pain	  as	  a	  central	  symptom	  for	  IBS-­‐	  the	  original	  Rome	  criteria	  had	  not	  
made	  this	  distinction.	  The	  Rome	  1	  criteria	  were	  published	  in	  1992.	  
Rome	  1	  Criteria	  
The	  patient	  should	  present	  with	  at	  least	  3	  months	  of	  continuous	  or	  recurrent	  symptoms	  for	  an	  IBS	  
diagnosis	  to	  be	  made:	   	  
Abdominal	  pain	  or	  discomfort,	  which	  is:	   	  
• Relieved	  with	  defaecation	   	  
• and/or	  associated	  with	  altered	  bowel	  frequency	   	  
• and/or	  associated	  with	  altered	  stool	  consistency	   	  
and/or	  two	  or	  more	  of	  the	  following,	  on	  at	  least	  1/4	  of	  days:	   	  
• Altered	  stool	  frequency	   	  
• Altered	  stool	  form	   	  
• Altered	  stool	  passage	  (straining,	  urgency	  or	  tenesmus)	   	  
• Passage	  of	  mucus	   	  







The	  Rome	  2	  criteria	  were	  published	  in	  2000.	  Its	  development	  was	  encouraged	  by	  increasing	  interest	  
from	  physicians	  and	  the	  pharmaceuticals	  industry.	  Significant	  funding	  streams	  were	  secured	  from	  
industry	  to	  support	  the	  Rome	  process.	  This	  allowed	  for	  the	  expansion	  of	  the	  number	  of	  committee	  
groups	  that	  assessed	  specific	  classes	  of	  FGID	  and	  enabled	  a	  more	  international	  contribution	  of	  
research	  consensus.	  
The	  Rome	  2	  criteria	  define	  IBS	  as	  recurrent	  abdominal	  pain	  or	  discomfort	  that	  presents	  over	  a	  12	  
week	  period	  in	  the	  preceding	  12	  months.	  The	  symptomatic	  weeks	  do	  not	  have	  to	  be	  consecutive.	  
These	  cardinal	  features	  of	  IBS	  may	  be	  accompanied	  by	  other	  supporting	  symptoms,	  such	  as	  bloating,	  
lethargy,	  urinary	  frequency,	  backache	  and	  dyspepsia.	   	  
The	  Rome	  committee	  acknowledged	  considerable	  overlap	  between	  various	  subtypes	  of	  FGID.	  As	  an	  
example,	  IBS	  patients	  have	  a	  similar	  clinical	  presentation	  to	  those	  with	  functional	  constipation	  (in	  
whom	  the	  infrequency	  of	  defaecation	  leads	  to	  abdominal	  distension	  and	  discomfort).	  
Rome	  2	  Criteria	  
Twelve	  inconsecutive	  weeks	  or	  more	  in	  the	  past	  12	  months	  of	  abdominal	  discomfort	  or	  pain	  that	  has	  
2	  out	  of	  3	  features:	   	  
• Relief	  with	  defaecation	   	  
• Associated	  with	  a	  change	  in	  the	  frequency	  of	  defaecation	  
• Associated	  with	  a	  change	  in	  the	  consistency	  of	  the	  stool	  
Associated	  symptoms	  which	  would	  give	  confidence	  to	  the	  clinician	  that	  pain	  was	  of	  an	  
abdominal	  origin:	  
• Abnormal	  stool	  frequency	  (>	  3/day	  or	  <	  3/week)	   	  
• Abnormal	  stool	  form	  (lumpy/hard	  or	  loose/watery)	  >	  1/4	  of	  bowel	  motions	   	  
• Abnormal	  stool	  passage	  (straining,	  urgency	  or	  feeling	  of	  incomplete	  evacuation)	  >	  1/4	  of	  
bowel	  motions	  
• Passage	  of	  mucus	  >	  1/4	  of	  bowel	  motions	   	  
• Bloating	  or	  feeling	  of	  abdominal	  distension	  >	  1/4	  of	  days	  
Rome	  3	  
The	  Rome	  3	  criteria	  were	  published	  in	  2007	  encompassing	  the	  committee’s	  recommendations	  in	  
light	  of	  advances	  in	  the	  medical	  literature.	  The	  most	  significant	  change	  was	  the	  timing	  of	  symptoms.	  




weeks	  in	  a	  12	  month	  period.	  The	  Rome	  3	  criteria	  now	  advocated	  that	  symptoms	  should	  be	  present	  
for	  3	  months	  in	  a	  6	  month	  period.	  The	  committee	  felt	  that	  the	  new	  time	  frame	  was	  less	  restrictive,	  
and	  easier	  to	  apply	  in	  the	  clinical	  and	  research	  environment.	   	  
Another	  modification	  to	  the	  definition	  of	  IBS	  was	  that	  the	  sub-­‐typing	  of	  IBS	  patients	  into	  diarrhoea-­‐
predominant,	  constipation-­‐predominant	  or	  mixed-­‐type	  groups	  should	  be	  based	  on	  stool	  consistency	  
alone	  (rather	  than	  any	  reference	  to	  frequency	  of	  defaecation).	   	  
With	  reference	  to	  the	  other	  FGIDs,	  the	  Rome	  Foundation	  significantly	  expanded	  their	  classification	  
of	  adolescent	  and	  paediatric	  disorders.	  
Rome	  3	  Criteria	  
Symptoms	  of	  recurrent	  abdominal	  pain	  or	  discomfort	  and	  a	  marked	  change	  in	  bowel	  habit	  for	  at	  
least	  six	  months,	  with	  symptoms	  experienced	  on	  at	  least	  three	  days	  of	  at	  least	  three	  months.	   	  
Two	  or	  more	  of	  the	  following	  must	  apply:	  
• Pain	  is	  relieved	  by	  a	  bowel	  movement	  
• Onset	  of	  pain	  is	  related	  to	  a	  change	  in	  frequency	  of	  stool	  
• Onset	  of	  pain	  is	  related	  to	  a	  change	  in	  the	  appearance	  of	  stool	  
The	  Rome	  committee	  recommended	  that	  for	  IBS	  patients	  to	  be	  included	  into	  clinical	  trials,	  they	  
should	  experience	  abdominal	  pain	  or	  discomfort	  for	  at	  least	  two	  days	  of	  the	  week.	  
Rome	  1	  vs.	  Rome	  2	  vs.	  Rome	  3	  vs.	  Manning	  Criteria:	  Implications	  for	  Research	  
With	  the	  constant	  evolution	  of	  the	  diagnostic	  criteria	  for	  Irritable	  Bowel	  Syndrome,	  there	  is	  a	  
considerable	  variation	  in	  the	  prevalence	  of	  the	  condition	  according	  to	  which	  criteria	  is	  employed.	  
Mearin	  et	  al.	  compared	  the	  Manning,	  Rome	  1	  and	  Rome	  2	  criteria	  in	  a	  population-­‐based	  survey	  of	  
2000	  randomised	  Spanish	  individuals,	  matched	  according	  to	  age,	  gender,	  socio-­‐economic	  class	  and	  
location.39	  Prevalence	  of	  IBS	  was	  10.3%	  (Manning	  criteria),	  12.1%	  (Rome	  1	  criteria)	  and	  3.3%	  (Rome	  
2).	  Indeed,	  more	  than	  two-­‐thirds	  of	  the	  subjects	  who	  fulfilled	  the	  Rome	  I	  criteria	  would	  have	  not	  
have	  been	  diagnosed	  with	  IBS	  if	  the	  Rome	  2	  criteria	  had	  been	  used.	  This	  led	  Boyce	  et	  al.	  to	  question	  
whether	  the	  Rome	  2	  criteria	  was	  unduly	  restrictive	  in	  clinical	  practice.40	   	  
The	  Rome	  3	  criteria	  are	  less	  limited	  in	  terms	  of	  duration	  of	  symptoms,	  and	  calculates	  a	  higher	  
prevalence	  of	  positive	  IBS	  cases.	  A	  study	  by	  Sperber	  et	  al.	  documented	  an	  extremely	  low	  prevalence	  
of	  IBS	  patients	  in	  a	  population	  of	  adult	  Israeli	  Jews	  using	  the	  Rome	  2	  criteria.41	  Using	  that	  same	  




prevalence	  of	  IBS	  rose	  dramatically	  from	  the	  original	  study	  figure	  of	  2.9%	  to	  11.4%	  when	  applying	  
the	  Rome	  3	  criteria.	   	  
The	  selection	  of	  diagnostic	  criteria	  has	  important	  ramifications	  in	  terms	  of	  identifying	  cases,	  patient	  
management	  and	  the	  construction	  of	  research	  methodology.	  
Approaching	  a	  Clinical	  Diagnosis	   	  
A	  diagnosis	  of	  IBS	  can	  only	  be	  made	  when	  there	  has	  been	  adequate	  provision	  to	  exclude	  other	  
disease	  processes.42	  A	  robust	  clinical	  history	  will	  identify	  any	  red	  flag	  symptoms	  that	  might	  point	  to	  
an	  organic	  pathology.	  These	  include	  unintentional	  and	  unexplained	  weight	  loss,	  rectal	  bleeding,	  and	  
a	  family	  history	  of	  bowel	  or	  ovarian	  cancer.	   	  
Examination	  of	  the	  patient	  may	  suggest	  clues	  pointing	  towards	  organic	  pathology-­‐	  clinical	  signs	  such	  
as	  cachexia,	  organomegaly	  or	  rectal	  masses	  would	  certainly	  warrant	  further	  investigation.	  Recent	  
interest	  has	  centred	  on	  the	  early	  presentation	  of	  ovarian	  cancer	  mimicking	  IBS.	  If	  an	  ovarian	  cause	  
were	  suspected,	  a	  pelvic	  examination	  with	  pelvic	  and/or	  trans-­‐vaginal	  ultrasound	  and	  cancer	  antigen	  
testing	  (CA-­‐125)	  would	  be	  required.	  
Red	  Flag	  Symptoms	   	  
The	  addition	  of	  red	  flag	  symptoms	  to	  the	  Manning	  criteria	  improves	  diagnostic	  accuracy.	  In	  a	  
retrospective	  analysis	  of	  98	  patients,	  Vanner	  et	  al.	  combined	  the	  absence	  of	  red	  flag	  symptoms	  with	  
the	  Rome	  1	  criteria,	  reporting	  a	  sensitivity	  of	  65%,	  specificity	  of	  100%,	  and	  positive	  predictive	  value	  
of	  100%.43	  The	  same	  study	  also	  prospectively	  assessed	  95	  patients	  who	  were	  Rome	  1	  positive	  for	  IBS	  
and	  red	  flag	  symptom	  negative.	  The	  positive	  predictive	  value	  in	  this	  group	  was	  98%-­‐	  none	  of	  these	  
patients	  required	  revision	  of	  their	  diagnosis	  during	  a	  2	  year	  follow-­‐up.	  
Alarm	  Symptoms	  
History	  
• Age	  of	  onset	  ≥	  50	  years	  old	  
• Weight	  loss	  
• Nocturnal	  or	  refractory	  diarrhoea	  
• Significant	  travel	  history	  suggestive	  of	  GI	  infection	  
• Severe	  constipation	  or	  diarrhoea	  







• Coeliac	  disease	  
• Colon	  cancer/polyps	  
• Inflammatory	  bowel	  disease	  
Alarm	  Signs	  
• Physical	  Examination	  
• Oral	  ulcers	  
• Fever	  
• Abdominal	  or	  rectal	  mass	  
• Rectal	  bleeding	  
• Rash	  
General	  Approach	  
A	  vital	  goal	  is	  to	  establish	  a	  constructive	  doctor/patient	  relationship.	  Research	  has	  proven	  that	  this	  
will	  improve	  patient	  satisfaction,	  symptom	  improvement	  and	  compliance	  of	  therapy.44,45	  Drossman	  
et	  al.	  published	  a	  set	  of	  guidelines	  to	  aid	  this	  process.	   	  
These	  guidelines	  are	  summarised:	  
1. Use	  a	  non-­‐judgmental	  patient-­‐centred	  approach	  to	  taking	  the	  history.	  
2. Assess	  what	  the	  patient’s	  level	  of	  understanding	  of	  their	  condition.	  
3. Be	  realistic	  in	  responding	  to	  a	  patient’s	  expectations.	  
4. Assess	  what	  exacerbating	  factors	  are	  present,	  with	  particular	  regard	  to	  stressors.	  
5. Establish	  consistent	  limits,	  for	  example	  with	  regard	  to	  analgesic	  use.	  
6. Examine	  the	  patient	  and	  implement	  cost-­‐effective	  investigation.	  
7. Involve	  the	  patient	  in	  the	  decision-­‐making	  process.	  
8. Pursue	  the	  best	  interests	  of	  the	  patient.	  
9. Establish	  robust	  links	  with	  the	  primary	  care	  giver	  of	  each	  and	  every	  patient.	  
The	  above	  approach	  should	  establish	  a	  robust	  rapport	  with	  a	  patient.	  However,	  it	  is	  also	  important	  
to	  identify	  specific	  exacerbating	  factors	  that	  have	  brought	  the	  patient	  into	  the	  clinic	  on	  that	  
particular	  day.	  These	  factors	  include	  whether	  the	  patient	  can	  identify	  specific	  exacerbating	  factors,	  
what	  the	  concerns	  of	  the	  patient	  are,	  whether	  there	  are	  any	  environmental	  factors	  or	  psychological	  
comorbidities,	  and	  whether	  there	  are	  any	  disturbances	  in	  daily	  functioning.	  Finally,	  it	  is	  important	  to	  




The	  clinician	  needs	  to	  be	  able	  to	  discern	  the	  physiological	  and	  psychological	  mechanisms	  that	  are	  
driving	  a	  patient’s	  symptoms,	  address	  psychosocial	  issues	  and	  direct	  treatment	  accordingly.	  






Patients	  with	  Irritable	  Bowel	  Syndrome	  have	  traditionally	  been	  categorised	  according	  to	  the	  
prevailing	  bowel	  habit,	  for	  example	  a	  constipation-­‐predominant	  phenotype.	  The	  grouping	  of	  
patients	  into	  clinical	  sub-­‐types	  seems	  to	  imply	  to	  the	  non-­‐specialist	  that	  patients	  within	  each	  group	  
have	  a	  shared	  aetiology	  to	  their	  symptoms.	  Unfortunately	  this	  is	  not	  the	  case.	  Furthermore	  there	  is	  
ample	  opportunity	  for	  patients	  to	  flit	  between	  various	  sub-­‐types	  over	  a	  period	  of	  time.46	   	  
IBS	  patients	  may	  fall	  into	  diarrhoea-­‐predominant	  (IBS-­‐D),	  constipation-­‐predominant	  (IBS-­‐C),	  mixed	  
(IBS-­‐M)	  or	  unsubtyped	  (IBS-­‐U)	  subtypes.	  The	  Rome	  2	  criteria	  demanded	  that	  in	  addition	  to	  an	  
assessment	  of	  the	  consistency	  of	  the	  stool,	  the	  prevailing	  bowel	  subtype	  should	  be	  qualified	  by	  time-­‐	  
abnormal	  frequency	  of	  defaecation	  was	  defined	  as	  opening	  the	  bowels	  less	  than	  once	  every	  3	  days	  
or	  more	  than	  3	  times	  in	  a	  single	  day.	   	  
Stool	  consistency	  is	  qualified	  by	  the	  ubiquitous	  Bristol	  Stool	  chart.	  This	  is	  a	  graphical	  representation	  
of	  stool	  consistency,	  graded	  from	  Type	  1	  (small,	  hard	  pellets	  of	  stool)	  though	  to	  Type	  7	  (entirely	  
liquid	  stool)	  
Garrigues	  et	  al.	  assessed	  517	  IBS	  patients	  over	  a	  12	  month	  period	  using	  diary	  cards	  and	  the	  Bristol	  
stool	  chart.47	  The	  bowel	  habit	  remained	  unchanged	  in	  a	  third	  of	  the	  patients,	  and	  the	  frequency	  of	  
constipation	  and	  diarrhoea	  showed	  few	  changes	  during	  the	  period	  of	  follow-­‐up.	  Approximately	  50%	  
of	  the	  changes	  in	  bowel	  habit	  occurred	  from/to	  IBS-­‐M	  and	  IBS-­‐U,	  and	  14%	  of	  the	  changes	  occurred	  
from	  IBS-­‐C	  to	  IBS-­‐D	  or	  vice	  versa.	  This	  last	  example	  reveals	  the	  IBS	  alternator,	  a	  subtype	  significantly	  
associated	  with	  the	  female	  gender	  (OR=	  2.65).	  Drossman	  recommended	  that	  the	  IBS	  alternator	  (IBS-­‐
A)	  be	  defined	  as	  at	  least	  one	  change	  between	  IBS-­‐D	  and	  IBS-­‐C	  by	  Rome	  II	  criteria	  over	  a	  1-­‐year	  
period.46	  
Natural	  history	  
The	  natural	  history	  of	  Irritable	  Bowel	  Syndrome	  is	  hugely	  variable,	  though	  most	  investigators	  and	  
patients	  would	  agree	  that	  the	  syndrome	  is	  a	  life-­‐long	  affliction	  and	  that	  symptoms	  and	  symptom	  
severity	  may	  vary	  over	  time.	   	  
A	  systematic	  review	  by	  El-­‐Serag	  et	  al.	  determined	  that	  2-­‐5%	  of	  patients	  who	  completed	  baseline	  
investigations	  were	  misdiagnosed	  as	  having	  IBS	  when	  in	  fact	  organic	  disease	  was	  present	  (follow-­‐up	  
time	  was	  6	  months	  to	  6	  years),	  though	  this	  range	  increases	  to	  2-­‐9%	  if	  30	  year	  follow-­‐up	  data	  is	  






months	  follow-­‐up,	  and	  that	  there	  was	  an	  81%	  concordance	  of	  symptoms	  in	  the	  same	  patients	  (who	  
were	  still	  symptomatic)	  after	  a	  further	  31	  month	  follow-­‐up.48	  Four	  studies	  reported	  on	  the	  
proportion	  of	  patients	  with	  unchanged	  symptoms	  (30–50%)	  and	  patients	  whose	  symptoms	  had	  
deteriorated	  (2–18%).	  Finally,	  5	  of	  the	  14	  papers	  calculated	  that	  the	  proportion	  of	  patients	  with	  
complete	  disappearance	  of	  symptoms	  ranged	  from	  12	  to	  38%	  (median	  follow-­‐up	  duration	  was	  2	  
years).	  
An	  interesting	  study	  by	  Talley	  conducted	  a	  postal	  symptom	  questionnaire	  on	  a	  random	  population	  of	  
residents	  in	  Olmsted	  Co,	  Minnesota.49	  The	  questionnaire	  was	  resubmitted	  to	  the	  same	  population	  
over	  a	  year	  later	  to	  assess	  symptom	  reproducibility.	  After	  correction	  for	  age	  and	  gender,	  the	  
prevalence	  rates	  for	  IBS	  were	  similar	  at	  the	  two	  time	  points.	  However,	  9%	  of	  the	  individuals	  who	  
were	  initially	  symptom-­‐free	  had	  acquired	  symptoms	  consistent	  with	  a	  diagnosis	  of	  IBS,	  and	  38%	  of	  
those	  with	  a	  diagnosis	  of	  IBS	  at	  baseline	  had	  become	  asymptomatic	  by	  the	  second	  questionnaire.	  
Lembo	  et	  al.	  assessed	  symptom	  duration,	  rectal	  sensitivity	  and	  psychometric	  studies	  between	  
controls,	  IBS	  patients	  with	  recent	  symptom	  onset	  and	  IBS	  patients	  with	  a	  long	  history	  of	  the	  
condition.50	  After	  the	  initial	  assessment,	  all	  subjects	  were	  invited	  to	  reappraise	  their	  symptoms	  with	  
a	  follow-­‐up	  questionnaire.	  The	  data	  reported	  that	  IBS	  patients	  with	  a	  recent	  onset	  of	  symptoms	  and	  
fewer	  psychological	  symptoms	  had	  a	  better	  prognosis	  than	  patients	  with	  long-­‐standing	  disease	  and	  
significant	  psychological	  comorbidity.	  
ASSOCIATED	  FUNCTIONAL	  GASTROINTESTINAL	  DISORDERS	  
Overlap	  of	  symptoms	  between	  any	  two	  FGIDs	  can	  range	  between	  4%	  and	  9%	  of	  the	  population.51	  
This	  can	  create	  diagnostic	  uncertainty,	  confusion	  for	  the	  patient,	  and	  questions	  over	  optimal	  
treatment	  approach.	  Furthermore,	  the	  presence	  of	  overlapping	  FGIDs	  suggests	  a	  common	  
pathophysiology	  which	  is	  dissonant	  to	  the	  accepted	  Rome	  understanding	  that	  FGIDs	  are	  discrete	  
entities.	   	  
Agréus	  et	  al.	  compared	  IBS	  with	  dyspepsia	  in	  a	  general	  population	  over	  12	  months.52	  Casual	  analysis	  
of	  their	  data	  shows	  that	  prevalence	  of	  the	  two	  conditions	  remained	  stable	  over	  the	  course	  of	  the	  
study.	  However	  closer	  inspection	  revealed	  that	  50%	  of	  patients	  (from	  either	  group)	  changed	  their	  
symptom	  profile	  and	  that	  87%	  of	  IBS	  patients	  fulfilled	  the	  criteria	  for	  dyspepsia.	  They	  concluded	  that	  
much	  of	  the	  variability	  in	  terms	  of	  onset	  and	  resolution	  of	  each	  disorder	  was	  due	  to	  the	  fact	  that	  






resolution.	  This	  conclusion	  was	  endorsed	  by	  Talley’s	  group	  which	  published	  a	  12	  year	  longitudinal	  
population-­‐based	  study	  that	  assessed	  FGIDs.53	  Data	  from	  this	  study	  reported	  that	  of	  those	  
symptomatic	  patients	  at	  baseline	  approximately	  20%	  had	  the	  same	  symptoms,	  40%	  had	  no	  
symptoms,	  and	  40%	  had	  different	  symptoms	  at	  follow-­‐up,	  more	  than	  a	  decade	  later.	  
ASSOCIATED	  NON-­‐GASTROINTESTINAL	  NON-­‐PSYCHIATRIC	  SYMPTOMATOLOGY	  
Non-­‐gastrointestinal	  non-­‐psychiatric	  symptoms	  are	  common	  in	  Irritable	  Bowel	  Syndrome.	  Whorwell	  
assessed	  100	  patients	  with	  IBS	  by	  documenting	  extra-­‐colonic	  features.54	  Symptoms	  included	  
nocturia,	  frequency	  and	  urgency	  of	  micturition,	  incomplete	  bladder	  emptying,	  back	  pain,	  an	  
unpleasant	  taste	  in	  the	  mouth,	  a	  constant	  feeling	  of	  tiredness	  and	  dyspareunia.	  The	  diversity	  of	  
extra-­‐colonic	  symptoms	  remained	  even	  when	  concomitant	  psychiatric	  comorbidity	  had	  been	  
corrected	  for.	  This	  highlights	  how	  Irritable	  Bowel	  Syndrome	  can	  present	  with	  a	  multiplicity	  of	  
symptoms	  external	  to	  the	  bowel-­‐	  a	  competent	  physician	  will	  be	  able	  to	  acknowledge	  these	  
complimentary	  symptoms,	  and	  not	  progress	  down	  an	  avenue	  of	  inappropriate	  investigation	  or	  
referral.	  
In	  terms	  of	  non-­‐gastrointestinal	  non-­‐psychiatric	  comorbidity,	  Whitehead	  published	  that	  
temporomandibular	  joint	  disorder	  (TMJD)55	  was	  the	  most	  common	  disorder	  associated	  with	  IBS	  (a	  
median	  of	  64%	  of	  patients	  with	  TMJD	  have	  IBS).	  Other	  associations	  include	  fibromyalgia	  (median	  of	  
49%	  have	  IBS),	  chronic	  fatigue	  syndrome	  (51%)	  and	  chronic	  pelvic	  pain	  (50%).	  A	  reasonable	  
conclusion	  from	  this	  is	  that	  there	  is	  a	  common	  pathogenetic	  pathway,	  perhaps	  suggesting	  an	  
underlying	  somatoform	  disorder.	  However,	  multivariate	  analysis	  of	  the	  dataset	  recommended	  that	  
the	  each	  disease	  state	  was	  a	  discrete	  entity.	  An	  alternate	  explanation	  is	  that	  if	  multiple	  disorders	  are	  
present	  then	  a	  primary	  psychogenic	  mechanism	  may	  be	  present.	  
PSYCHIATRIC	  COMORBIDITY	  
Irritable	  Bowel	  Syndrome	  is	  not	  associated	  with	  any	  one	  psychiatric	  disorder.	  However,	  when	  
symptoms	  of	  anxiety	  or	  depression	  become	  prominent	  and	  persistent,	  a	  formal	  psychiatric	  diagnosis	  
may	  be	  considered.	  Indeed,	  the	  recognition	  and	  assessment	  of	  concomitant	  psychiatric	  disorders	  
must	  be	  given	  as	  much	  attention	  as	  the	  treatment	  of	  the	  gastrointestinal	  symptomatology.	   	  
Studies	  show	  that	  the	  prevalence	  of	  psychiatric	  comorbidity	  is	  high-­‐	  affective	  or	  anxiety	  disorders	  






conditions	  of	  between	  6	  and	  25%	  in	  patients	  with	  established	  organic	  gastrointestinal	  disease,	  and	  8	  
to	  18%	  in	  control	  subjects.11,56-­‐60	  
The	  association	  between	  psychiatric	  comorbidity	  and	  Irritable	  Bowel	  Syndrome	  is	  heightened	  in	  IBS	  
patients	  who	  seek	  medical	  services.61	  Sandler	  et	  al.	  observed	  that	  patients	  with	  bowel	  dysfunction	  
who	  presented	  for	  medical	  consultation	  were	  more	  likely	  to	  have	  abdominal	  pain	  than	  the	  non-­‐
consulters,	  but	  this	  could	  not	  fully	  explain	  the	  reason	  for	  the	  visits	  to	  the	  doctor.62	  In	  addition,	  those	  
patients	  going	  to	  the	  doctor	  were	  more	  likely	  to	  be	  concerned	  about	  non-­‐gastrointestinal	  symptoms.	  
Given	  the	  accepted	  prevalence	  of	  psychological	  comorbidity	  in	  IBS,	  this	  could	  suggest	  altered	  
behavioural	  influences	  that	  precipitate	  health	  care	  seeking.	   	  
Kettell	  reviewed	  24	  IBS	  consulters	  and	  24	  IBS	  non-­‐consulters	  with	  an	  array	  of	  psychometric	  tests.63	  
The	  striking	  difference	  between	  the	  two	  groups	  was	  that	  mean	  negative	  life	  event	  scores,	  and	  scores	  
for	  anxiety	  and	  depression	  were	  higher	  in	  the	  group	  who	  consulted.	  The	  consulting	  patients	  seemed	  
to	  be	  more	  concerned	  about	  the	  potentially	  serious	  nature	  of	  their	  symptoms,	  with	  10	  of	  the	  24	  
consulting	  patients	  speculating	  that	  they	  may	  have	  cancer.	  
Life	  events	  
Serious	  life	  events	  may	  serve	  as	  the	  precipitant	  for	  the	  onset	  of	  FGIDs,	  or	  may	  act	  to	  propagate	  
symptomatology.	  The	  strength	  of	  this	  association	  is	  marked-­‐	  Creed	  et	  al.	  observed	  that	  two	  thirds	  of	  
patients	  with	  FGIDs	  acknowledged	  a	  serious	  life	  event	  compared	  to	  a	  quarter	  of	  the	  control	  
population	  under	  review.64	   	  
Whitehead	  corrected	  for	  concomitant	  psychiatric	  disease	  yet	  still	  found	  that	  there	  was	  significantly	  
higher	  levels	  of	  stress	  in	  an	  IBS	  cohort	  compared	  to	  controls	  or	  patients	  with	  non-­‐IBS	  functional	  
disorders.65	  Even	  more	  interesting	  was	  the	  analysis	  of	  the	  time	  course	  of	  stressful	  events-­‐	  the	  
introduction	  of	  a	  stressor	  in	  a	  three	  month	  period	  was	  significantly	  associated	  with	  the	  development	  
or	  worsening	  of	  bowel	  dysfunction	  in	  the	  following	  three	  month	  period.	  Stress	  was	  positively	  
correlated	  with	  the	  number	  of	  disability	  days	  (days	  off	  work	  or	  days	  seeking	  medical	  services).	  
Regression	  analysis	  showed	  that	  the	  regression	  line	  relating	  stress	  to	  bowel	  symptoms	  was	  steeper	  
in	  IBS	  than	  in	  controls	  and	  (non-­‐IBS)	  functional	  bowel	  disease.	  This	  suggests	  that	  IBS	  patients	  are	  






Chronic	  life	  stress	  measures	  and	  symptom	  severity	  markers	  were	  performed	  on	  IBS	  patients	  over	  a	  
16	  month	  longitudinal	  study	  period.66	  The	  results	  concluded	  that	  chronic	  life	  stress	  was	  a	  powerful	  
predictor	  of	  symptom	  intensity,	  and	  that	  nearly	  all	  of	  the	  variance	  of	  an	  individual’s	  symptom	  
intensity	  could	  be	  explained	  by	  the	  severity	  of	  chronic	  threat	  during	  the	  previous	  6	  months	  or	  more.	  
Furthermore,	  for	  the	  majority	  of	  IBS	  patients,	  stress	  above	  a	  critical	  threshold	  predicts	  a	  failure	  of	  
symptom	  improvement	  or	  resolution.	  
Abuse	  
The	  association	  of	  Irritable	  Bowel	  Syndrome	  with	  previous	  physical	  or	  sexual	  abuse	  is	  a	  controversial	  
and	  inflammatory	  subject.	  The	  link	  was	  first	  proposed	  by	  Drossman	  in	  1990.67	  He	  assessed	  a	  
consecutive	  cohort	  of	  female	  patients	  with	  functional	  symptoms	  who	  had	  been	  referred	  to	  a	  
university-­‐based	  gastroenterology	  practice.	  A	  staggering	  44%	  of	  the	  208	  patients	  admitted	  to	  a	  
history	  of	  sexual	  or	  physical	  abuse.	  Nearly	  all	  of	  those	  who	  had	  been	  physically	  abused	  were	  sexually	  
abused.	  Furthermore,	  approximately	  a	  third	  of	  patients	  had	  never	  admitted	  this	  fact	  before,	  and	  
only	  17%	  confided	  that	  their	  gastroenterologists	  were	  aware	  of	  the	  abuse.	  By	  comparing	  this	  group	  
to	  a	  population	  with	  organic	  disease,	  functional	  patients	  were	  more	  likely	  to	  report	  forced	  
intercourse,	  physical	  abuse,	  chronic	  abdominal	  pain	  and	  increased	  surgical	  procedures.	  This	  study	  
not	  only	  suggested	  a	  causative	  link,	  but	  more	  disturbingly	  it	  highlighted	  that	  abuse	  was	  prevalent,	  
concealed	  and	  recurrent.	  
Supporting	  data	  came	  from	  Talley’s	  group.68	  This	  study	  extended	  the	  line	  of	  enquiry	  by	  questioning	  
whether	  abuse	  was	  prevalent	  in	  community-­‐based	  IBS	  patients,	  as	  opposed	  to	  those	  who	  had	  been	  
referred	  on	  to	  secondary	  or	  tertiary	  centres.	  919	  randomised	  individuals	  in	  the	  community	  
responded	  to	  a	  self-­‐report	  postal	  questionnaire.	  Age	  and	  sex-­‐adjusted	  prevalence	  of	  abuse	  was	  26%,	  
and	  there	  was	  a	  significant	  association	  between	  IBS	  and	  sexual	  abuse,	  emotional	  or	  verbal	  abuse,	  
and	  abuse	  in	  childhood	  and	  adulthood.	  Furthermore,	  those	  presenting	  to	  gastroenterologists	  for	  
specialist	  opinion	  were	  more	  likely	  to	  have	  had	  an	  abuse	  history,	  suggesting	  increased	  health	  care	  
utilisation	  in	  this	  group	  of	  patients.	   	  
A	  study	  a	  year	  later	  by	  the	  same	  group	  compared	  an	  outpatient	  sample	  of	  functional	  patients	  with	  
patients	  with	  organic	  disease.69	  Differences	  in	  abuse	  prevalence	  were	  not	  significant	  between	  the	  
two	  groups.	  However,	  IBS-­‐type	  symptoms	  were	  more	  prominent	  in	  those	  patients	  who	  reported	  






Leroi	  et	  al.	  evaluated	  the	  relationship	  between	  sexual	  abuse	  and	  distribution	  of	  symptoms.70	  344	  
patients	  presenting	  to	  either	  a	  university-­‐based	  tertiary	  referral	  centre	  or	  a	  gastroenterology	  private	  
practice	  were	  categorised	  according	  to	  whether	  they	  had	  a	  functional	  or	  an	  organic	  presentation.	  
40%	  of	  the	  functional	  patients	  admitted	  sexual	  abuse	  compared	  to	  10%	  of	  the	  organic	  patients.	  
Analysis	  of	  symptom	  distribution	  revealed	  that	  abused	  patients	  were	  more	  likely	  to	  complain	  of	  
constipation	  and	  diarrhoea.	  Anismus	  was	  more	  common	  in	  sexual	  abuse,	  and	  the	  prevalence	  of	  
abuse	  was	  significantly	  greater	  in	  patients	  with	  lower	  rather	  than	  more	  proximal	  functional	  
gastrointestinal	  symptoms	  (P	  <	  0.002).	  
Mood	  and	  Anxiety	  Disorders	  
Associated	  mood	  disorders	  in	  IBS	  include	  depression	  and	  dysthymic	  states.	  Anxiety	  disorders	  include	  
panic,	  generalised	  anxiety	  and	  post-­‐traumatic	  stress	  disorder.	  The	  severity	  of	  psychological	  distress	  
is	  closely	  associated	  with	  health	  care-­‐seeking	  behaviour.	  Those	  IBS	  patients	  who	  present	  with	  
psychological	  distress	  are	  more	  amenable	  to	  psychological	  intervention	  than	  patients	  who	  have	  
personality	  disorders.	   	  
Gwee	  et	  al.	  utilised	  psychometric	  testing	  in	  post-­‐gastroenteritis	  patients	  over	  a	  6	  month	  period.71	  Of	  
the	  patients	  who	  went	  on	  to	  be	  diagnosed	  with	  IBS,	  increased	  baseline	  scores	  were	  seen	  for	  anxiety,	  
depression,	  somatisation,	  and	  neurotic	  traits.	  Repeat	  assessment	  of	  these	  psychological	  parameters	  
3	  months	  after	  the	  initial	  illness	  showed	  that	  the	  psychological	  distress	  was	  maintained	  over	  time.	   	  
Spiller’s	  group	  extended	  the	  scope	  of	  Gwee’s	  earlier	  work	  by	  constructing	  a	  study	  incorporating	  a	  6	  
year	  follow-­‐up	  of	  post-­‐gastroenteritis	  patients.72	  This	  study	  demonstrated	  that	  anxiety	  and	  
depression	  can	  be	  important	  predictors	  in	  the	  development	  and	  maintenance	  of	  symptoms	  in	  post-­‐
infectious	  IBS-­‐	  only	  one	  patient	  with	  a	  positive	  history	  of	  anxiety	  or	  depression	  had	  symptom	  
resolution	  after	  the	  initial	  illness.	  This	  was	  one	  subject	  out	  of	  a	  total	  of	  24	  patients	  who	  had	  been	  
diagnosed	  with	  IBS	  from	  the	  original	  cohort	  of	  436	  post-­‐GE	  patients.	   	  
Personality	  disorders	  
Research	  has	  failed	  to	  identify	  a	  psychological	  trait	  that	  is	  common	  to	  IBS	  patients.	  Controlled	  
studies	  have	  shown	  that	  anxiety	  and	  neurotic	  traits	  may	  be	  raised	  in	  IBS	  consulters	  compared	  to	  IBS	  
non-­‐consulters	  or	  controls61	  However,	  such	  deductions	  may	  be	  confounded	  by	  the	  self-­‐selection	  of	  






personality	  disorders	  in	  IBS	  are	  the	  fact	  that	  IBS	  patients	  may	  score	  more	  highly	  on	  personality	  
scores	  when	  symptomatic,	  and	  that	  personality	  scores	  will	  reduce	  on	  symptom	  resolution.74	  This	  
makes	  inferences	  about	  causality	  difficult.	  
The	  anxious	  or	  avoidant	  personality	  disorder	  may	  underlie	  increased	  anxiety	  levels	  seen	  in	  a	  limited	  
subset	  of	  IBS	  patients.	  Personality	  disorders	  are	  deeply	  ingrained	  traits	  that	  present	  during	  early	  
adult	  life,	  and	  are	  characterised	  by	  rigid,	  persistent	  patterns	  of	  cognition,	  emotions	  and	  behaviour.	  
The	  underlying	  belief	  systems	  informing	  these	  patterns	  of	  behaviour	  are	  referred	  to	  as	  fixed	  
fantasies	  or	  dysfunctional	  schemata.	  The	  inflexibility	  and	  pervasiveness	  of	  behavioural	  patterns	  
arising	  from	  a	  personality	  disorder	  may	  precipitate	  significant	  social	  dysfunction	  in	  an	  individual.	  
Furthermore,	  treatment	  of	  a	  personality	  disorder	  is	  notoriously	  difficult	  to	  treat.	  
Talley	  explored	  the	  link	  between	  abuse,	  neuroticism	  and	  Irritable	  Bowel	  Syndrome.75	  Univariate	  
analysis	  showed	  that	  IBS	  was	  correlated	  with	  childhood	  but	  not	  adult	  abuse,	  and	  that	  neuroticism	  
and	  psychological	  morbidity	  were	  associated	  with	  abuse	  in	  childhood,	  abuse	  in	  adulthood,	  and	  IBS.	  
After	  controlling	  for	  age,	  gender	  and	  psychological	  factors,	  the	  relationship	  between	  childhood	  
abuse	  and	  IBS	  was	  not	  maintained.	  This	  prompted	  speculation	  that	  childhood	  abuse	  may	  stimulate	  
the	  expression	  of	  neuroticism	  which	  can	  then	  precipitate	  the	  later	  development	  of	  IBS.	  
DIFFERENTIAL	  DIAGNOSIS	  
Organic	  processes	  which	  mimic	  the	  symptoms	  of	  IBS	  are	  legion.	  Differential	  diagnoses	  range	  from	  
inflammatory	  bowel	  disease,	  gynaecological	  disease,	  the	  causes	  of	  malabsorption	  (for	  example	  
Coeliac	  disease),	  neoplasia,	  infection,	  endocrine	  dysfunction,	  psychiatric	  disease	  and	  food	  
intolerance.	  Such	  a	  broad	  range	  of	  differential	  diagnoses	  presents	  a	  diagnostic	  challenge	  to	  the	  
physician	  and	  an	  economic	  challenge	  to	  the	  government.	  With	  a	  10	  to	  20%	  UK	  prevalence,	  and	  a	  
50%	  likelihood	  that	  a	  patient	  with	  symptoms	  will	  present	  to	  primary	  care	  services,	  the	  cost	  
implications	  are	  enormous.32	  Emerging	  trends	  highlight	  the	  prevalence	  of	  newly	  diagnosed	  IBS	  in	  the	  
elderly	  population.6,76	  This	  is	  an	  age	  group	  which	  is	  characterised	  by	  polypharmacy	  and	  co-­‐morbidity,	  
further	  confusing	  the	  diagnostic	  process.	  Therefore	  recent	  interest	  has	  centred	  on	  the	  importance	  of	  








Food	  Allergy	  and	  Intolerance	  
Adverse	  reactions	  to	  food	  may	  result	  from	  direct	  toxicity	  of	  the	  ingested	  food	  or	  an	  immune-­‐
response	  to	  non-­‐toxic	  foods.	  Immune-­‐reactions	  to	  food	  are	  denoted	  food	  allergies,	  and	  may	  involve	  
IgE	  pathways.77	  In	  contrast,	  food	  intolerance	  is	  a	  non-­‐immune-­‐mediated	  response	  to	  immunological,	  
pharmacological,	  toxic,	  infectious,	  idiosyncratic,	  metabolic	  and	  neuropsychological	  processes.78	  
Many	  people	  in	  the	  community	  feel	  that	  they	  have	  food	  intolerance,	  as	  evidenced	  by	  a	  high	  
response	  rate	  in	  self-­‐reporting	  questionnaires.	  Burr	  et	  al.	  reported	  food	  intolerance	  in	  19%	  of	  men	  
and	  26%	  of	  women	  who	  responded	  to	  their	  self-­‐report	  questionnaires.	  Of	  the	  524	  subjects	  polled,	  a	  
random	  subset	  of	  99	  females	  had	  blood	  tests	  to	  quantify	  plasma	  IgE	  levels.	  The	  plasma	  IgE	  levels	  
were	  found	  to	  be	  significantly	  lower	  in	  this	  group,	  suggesting	  that	  food	  allergy	  was	  not	  a	  mechanism	  
driving	  their	  food	  intolerance.79	   	  
In	  summary,	  dietary	  exclusion	  may	  be	  of	  value	  to	  a	  minority	  of	  IBS	  patients,	  but	  the	  diagnosis	  of	  food	  
intolerance	  should	  be	  viewed	  with	  some	  reservation	  given	  the	  poor	  predictive	  value	  of	  a	  dietary	  
history.	  
Lactose	  intolerance	  
Lactose	  intolerance	  is	  the	  inability	  to	  digest	  lactose,	  a	  disaccharide	  found	  in	  mammalian	  milk.	  It	  is	  
caused	  by	  a	  deficiency	  or	  insufficiency	  of	  lactase,	  and	  produces	  similar	  symptoms	  to	  IBS.	  Its	  diagnosis	  
is	  made	  by	  a	  positive	  hydrogen	  breath	  test.	   	  
Lactose	  intolerance	  does	  not	  predispose	  one	  to	  IBS80,81,	  but	  there	  may	  be	  an	  increased	  sensitivity	  to	  
luminal	  distension	  by	  lactose	  in	  IBS	  patients.82	  Parker	  et	  al.	  documented	  lactose	  malabsorption	  in	  
27%	  of	  a	  cohort	  of	  122	  IBS	  patients.83	  The	  introduction	  of	  a	  lactose-­‐restricted	  diet	  in	  those	  who	  
tested	  positive	  did	  not	  yield	  any	  particular	  improvement	  in	  their	  symptoms.	  Despite	  the	  relatively	  
high	  prevalence	  of	  lactose	  malabsorption	  (almost	  a	  third	  of	  their	  IBS	  patients),	  they	  questioned	  the	  
validity	  of	  chasing	  this	  diagnosis,	  since	  its	  treatment	  did	  not	  offer	  symptomatic	  benefit.	   	  
Post-­‐Infectious	  IBS	  
The	  observation	  that	  infection	  predisposes	  to	  IBS	  is	  well	  recognised.84	  This	  will	  be	  discussed	  at	  length	  
in	  later	  chapters.	  The	  emergence	  of	  functional	  symptoms	  in	  someone	  with	  established	  inflammatory	  






quiescent	  colitis,	  and	  noted	  that	  a	  third	  of	  them	  had	  symptoms	  consistent	  with	  IBS.85	  The	  
mechanism	  for	  this	  may	  be	  that	  inflammation	  produces	  a	  up-­‐regulation	  in	  visceral	  sensitivity	  and	  a	  
change	  in	  sensorimotor	  function	  that	  persists	  even	  when	  the	  inflammatory	  infiltrate	  has	  
retreated.88,89	  
Antibiotic-­‐associated	  Diarrhoea	  
Careful	  history	  taking	  ensures	  that	  the	  timing	  of	  antibiotic	  exposure	  with	  the	  development	  of	  
diarrhoea	  should	  leave	  little	  doubt	  as	  to	  the	  aetiology	  of	  the	  symptoms.	  Antibiotic-­‐diarrhoea	  has	  a	  
spectrum	  of	  disease	  severity	  ranging	  from	  nuisance	  diarrhoea	  to	  life-­‐threatening	  colitis.	  Antibiotics	  
produce	  a	  change	  in	  the	  gut	  microflora	  rendering	  it	  vulnerable	  to	  opportunistic	  pathological	  
colonisation.	   	  
Primary	  Idiopathic	  Bile	  Acid	  Malabsorption	  
Primary	  idiopathic	  bile	  acid	  malabsorption	  (IBAM)	  causes	  IBS-­‐like	  symptoms	  with	  diarrhoea	  being	  
the	  predominant	  complaint.	  Many	  cases	  of	  IBAM	  have	  been	  misdiagnosed	  as	  diarrhoea-­‐
predominant	  IBS.90	  Studies	  show	  that	  between	  30%	  and	  50%	  of	  those	  with	  chronic	  unexplained	  
diarrhoea	  have	  positive	  75SeHCAT	  tests.91-­‐93	  A	  useful	  approach	  would	  be	  to	  offer	  a	  therapeutic	  trial	  of	  
Cholestyramine	  to	  those	  patients	  with	  D-­‐IBS	  who	  do	  not	  respond	  to	  standard	  therapy.	  
Endocrine	  Causes	  of	  Diarrhoea	  
Conditions	  such	  as	  carcinoid,	  thyrotoxicosis,	  medullary	  carcinoma	  of	  the	  thyroid,	  gastrinomas,	  
VIPomas,	  glucagonomas	  and	  somatostatinomas	  may	  produce	  diarrhoea.	  They	  are	  rare	  conditions	  
but	  may	  represent	  the	  driving	  pathology	  in	  someone	  labelled	  as	  being	  a	  refractory	  IBS	  patient.	  
Other	  Forms	  of	  Colitis	  
Colitis	  has	  many	  aetiologies	  including	  idiopathic	  colitis	  (Crohn’s,	  Ulcerative	  Colitis	  or	  Microscopic	  
Colitis),	  ischaemic	  colitis,	  vasculitis,	  toxic	  (chemical)	  colitis	  and	  infective	  colitis.	  Diagnosis	  relies	  on	  
careful	  history,	  the	  acknowledgement	  of	  unusual	  symptoms	  that	  do	  not	  fit	  within	  the	  framework	  of	  
the	  Rome	  criteria,	  endoscopic	  evaluation	  and	  reconsideration	  of	  alternative	  diagnoses	  in	  refractory	  








This	  is	  a	  condition	  characterised	  by	  the	  occurrence	  of	  symptoms	  of	  intestinal	  obstruction	  in	  the	  
absence	  of	  demonstrable	  organic	  obstruction.	  The	  clinical	  presentation	  may	  be	  acute	  or	  insidious.	  It	  
is	  this	  latter	  group	  which	  may	  simulate	  IBS-­‐type	  symptoms,	  particularly	  abdominal	  bloating.	   	  
Hirschsprung’s	  Disease	  
Hirschsprung	  lent	  his	  name	  to	  the	  condition	  of	  congenital	  aganglionic	  megacolon	  in	  1888.	  Diagnosis	  
is	  usually	  made	  in	  the	  post-­‐natal	  period	  with	  failure	  to	  pass	  meconium	  within	  48	  hours	  of	  birth,	  
increasing	  abdominal	  distension,	  vomiting	  or	  neonatal	  enterocolitis	   	  
	  






EXCLUDING	  THE	  DIFFERENTIAL	  DIAGNOSIS	  
History	  
The	  advantages	  of	  using	  an	  internationally-­‐endorsed	  consensus-­‐led	  instrument	  for	  the	  diagnosis	  of	  
Irritable	  Bowel	  Syndrome	  are	  that	  there	  is	  increased	  physician	  confidence	  in	  the	  diagnosis	  and	  
increased	  patient	  confidence	  in	  this	  dynamic	  diagnosis-­‐making	  process.	  Given	  the	  absence	  of	  
worrying	  features,	  there	  is	  a	  potential	  to	  minimise	  invasive	  and	  costly	  investigations,	  a	  benefit	  to	  
both	  patient	  and	  state.	   	  
The	  presence	  of	  Rome	  3-­‐compliant	  abdominal	  pain	  and	  bowel	  dysfunction	  with	  no	  red	  flag	  
symptoms	  should	  provide	  a	  clinician	  with	  ample	  conviction	  for	  diagnosis.	  Research	  has	  shown	  that	  
such	  a	  clinical	  presentation	  will	  have	  a	  high	  positive	  predictive	  value	  for	  a	  diagnosis	  of	  IBS.	  If	  red	  flag	  
symptoms	  are	  manifest,	  they	  have	  little	  discriminatory	  power	  in	  differentiating	  functional	  disease	  
from	  organic	  disease.42	  Symptoms	  normally	  attributable	  to	  IBS	  may	  also	  be	  present	  (though	  not	  
typical)	  in	  other	  disease	  states-­‐	  Isgar	  demonstrated	  that	  a	  third	  of	  patients	  with	  ulcerative	  colitis	  in	  
remission	  fulfilled	  the	  criteria	  for	  IBS.85	  
Examination	  
Examination	  of	  a	  patient	  with	  IBS	  will	  be	  mostly	  unremarkable,	  though	  comorbid	  medical	  signs	  may	  
be	  elicited.	  The	  abdominal	  examination	  may	  reveal	  abdominal	  distension,	  the	  scars	  of	  previous	  
procedures,	  for	  example	  diagnostic	  laparotomies,	  and	  generalised	  or	  focal	  abdominal	  tenderness.	  
Abdominal	  tenderness	  must	  be	  carefully	  stratified	  according	  to	  its	  origin,	  emanating	  from	  either	  the	  
anterior	  abdominal	  wall	  or	  the	  viscera.	  Carnett’s	  sign	  produces	  increased	  focal	  abdominal	  
tenderness	  (by	  asking	  the	  patient	  to	  contract	  the	  abdominal	  wall	  musculature)	  if	  abdominal	  wall	  
pain	  is	  present.	  
Primary	  Care	  
The	  depth	  of	  investigation	  is	  determined	  by	  careful	  exposition	  of	  the	  history,	  taking	  into	  account	  
age,	  atypical	  features,	  recent	  change	  in	  bowel	  habit,	  red	  flag	  symptoms	  and	  family	  history	  of	  organic	  
disease	  (in	  particular	  colorectal	  cancer	  and	  inflammatory	  bowel	  disease).	  A	  routine	  set	  of	  blood	  tests	  
including	  full	  blood	  count,	  liver	  function	  tests,	  inflammatory	  markers,	  thyroid	  function	  and	  






antibodies)	  is	  an	  acceptable	  screening	  tool	  for	  suspected	  IBS.	  Family	  history	  of	  colorectal	  cancer	  with	  
a	  change	  in	  bowel	  habit	  and	  anaemia	  would	  be	  an	  indication	  for	  faecal	  occult	  blood	  testing.	  Acute	  
onset	  diarrhoea	  is	  presumed	  to	  be	  of	  an	  infective	  origin	  until	  proven	  otherwise	  by	  stool	  microscopy	  
and	  culture.	  
Secondary	  Care	  
Tests	  to	  exclude	  more	  esoteric	  conditions	  are	  indicated.	  Investigations	  may	  include	  lactose	  tolerance	  
testing,	  breath	  tests	  for	  small	  bowel	  bacterial	  overgrowth,	  urinary	  screening	  for	  laxative	  abuse	  and	  
neuroendocrine	  screening.	  Radiological	  imaging	  can	  delineate	  slow-­‐transit	  constipation	  with	  transit	  
studies,	  and	  intra-­‐abdominal	  or	  pelvic	  pathology	  using	  ultrasonography	  and	  CT	  scans.	  At	  this	  point	  in	  
the	  investigative	  journey,	  recourse	  to	  endoscopy,	  employing	  either	  flexible	  sigmoidoscopy	  or	  
colonoscopy	  should	  be	  considered.	  
The	  Value	  Of	  Diagnostic	  Testing	  
An	  important	  review	  published	  by	  Cash	  et	  al.	  addressed	  the	  value	  of	  diagnostic	  testing	  in	  patients	  
who	  met	  symptom	  criteria	  for	  IBS.94	   	  
The	  results	  from	  the	  study	  are	  summarised	  as	  follows:	  there	  was	  a	  higher	  prevalence	  of	  Coeliac	  
disease	  in	  the	  IBS	  population	  compared	  to	  the	  general	  population;	  there	  was	  no	  difference	  in	  the	  
prevalence	  of	  colorectal	  cancer,	  inflammatory	  bowel	  disease,	  thyroid	  disease	  and	  lactose	  intolerance	  
between	  the	  two	  groups;	  the	  multiplicity	  of	  tests	  inflicted	  on	  a	  patient	  including	  colonoscopy,	  
ultrasound,	  stool	  ova	  and	  parasite	  testing,	  faecal	  occult	  bloods	  and	  hydrogen	  breath	  testing	  were	  
largely	  redundant,	  given	  that	  they	  were	  unlikely	  to	  demonstrate	  organic	  disease.	  
Global	  approach	  to	  management	  
Evidence	  to	  support	  the	  comprehensive	  investigation	  of	  suspected	  IBS	  patients	  is	  limited.	  The	  
approach	  favoured	  by	  the	  Rome	  Foundation	  is	  based	  on	  the	  idea	  of	  a	  positive	  diagnostic	  process,	  
namely	  to	  identify	  and	  be	  confident	  in	  the	  symptomatology	  that	  supports	  the	  diagnosis	  of	  IBS.	  The	  
traditional	  and	  time-­‐honoured	  approach	  to	  dealing	  with	  a	  suspected	  IBS	  patient	  was	  to	  exclude	  
organic	  pathology,	  and	  then,	  almost	  by	  accident,	  arrive	  at	  the	  diagnosis.	  This	  approach	  has	  now	  
been	  discredited.	  The	  review	  by	  Cash	  et	  al.	  highlights	  how	  little	  the	  investigative	  process	  adds	  to	  the	  






improve	  the	  confidence	  of	  the	  patient	  concerning	  the	  medical	  system	  and	  reduce	  potential	  
complications	  arising	  from	  over-­‐investigation.	  
The	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  published	  guidelines	  on	  the	  management	  of	  
IBS	  in	  February	  2008.95	  The	  guidance	  recommended	  that	  the	  following	  tests	  should	  be	  performed	  in	  
someone	  presenting	  with	  Rome-­‐positive	  symptoms	  for	  IBS:	  
• Full	  blood	  count	  (FBC)	  
• Erythrocyte	  sedimentation	  rate	  (ESR)	  or	  plasma	  viscosity	   	  
• C-­‐reactive	  protein	  (CRP)	  
• Antibody	  testing	  for	  coeliac	  disease	  (endomysial	  antibodies	  or	  tissue	  transglutaminase)	  
There	  was	  little	  evidence	  to	  support	  routine	  blood	  testing.	  However	  the	  costs	  of	  such	  tests	  are	  
minimal.	  Furthermore	  the	  opportunity	  to	  be	  able	  to	  show	  patients	  that	  routine	  blood	  are	  normal	  
was	  felt	  to	  be	  useful	  in	  maintaining	  a	  positive	  diagnostic	  process.	  
Investigations	  that	  were	  deemed	  to	  be	  inappropriate	  for	  the	  routine	  investigation	  of	  suspected	  IBS	  
patients:	  
• Abdominal	  ultrasound	  
• Barium	  enema	  
• Rigid/flexible	  sigmoidoscopy	  
• Colonoscopy	  
• Thyroid	  function	  tests	  
• Faecal	  ova	  and	  parasite	  test	  
• Faecal	  occult	  blood	  testing	  
• Hydrogen	  breath	  test	  (for	  lactose	  intolerance	  and	  bacterial	  overgrowth)	  
The	  important	  caveat	  to	  this	  platitude	  for	  the	  non-­‐investigation	  of	  suspected	  IBS	  patients	  is	  that	  any	  
individual	  with	  red	  flag	  symptoms	  should	  be	  investigated	  in	  a	  manner	  appropriate	  to	  exclude	  serious	  
organic	  pathology.	   	  






TREATING	  IRRITABLE	  BOWEL	  SYNDROME	  
Treatment	  of	  Irritable	  Bowel	  Syndrome	  is	  informed	  by	  a	  step-­‐wise,	  progressive	  approach	  founded	  on	  
a	  confident	  diagnosis.	  Vacillation	  and	  incoherence	  in	  the	  diagnostic	  process,	  a	  long	  and	  drawn	  out	  
period	  of	  investigation	  and	  an	  illogical,	  haphazard	  prescription	  of	  therapy	  achieves	  very	  little.	  
Repeated	  investigations	  undermine	  the	  confidence	  of	  the	  patient	  with	  the	  physician.96	  Education	  of	  
the	  patient	  about	  the	  nature	  of	  the	  condition,	  and	  how	  their	  symptoms	  fit	  within	  the	  syndrome	  
complex	  is	  paramount.	  O’Sullivan	  assessed	  a	  cohort	  of	  70	  adult	  IBS	  patients97:	  77%	  felt	  that	  their	  
knowledge	  of	  the	  condition	  was	  inadequate,	  with	  prevailing	  concerns	  centred	  on	  diet	  and	  cancer	  
risk.	  Furthermore	  a	  significant	  negative	  correlation	  between	  perceived	  knowledge	  and	  length	  of	  
hospital	  consulting	  was	  established.	  The	  study	  concluded	  that	  patient	  education	  could	  reduce	  health	  
care	  utilisation.	   	  
During	  a	  consultation,	  the	  physician	  needs	  to	  be	  attuned	  to	  the	  concerns	  of	  the	  patient,	  and	  identify	  
significant	  impairment	  in	  quality	  of	  life,	  adjusting	  treatment	  accordingly.	  Psychological	  comorbidity	  
will	  alter	  the	  perception	  of	  somatic	  symptoms.	  The	  development	  of	  a	  robust	  doctor-­‐physician	  
relationship,	  with	  enquiry	  into	  daily	  stressors,	  problems	  at	  work,	  family	  or	  marital	  discord	  and	  recent	  
bereavement	  have	  been	  shown	  to	  reduce	  health	  care	  costs	  and	  the	  number	  of	  medical	  consultations	  
for	  IBS	  symptoms.	  A	  study	  by	  Owen	  et	  al.	  featured	  a	  review	  of	  the	  medical	  records	  of	  112	  patients	  
with	  IBS.98	  The	  presence	  of	  documentation	  in	  the	  medical	  notes	  about	  psychosocial	  factors	  was	  
viewed	  as	  evidence	  of	  a	  positive	  patient-­‐physician	  relationship.	  Analysis	  of	  the	  data	  showed	  that	  
such	  documentation	  was	  associated	  with	  decreased	  patient	  consultation	  over	  time.	  
CONSERVATIVE	  MANAGEMENT	  
Patient	  education	  may	  be	  tailored	  to	  the	  individual	  or	  it	  may	  take	  place	  in	  a	  group	  setting	  or	  as	  part	  
of	  a	  multidisciplinary	  approach.	  Patients	  are	  more	  responsive	  to	  advice	  on	  changes	  to	  lifestyle,	  for	  
example	  dietary	  advice,	  explanation,	  encouraging	  exercise,	  reassurance	  and	  stress	  management,	  
than	  to	  discussion	  about	  pharmacological	  therapy.99	  Even	  with	  these	  simple	  and	  inexpensive	  
interventions,	  the	  majority	  of	  patients	  will	  have	  satisfactory	  (though	  not	  complete)	  relief	  of	  
symptoms.	  Relief	  of	  fear	  and	  the	  reassurance	  that	  symptoms	  are	  not	  attributable	  to	  cancer	  are	  
important	  treatment	  goals.	  Thompson	  et	  al.	  assessed	  over	  3000	  primary	  care	  patients,	  identifying	  76	  






Predictors	  for	  referral	  for	  specialist	  opinion	  were	  the	  denial	  of	  the	  role	  of	  stress,	  insistence	  on	  
multiple	  tests	  and	  the	  frequency	  of	  defaecation.	  
Self-­‐Management	  
Empowering	  the	  individual	  to	  deal	  with	  his	  or	  her	  own	  symptoms	  can	  be	  a	  constructive	  therapeutic	  
strategy.	  Heitkemper	  allocated	  randomised	  IBS	  patients	  to	  either	  standard	  of	  care	  IBS	  management,	  
a	  multi-­‐component	  8	  session	  program	  (Comprehensive	  group)	  comprising	  weekly	  one	  hour	  sessions	  
with	  a	  specialist	  nurse	  practitioner	  on	  a	  one	  to	  one	  basis,	  and	  a	  one	  off	  single	  session	  with	  a	  
specialist	  nurse	  practitioner	  (Brief	  group).101	  The	  sessions	  featured	  advice	  on	  symptom	  awareness,	  
reassurance,	  dietary	  counselling,	  relaxation	  techniques	  and	  cognitive-­‐behavioural	  strategies.	  Each	  
session	  was	  tailored	  to	  the	  individual.	  Homework	  was	  assigned	  at	  the	  end	  of	  each	  session,	  re-­‐
presented	  at	  the	  next	  session,	  and	  specific	  symptom	  management	  plans	  were	  constructed.	  12	  
month	  follow-­‐up	  demonstrated	  significantly	  improved	  psychological	  and	  quality	  of	  life	  scores	  (SCL-­‐
90,	  IBSQOL)	  and	  reduced	  abdominal	  pain	  and	  functional	  impairment	  compared	  to	  those	  managed	  
using	  the	  standard	  of	  care	  approach.	  
Multidisciplinary	  Team	  
The	  role	  of	  the	  multidisciplinary	  team	  was	  assessed	  by	  Saito	  et	  al.	  by	  comparing	  a	  group	  of	  IBS	  
patients	  who	  attended	  a	  one	  day	  multidisciplinary	  group	  program	  of	  IBS	  education	  with	  a	  group	  of	  
patients	  who	  did	  not	  attend.102	  At	  6	  months	  follow-­‐up,	  29%	  of	  those	  attending	  the	  IBS	  class	  did	  not	  
meet	  the	  Rome	  criteria	  for	  IBS	  at	  6	  months	  follow-­‐up	  compared	  to	  11%	  of	  the	  non-­‐attenders.	  Class	  
attendance	  predicted	  higher	  odds	  of	  not	  meeting	  the	  Rome	  criteria	  at	  follow-­‐up.	  Class	  attendance	  
was	  associated	  with	  an	  improvement	  in	  Health-­‐Promoting	  Lifestyle	  Profile	  scores	  on	  multivariate	  
analysis,	  though	  interestingly,	  it	  was	  not	  associated	  with	  change	  in	  pain,	  quality	  of	  life,	  satisfaction,	  
or	  health	  care	  utilisation.	  The	  authors	  concluded	  that	  the	  multidisciplinary	  educational	  approach	  
might	  be	  a	  model	  of	  care	  that	  should	  be	  incorporated	  into	  routine	  clinical	  practice.	  
Diet	  and	  Exercise	  
The	  symptoms	  of	  Irritable	  Bowel	  Syndrome	  may	  be	  exacerbated	  by	  a	  variety	  of	  dietary	  factors.	  The	  
unremitting	  identification	  of	  dietary	  factors	  that	  contribute	  to	  symptom	  generation,	  and	  the	  






presentation.	  No	  single,	  uniform	  diet	  can	  be	  ascribed	  to	  the	  IBS	  population.	  Therefore	  the	  individual	  
must	  be	  encouraged	  to	  identify	  for	  him	  or	  herself	  the	  foodstuffs	  that	  cause	  and	  prolong	  symptoms.	   	  
Many	  people	  with	  IBS	  are	  said	  to	  have	  food	  intolerance.	  This	  is	  terminology	  which	  must	  be	  
differentiated	  from	  true	  immunologically-­‐mediated	  food	  allergy.	  The	  central	  tenet	  of	  food	  
intolerance	  is	  that	  withdrawal	  of	  the	  foodstuff	  produces	  a	  resolution	  of	  symptoms	  whilst	  
reintroduction	  will	  prompt	  recurrence.	   	  
Fibre	  
Dietary	  fibre	  comprises	  plant-­‐derived	  non-­‐starch	  polysaccharides	  such	  as	  cellulose	  and	  other	  plant	  
components.	  Fibre	  is	  not	  digested	  by	  the	  gastrointestinal	  tract,	  and	  moves	  steadily	  through	  the	  
digestive	  system,	  absorbing	  water,	  contributing	  to	  the	  faecal	  bulk	  and	  easing	  defaecation.	  Research	  
assessing	  the	  use	  of	  fibre	  in	  the	  treatment	  of	  IBS	  is	  conflicted,	  largely	  due	  poor	  study	  methodologies	  
and	  high	  placebo	  responses.	  Furthermore,	  some	  types	  of	  insoluble	  fibre	  may	  exacerbate	  symptoms.	  
The	  traditional	  approach	  of	  the	  gastroenterologist	  has	  been	  to	  advocate	  the	  increased	  intake	  of	  fibre	  
to	  improve	  transit	  time.103	  Studies	  assessing	  fibre	  intake	  in	  IBS	  have	  produced	  little	  favourable	  
evidence	  in	  the	  support	  of	  this	  approach,	  and	  some	  studies	  report	  a	  worsening	  of	  symptoms	  if	  fibre	  
is	  prescribed.104,105	   	  
Starch	  
Resistant	  starches	  are	  large	  carbohydrate	  polymers	  that	  are	  poorly	  absorbed	  by	  the	  stomach	  or	  
small	  intestine.	  By	  definition,	  starch	  that	  manages	  to	  travel	  undigested	  all	  the	  way	  through	  the	  
proximal	  and	  mid	  gut	  to	  the	  colon	  is	  termed	  a	  resistant	  starch.	  Reduction	  in	  resistant	  starches	  may	  
produce	  an	  improvement	  in	  bloating	  and	  excessive	  flatus.	   	  
Lactose	  
IBS	  patients	  commonly	  describe	  lactose	  intolerance.	  A	  careful	  elimination	  of	  lactose	  and	  subsequent	  
reintroduction	  may	  be	  indicated	  in	  those	  patients	  who	  complain	  of	  diarrhoea	  and	  excessive	  flatus	  
after	  lactose	  ingestion.	  However,	  it	  must	  be	  noted	  that	  reported	  lactose	  intolerance	  correlates	  
poorly	  with	  true	  lactose	  malabsorption.	  Suarez	  et	  al.	  demonstrated	  this	  beautifully	  by	  giving	  either	  
240	  ml	  of	  lactose-­‐containing	  or	  lactose-­‐deficient	  milk	  to	  subjects	  who	  reported	  severe	  lactose	  
intolerance.106	  There	  was	  no	  statistical	  difference	  in	  symptomatology	  (bloating,	  abdominal	  pain,	  







Physical	  activity	  has	  a	  significant	  impact	  in	  reducing	  the	  risk	  of	  major	  disease	  including	  ischaemic	  
heart	  disease,	  stroke	  and	  hypertension.	  Exercise	  can	  alleviate	  the	  symptoms	  of	  musculoskeletal	  
pathology,	  e.g.	  back	  pain	  and	  osteoporosis,	  and	  mood	  dysfunction,	  e.g.	  dysthmic	  states	  and	  anxiety.	   	  
Laxatives	  
Constipation-­‐predominant	  IBS	  patients	  gravitate	  towards	  increased	  dietary	  fibre	  or	  laxatives	  to	  
improve	  bowel	  habit.	  Stimulant	  laxatives	  are	  not	  recommended	  in	  IBS	  owing	  to	  their	  erratic	  mode	  of	  
action	  and	  side	  effect	  profile	  (e.g.	  tachyphylaxis).	  Inorganic	  salt-­‐based	  laxatives	  (e.g.	  polyethylene	  
glycol)	  are	  better	  tolerated	  than	  organic	  alcohols	  and	  sugars	  (e.g.	  Lactulose)	  which	  may	  exacerbate	  
bloating	  and	  flatulence.107	  
Aloe	  Vera	  
A	  randomised	  double	  blind	  placebo-­‐controlled	  trial	  by	  Davis	  et	  al.	  failed	  to	  discern	  a	  therapeutic	  
benefit	  of	  treating	  IBS	  patients	  with	  Aloe	  Vera	  over	  placebo.108	  
Complementary	  and	  Alternative	  Medicine	  
Complementary	  medicine	  is	  widely	  used	  by	  the	  IBS	  population.	  van	  Tilburg	  et	  al.	  reported	  that	  
alternative	  medicines	  were	  used	  by	  35%	  of	  a	  population	  of	  patients	  with	  functional	  bowel	  disorders	  
with	  a	  median	  expenditure	  of	  $200	  per	  patient.109	  Increased	  use	  of	  complementary	  therapies	  was	  
associated	  with	  higher	  education,	  anxiety,	  younger	  age	  and	  the	  female	  gender.	   	  
Acupuncture	  
Acupuncture	  has	  been	  shown	  to	  short	  term	  relief	  of	  symptoms	  in	  IBS,	  although	  controversy	  rages	  as	  
to	  whether	  it	  is	  nothing	  more	  than	  a	  placebo	  response.	  Schneider	  et	  al.	  published	  a	  study	  that	  
randomised	  IBS	  patients	  to	  acupuncture	  or	  sham	  acupuncture	  (using	  the	  Streitberger	  needle).110	  
After	  ten	  sessions	  of	  therapy,	  both	  groups	  showed	  improvements	  in	  quality	  of	  life	  from	  baseline,	  
assessed	  using	  the	  functional	  digestive	  diseases	  quality	  of	  life	  questionnaire	  (FDDQL).	  There	  was	  no	  
statistical	  difference	  between	  the	  two	  groups,	  endorsing	  the	  role	  of	  the	  placebo	  response.	   	  
Reflexology	  
Tovey	  et	  al.	  were	  responsible	  for	  the	  only	  study	  of	  reflexology	  in	  IBS.111	  Thirty-­‐four	  patients	  were	  
randomised	  to	  receiving	  reflexology-­‐congruent	  foot	  massage	  or	  just	  a	  foot	  massage.	  Reflexology	  did	  








Anti-­‐motility	  drugs	  are	  a	  useful	  therapy	  for	  patients	  with	  diarrhoea-­‐predominant	  IBS.	  Changes	  in	  
small	  and	  large	  bowel	  contractility,	  increased	  intestinal	  secretions	  and	  reduced	  intestinal	  absorption	  
may	  produce	  a	  diarrhoea-­‐predominant	  clinical	  picture.	  The	  main	  categories	  of	  anti-­‐motility	  drugs	  
used	  in	  IBS	  are	  Loperamide,	  Co-­‐phenotrope,	  Codeine	  Phosphate	  and	  Morphine-­‐containing	  
compounds	  
Loperamide	  
Loperamide	  is	  an	  opioid	  receptor	  analogue.	  Its	  main	  site	  of	  action	  is	  the	  μ-­‐opioid	  receptors	  in	  the	  
myenteric	  plexus	  of	  the	  large	  bowel.	  It	  does	  not	  cross	  the	  blood	  brain	  barrier,	  and	  therefore	  does	  
not	  have	  the	  same	  stimulatory	  effects	  on	  the	  central	  nervous	  system	  as	  other	  opioid	  analogues.	  The	  
clinical	  effect	  of	  Loperamide	  is	  to	  reduce	  colonic	  peristalsis	  and	  secretion,	  resulting	  in	  longer	  
gastrointestinal	  transit	  time	  and	  increased	  absorption	  of	  fluids	  and	  electrolytes	  from	  the	  
gastrointestinal	  tract.	   	  
Co-­‐phenotrope	  
Co-­‐phenotrope	  is	  composed	  of	  2	  pharmacologically	  active	  compounds	  Diphenoxylate	  and	  Atropine.	  
Diphenoxylate	  is	  responsible	  for	  the	  anti-­‐diarrhoeal	  properties112-­‐114	   	  
Antispasmodics	  
Antispasmodics	  are	  targeted	  at	  the	  visceral	  dysmotility	  and	  enhanced	  colonic	  contractility	  seen	  in	  
IBS	  patients,	  particularly	  of	  the	  diarrhoea-­‐predominant	  subtype.	  Anti-­‐spasmodics	  have	  been	  subject	  
to	  a	  proliferation	  of	  clinical	  research	  and	  meta-­‐analysis.115-­‐119	  Poynard’s	  2001	  meta-­‐analysis	  assessed	  
23	  randomised	  clinical	  trials	  that	  investigated	  anti-­‐spasmodic	  therapy	  in	  IBS.	  The	  mean	  percentage	  
of	  patients	  responding	  to	  the	  anti-­‐spasmodics	  was	  56%	  compared	  to	  37%	  in	  the	  control	  groups	  when	  
looking	  at	  global	  symptom	  scores.	  Abdominal	  pain	  was	  improved	  in	  53%	  of	  patients	  in	  the	  active	  
groups	  compared	  to	  41%	  in	  the	  placebo	  groups.	   	  
Probiotics	  
Emerging	  data	  suggests	  the	  clinical	  utility	  of	  probiotics	  in	  IBS.	  The	  research	  that	  has	  been	  carried	  out	  






probiotic	  used,	  the	  duration	  of	  treatment	  and	  the	  study	  design.	  Some	  studies	  have	  used	  a	  single	  
bacterial	  isolate	  whereas	  others	  have	  used	  a	  cocktail	  of	  strains	  making	  interpretation	  of	  data	  
difficult.	  Further	  studies	  need	  to	  be	  conducted	  into	  the	  use	  of	  probiotics	  in	  IBS,	  principally	  trying	  to	  
identify	  the	  optimum	  strain,	  dose	  and	  duration	  of	  therapy.	  At	  present	  the	  mechanism	  of	  action	  of	  
probiotics	  can	  only	  be	  surmised.	   	  
Antidepressants	  
Antidepressant	  therapy	  in	  IBS	  is	  primary	  aimed	  at	  harnessing	  the	  analgesic	  rather	  than	  the	  anti-­‐
depressant	  properties	  of	  the	  medication.	  It	  is	  necessary	  to	  make	  this	  distinction	  clear	  to	  patients	  in	  
order	  to	  improve	  compliance.	   	  
Tricyclic	  Antidepressants	  
Tricyclic	  antidepressants	  (TCAs)	  are	  a	  popular	  choice	  for	  refractory	  IBS	  symptoms	  with	  the	  
predominant	  action	  being	  to	  reduce	  abdominal	  pain.120	  Studies	  that	  have	  attempted	  to	  demonstrate	  
an	  improvement	  in	  visceral	  hypersensitivity	  by	  using	  TCAs	  have	  not	  been	  so	  convincing.121	  Over	  10%	  
of	  IBS	  patients	  are	  subjected	  to	  a	  trial	  with	  a	  TCA.122	  Many	  studies	  support	  the	  superiority	  of	  low-­‐
dose	  TCAs	  over	  placebo	  in	  IBS.123	   	  
Selective	  Serotonin	  Reuptake	  Inhibitors	  
Selective	  Serotonin	  Reuptake	  Inhibitors	  (SSRIs)	  are	  a	  newer	  class	  of	  anti-­‐depressant	  compared	  to	  the	  
TCAs,	  and	  benefit	  from	  having	  a	  much	  more	  specific	  pharmacological	  action.	  In	  the	  context	  of	  IBS,	  
selective	  Serotonin	  reuptake	  inhibitors	  have	  been	  the	  subject	  of	  four	  randomised	  control	  trials.124-­‐127	  
All	  four	  studies	  seemed	  to	  suggest	  an	  improvement	  in	  overall	  well-­‐being	  on	  an	  SSRI.	  
PSYCHOLOGICAL	  THERAPY	  
Self-­‐Help	  Groups	  
Simple	  interventions	  such	  as	  providing	  self-­‐help	  guidelines	  for	  patients	  with	  IBS	  can	  be	  effective	  in	  
terms	  of	  symptom	  relief	  and	  cost	  benefit.	  Robinson	  et	  al.	  randomised	  IBS	  patients	  to	  receive	  a	  self-­‐
help	  guide	  on	  its	  own,	  to	  receive	  the	  guide	  in	  conjunction	  with	  a	  self-­‐help	  group	  session	  or	  to	  receive	  
none	  of	  the	  interventions	  (control	  group)	  in	  a	  primary	  care	  setting.128	  One	  year	  follow-­‐up	  showed	  a	  
60%	  reduction	  in	  primary	  care	  consultations	  and	  decreased	  perceived	  symptom	  scores	  in	  the	  IBS	  
cohort	  that	  received	  the	  both	  the	  self-­‐help	  guideline	  and	  the	  group	  session.	  Clearly,	  patient	  






understanding	  of	  their	  condition.129	  This	  approach	  when	  combined	  with	  rational	  advice	  about	  
modifying	  lifestyle	  measures	  (including	  diet)	  allows	  patients	  to	  assume	  a	  degree	  of	  mastery	  over	  
their	  symptoms.	  Effective	  coping	  and	  quality	  of	  life	  are	  nurtured	  by	  the	  development	  of	  shared	  
management	  between	  the	  patient	  and	  physician.130,131	  Patients	  who	  continue	  to	  attribute	  their	  
symptoms	  to	  undiagnosed	  organic	  disease	  are	  predisposed	  to	  multiple	  consultations	  in	  primary	  care	  
and	  subsequent	  referral	  to	  secondary	  care.	  
Relaxation	  Therapy	  
Stress	  is	  identified	  by	  many	  IBS	  patients	  as	  a	  potent	  exacerbant	  of	  symptoms.	  The	  role	  of	  relaxation	  
therapy	  is	  aimed	  at	  reducing	  the	  burden	  of	  daily	  stressors	  to	  reduce	  symptomatology.	  Forbes	  et	  al.	  
compared	  the	  use	  of	  a	  simple	  relaxation	  tape	  with	  hypnotherapy	  in	  a	  group	  of	  refractory	  IBS	  
patients	  over	  a	  12	  week	  prospective	  study	  period.132	  The	  study	  proposed	  that	  hypnotherapy	  was	  the	  
superior	  treatment.	  However,	  the	  audiotape	  still	  demonstrated	  a	  valuable	  therapeutic	  effect,	  and	  
therefore	  should	  be	  considered	  as	  a	  viable	  second-­‐line	  treatment	  in	  resistant	  IBS.	   	  
Biofeedback	  
Biofeedback	  is	  a	  multi-­‐component	  discipline	  that	  incorporates	  patient	  education,	  relaxation	  therapy,	  
thermal	  biofeedback	  treatment	  and	  the	  development	  of	  coping	  strategies	  for	  daily	  stressors.	  
Biofeedback	  has	  been	  shown	  to	  be	  more	  effective	  than	  symptom	  monitoring	  in	  the	  treatment	  of	  IBS	  
although	  other	  factors	  may	  be	  just	  as	  useful.	  
Hypnotherapy	   	  
Hypnotherapy	  has	  become	  an	  important	  treatment	  modality	  for	  refractory	  Irritable	  Bowel	  
Syndrome.	  A	  landmark	  study	  by	  Whorwell	  et	  al.	  in	  1984	  documented	  a	  clear	  improvement	  in	  
symptoms	  scores	  in	  patients	  treated	  for	  3	  months	  with	  hypnotherapy	  compared	  to	  those	  treated	  
with	  psychotherapy	  and	  a	  drug	  placebo.	  A	  systematic	  review	  in	  2005	  consolidated	  the	  proliferation	  
of	  research	  in	  the	  intervening	  years	  that	  was	  concerned	  with	  the	  clinical	  utility	  of	  hypnotherapy	  in	  
IBS.133	  Fourteen	  studies	  were	  identified,	  of	  which	  8	  featured	  control	  groups.	  The	  review	  concluded	  
that	  hypnotherapy	  consistently	  improved	  both	  colonic	  and	  extra-­‐colonic	  symptoms	  in	  the	  majority	  
of	  IBS	  patients.	  According	  to	  the	  standards	  imposed	  by	  the	  Clinical	  Psychology	  Division	  of	  American	  






as	  being	  both	  efficacious	  and	  specific”.	  Of	  all	  the	  psychological	  therapies	  available	  to	  IBS,	  
hypnotherapy	  is	  the	  most	  extensively	  researched	  medium.134	  
Hypnotherapy	  is	  most	  effective	  when	  performed	  with	  a	  therapist,	  although	  self-­‐taught	  
hypnotherapy	  tapes	  have	  become	  widely	  available.135	  A	  recent	  study	  has	  established	  that	  the	  effects	  
of	  hypnotherapy	  may	  persist	  even	  at	  5	  year	  follow-­‐up.136	  The	  mechanisms	  that	  drive	  symptomatic	  
relief	  are	  not	  known.	  Apart	  from	  the	  moderation	  and	  manipulation	  of	  psychological	  processes,	  
hypnotherapy	  has	  been	  shown	  to	  normalise	  disordered	  rectal	  sensitivity,137,138	  and	  to	  alter	  colonic	  
motility.	  IBS-­‐cognitions	  and	  health-­‐related	  quality	  of	  life	  improve	  in	  tandem	  with	  the	  improvement	  
of	  colonic	  symptoms.139	  
Hypnotherapy	  is	  expensive,	  time-­‐consuming	  and	  poorly	  available.	  A	  typical	  treatment	  regime	  
comprises	  12	  weekly	  sessions	  with	  a	  trained	  therapist.	  Evidence	  for	  the	  long-­‐term	  persistence	  of	  
symptomatic	  benefit	  after	  hypnotherapy	  and	  the	  reduction	  in	  drug	  and	  consultation	  costs	  produce	  
powerful	  arguments	  for	  its	  use	  in	  refractory	  IBS	  patients.	  Research	  has	  started	  to	  identify	  which	  
patients	  will	  be	  most	  amenable	  to	  hypnotherapy.	  Whorwells’s	  group	  published	  a	  recent	  abstract	  
suggesting	  that	  if	  a	  patient	  perceives	  his	  or	  her	  illness	  as	  visual	  representation,	  then	  they	  will	  be	  
more	  likely	  to	  respond	  to	  hypnotherapy	  than	  patients	  who	  use	  literary	  or	  visceral	  abstractions.	  
Hypnotherapy	  seems	  to	  benefit	  all	  subtypes	  of	  IBS	  with	  the	  curious	  exception	  of	  diarrhoea-­‐
predominant	  males.140	  
Cognitive	  Behavioural	  Therapy	  
Cognitive	  behavioural	  therapy	  (CBT)	  is	  founded	  on	  the	  concept	  of	  social	  learning	  theory,	  originally	  
expounded	  by	  the	  work	  of	  Gabriel	  Tarde	  in	  the	  19th	  century.	  This	  states	  that	  behaviour	  is	  a	  reaction	  
to	  social	  observation	  and	  social	  consequence	  leading	  to	  the	  development	  of	  new	  imitatory	  
behaviour.	  As	  an	  example,	  a	  particular	  behaviour	  may	  induce	  increased	  attention	  on	  that	  individual,	  
thereby	  promoting	  that	  behaviour	  through	  reinforcement.	  Cognitive	  behavioural	  therapy	  targets	  
specific	  behavioural	  patterns,	  focusing	  on	  a	  cognitive	  approach	  to	  amplify	  or	  reduce	  that	  behaviour.	  
In	  the	  context	  of	  IBS,	  CBT	  can	  highlight	  abnormal	  illness	  cognitions	  and	  chronic	  pain	  behaviour.141	  
Cognitive	  behavioural	  therapy	  may	  be	  effective	  in	  reducing	  co-­‐existing	  psychological	  symptoms	  in	  
IBS	  patients,	  notably	  anxiety	  and	  depression.142	  Furthermore,	  as	  a	  general	  point,	  CBT	  may	  enable	  






Cognitive	  behavioural	  therapy	  is	  usually	  not	  a	  single	  specific	  therapy.	  Many	  centres	  recommend	  a	  
multi-­‐component	  approach	  with	  an	  amalgamation	  of	  cognitive	  and	  behavioural	  interventions,	  
stress-­‐management,	  relaxation	  therapy,	  pain	  management	  and	  assertiveness	  training.	  The	  ultimate	  
goal	  is	  to	  address	  behaviour	  that	  impacts	  on	  bowel	  habit	  and	  to	  reduce	  the	  psychosocial	  distress	  
that	  it	  causes.	   	  
The	  first	  study	  to	  assess	  CBT	  in	  IBS	  was	  performed	  by	  Bennett	  and	  Wilkinson	  in	  1985.143	  Twelve	  IBS	  
patients	  underwent	  an	  8	  week	  multi-­‐component	  plan	  (stress-­‐management	  training,	  cognitive	  
therapy	  and	  contingency	  management)	  in	  contrast	  to	  12	  patients	  assigned	  to	  best	  medical	  care	  
(fluphenazine/nortriptyline	  with	  an	  anti-­‐spasmodic).	  Anxiety	  levels	  were	  reduced	  in	  the	  treatment	  
group.	  Both	  groups	  demonstrated	  a	  similar	  improvement	  in	  gastrointestinal	  symptoms,	  fatigue	  and	  
functional	  impairment.	  Since	  this	  initial	  work,	  the	  studies	  investigating	  CBT	  in	  IBS	  have	  become	  more	  
sophisticated	  and	  better	  powered.	  Cognitive	  behavioural	  therapy	  has	  been	  established	  as	  superior	  
treatment	  to	  conservative	  management	  or	  self-­‐help	  support	  groups.144,145	   	  
Toner	  et	  al.	  published	  a	  series	  of	  101	  IBS	  patients	  randomised	  to	  either	  CBT,	  attentional-­‐placebo	  
control	  or	  best	  medical	  care.141	  Symptoms	  of	  depression	  and	  bloating	  improved	  compared	  to	  
controls.	  Scores	  reflecting	  greater	  patient	  satisfaction	  with	  therapy	  were	  higher	  in	  the	  CBT	  group	  
compared	  to	  controls.	  
Drossman	  et	  al.	  enrolled	  431	  IBS	  patients	  into	  a	  randomised	  comparator-­‐controlled,	  multi-­‐centre	  
trial	  pitting	  CBT	  against	  education,	  desipramine	  and	  placebo.120	  The	  patients	  were	  female	  with	  a	  
moderate	  to	  severe	  disease	  severity.	  Intention-­‐to-­‐treat	  analysis	  demonstrated	  that	  CBT	  was	  
significantly	  more	  effective	  than	  the	  education	  group	  unless	  there	  was	  co-­‐existent	  depression	  (70%	  
response	  rate	  compared	  to	  37%);	  desipramine	  was	  of	  no	  benefit	  compared	  to	  controls	  on	  an	  
intention	  to	  treat	  analysis,	  but	  showed	  benefit	  when	  using	  a	  per-­‐protocol	  analysis.	  The	  aim	  of	  this	  
study	  was	  to	  assess	  the	  efficacy	  of	  CBT	  against	  an	  education	  control	  and	  desipramine	  against	  
placebo-­‐	  there	  was	  no	  design	  to	  directly	  compare	  CBT	  to	  desipramine.	  Furthermore	  CBT	  seemed	  to	  
improve	  global	  satisfaction	  and	  quality	  of	  life	  rather	  than	  abdominal	  pain.	  
Psychodynamic	  Interpersonal	  Psychotherapy	  
Psychotherapy	  explores	  the	  complicated	  interpersonal	  problems	  that	  patients	  have	  experienced.	  A	  






that	  persist	  into	  adulthood.	  It	  is	  the	  responsibility	  of	  the	  therapist	  to	  identify	  these	  areas	  of	  distress,	  
to	  gently	  stimulate	  discussion	  and	  to	  allow	  time	  for	  reflection.	  During	  the	  sessions	  the	  patient	  may	  
reproduce	  anxieties	  around	  the	  areas	  of	  conflict	  which	  induce	  IBS-­‐like	  symptoms.	  By	  revisiting	  these	  
topics,	  a	  clear	  progression	  and	  link	  can	  be	  established	  between	  psychological	  distress	  and	  symptom	  
generation.	  This	  allows	  the	  patient	  to	  develop	  a	  greater	  understanding	  about	  what	  is	  causing	  his/her	  
symptoms.	  With	  practise	  the	  patient	  can	  develop	  the	  skills	  required	  to	  minimise	  the	  psychological	  
burden	  in	  order	  to	  improve	  the	  bowel	  habit.	  
Psychotherapy	  can	  be	  a	  profoundly	  time-­‐consuming	  process	  featuring	  weekly	  or	  fortnightly	  sessions	  
for	  a	  few	  years.	  Short	  courses	  of	  psychotherapy	  may	  also	  be	  instigated	  featuring	  between	  10	  and	  20	  
sessions	  that	  specifically	  focus	  on	  one	  particular	  aspect	  of	  a	  patient’s	  behaviour,	  termed	  focal	  
psychotherapy.	  Psychotherapy	  also	  demands	  a	  robust	  relationship	  between	  patient	  and	  therapist,	  
and	  the	  motivation	  of	  the	  patient	  to	  undergo	  such	  a	  time-­‐intensive	  intervention.	  
Psychotherapy	  has	  been	  shown	  to	  be	  effective	  in	  treating	  IBS	  patients	  refractory	  to	  conventional	  
medical	  therapy.124,146,147	  The	  methodological	  sanctity	  of	  some	  of	  the	  earlier	  studies	  assessing	  
psychotherapy	  in	  IBS	  has	  been	  questioned.	   	  
A	  large	  study	  conducted	  by	  Creed	  et	  al.	  randomised	  IBS	  patients	  to	  8	  weekly	  sessions	  of	  
psychotherapy,	  20mg	  of	  Paroxetine	  daily	  or	  routine	  medical	  care.124	  Both	  the	  active	  treatments	  were	  
found	  to	  be	  effective-­‐	  increased	  scores	  for	  the	  physical	  aspects	  of	  health-­‐related	  quality	  of	  life	  were	  
seen	  in	  both	  groups	  although	  psychological	  scores	  remained	  non-­‐significant.	  Interestingly	  at	  1	  year	  
follow-­‐up	  psychotherapy	  was	  associated	  with	  reduced	  health	  care	  costs	  (not	  seen	  in	  the	  Paroxetine	  
group),	  suggesting	  that	  even	  a	  brief	  (8	  week)	  trial	  of	  psychotherapy	  is	  clinically	  and	  cost-­‐effective.	  A	  
further	  point	  to	  draw	  from	  this	  study	  is	  that	  the	  improved	  health-­‐related	  quality	  of	  life	  scores	  seen	  in	  
the	  psychotherapy	  group	  did	  not	  significantly	  improve	  abdominal	  pain	  scores,	  and	  the	  positive	  
therapeutic	  differences	  could	  not	  be	  entirely	  attributable	  to	  changes	  in	  psychological	  profile.	  
Psychotherapy	  has	  been	  demonstrated	  to	  increase	  tolerance	  to	  rectal	  balloon	  distension.148	  Balloon	  
distension	  using	  a	  barostat	  is	  a	  technique	  used	  as	  a	  biomarker	  for	  visceral	  hypersensitivity.	  However,	  
the	  increased	  tolerance	  may	  be	  secondary	  to	  improved	  psychological	  status	  (e.g.	  improved	  
depression	  scores)	  rather	  than	  a	  change	  to	  primary	  visceral	  afferent	  nociceptive	  signalling.	  







CHAPTER	  ONE,	  SECTION	  2:	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
PATHOGENESIS	  OF	  IRRITABLE	  BOWEL	  SYNDROME	  
The	  mechanisms	  that	  underlie	  IBS	  are	  poorly	  understood.	  The	  current	  understanding	  is	  based	  on	  the	  
concept	  of	  the	  Brain	  Gut	  Axis	  which	  describes	  the	  interaction	  between	  central	  (e.g.	  sensory	  cortex,	  
central	  pain	  centres,	  hypothalamic-­‐pituitary	  adrenal	  axis)	  and	  local	  structures	  (e.g.	  colonic	  mucosa	  
and	  sensory	  afferent	  nerve	  fibres).	  The	  Brain	  Gut	  Axis	  determines	  how	  the	  psychological	  state	  and	  
the	  stress	  response	  influence	  the	  perception	  of	  painful	  and	  non-­‐painful	  stimuli	  from	  the	  gut.	  
Pathophysiological	  mechanisms	  which	  may	  influence	  pain	  perception	  from	  within	  the	  gut	  wall	  
include	  colonic	  dysmotility,	  visceral	  hypersensitivity,	  abnormal	  fermentation,	  post-­‐infective	  bowel	  
dysfunction	  and	  immune	  activation.	  
PSYCHOPATHOLOGY	  
Chaudhary	  and	  Truelove	  described	  the	  condition	  of	  Irritable	  Colon	  Syndrome,	  subsequently	  to	  be	  
renamed	  Irritable	  Bowel	  Syndrome,	  in	  their	  landmark	  study	  in	  1962.84	  One	  hundred	  and	  thirty	  
patients	  were	  identified	  with	  recurrent	  abdominal	  pain	  and	  disordered	  bowel	  habit	  with	  no	  evidence	  
of	  organic	  pathology	  that	  could	  explain	  their	  symptoms.	  The	  cohort	  of	  patients	  was	  subdivided	  
according	  to	  prevailing	  bowel	  habit-­‐	  the	  spastic	  colon	  group	  and	  the	  painless	  diarrhoea	  group-­‐	  and	  
the	  raw	  demographics	  data	  was	  presented.	  The	  importance	  of	  this	  paper	  was	  that	  no	  only	  did	  it	  give	  
a	  name	  and	  prominence	  to	  a	  syndrome	  that	  had	  perplexed	  the	  medical	  profession	  for	  many	  years-­‐	  
terms	  such	  as	  “membranous	  enteritis”	  and	  “neurogenic	  colitis”	  had	  been	  proposed	  by	  earlier	  
authors-­‐	  but	  it	  also	  sought	  to	  identify	  predisposing	  factors	  to	  the	  condition.	  Chaudhary	  and	  Truelove	  
demonstrated	  that	  psychological	  factors	  were	  “incriminated”	  in	  more	  than	  80%	  of	  the	  patients,	  that	  
females	  were	  more	  likely	  to	  have	  psychological	  comorbidity,	  and	  that	  prominent	  psychological	  
factors	  predicted	  a	  worse	  prognosis.	  
Patients	  with	  IBS	  are	  more	  likely	  to	  use	  health	  care	  resources	  and	  to	  undergo	  comprehensive	  
investigation	  to	  exclude	  organic	  disease.	  IBS	  patients	  with	  psychological	  comorbidity	  are	  more	  likely	  
to	  present	  for	  repeat	  medical	  consultations	  than	  IBS	  patients	  who	  are	  psychologically	  unaffected.	  
Female	  IBS	  patients	  in	  primary	  care	  are	  more	  affected	  by	  the	  physical	  and	  psychosocial	  symptoms	  
than	  their	  male	  counterparts.	  These	  findings	  propose	  a	  number	  of	  ideas	  about	  the	  pathogenesis	  of	  






unrelated	  to	  the	  abdominal	  symptomatology.	  It	  is	  important	  to	  note	  that	  the	  presence	  of	  
psychological	  comorbidity	  in	  a	  patient	  with	  abdominal	  symptoms	  does	  not	  imply	  causation.	  So,	  in	  
effect,	  the	  psychosocial	  burden	  may	  merely	  be	  a	  concurrent,	  though	  hardly	  innocent,	  bystander.	  
Secondly,	  chronic	  abdominal	  pain,	  the	  constant	  need	  to	  take	  refuge	  in	  the	  lavatory	  and	  the	  social	  
embarrassment	  and	  stigma	  of	  the	  condition	  may	  conspire	  to	  cause	  distress	  and	  psychological	  
dysfunction.	  The	  final	  explanation	  that	  IBS	  is	  primarily	  a	  psychiatric	  disease	  that	  manifests	  in	  somatic	  
symptomatology.	  Researchers	  have	  looked	  at	  this	  mechanism,	  by	  comparing	  patients	  with	  
psychiatric	  disease	  to	  IBS	  patients	  with	  psychological	  comorbidity,	  and	  found	  striking	  similarities	  
between	  both	  groups	  in	  terms	  of	  psychological	  and	  somatic	  function.	  Additional	  weight	  to	  this	  
particular	  argument	  is	  that	  the	  era	  of	  psychological	  intervention	  is	  now	  firmly	  established	  for	  
treating	  IBS	  patients	  with	  refractory	  symptoms.	  Methods	  such	  as	  cognitive	  behavioural	  therapy,	  
psychodynamic	  interpersonal	  psychotherapy	  and	  behavioural	  therapy	  are	  valid,	  viable	  and	  
increasingly	  popular	  treatment	  options.	   	  
Irritable	  Bowel	  Syndrome	  may	  represent	  a	  disparate	  and	  heterogeneous	  group	  of	  patients	  who	  are	  
grouped	  together	  solely	  by	  virtue	  of	  the	  fact	  that	  they	  have	  abdominal	  pain.	  Variations	  in	  psychiatric	  
or	  psychological	  comorbidity	  will	  therefore	  reflect	  the	  differing	  underlying	  aetiologies.	  If	  a	  primary	  
psychogenic	  process	  is	  dominant	  in	  the	  generation	  of	  IBS	  symptoms,	  this	  may	  represent	  a	  central	  
somatoform-­‐type	  presentation.	  In	  other	  words,	  the	  psychological	  state	  is	  outwardly	  represented	  in	  
the	  language	  of	  somatic	  symptomatology.	  There	  is	  some	  evidence	  of	  this	  in	  the	  literature.	  Levy	  et	  al.	  
documented	  that	  78%	  of	  the	  extra	  visits	  to	  a	  medical	  practitioner	  by	  over-­‐attending	  IBS	  patients	  are	  
for	  non-­‐gastrointestinal	  symptoms.	  If	  a	  non-­‐psychiatric	  process	  is	  dominant,	  one	  would	  expect	  IBS	  to	  
share	  a	  common	  and	  unique	  aetiology	  with	  related	  disorders.	  Whitehead	  et	  al.	  addressed	  the	  issue	  
of	  whether	  IBS	  patients	  were	  at	  risk	  of	  specific	  comorbid	  disorders	  or	  whether	  IBS	  patients	  
elaborated	  and	  over-­‐reported	  their	  symptoms.	  A	  cohort	  of	  3153	  IBS	  patients	  was	  compared	  to	  age	  
and	  gender-­‐matched	  controls	  and	  a	  cohort	  of	  patients	  with	  Inflammatory	  Bowel	  Disease.	  Patients	  
were	  categorised	  into	  whether	  they	  had	  gastrointestinal,	  psychiatric	  or	  non-­‐gastrointestinal	  somatic	  
complaints.	  The	  non-­‐gastrointestinal	  somatic	  group	  was	  sub-­‐divided	  into	  whether	  diagnosis	  was	  
achieved	  through	  symptom-­‐based	  or	  biomarker-­‐based	  methods.	  The	  results	  showed	  that	  IBS	  were	  
more	  likely	  to	  have	  concomitant	  somatic	  disorders	  than	  controls	  and	  that	  somatic	  comorbidity	  was	  
positively	  correlated	  with	  psychiatric	  comorbidity.	  However	  there	  were	  no	  unique	  associations	  






disordered	  symptom	  perception	  and	  pain	  amplification	  rather	  than	  any	  shared	  pathophysiology,	  and	  
that	  psychiatric	  comorbidity	  could	  influence	  but	  not	  entirely	  explain	  somatic	  comorbidity.	  
ABNORMAL	  ILLNESS	  BEHAVIOUR	  
The	  repeated	  presentation	  of	  IBS	  patients	  to	  medical	  services	  may	  be	  related	  to	  abnormal	  illness	  
behaviour.	  This	  describes	  the	  relationship	  of	  the	  patient	  to	  his	  or	  her	  prevailing	  symptomatology.	  
Changes	  in	  symptom	  perception	  regardless	  of	  any	  objective	  change	  in	  clinical	  presentation	  may	  be	  
sufficient	  to	  produce	  health-­‐care	  seeking	  behaviour.	  Negative	  cognitions	  about	  one’s	  symptoms,	  
worries	  about	  the	  future	  and	  a	  constant	  fear	  that	  abdominal	  symptoms	  are	  harbingers	  of	  a	  
cancerous	  lesion	  are	  consistently	  reported	  in	  the	  IBS	  literature.	  In	  addition	  to	  seeking	  out	  medical	  
services,	  abnormal	  illness	  behaviour	  may	  take	  the	  form	  of	  hypochondriac	  beliefs,	  disorders	  of	  affect,	  
denial	  and	  the	  conviction	  of	  undiagnosed	  disease.	  
Abnormal	  illness	  behaviour	  was	  first	  described	  by	  Pilowsky	  in	  1969.150	  His	  definition	  described	  “the	  
persistence	  of	  a	  maladaptive	  mode	  of	  experiencing,	  perceiving,	  evaluating	  and	  responding	  to	  one’s	  
health	  status,	  despite	  the	  fact	  that	  a	  doctor	  has	  provided	  a	  lucid	  and	  accurate	  appraisal	  of	  the	  
situation	  and	  management	  to	  be	  followed	  (if	  any),	  with	  opportunities	  for	  discussion,	  negotiation,	  
and	  clarification	  based	  on	  adequate	  assessment	  of	  all	  relevant	  biological,	  psychological,	  social	  and	  
cultural	  factors”.151	  His	  definition	  was	  an	  abstraction	  of	  the	  concept	  of	  illness	  behaviour,	  as	  proposed	  
by	  Mechanic.152	  This	  states	  that	  when	  an	  individual	  becomes	  unwell	  and	  assumes	  the	  sick	  role,153	  a	  
series	  of	  adaptive	  (or	  maladaptive)	  behaviours	  ensues,	  differentiating	  the	  well	  individual	  from	  the	  
unwell	  individual.	  This	  change	  of	  behaviour	  is	  designed	  to	  promote	  a	  return	  to	  health.	  However	  
deviant	  behaviour	  may	  encourage	  a	  pathological	  protraction	  of	  the	  sick	  role,	  namely	  abnormal	  
illness	  behaviour.	  
The	  development	  of	  abnormal	  illness	  behaviour	  may	  result	  from	  a	  disordered	  assimilation	  of	  
witnessed	  behaviours	  in	  childhood.	  IBS	  patients	  adopt	  abnormal	  illness	  behaviour	  primarily	  through	  
two	  mechanisms-­‐	  the	  adoption	  of	  the	  sick	  role	  and	  the	  modelling	  of	  illness	  behaviour	  from	  parents.	  
Levy	  et	  al.	  illustrated	  this	  latter	  point	  when	  he	  reported	  that	  the	  children	  of	  IBS	  patients	  consulted	  
medical	  services	  far	  more	  than	  children	  of	  non-­‐IBS	  patients,	  both	  for	  gastrointestinal	  and	  non-­‐
gastrointestinal	  complaints.154	  By	  asking	  patients	  about	  the	  symptoms	  they	  experienced	  in	  childhood	  






dysfunction,	  abdominal	  pain	  and	  healthcare	  utilisation	  when	  compared	  to	  patients	  who	  did	  not	  go	  
to	  see	  their	  doctors	  (non-­‐consulters)	  and	  asymptomatic	  controls.155	  
Whitehead	  et	  al.	  compared	  IBS	  patients	  with	  patients	  with	  peptic	  ulcer	  disease.156	  The	  data	  showed	  
that	  IBS	  patients	  were	  more	  likely	  to	  have	  a	  multiple	  somatic	  complaints,	  to	  view	  their	  symptoms	  as	  
being	  more	  significant	  than	  other	  people	  and	  to	  visit	  the	  doctor	  with	  increased	  frequency	  for	  minor	  
illnesses.	  IBS	  patients	  were	  more	  likely	  to	  have	  had	  2	  or	  more	  colds	  during	  the	  past	  year,	  that	  their	  
colds	  were	  more	  serious	  than	  those	  of	  other	  people	  and	  that	  they	  would	  rather	  attend	  a	  medical	  
consultation	  than	  attempt	  to	  get	  better	  by	  themselves.	  There	  were	  no	  differences	  between	  the	  two	  
groups	  with	  regards	  to	  depression	  or	  anxiety.	  IBS	  patients	  were	  more	  likely	  to	  have	  been	  given	  treats	  
such	  as	  sweets,	  toys,	  gifts	  or	  food	  (such	  as	  ice	  cream)	  during	  episodes	  of	  sickness.	  The	  direct	  
reinforcement	  of	  somatic	  complaints	  using	  a	  reward	  system	  was	  compelling	  evidence	  of	  learned	  
illness	  behaviour	  in	  IBS.	  
Another	  explanation	  for	  the	  observation	  that	  IBS	  patients	  beget	  IBS	  children	  may	  be	  a	  due	  to	  the	  fact	  
that	  there	  is	  a	  genetic	  or	  hereditary	  factor.	  Levy	  assessed	  the	  prevalence	  of	  80	  health	  disorders	  (one	  
of	  which	  was	  IBS)	  in	  populations	  of	  monozygotic	  and	  dizygotic	  twins.	  Concordance	  of	  IBS	  was	  
significantly	  higher	  in	  monozygotic	  twins	  than	  the	  dizygotic	  twins	  (17.2%	  vs.	  8.4%)	  favouring	  a	  
genetic	  lineage.	  However,	  the	  proportion	  of	  dizygotic	  twins	  with	  IBS	  who	  had	  mothers	  with	  IBS	  
(15.2%)	  was	  greater	  than	  the	  proportion	  of	  dizygotic	  twins	  with	  IBS	  who	  had	  co-­‐twins	  with	  IBS	  
(6.7%).	  A	  parent	  with	  IBS	  was	  an	  independent	  predictor	  of	  IBS,	  and	  that	  this	  association	  was	  stronger	  
than	  having	  a	  twin	  with	  IBS.	  The	  authors	  concluded	  that	  although	  genetic	  factors	  were	  important,	  
social	  learning	  of	  abnormal	  illness	  behaviours	  passing	  from	  parent	  to	  child	  were	  more	  powerful	  
influences.	  
Whitehead	  demonstrated	  that	  there	  was	  a	  positive	  correlation	  between	  childhood	  reinforcement	  of	  
the	  sick	  role	  and	  the	  development	  of	  abnormal	  illness	  behaviour	  in	  later	  life,	  even	  when	  significant	  
confounders	  such	  as	  neuroticism	  and	  stress	  had	  been	  accounted	  for.157	  Another	  curious	  observation	  
was	  that	  abnormal	  learning	  behaviour	  was	  a	  specific	  phenomenon-­‐	  childhood	  menstrual	  symptom	  
reinforcement	  predicted	  abnormal	  menstrual	  illness	  behaviour	  but	  not	  abnormal	  illness	  behaviour	  
for	  other	  symptoms,	  such	  as	  cold	  illness	  behaviour	  or	  bowel	  illness	  behaviour.	   	  
The	  relationship	  between	  how	  parents	  deal	  with	  their	  own	  symptoms	  and	  the	  somatic	  complaints	  of	  






adulthood.	  This	  is	  important	  because	  it	  suggests	  that	  recognition	  and	  resolution	  of	  childhood	  
reinforcement	  may	  prevent	  adult	  comorbidity.	  A	  fascinating	  insight	  into	  social	  learning	  was	  provided	  
by	  the	  observation	  that	  a	  child	  would	  be	  more	  likely	  to	  develop	  recurrent	  abdominal	  pain	  if	  his	  (or	  
her)	  mother	  suffered	  from	  abdominal	  pain	  when	  compared	  to	  the	  father	  having	  abdominal	  pain.	  The	  
inference	  is	  that	  a	  child	  spends	  much	  more	  time	  in	  the	  company	  of	  the	  mother	  during	  those	  
impressionable	  years	  than	  the	  father.158,159	  This	  may	  have	  far-­‐reaching	  repercussions-­‐	  8%	  of	  children	  
experience	  recurrent	  functional	  abdominal	  pain,	  and	  of	  these	  18-­‐61%	  will	  go	  on	  to	  develop	  
abdominal	  pain	  or	  IBS	  5-­‐30	  years	  later.	  
Koloski	  et	  al.	  investigated	  the	  relationship	  between	  abnormal	  illness	  behaviour	  and	  health	  care	  
seeking	  in	  IBS	  and	  functional	  dyspepsia.160	  Powered	  by	  the	  Abnormal	  Illness	  Behaviour	  
Questionnaire	  and	  the	  Social	  Learning	  of	  Illness	  Behaviour	  scale,	  this	  study	  consulted	  a	  
representative	  sample	  of	  the	  Australian	  public	  using	  a	  postal	  survey.	  Contrary	  to	  the	  authors’	  
expectations,	  the	  parameters	  for	  abnormal	  illness	  behaviour	  did	  not	  differentiate	  between	  IBS	  
consulters	  and	  IBS	  non-­‐consulters.	  The	  unshakeable	  conviction	  that	  a	  patient	  has	  serious	  disease	  
despite	  every	  reassurance	  to	  the	  contrary	  (assessed	  using	  the	  Disease	  Conviction	  scale)	  emerged	  as	  
the	  only	  independent	  predictor	  of	  having	  a	  diagnosis	  of	  IBS.	  Their	  conclusion	  was	  that	  IBS	  patients	  
were	  characterised	  by	  the	  belief	  that	  significant	  pathology	  was	  present,	  but	  that	  this	  did	  not	  reflect	  
in	  health	  care	  seeking.	  This	  study	  sits	  at	  odds	  to	  other	  research	  that	  has	  demonstrated	  a	  link	  
between	  abnormal	  illness	  behaviour	  and	  health	  care	  seeking	  in	  IBS	  patients.61	  Previous	  work	  by	  
Talley	  et	  al.	  could	  not	  provide	  an	  association	  between	  health	  care	  seeking	  in	  IBS	  and	  psychological	  
factors	  (including	  neuroticism)	  or	  abuse	  history.161	  Only	  increased	  duration	  of	  abdominal	  pain	  and	  
increased	  pain	  severity	  were	  independent	  predictors	  of	  health	  care	  seeking.	  
Research	  that	  focuses	  on	  childhood	  symptomatology	  in	  retrospective	  studies	  is	  vulnerable	  to	  recall	  
bias.	  Collateral	  history	  from	  parents	  is	  not	  usually	  available.	  Furthermore	  the	  methodology	  of	  self-­‐
report	  studies	  when	  investigating	  abnormal	  illness	  behaviour	  may	  be	  inherently	  flawed.	  A	  solution	  to	  
this	  is	  to	  construct	  a	  prospective	  study	  assessing	  childhood	  symptoms,	  illness	  behaviour	  and	  
healthcare	  seeking.	  Howell	  et	  al.	  managed	  to	  achieve	  this	  by	  studying	  a	  prospective	  longitudinal	  
birth	  cohort.162	  The	  study	  demonstrated	  that	  IBS	  at	  the	  age	  of	  26	  years	  was	  significantly	  more	  
common	  among	  individuals	  with	  a	  history	  of	  chronic	  abdominal	  pain	  between	  the	  ages	  of	  7	  and	  9.	  
This	  was	  assessed	  by	  clinical	  history	  (OR:	  1.85,	  P=0.02),	  parental	  report	  (OR:	  1.82,	  P=	  0.03)	  and	  






Abnormal	  illness	  behaviour	  must	  be	  viewed	  in	  the	  context	  of	  a	  patient’s	  subjective	  appreciation	  of	  
their	  symptoms.	  This	  is	  formed	  from	  personal	  belief	  systems,	  childhood	  experiences,	  knowledge	  of	  
the	  disease	  processes	  and	  various	  cultural	  and	  social	  references.	  Gick	  et	  al.	  assessed	  a	  group	  of	  
university	  students	  to	  determine	  whether	  one’s	  perception	  of	  illness	  had	  any	  relationship	  with	  
health	  care	  seeking.163	  Whilst	  there	  were	  no	  differences	  in	  neurotic	  traits	  between	  students	  with	  IBS	  
who	  consulted	  their	  doctors	  compared	  to	  those	  students	  who	  did	  not	  consult,	  the	  significant	  finding	  
was	  that	  students	  who	  were	  bothered	  about	  their	  symptoms	  and	  who	  questioned	  the	  meaning	  of	  
their	  symptoms	  were	  more	  likely	  to	  seek	  health	  care	  services.	  A	  study	  by	  Kettel	  et	  al.	  confirmed	  that	  
anxiety	  about	  the	  potentially	  serious	  nature	  of	  a	  patient’s	  IBS	  symptoms	  (and	  symptom	  severity)	  
differentiated	  IBS	  consulters	  and	  from	  IBS	  non-­‐consulters.63	  Similar	  studies	  have	  confirmed	  that	  
anxiety	  related	  to	  the	  prevailing	  symptoms	  and	  the	  fear	  of	  serious	  disease	  acts	  as	  an	  independent	  
predictor	  for	  healthcare	  seeking.164	  
BIOPSYCHOSOCIAL	  MODEL	  OF	  FGIDS	  
Classical	  psychosomatic	  theory	  suggested	  that	  a	  common	  psychologically-­‐mediated	  pathogenetic	  
mechanism	  was	  responsible	  for	  many	  medical	  disorders	  in	  the	  early	  1950s.	  Such	  disorders	  included	  
asthma,	  allergy,	  false	  pregnancy,	  coeliac	  disease,	  peptic	  ulcer	  and	  migraine.	  That	  psychological	  
dysfunction	  was	  the	  primary	  mechanism	  of	  symptom	  generation	  was	  based	  on	  the	  fact	  that	  the	  
popular	  implementation	  of	  psychoanalysis	  had	  a	  beneficial	  therapeutic	  effect-­‐	  ergo,	  all	  conditions	  
must	  have	  at	  their	  heart	  emotional	  conflict.	  This	  concept	  was	  quickly	  discredited.	  Its	  demise	  
prompted	  a	  radical	  shift	  to	  the	  opposite	  end	  of	  the	  spectrum,	  introducing	  an	  era	  of	  scientific	  
research	  that	  sought	  to	  discover	  various	  biological	  markers	  for	  the	  functional	  disorders.	  This	  was	  
termed	  the	  biomedical	  model	  of	  medicine.	  
In	  1977,	  Engel	  proposed	  the	  biopsychosocial	  model.165	  This	  was	  a	  reaction	  to	  the	  biomedical	  model	  
that	  attempted	  to	  explain	  every	  characteristic	  of	  disease	  presentation	  by	  pathological	  abnormality.	  
Engel	  argued	  that	  disease	  phenotype	  was	  the	  fusion	  of	  biological	  processes,	  psychological	  state	  and	  
social	  factors,	  thereby	  creating	  a	  holistic	  approach	  to	  disease	  conceptualisation.	  The	  biopsychosocial	  
model	  was	  readily	  embraced	  because	  it	  could	  start	  to	  explain	  the	  relationship	  between	  an	  individual,	  
his	  body,	  his	  emotions	  and	  his	  environment.	  It	  also	  allowed	  the	  development	  of	  sensitive	  
psychological	  and	  psychosocial	  instruments	  to	  be	  constructed	  in	  order	  to	  assess	  psychological	  







POST-­‐INFECTIOUS	  IRRITABLE	  BOWEL	  SYNDROME	  
The	  prevalence	  of	  Post-­‐infectious	  Irritable	  Bowel	  Syndrome	  (PI-­‐IBS)	  is	  as	  high	  as	  17%	  in	  the	  United	  
Kingdom,	  although	  there	  seems	  to	  be	  a	  wide	  geographical	  variation	  with	  reported	  prevalence	  as	  low	  
as	  6%	  in	  US	  tertiary	  care.166	  Post-­‐infectious	  Irritable	  Bowel	  syndrome	  represents	  a	  subgroup	  of	  
patients	  who	  were	  asymptomatic	  until	  the	  index	  episode	  of	  gastroenteritis.	  During	  this	  phase,	  the	  
immunological	  insult	  from	  the	  enteric	  pathogen	  induces	  a	  process	  of	  visceral	  sensitisation.	  The	  
patient	  begins	  to	  experience	  the	  symptoms	  of	  IBS	  in	  the	  post-­‐acute	  setting,	  and	  these	  symptoms	  
may	  persist	  indefinitely.	  Rodruigez	  et	  al.	  proposed	  a	  relative	  risk	  of	  11.9	  of	  developing	  PI-­‐IBS	  in	  the	  
12	  month	  period	  after	  an	  episode	  of	  bacterial	  gastroenteritis.167	  Risk	  factors	  for	  the	  development	  of	  
PI-­‐IBS	  include	  the	  severity	  of	  the	  index	  infection	  (including	  prolonged	  fever),	  bacterial	  toxigenicity,	  
younger	  age,	  being	  female	  and	  various	  psychiatric	  co-­‐morbidities	  including	  neuroticism,	  anxiety,	  
depression	  and	  hypochondriasis.168,169	  
The	  link	  between	  enteric	  infection	  and	  post-­‐infectious	  abdominal	  pain	  and	  bowel	  dysfunction	  (what	  
we	  would	  now	  term	  PI-­‐IBS)	  started	  to	  emerge	  at	  the	  end	  of	  the	  second	  world	  war-­‐	  British	  troops	  
returning	  from	  the	  African	  theatre	  of	  war	  complained	  of	  persistent	  symptoms	  following	  on	  from	  
amoebic	  dysentery.170	  The	  clinical	  course	  of	  IBS	  varies	  from	  individual	  to	  individual.	  A	  prospective	  
study	  was	  undertaken	  by	  Okhuysen	  et	  al.	  which	  observed	  North	  American	  students	  on	  their	  travels	  
to	  Mexico.171	  One	  hundred	  and	  sixty-­‐nine	  students	  entered	  the	  trial	  and	  completed	  gastrointestinal	  
questionnaires	  during	  the	  5	  week	  stay	  in	  Mexico.	  They	  were	  followed	  up	  for	  6	  months	  on	  their	  
return	  back	  to	  the	  United	  States.	  63%	  reported	  episodes	  of	  diarrhoea	  in	  Mexico,	  mostly	  due	  to	  E.	  coli	  
sepsis.	  Among	  the	  affected	  students,	  persistent	  symptoms	  were	  seen	  at	  6	  months,	  including	  
diarrhoea	  (18%),	  abdominal	  pain	  (18%)	  and	  frequency	  (9%).	  10%	  of	  the	  infected	  students	  met	  the	  
criteria	  for	  PI-­‐IBS.	  These	  findings	  substantiated	  an	  earlier	  prospective	  case-­‐controlled	  study	  by	  Parry	  
et	  al.172	  This	  study	  reported	  an	  incidence	  of	  PI-­‐IBS	  (using	  Rome	  2	  criteria)	  in	  16.7%	  of	  the	  patients	  
who	  had	  laboratory-­‐confirmed	  gastroenteritis,	  and	  functional	  diarrhoea	  in	  six	  other	  cases	  (5.6%).	  
The	  odds	  ratio	  for	  acquiring	  IBS	  following	  bacterial	  infection	  was	  10.1	  (95%	  CI	  =	  3.32-­‐30.69)	  
compared	  to	  controls.	  Follow-­‐up	  at	  3	  month	  and	  6	  month	  time	  points	  remained	  consistent	  between	  






The	  medical	  literature	  reports	  numerous	  studies	  investigating	  different	  species	  of	  enteric	  pathogen.	  
The	  largest	  study	  on	  PI-­‐IBS	  featured	  stool-­‐positive	  Campylobacter	  jejuni	  infection	  (Reference).	  Of	  the	  
840	  patients	  were	  enrolled,	  13.8%	  (103	  patients)	  fulfilled	  Rome	  1	  criteria	  for	  IBS	  after	  the	  
gastroenteritis.	  It	  is	  important	  to	  note	  that	  those	  patients	  with	  pre-­‐existing	  IBS	  (numbering	  46	  in	  
total)	  were	  excluded	  from	  these	  results.	  The	  incorporation	  of	  Rome	  2	  sub-­‐typing	  identified	  
diarrhoea-­‐predominant	  IBS	  as	  the	  most	  common	  form	  (63%)	  compared	  to	  constipation-­‐predominant	  
IBS	  (13%)	  and	  alternating	  sub-­‐type	  (24%).	  Reference.	  
Other	  bacterial	  pathogens	  may	  precipitate	  PI-­‐IBS	  including	  Salmonella173,174,	  and	  Shigella.175	  This	  
latter	  study	  reported	  an	  odds	  ratio	  of	  developing	  PI-­‐IBS	  after	  Shigellosis	  of	  2.09,	  somewhat	  lower	  
than	  other	  studies,	  and	  discovered	  that	  the	  duration	  of	  diarrhoea	  was	  an	  independent	  risk	  factor	  of	  
PI-­‐IBS.	  A	  3	  year	  follow-­‐up	  of	  the	  same	  patient	  population	  demonstrated	  that	  25%	  returned	  to	  a	  
normal	  bowel	  habit.176	  A	  recent	  Turkish	  study	  has	  implicated	  Trichinella	  in	  PI-­‐IBS.177	  Indeed,	  the	  
increased	  risk	  of	  PI-­‐IBS	  following	  bacterial	  appears	  non-­‐specific-­‐	  single	  species	  studies	  and	  dual	  
infection	  studies	  (such	  as	  the	  co-­‐infection	  of	  Campylobacter	  and	  E.	  coli	  in	  a	  large	  waterborne	  
outbreak	  of	  bacterial	  dysentery178)	  yield	  similar	  conclusions.	  Viral	  gastroenteritis	  is	  a	  much	  more	  
common	  phenomenon,	  displaying	  a	  more	  benign	  clinical	  course.	  Its	  role	  in	  the	  development	  of	  PI-­‐IBS	  
is	  thought	  to	  be	  less	  potent	  than	  bacillary	  gastroenteritis.179	  This	  observation	  is	  substantiated	  by	  
meta-­‐analysis	  by	  Halvorson	  et	  al.	  which	  demonstrated	  that	  the	  risk	  of	  PI-­‐IBS	  was	  higher	  in	  bacterial	  
gastroenteritis	  compared	  to	  non-­‐bacterial	  gastroenteritis,	  and	  that	  bacterial	  gastroenteritis	  was	  
associated	  with	  a	  more	  severe	  symptomatology	  (vomiting,	  fever,	  abdominal	  pain	  and	  diarrhoea).180	   	  
Meta-­‐analysis	  of	  the	  incidence	  and	  prognosis	  of	  PI-­‐IBS	  by	  Thabane	  et	  al.	  concluded	  that	  there	  is	  
about	  a	  6-­‐fold	  increased	  incidence	  in	  PI-­‐IBS	  following	  bacterial	  infection.169	  This	  was	  computed	  from	  
pooled	  data	  from	  9	  published	  prospective	  trials.	  Figure	  1.2.1	  shows	  this	  meta-­‐analysis.	  






Figure	  1.2.1	  Incidence	  of	  Post-­‐infectious	  Irritable	  Bowel	  Syndrome	   	  
	  
Adapted	  from	  M.	  THABANE,	  D.	  T.	  KOTTACHCHI	  &	  J.	  K.	  MARSHAL,	  Alimentary	  Pharmacology	  &	  Therapeutics	  Vol.	  26,	  4	  
Pages:	  535-­‐544	  
An	  important	  study	  by	  Spence	  et	  al.	  investigated	  the	  psychology	  of	  PI-­‐IBS.181	  620	  primary	  care	  
patients	  who	  were	  stool-­‐positive	  for	  Campylobacter	  with	  no	  preceding	  history	  of	  IBS	  or	  significant	  
bowel	  pathology	  were	  recruited	  into	  a	  prospective	  study.	  Psychometric	  questionnaires	  were	  
competed	  at	  the	  beginning	  of	  the	  study.	  These	  questionnaires	  were	  validated	  instruments	  for	  
assessing	  levels	  of	  stress,	  mood,	  perfectionism,	  negative	  illness	  beliefs	  and	  negative	  illness	  
behaviours.	  49	  patients	  met	  the	  criteria	  for	  IBS	  at	  3	  and	  6	  months	  follow-­‐up.	  Those	  who	  developed	  
PI-­‐IBS	  were	  found	  to	  have	  significantly	  higher	  levels	  of	  stress,	  anxiety,	  somatisation	  and	  negative	  
illness	  beliefs	  at	  the	  time	  of	  infection	  compared	  to	  those	  patients	  who	  did	  not	  develop	  IBS.	  
Furthermore	  they	  were	  more	  likely	  to	  remain	  active	  despite	  their	  symptomatology	  until	  they	  were	  
forced	  to	  rest,	  displaying	  “all-­‐or-­‐nothing	  behaviour”.	  Spence	  et	  al.	  have	  raised	  a	  fascinating	  insight	  
into	  the	  pathogenesis	  of	  PI-­‐IBS-­‐	  enteric	  infection	  is	  by	  definition	  the	  trigger	  for	  symptom-­‐onset,	  but	  
psychopathology	  may	  be	  the	  propagating	  factor.	  An	  earlier	  study	  by	  Dunlop	  et	  al.	  demonstrated	  that	  
depression	  and	  increased	  enterochromaffin	  cell	  counts	  were	  independent	  risk	  factors	  for	  the	  









INFLAMMATION	  IN	  IRRITABLE	  BOWEL	  SYNDROME	  
The	  observation	  that	  enteric	  infection	  predisposes	  to	  IBS	  has	  resulted	  in	  research	  looking	  for	  an	  
immunological	  explanation	  for	  symptom	  generation.	  Studies	  in	  the	  last	  five	  years	  have	  
demonstrated	  that	  IBS	  patients	  may	  have	  raised	  levels	  of	  inflammatory	  mediators.	  Various	  
approaches	  for	  the	  investigation	  of	  inflammation	  in	  IBS	  have	  been	  used	  including	  colonic	  mucosal	  
sampling,	  peripheral	  blood	  mononuclear	  cell	  (PBMC)	  sampling	  and	  PCR	  techniques.	  A	  novel	  
technique	  uses	  the	  mucosal	  patch	  technique-­‐	  this	  comprises	  the	  placement	  of	  cellulose	  patches	  
adjacent	  to	  the	  rectal	  mucosa,	  secured	  by	  rectal	  balloon.183	  Inflammatory	  mediators	  are	  evolved	  
from	  the	  mucosa	  and	  then	  absorbed	  by	  the	  patches.	  The	  study	  neatly	  demonstrates	  markedly	  raised	  
inflammatory	  mediators	  (myeloperoxidase	  from	  neutrophils;	  eosinophil	  cationic	  protein	  from	  
eosinophils)	  in	  active	  Ulcerative	  Colitis,	  and	  raised	  levels	  in	  IBS	  patients	  compared	  to	  controls.	  
Interestingly,	  the	  levels	  that	  were	  seen	  in	  the	  IBS	  patients	  were	  equivalent	  to	  those	  acquired	  from	  
patients	  with	  inactive	  Ulcerative	  Colitis.	  
Schoepfer	  et	  al.	  evaluated	  the	  recent	  introduction	  of	  faecal	  inflammatory	  markers	  showing	  
encouraging	  sensitivities	  and	  specificities	  for	  differentiating	  IBS	  from	  Inflammatory	  Bowel	  Disease-­‐	  
see	  earlier	  references	  to	  this	  study.184	   	  
CYTOKINES	  
The	  increasingly	  prolific	  use	  of	  cytokine	  analysis	  in	  IBS	  has	  presented	  data	  suggesting	  that	  low-­‐grade	  
inflammation	  may	  represent	  an	  important	  pathogenetic	  mechanism.	  Dunlop	  et	  al.	  demonstrated	  
increased	  enterochromaffin	  cell	  (EC)	  density	  and	  lamina	  propria	  T	  cell	  lymphocytes	  in	  rectal	  mucosal	  
biopsies	  taken	  from	  PI-­‐IBS	  patients	  compared	  to	  active	  controls	  and	  healthy	  volunteers.182	  Animal	  
studies	  have	  shown	  that	  EC	  hyperplasia	  is	  dependent	  on	  T	  cell	  activity-­‐	  specific	  T	  cell	  deficiencies	  can	  
be	  artificially	  recreated	  using	  T	  cell	  knockout	  mice,	  resulting	  in	  decreased	  EC	  hyperplasia	  and	  
infection-­‐induced	  mastocytosis.185	   	  
Wang	  et	  al.	  confirmed	  the	  increased	  expression	  of	  IL-­‐1β	  mRNA	  in	  recto-­‐sigmoid	  and	  terminal	  ileal	  
mucosal	  biopsies	  taken	  from	  PI-­‐IBS	  patients	  compared	  to	  controls.186	  This	  particular	  study	  also	  
demonstrated	  increased	  mast	  cell	  density	  in	  the	  ileal	  biopsies	  in	  both	  PI-­‐IBS	  and	  non-­‐PI-­‐IBS	  patients	  
compared	  to	  controls,	  with	  increased	  nerve	  fibre	  staining	  (using	  specific	  stains	  for	  neurone	  specific	  






cell	  clusters.	  This	  data	  suggests	  a	  complicated	  relationship	  between	  immunological	  factors	  and	  the	  
nervous	  system.	   	  
The	  failure	  of	  the	  down-­‐regulation	  of	  inflammatory	  processes	  as	  represented	  by	  persistently	  raised	  
levels	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  IL-­‐1β	  may	  be	  responsible	  for	  ongoing	  symptomatology.	  
An	  elegant	  prospective	  study	  by	  Gwee	  et	  al.	  harvested	  rectal	  mucosal	  biopsies	  from	  PI-­‐IBS	  patients,	  
a	  positive	  control	  population	  comprising	  patients	  who	  had	  contracted	  gastroenteritis	  but	  not	  the	  
sequelae	  of	  PI-­‐IBS,	  and	  a	  negative	  control	  population	  who	  did	  not	  present	  with	  gastroenteritis.187	  
Flexible	  sigmoidoscopy	  was	  carried	  out	  at	  the	  index	  infection	  and	  three	  months	  afterwards.	  Reverse	  
trancriptase	  polymerase	  chain	  reaction	  (rt-­‐PCR)	  techniques	  assessed	  the	  expression	  of	  IL-­‐1β	  mRNA	  
and	  its	  receptor	  antagonist	  IL-­‐1ra.	  The	  results	  showed	  significantly	  raised	  IL-­‐1β	  mRNA	  in	  PI-­‐IBS	  
patients	  compared	  to	  the	  active	  control	  at	  0	  and	  3	  months,	  and	  that	  this	  difference	  was	  not	  only	  
persistent	  over	  time	  but	  seemed	  to	  become	  more	  accentuated	  over	  time.	  The	  difference	  in	  IL-­‐1β	  
mRNA	  expression	  between	  the	  positive	  and	  negative	  controls	  reached	  statistical	  significance.	  
At	  an	  immunohistochemical	  level,	  an	  earlier	  study	  by	  Chadwick	  et	  al.	  featured	  colonic	  mucosal	  
biopsies	  of	  patients	  who	  satisfied	  the	  Rome	  1	  criteria	  for	  IBS	  and	  a	  group	  of	  asymptomatic	  
controls.188	  38	  of	  the	  77	  IBS	  patients	  had	  normal	  histology	  but	  increased	  intra-­‐epithelial	  lymphocytes	  
and	  lamina	  propria	  CD3+	  and	  CD25+	  cells	  compared	  to	  controls.	  31	  of	  the	  77	  patients	  had	  non-­‐
specific	  microscopic	  inflammation	  on	  histology	  and	  increased	  numbers	  of	  neutrophil	  lymphocytes	  
and	  mast	  cells.	  The	  final	  group,	  numbering	  8	  of	  the	  77	  patients,	  had	  histological	  and	  
immunohistochemical	  features	  consistent	  with	  lymphocytic	  colitis.	  
Gonsalkorale	  et	  al.	  suggested	  a	  genetic	  imbalance	  of	  pro-­‐inflammatory	  to	  anti-­‐inflammatory	  
cytokines.189	  Spiller	  et	  al.	  showed	  an	  increase	  in	  activated	  T	  cells,	  mast	  cells	  and	  pro-­‐inflammatory	  
cytokines	  in	  P-­‐IBS	  patients.190	   	  
A	  study	  by	  Söderholm	  et	  al.	  used	  maternal	  separation	  rat	  models	  to	  integrate	  the	  concept	  of	  stress	  
and	  cytokine	  dysfunction	  into	  the	  overall	  understanding	  of	  disease	  pathogenesis.	  The	  authors	  
demonstrated	  increased	  intestinal	  permeability	  and	  HPA	  axis	  activation	  by	  stress	  induced	  by	  
maternal	  separation,	  leading	  to	  colonic	  mucosal	  barrier	  dysfunction.191	   	  
In	  a	  subsequent	  study,	  the	  addition	  of	  probiotics	  to	  manipulate	  and	  control	  the	  gut	  microbiota	  






maternal	  separation	  paradigm.192	  The	  authors	  hypothesised	  that	  stress-­‐induced	  enhanced	  mucosal	  
permeability	  with	  up-­‐regulation	  of	  the	  HPA	  axis	  facilitated	  the	  entry	  of	  unfavourable	  bacteria	  and	  
the	  propagation	  of	  the	  inflammatory	  process.193	  
The	  relationship	  between	  cytokine	  expression	  and	  symptom	  generation	  is	  critical	  to	  substantiate	  the	  
role	  of	  inflammation	  in	  IBS.	  Work	  by	  Barbara	  et	  al.	  highlighted	  the	  proximity	  of	  mast	  cells	  to	  enteric	  
nerve	  fibres	  suggesting	  a	  direct	  interface	  between	  the	  immunological	  and	  nervous	  systems.194	  
Furthermore	  the	  group	  presented	  data	  that	  found	  positive	  correlations	  between	  the	  density	  of	  mast	  
cells	  and	  subjective	  reports	  of	  pain	  intensity.	   	  
Animal	  studies	  have	  shown	  the	  direct	  effects	  of	  administering	  cytokines	  on	  afferent	  nerve	  function.	  
A	  novel	  study	  by	  Blackshaw’s	  group	  isolated	  PBMCs	  from	  two	  separate	  populations,	  namely	  IBS	  
patients	  and	  a	  control	  sample.	  The	  addition	  of	  the	  cytokine-­‐rich	  PBMC	  milieu	  to	  the	  mucosal	  rodent	  
spinal	  afferent	  produced	  a	  60%	  increase	  in	  afferent	  nerve	  transmission	  from	  the	  supernatant	  taken	  
from	  IBS	  patients	  but	  not	  controls.	  Whether	  this	  is	  sufficient	  evidence	  to	  explain	  the	  differences	  in	  
visceral	  perception	  between	  the	  two	  groups	  remains	  to	  be	  seen.	  However	  when	  viewed	  in	  
conjunction	  with	  the	  aforementioned	  Barbara	  et	  al.	  paper,	  it	  offers	  valuable	  insights	  into	  the	  
potential	  for	  direct	  manipulation	  of	  the	  nervous	  system	  through	  local	  inflammatory	  changes.	   	  
Other	  evidence	  that	  endorses	  the	  role	  of	  inflammation	  on	  visceral	  hypersensitivity	  is	  the	  scientific	  
interrogation	  of	  the	  more	  traditional	  inflammatory	  disease	  states	  such	  as	  Crohn’s	  disease	  or	  
ulcerative	  colitis.	  Some	  studies	  have	  identified	  increased	  rectal	  sensitivity	  in	  active	  Ulcerative	  
Colitis.195,196	  However	  Chang	  et	  al.’s	  paper	  found	  an	  attenuation	  of	  rectal	  perception	  in	  patients	  with	  
mild	  chronic	  Ulcerative	  Colitis.	  In	  contrast	  the	  IBS	  patients	  in	  the	  separate	  arm	  of	  the	  study	  were	  
found	  to	  have	  exacerbated	  rectal	  perception.197	  This	  led	  the	  authors	  to	  conclude	  that	  variations	  in	  
the	  local	  inflammatory	  environment	  may	  be	  responsible	  for	  this	  observation.	  Conversely,	  the	  up	  –
regulation	  of	  centrally-­‐driven	  anti-­‐nociceptive	  pathways	  primed	  by	  months,	  even	  years	  of	  chronic	  
inflammation	  may	  be	  the	  driving	  mechanism.	  
MUCOSAL	  PERMEABILITY	  
Spiller	  et	  al.	  assessed	  gut	  permeability	  in	  PI-­‐IBS	  patients	  using	  lactulose/mannitol	  ratio	  testing.190	  
Lactulose/mannitol	  permeability	  studies	  require	  a	  subject	  to	  drink	  an	  oral	  load	  of	  lactulose	  and	  
mannitol.	  Overnight	  urinary	  collection	  allows	  one	  to	  compute	  the	  fractional	  excretion	  of	  each	  sugar-­‐	  






mannitol	  ratio	  is	  calculated	  as	  the	  fractional	  excretion	  of	  lactulose	  divided	  by	  that	  of	  mannitol,	  with	  
normal	  values	  being	  less	  than	  0.025.198	  The	  Spiller	  study	  showed	  that	  infection	  with	  Campylobacter	  
jejuni	  enteritis	  was	  associated	  with	  increased	  gut	  permeability	  during	  the	  acute	  phase	  and	  at	  a	  3	  
months.	  Furthermore,	  histological	  assessment	  showed	  raised	  EC	  cells	  and	  intra-­‐epithelial	  cells.	   	  
Spiller’s	  data	  set	  was	  endorsed	  by	  Marshall	  et	  al.199	  The	  Marshall	  study	  revisited	  a	  population	  of	  
patients	  who	  had	  dual	  infection	  with	  Campylobacter	  and	  E.	  coli	  following	  the	  widespread	  
contamination	  of	  a	  municipal	  water	  source	  in	  Walkerton,	  Ontario.	  This	  outbreak	  affected	  as	  many	  as	  
2300	  local	  residents	  leading	  to	  twenty-­‐seven	  patients	  developing	  haemolytic	  uraemic	  syndrome	  and	  
six	  deaths.	  132	  IBS	  patients	  (27	  of	  these	  patients	  had	  the	  diagnosis	  of	  IBS	  before	  the	  outbreak)	  were	  
compared	  to	  86	  non-­‐IBS	  controls.	  Lactulose-­‐mannitol	  ratios	  were	  again	  employed	  to	  assess	  gut	  
permeability.	  IBS	  cases	  were	  more	  likely	  to	  have	  increased	  gut	  permeability	  than	  controls-­‐	  
lactulose/mannitol	  ratios	  greater	  than	  0.02	  were	  seen	  in	  35%	  of	  the	  IBS	  cases	  compared	  to	  13%	  of	  
the	  controls-­‐	  and	  increased	  gut	  permeability	  was	  associated	  with	  increased	  stool	  frequency	  in	  the	  
cases.	  The	  interesting	  point	  to	  draw	  from	  this	  is	  that	  a	  significant	  enteric	  infection	  causes	  a	  
persistently	  dysfunctional	  gastrointestinal	  mucosa,	  as	  evidenced	  by	  a	  sustained	  immunological	  
response	  and	  altered	  permeability.	  Researchers	  now	  hypothesise	  that	  altered	  permeability	  may	  
serve	  as	  an	  entry	  point	  for	  luminal	  bacteria	  and	  antigens,	  thereby	  perpetuating	  the	  inflammatory	  
response	  and	  maintaining	  symptomatology.	  
Dunlop	  et	  al.	  extended	  the	  scope	  of	  these	  earlier	  studies	  by	  exploring	  gut	  permeability	  in	  both	  the	  
proximal	  small	  and	  the	  large	  bowel	  in	  PI-­‐IBS	  and	  constipation-­‐predominant	  patients	  (IBS-­‐C)	  ,	  and	  in	  
PI-­‐IBS	  and	  non-­‐PI-­‐IBS	  diarrhoea-­‐predominant	  patients.200	  The	  results	  showed	  that	  PI-­‐IBS	  patients	  had	  
increased	  small	  bowel	  permeability	  compared	  to	  the	  IBS-­‐C,	  and	  of	  the	  diarrhoea-­‐predominant	  
cohort,	  a	  non-­‐infectious	  aetiology	  appeared	  to	  produce	  a	  greater	  increase	  in	  permeability	  compared	  
to	  the	  PI-­‐IBS	  group.	  What	  emerges	  from	  this	  study	  is	  that	  enteric	  infection	  is	  an	  important	  
mechanism	  in	  producing	  sustained	  mucosal	  defects,	  but	  that	  other	  mechanisms	  are	  also	  implicated.	  
The	  observation	  that	  gut	  permeability	  is	  increased	  as	  a	  result	  of	  enteric	  infection	  may	  be	  due	  
disruption	  of	  the	  tight	  junctions	  at	  the	  level	  of	  the	  mucosa.	  A	  review	  by	  Berkes	  et	  al.	  explored	  the	  
concept	  of	  mucosal	  barrier	  dysfunction	  secondary	  to	  enteritis	  from	  various	  pathogens	  including	  E.	  
coli,	  Bacteroides	  fragilis,	  Campylobacter	  jejuni	  and	  Vibrio	  cholerae.201	  During	  an	  episode	  of	  






alterations	  in	  the	  structure	  and	  function	  of	  the	  tight	  junction	  barrier,	  changes	  in	  electrolyte	  and	  fluid	  
secretion,	  and	  stimulation	  of	  the	  inflammatory	  cascade.	  In	  the	  post-­‐acute	  phase,	  the	  inability	  to	  
restore	  the	  integrity	  of	  the	  mucosal	  barrier	  by	  repairing	  the	  tight	  junction	  interface	  may	  be	  a	  
pathogenetic	  feature	  of	  PI-­‐IBS.	   	  
Research	  from	  different	  disease	  processes	  can	  help	  to	  determine	  whether	  the	  features	  of	  increased	  
gut	  permeability	  have	  any	  significant	  role	  in	  the	  propagation	  of	  symptoms.	  Increased	  gut	  
permeability	  has	  been	  shown	  to	  identify	  Crohn’s	  patients	  in	  clinical	  remission	  who	  have	  an	  increased	  
risk	  of	  clinical	  relapse.202	  Increased	  gut	  permeability	  has	  been	  noted	  in	  first	  degree	  relatives	  of	  those	  
with	  Crohn’s	  disease.203	  Other	  studies	  investigating	  Coeliac	  disease	  have	  discovered	  increased	  gut	  
permeability,	  a	  mechanism	  that	  possibly	  allows	  the	  unchecked	  entry	  of	  gluten	  and	  other	  antigens	  to	  
interface	  with	  the	  lamina	  propria	  thereby	  starting	  and	  maintaining	  an	  immunological	  response.204	  A	  
salient	  paper	  by	  Clayburgh	  et	  al.	  uses	  a	  rat	  model	  of	  T	  cell-­‐mediated	  diarrhoea	  featuring	  a	  myosin	  
light	  chain	  kinase	  knockout	  species	  (MLCK).205	  MLCK	  produces	  phosphorylation	  of	  myosin	  II	  light	  
chain	  (MLC),	  altering	  the	  contractility	  of	  the	  mucosal	  cytoskeleton	  and	  promoting	  permeability.	  By	  
knocking	  out	  MLCK,	  the	  data	  showed	  that	  tight	  junction	  disruption,	  protein	  leak	  and	  diarrhoea	  
induced	  by	  T	  cell	  activation	  was	  inhibited.	  The	  relevance	  of	  MLC	  phosphorylation	  in	  the	  clinical	  area	  
is	  corroborated	  by	  research	  that	  shows	  increased	  MLC	  phosphorylation	  in	  inflammatory	  bowel	  
disease.206	  Furthermore,	  in	  vivo	  and	  in	  vitro	  studies	  have	  established	  a	  link	  between	  TNF-­‐α	  and	  
increased	  MLC	  phosphorylation.205,207	  
VISCERAL	  HYPERSENSITIVITY	  
Recto-­‐sigmoid	  distension	  studies	  have	  shown	  lowered	  pain	  thresholds	  in	  IBS	  patients	  compared	  to	  
healthy	  volunteers.208	  Visceral	  hypersensitivity,	  colonic	  dysmotility,	  infection	  and	  immune	  activation	  
have	  been	  implicated	  in	  altering	  pain	  thresholds	  at	  a	  local	  gut	  level	  in	  IBS.	  At	  a	  brain	  level,	  central	  
processing	  abnormalities	  of	  sensory	  afferent	  signalling	  have	  been	  described.	  Previous	  work	  on	  
human	  visceral	  pain	  models,	  suggests	  that	  the	  final	  expression	  of	  symptoms	  is	  determined	  by	  gut	  
related	  processes	  in	  conjunction	  with	  cortical	  perception	  of	  stimuli.	  Studies	  on	  the	  cortical	  
processing	  of	  visceral	  afferent	  information	  investigated	  the	  mechanisms	  in	  non	  cardiac	  chest	  pain	  as	  
a	  disease	  model.	  Cortical	  evoked	  potentials	  (CEP)	  to	  oesophageal	  stimuli	  revealed	  three	  distinct	  
clinical	  phenotypic	  profiles.209	  One	  group	  described	  as	  over-­‐reporters	  of	  symptoms	  showed	  no	  
increased	  pain	  threshold	  and	  no	  changes	  in	  CEP	  waveforms	  compared	  to	  healthy	  controls.	  The	  






detected	  as	  reduced	  latency	  and	  CEP	  peak	  amplitude	  suggesting	  true	  heightened	  visceral	  afferent	  
input	  with	  normal	  latency	  and	  low	  CEP	  amplitude	  in	  keeping	  with	  a	  hyper	  vigilant	  state.	  The	  rectal	  
equivalent	  of	  this	  model	  has	  been	  validated	  in	  healthy	  volunteers.210	  
AUTONOMIC	  DYSFUNCTION	  
Murray	  et	  al.	  investigated	  autonomic	  function	  in	  IBS	  patients	  by	  assessing	  rectal	  mucosal	  blood	  flow	  
(used	  as	  a	  biomarker	  for	  autonomic	  function)	  and	  vesico-­‐somatic	  sensitivity	  following	  acute	  
psychological	  and	  physical	  stress.211	  Physical	  stress	  was	  elicited	  by	  the	  cold	  pressor	  test	  in	  which	  a	  
hand	  is	  placed	  in	  a	  bucket	  of	  iced	  water	  as	  the	  test	  is	  being	  conducted.	  He	  demonstrated	  that	  acute	  
stress	  alters	  gut-­‐specific	  efferent	  autonomic	  innervation	  in	  both	  controls	  and	  patients	  with	  IBS,	  
although	  normalisation	  is	  delayed	  in	  IBS.	  
HYPOTHALAMIC-­‐PITUITARY	  AXIS	  
The	  emerging	  role	  of	  the	  Hypothalamic-­‐Pituitary-­‐Adrenal	  Axis	  (HPA	  axis)	  in	  the	  pathogenesis	  of	  IBS	  
has	  focused	  attention	  on	  the	  hypothalamic	  hormone,	  corticotrophin-­‐releasing	  factor	  (CRF).	  CRF	  
signalling	  pathways	  are	  fundamental	  components	  of	  the	  acute	  stress	  response	  because	  they	  induce	  
endocrine,	  behavioural,	  and	  immune	  changes	  in	  response	  to	  the	  impending	  danger.	  Studies	  
investigating	  CRF1	  pathway	  activation	  induce	  clinical	  symptoms	  similar	  to	  that	  of	  diarrhoea-­‐
predominant	  IBS,	  namely	  abdominal	  discomfort,	  diarrhoea,	  anxiety,	  and	  hypervigilant	  behaviour.	  
Physiological	  effects	  have	  been	  studied	  by	  intravenous	  or	  intraperitoneal	  injection	  of	  CRF	  agonists,	  
resulting	  in	  gastric	  stasis	  and	  increased	  colonic	  motility.	   	  
HPA	  axis	  over-­‐stimulation	  is	  associated	  with	  the	  pathophysiological	  development	  of	  stress-­‐related	  
psychiatric	  co-­‐morbidity.	  Primary	  psychiatric	  disease	  such	  as	  schizophrenia,	  panic	  disorders	  and	  
depression	  are	  associated	  with	  IBS-­‐like	  symptoms.	  Conversely	  there	  is	  an	  increased	  prevalence	  of	  
psychiatric	  co-­‐morbidity	  in	  patients	  with	  IBS.	  The	  relationship	  between	  psychiatric	  symptomatology	  
and	  IBS	  is	  so	  profound	  (and	  the	  HPA	  axis	  lies	  at	  the	  heart	  of	  this)	  that	  the	  administration	  of	  selective	  
CRF1	  receptor	  antagonists	  as	  a	  novel	  treatment	  for	  patients	  with	  severe	  depression	  had	  the	  
additional	  effect	  of	  improving	  colonic	  motility	  and	  visceral	  hypersensitivity	  in	  a	  sub-­‐group	  of	  treated	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RESEARCH	  INSTRUMENTS	  USED	  IN	  THE	  STUDY	  PROTOCOLS	  
CLINICAL	  SCORING	  SYSTEMS	  
IRRITABLE	  BOWEL	  SEVERITY	  SCORING	  SYSTEM	  
The	  Irritable	  Bowel	  Severity	  Scoring	  System	  (IBSSS)	  was	  developed	  by	  Professor	  Whorwell’s	  group	  in	  
Manchester	  to	  serve	  as	  a	  simple,	  concise	  clinical	  symptom	  severity	  scoring	  tool	  for	  IBS.212	  
Drossman’s	  Functional	  Bowel	  Disorder	  Severity	  Index	  (FBDSI)	  had	  been	  championed	  2	  years	  earlier	  
for	  this	  purpose.213	  However,	  it	  was	  a	  global	  symptom	  assessment	  index	  directed	  at	  functional	  bowel	  
disease,	  i.e.	  it	  was	  not	  specific	  to	  IBS,	  and	  therefore	  was	  thought	  to	  be	  too	  underpowered	  to	  
characterise	  the	  day	  to	  day	  changes	  in	  IBS	  symptom	  severity.	  
The	  IBSSS	  assesses	  the	  various	  dimensions	  of	  the	  IBS	  presentation,	  ranging	  from	  primary	  colonic	  
symptoms,	  extra-­‐colonic	  symptoms,	  quality	  of	  life	  measures	  and	  psychological	  profiling.	  The	  
questionnaire	  comprises	  5	  items	  that	  reflect	  symptoms	  activity	  over	  the	  last	  10	  days:	  (1)	  severity	  of	  
abdominal	  pain,	  (2)	  frequency	  of	  abdominal	  pain,	  (3)	  severity	  of	  abdominal	  distension	  or	  tightness,	  
(4)	  dissatisfaction	  with	  bowel	  habits,	  and	  (5)	  interference	  of	  IBS	  with	  life	  in	  general.	  The	  first	  page	  
comprises	  demographic	  data,	  the	  second	  page	  features	  the	  severity	  scoring	  system,	  and	  pages	  three	  
and	  four	  explore	  additional	  information.	   	  
In	  its	  trial	  phase	  the	  IBSSS	  was	  completed	  by	  61	  IBS	  patients	  of	  varying	  degrees	  of	  clinical	  severity	  
(determined	  by	  a	  preceding	  clinical	  consultation,	  and	  classified	  as	  mild,	  moderate	  or	  severe),	  and	  40	  
randomly	  selected	  controls.	  The	  questionnaire	  data	  was	  collected	  independently	  by	  a	  person	  blinded	  
to	  the	  results	  of	  the	  clinical	  assessment.	  An	  additional	  group	  of	  40	  IBS	  patients	  were	  asked	  to	  
complete	  the	  questionnaire	  a	  second	  time	  (within	  24	  hours	  of	  their	  clinical	  consultation)	  to	  assess	  
for	  reproducibility	  of	  the	  data.	  A	  final	  group	  completed	  the	  questionnaires	  before	  and	  after	  a	  trial	  of	  
hypnotherapy	  to	  determine	  the	  sensitivity	  of	  the	  questionnaire	  to	  clinical	  change.	  
Statistical	  analysis	  showed	  that	  controls	  scored	  less	  than	  75	  out	  of	  a	  possible	  total	  of	  500.	  Mild	  IBS	  
scored	  between	  75	  and	  175,	  moderate	  IBS	  scored	  between	  175	  to	  300	  and	  severe	  IBS	  scored	  greater	  
than	  300.	  IBS	  patients	  scoring	  less	  than	  75	  were	  deemed	  to	  be	  in	  clinical	  remission.	  The	  






improved	  after	  treatment	  had	  a	  statistically	  significant	  improvement	  in	  their	  severity	  scores	  
compared	  to	  baseline.	  
VERBAL	  DESCRIPTOR	  VISUAL	  ANALOGUE	  SCALE	  
The	  Visual	  Analogue	  Scale	  (VAS)	  is	  a	  validated	  psychometric	  instrument	  for	  assessing	  a	  subject’s	  
agreement	  with	  a	  statement.214	  The	  subject	  is	  asked	  to	  mark	  a	  position	  on	  a	  continuous	  line	  
between	  two	  end-­‐points	  which	  represent	  the	  polar	  opposites	  of	  no	  agreement	  and	  total	  agreement	  
respectively.	  Visual	  analogue	  scales	  have	  been	  used	  for	  many	  years,	  and	  have	  found	  particular	  use	  in	  
the	  arena	  of	  subjective	  pain	  assessment.	  
Visual	  analogue	  scales	  are	  quick	  to	  perform	  and	  calculate	  data,215,216	  produce	  continuous	  or	  
analogue	  data	  (compared	  to	  alternative	  scoring	  systems	  such	  as	  the	  Likert	  scale	  which	  produces	  
discrete	  scores217),	  facilitate	  the	  use	  of	  parametric	  statistical	  analysis,	  and	  can	  be	  used	  regardless	  of	  
language	  barriers.218	  
Variations	  on	  the	  theme	  of	  visual	  analogue	  scales	  exist,	  according	  to	  the	  orientation	  of	  the	  scale	  
(vertical	  or	  horizontal),	  the	  size	  of	  the	  scale,	  the	  presence	  or	  absence	  of	  verbal	  descriptors,	  whether	  
the	  scales	  are	  graded	  or	  not,	  or	  even	  whether	  the	  scales	  have	  a	  curvilinear	  format.	  A	  study	  by	  
Sriwatanakul	  et	  al.	  concluded	  that	  a	  horizontal	  linear	  graded	  VAS	  without	  verbal	  descriptors	  was	  the	  
optimal	  configuration.219	  
Deficiencies	  of	  the	  VAS	  include	  the	  fact	  that	  health	  professions	  can	  identify	  a	  1	  point	  change	  on	  a	  
Likert	  scale	  far	  more	  easily	  than	  a	  10	  point	  change	  on	  a	  VAS,216	  some	  patients	  find	  the	  VAS	  difficult	  to	  
complete	  and	  comprehend,220	  and	  that	  if	  the	  VAS	  includes	  grading,	  verbal	  or	  numerical	  labels,	  then	  
it	  predisposes	  to	  a	  clustering	  of	  responses	  around	  the	  labels,	  making	  data	  interpretation	  more	  
difficult.221	  
The	  VAS	  has	  been	  used	  widely	  in	  the	  research	  of	  Irritable	  Bowel	  Syndrome	  for	  the	  assessment	  of	  
symptomatology,	  to	  determine	  drug	  efficacy	  in	  therapeutic	  trials	  and	  to	  serve	  as	  an	  instrument	  for	  









HOSPITAL	  ANXIETY	  AND	  DISEASE	  SCALE	  
This	  is	  a	  scale	  that	  was	  proposed	  by	  Zigmond	  and	  Snaith	  in	  1983	  to	  assess	  whether	  anxiety	  and	  
depression	  were	  contributing	  to	  the	  distress	  of	  patients	  who	  attended	  non-­‐psychiatric	  departments	  
in	  general	  hospitals.224	  It	  specifically	  targeted	  a	  group	  of	  patients	  that	  were	  physically	  ill,	  rather	  than	  
having	  suspected	  primary	  psychiatric	  disease.	  The	  Hospital	  Anxiety	  and	  Depression	  Scale	  (HADS)	  was	  
built	  around	  the	  concept	  of	  anhedonia,	  a	  sensitive	  marker	  of	  biological	  dysfunction	  secondary	  to	  
depression.	  The	  authors	  postulated	  that	  this	  state	  of	  “biogenic	  depression”	  would	  be	  drug-­‐
responsive.	  The	  HADS	  discarded	  the	  all-­‐inclusive	  definitions	  of	  depression	  that	  described	  a	  much	  
broader	  range	  of	  psychological	  upset.	  This	  was	  an	  important	  distinction	  since	  earlier	  self-­‐assessment	  
questionnaires	  concentrated	  on	  somatic	  symptomatology,	  and	  as	  a	  result	  they	  were	  less	  applicable	  
for	  the	  assessment	  of	  patients	  with	  physical	  illness.	   	  
The	  HADS	  was	  readily	  embraced	  owing	  to	  the	  fact	  the	  scale	  was	  easy	  to	  complete,	  it	  achieved	  a	  
consistency	  of	  results	  that	  stood	  comparison	  with	  data	  from	  other	  more	  ponderous	  and	  unwieldy	  
tests,	  and	  because	  it	  was	  amenable	  to	  being	  translated	  into	  many	  different	  languages.	  Furthermore,	  
it	  did	  not	  assess	  severe	  psychopathological	  symptoms,	  making	  it	  altogether	  more	  palatable	  for	  
medical	  rather	  than	  psychiatric	  patients.	  This	  meant	  that	  it	  was	  powered	  to	  identify	  the	  more	  subtle	  
presentations	  of	  psychiatric	  disorder.	  Biological	  symptoms	  of	  depression	  which	  could	  also	  be	  
explained	  by	  concomitant	  medical	  illness	  were	  omitted.	  These	  included	  symptoms	  such	  as	  
headache,	  weight	  loss,	  dizziness	  and	  fatigue.	  In	  practice,	  the	  HADS	  seemed	  much	  better	  equipped	  to	  
be	  the	  quick	  and	  efficient	  research	  tool	  that	  clinicians	  demanded.	  
The	  Hospital	  Anxiety	  and	  Depression	  Scale	  (HADS)	  has	  two	  sub-­‐scales,	  with	  seven	  questions	  each	  
being	  allocated	  to	  the	  analysis	  of	  anxiety	  and	  depression	  respectively.	  Each	  item	  is	  scored	  on	  a	  4	  
point	  scale	  from	  0	  to	  3,	  allowing	  for	  a	  maximum	  score	  of	  21	  in	  each	  category.	  Zigmond	  and	  Snaith	  
originally	  proposed	  two	  thresholds	  to	  discriminate	  cases	  from	  non-­‐cases.	  A	  score	  of	  8	  or	  more	  
defined	  the	  low	  threshold.	  A	  high	  threshold	  was	  denoted	  as	  being	  a	  score	  of	  11	  or	  more.	  This	  was	  







In	  the	  construction	  of	  the	  HADS,	  Zigmond	  and	  Snaith	  had	  been	  influenced	  by	  the	  Klein’s	  hypothesis	  
that	  anhedonia	  was	  a	  type	  of	  depressive	  disorder	  that	  reflected	  neurotransmitter	  disturbance,	  a	  
state	  likely	  to	  resolve	  spontaneously	  or	  be	  ameliorated	  by	  antidepressant	  therapy.	  Anhedonia	  is	  one	  
of	  the	  two	  criteria	  required	  for	  the	  definition	  of	  “major	  depressive	  disorder”.	  Its	  adoption	  as	  the	  
driving	  force	  for	  the	  depression	  sub-­‐scale	  was	  inspired.	  It	  serves	  as	  a	  non-­‐specific	  marker	  of	  
depression,	  allowing	  the	  scale	  to	  cast	  aside	  somatic	  symptoms.	   	  
The	  HADS	  is	  a	  competent	  and	  reliable	  instrument	  for	  isolating	  possible	  cases	  of	  psychiatric	  disorder.	  
In	  clinical	  practice,	  someone	  who	  scores	  highly	  on	  the	  HADS	  would	  then	  be	  subject	  to	  a	  
comprehensive	  psychiatric	  work-­‐up,	  in	  which	  a	  definitive	  diagnosis	  would	  be	  made	  and	  appropriate	  
treatment	  implemented.	   	  
EYSENCK	  PERSONALITY	  QUESTIONNAIRE	  
The	  Eysenck	  Personality	  Questionnaire	  is	  an	  evolution	  of	  previous	  work	  on	  psychometric	  and	  
experimental	  studies	  that	  expounded	  the	  dimensions	  of	  personality.	  It	  was	  first	  published	  by	  
Eysenck	  in	  1975,	  and	  later	  revised	  in	  1985.	  Its	  lineage	  dates	  back	  to	  the	  publication	  of	  the	  Maudsley	  
Medical	  Questionnaire,	  an	  instrument	  used	  to	  assess	  neuroticism	  or	  emotionality	  (N	  scale).	  The	  
dimensions	  of	  extraversion	  and	  introversion	  (E	  scale)	  were	  added	  to	  this	  questionnaire	  to	  produce	  
the	  Maudsley	  Personality	  Inventory.	  Later	  additions	  included	  the	  dimension	  of	  lie	  (L	  scale),	  published	  
in	  the	  Eysenck	  Personality	  Inventory.	  The	  final	  new	  variable,	  the	  dimension	  of	  psychoticism	  (P	  scale)	  
gave	  birth	  to	  the	  Eysenck	  Personality	  Questionnaire.	  
Eysenck’s	  work	  was	  born	  out	  of	  the	  concept	  that	  personality	  flowed	  from	  one’s	  genetic	  inheritance.	  
He	  described	  this	  as	  one’s	  temperament.	  Temperament	  is	  an	  immutable	  force-­‐	  the	  primary	  
component	  of	  personality-­‐	  and	  that	  learned	  behaviour	  was	  of	  secondary	  importance.	  The	  
Dimensions	  of	  Personality	  (Eysenck,	  1947)	  identified	  two	  major	  and	  contrasting	  dimensions	  of	  
personality,	  Extraversion-­‐Introversion	  and	  Neuroticism.	  This	  provided	  a	  two	  dimensional	  landscape	  
in	  which	  the	  previous	  hypothesis	  of	  temperament-­‐	  dating	  back	  to	  Hippocrates-­‐	  could	  be	  inserted.	  
This	  defined	  four	  temperaments	  or	  personality	  types.	  These	  included	  choleric	  type	  (high	  N	  and	  high	  
E),	  melancholic	  type	  (high	  N	  and	  low	  E),	  sanguine	  type	  (low	  N	  and	  high	  E),	  and	  phlegmatic	  type	  (low	  
N	  and	  low	  E).	  Extraversion	  was	  defined	  as	  the	  ability	  to	  enjoy	  positive	  events,	  whereas	  neuroticism	  
was	  the	  tendency	  to	  experience	  negative	  emotions.	  E	  and	  N	  combine	  to	  form	  the	  most	  robust	  






The	  Scientific	  Study	  of	  Personality	  (Eysenck,	  1952)	  suggested	  that	  psychoticism	  was	  the	  elusive	  third	  
dimension	  of	  personality	  and	  that	  it	  was	  independent	  of	  E	  and	  N.	  It	  was	  based	  on	  the	  concept	  that	  
psychopathology	  was	  a	  progression	  of	  clinical	  severity.	  In	  other	  words,	  psychopathology	  emanated	  
from	  exaggerations	  beyond	  the	  norm,	  rather	  than	  being	  a	  distinct	  entity.	  Therefore	  psychoticism	  
outlined	  traits	  of	  psychoticism	  that	  at	  their	  most	  extreme	  form	  would	  give	  rise	  to	  frank	  psychosis.	  
Within	  the	  normal	  ranges,	  they	  are	  nothing	  more	  than	  traits.	  The	  other	  construct	  that	  formed	  
Eysenck’s	  hypothesis	  was	  that	  psychosis	  and	  neuroticism	  were	  independent	  of	  each	  other.	  Heath	  
and	  Martin	  (1990)	  went	  onto	  to	  crystallise	  Eysenck’s	  definition	  of	  psychoticism,	  "It	  is	  conceptualized	  
as	  a	  continuum	  of	  liability	  to	  psychosis	  (principally	  schizophrenia	  and	  bipolar	  affective	  disorder)	  with	  
'psychopathy'	  (i.e.,	  anti-­‐social	  behaviour)	  defined	  as	  'a	  halfway	  stage	  towards	  psychosis'".	  
The	  Extrovert	  
This	  is	  a	  personality	  trait	  that	  describes	  someone	  who	  is	  sociable,	  outgoing	  and	  who	  has	  many	  
friends.	  He	  is	  generally	  impulsive,	  likes	  practical	  jokes	  and	  enjoys	  change.	  He	  finds	  studying	  and	  
reading	  difficult,	  and	  can	  be	  short-­‐tempered	  and	  aggressive.	  Extroverts	  are	  chronically	  under-­‐
aroused-­‐	  his	  personality	  is	  dependent	  on	  external	  stimulation	  for	  cortical	  arousal,	  as	  described	  in	  
Eysenck’s	  arousal	  theory	  of	  extraversion.	  Cortical	  arousal	  has	  an	  optimal	  level-­‐	  under	  or	  over-­‐arousal	  
lead	  to	  deficiencies	  of	  performance	  and	  productivity.	   	  
The	  Introvert	  
An	  introvert	  is	  chronically	  over-­‐aroused.	  This	  leads	  to	  the	  desire	  to	  seek	  out	  peaceful,	  tranquil	  
environments	  in	  compensation.	  An	  introvert	  is	  reserved	  and	  retiring,	  likes	  books,	  is	  serious	  about	  
day-­‐to-­‐day	  affairs	  and	  shies	  away	  from	  excitement.	  He	  is	  reliable,	  avoids	  displays	  of	  aggression,	  and	  
does	  not	  act	  on	  impulse.	  
The	  Neurotic	  (Emotionally	  Unstable)	  
This	  is	  an	  individual	  who	  worries	  all	  the	  time,	  is	  moody	  and	  anxious	  and	  prone	  to	  depression.	  He	  
reacts	  too	  quickly	  to	  emotional	  issues	  and	  at	  a	  level	  out	  of	  proportion	  to	  the	  stimulus.	  Furthermore	  
it	  takes	  much	  longer	  for	  him	  to	  return	  to	  a	  normal	  range	  of	  functioning	  following	  emotional	  upset.	  









The	  Emotionally	  Stable	  
These	  individuals	  remain	  composed	  and	  in	  control,	  displaying	  good	  emotional	  mastery.	  Emotional	  
response	  in	  extreme	  situations	  is	  slow,	  progressive	  and	  quick	  to	  return	  to	  baseline.	  In	  short,	  these	  
people	  remain	  undaunted	  by	  pressure	  situations.	  
The	  Psychotic	  (Tough-­‐Mindedness)	  
A	  lonesome	  figure	  removed	  from	  any	  care	  or	  sympathy	  for	  his	  fellow	  man,	  and	  displaying	  a	  
readiness	  for	  hostility	  and	  aggression.	  He	  is	  devoid	  of	  feelings	  and	  emotional	  sensitivity,	  and	  finds	  
the	  concept	  of	  socialising	  difficult	  and	  awkward.	  He	  likes	  to	  make	  fun	  of	  and	  denigrate	  those	  around	  
him	  whether	  they	  are	  strangers,	  loved	  ones	  or	  family,	  and	  there	  is	  an	  undercurrent	  of	  cruelty	  and	  
inhumanity	  to	  his	  social	  interaction.	  This	  is	  compounded	  by	  an	  unhealthy	  taste	  for	  danger,	  
impulsiveness,	  non-­‐conformity	  and	  a	  penchant	  for	  the	  eccentric.	  The	  polar	  opposite	  to	  psychoticism	  
is	  socialisation	  (low	  P	  scores).	  
With	  the	  incorporation	  of	  the	  psychoticism	  scale	  into	  the	  Eysenck	  Personality	  Inventory,	  Eysenck	  was	  
keen	  to	  allay	  fears	  that	  those	  scoring	  highly	  on	  the	  P	  scale	  had	  pathological	  phenotypes-­‐	  the	  EPQR	  
was	  a	  measure	  of	  psychological	  variables	  based	  around	  a	  normal	  non-­‐pathological	  population,	  and	  
should	  therefore	  only	  be	  used	  in	  said	  populations.	   	  
The	  Lie	  Scale	  
This	  is	  a	  measure	  of	  dissimulation.	  It	  describes	  a	  tendency	  to	  pretend	  that	  things	  are	  better	  than	  
they	  actually	  are.	  Eysenck	  and	  Michaelis	  demonstrated	  that	  the	  L	  scale	  can	  be	  manipulated	  by	  
situations	  in	  which	  there	  are	  greater	  (or	  lesser)	  motivations	  to	  dissimulate.	  They	  showed	  that	  if	  you	  
place	  individuals	  in	  low	  dissimulation	  environments	  lower	  L	  scores	  would	  be	  recorded.	  Conceptually	  
this	  would	  advocate	  that	  if	  there	  are	  lower	  L	  scores,	  then	  the	  test	  should	  become	  more	  unreliable	  
and	  inconsistent,	  since	  there	  should	  be	  a	  greater	  variability	  in	  those	  factors	  that	  the	  test	  does	  not	  
examine.	  Empirical	  data	  does	  not	  support	  this-­‐	  there	  is	  no	  lowering	  of	  the	  reliability	  of	  the	  test	  in	  an	  
environment	  of	  low	  motivation	  for	  dissimulation.	  This	  would	  suggest	  that	  in	  addition	  to	  
dissimulation,	  the	  L	  scale	  also	  unearths	  a	  stable	  personality	  factor	  which	  Eysenck	  proposed	  as	  some	  
degree	  of	  social	  naivety	  or	  conformity.	  Another	  characteristic	  of	  the	  L	  scale	  is	  that	  scores	  increase	  
with	  age.	  X	  speculated	  that	  this	  was	  part	  of	  a	  social	  desirability	  model-­‐	  as	  people	  get	  old	  and	  infirm,	  








Combined	  analysis	  of	  the	  three	  personality	  scales	  across	  two	  groups	  of	  individuals,	  criminals	  and	  
non-­‐criminals,	  highlighted	  a	  number	  of	  questions	  that	  proved	  to	  be	  highly	  discriminatory.	  These	  
questions	  were	  incorporated	  into	  an	  offshoot	  scale,	  the	  Criminality	  scale,	  that	  served	  to	  distinguish	  
those	  with	  criminal,	  recidivist	  tendencies	  from	  those	  who	  did	  not.	  
Addiction	  Scale	  
Analysis	  of	  a	  cohort	  of	  drug	  addicts	  compared	  to	  controls	  allowed	  Eysenck	  to	  determine	  which	  of	  the	  
questions	  in	  the	  EPQ	  were	  powered	  to	  differentiate	  these	  two	  groups.	  Thirty-­‐two	  questions	  were	  
selected,	  each	  with	  a	  statistical	  significance	  of	  p	  <	  0.001	  (in	  the	  male	  population)	  to	  enable	  this	  
differentiation.	  Test-­‐retest	  reliability	  analysis	  in	  subsequent	  studies	  proved	  that	  the	  Addiction	  scale	  
was	  robust	  and	  reproducible.	  
Clinical	  Application	  of	  the	  EPQ-­‐R	  
The	  EPQ-­‐R	  must	  not	  be	  used	  as	  a	  blunt	  instrument	  to	  identify	  and	  diagnose	  psychiatric	  comorbidity.	  
Its	  purpose	  is	  to	  examine	  an	  individual	  for	  subtle	  psychological	  traits	  that	  may	  give	  some	  insight	  into	  
the	  why	  an	  individual	  is	  behaving	  in	  a	  certain	  way,	  and	  why	  he	  or	  she	  is	  finding	  the	  challenges	  of	  life	  
so	  formidable.	   	  
Eysenck	  and	  IBS	  
PubMed	  searching	  using	  the	  parameters	  “Eysenck”	  and	  “Irritable	  Bowel	  Syndrome”	  yielded	  8	  results.	  
Toner	  et	  al.	  found	  greater	  L	  scale	  scores	  in	  IBS	  patients	  compared	  to	  controls.225	  They	  proposed	  a	  
conceptual	  model	  asserting	  that	  some	  IBS	  patients	  have	  a	  self-­‐schema,	  an	  ingrained	  knowledge	  of	  
self,	  built	  around	  social	  desirability.	  Dinan	  et	  al.	  confirmed	  that	  IBS	  patients	  had	  greater	  scores	  for	  
neuroticism	  and	  introversion	  compared	  to	  patients	  with	  peptic	  ulcer	  disease.226	  Increased	  
neuroticism	  in	  female	  IBS	  patients	  but	  not	  male	  IBS	  patients	  was	  noted	  by	  Fock	  et	  al.227	  who	  
compared	  IBS	  with	  inflammatory	  bowel	  disease	  controls.	  Fock	  also	  showed	  that	  there	  were	  lower	  L	  
scores	  in	  the	  IBS	  group	  compared	  to	  the	  IBD	  controls.	  In	  contrast,	  Talley	  found	  that	  IBS	  was	  
significantly	  associated	  with	  somatisation	  (using	  the	  Psychosomatic	  Symptom	  Checklist)	  and	  lifetime	  
depression	  but	  not	  neuroticism.228	  Two	  years	  later	  he	  concluded	  that	  neuroticism	  and	  psychological	  
co-­‐morbidity	  were	  not	  significant	  predictors	  in	  health-­‐seeking	  behaviour	  in	  community	  subjects	  with	  
IBS.229	  Talley	  once	  more	  employed	  the	  EPQ	  to	  investigate	  the	  relationship	  between	  abuse	  and	  IBS.	  






that	  abuse	  in	  childhood	  but	  not	  adulthood	  was	  associated	  with	  IBS	  using	  univariate	  analysis.	  Given	  
that	  neuroticism	  and	  psychological	  morbidity	  were	  also	  univariately	  associated	  with	  abuse	  in	  
childhood	  and	  abuse	  in	  adulthood	  and	  IBS,	  they	  hypothesised	  that	  abuse	  may	  induce	  the	  expression	  
of	  neuroticism	  that	  precipitates	  the	  later	  development	  of	  IBS.75	  
WHITELEY	  INDEX	  
The	  Whiteley	  Index	  was	  developed	  by	  Pilowsky	  in	  1967	  and	  is	  considered	  to	  be	  the	  definitive	  
instrument	  for	  assessing	  hypochondriacal	  beliefs	  and	  anxieties.230	  Pilowsky	  asked	  100	  medical,	  
nursing	  and	  ancillary	  staff	  of	  the	  United	  Sheffield	  Hospitals	  to	  give	  their	  own	  definitions	  of	  
hypochondriasis.	  These	  definitions	  were	  pooled	  together,	  and	  a	  questionnaire	  was	  born	  from	  the	  
various	  observations.	  
In	  the	  40	  years	  since	  its	  publication,	  the	  Whiteley	  Index,	  as	  it	  became	  known,	  is	  still	  one	  of	  the	  most	  
widely	  used	  scales	  for	  assessing	  hypochondriasis.	   	  
PATIENT	  HEALTH	  QUESTIONNAIRE	  15	  
The	  Patient	  Health	  Questionnaire-­‐15	  is	  a	  15	  point	  questionnaire	  developed	  from	  the	  Patient	  Health	  
Questionnaire	  (PHQ).	  The	  Patient	  Health	  Questionnaire231	  was	  conceived	  as	  a	  self-­‐administered	  
version	  of	  the	  PRIME-­‐MD	  diagnostic	  instrument	  for	  common	  mental	  disorders.232	   	  
The	  PRIME-­‐MD	  screened	  for	  the	  five	  most	  common	  psychiatric	  disorders	  in	  primary	  practice,	  namely	  
depressive,	  anxiety,	  alcohol,	  somatoform	  and	  eating	  disorders.	  It	  has	  been	  widely	  used,	  and	  its	  
refinement	  into	  easy	  to	  complete,	  self-­‐administered	  versions,	  namely	  the	  PHQ	  (and	  the	  abbreviated	  
PHQ	  subsets)	  makes	  it	  even	  more	  attractive.	  
The	  PHQ	  was	  published	  by	  Spitzer	  et	  al.	  in	  1999.231	  Spitzer	  had	  concluded	  that	  even	  though	  the	  
PRIME-­‐MD	  only	  took	  8.4	  minutes	  to	  administer,	  it	  was	  still	  considered	  to	  be	  too	  time-­‐consuming	  for	  
primary	  practice.	  The	  PHQ	  took	  the	  2	  central	  components	  of	  the	  PRIME-­‐MD,	  the	  patient	  
questionnaire	  and	  the	  clinical	  evaluation,	  and	  concentrated	  the	  process	  into	  a	  3	  page	  form.	  It	  
assesses	  eight	  diagnoses,	  divided	  into	  threshold	  disorders	  (which	  correspond	  to	  specific	  DSM-­‐IV	  
diagnoses:	  major	  depressive	  disorder,	  panic	  disorder	  and	  bulimia	  nervosa)	  and	  subthreshold	  
disorders	  (disorders	  whose	  criteria	  encompass	  fewer	  symptoms	  than	  are	  required	  for	  any	  specific	  






disorders,	  probable	  alcohol	  abuse	  or	  dependence,	  binge	  eating	  disorder	  and	  probable	  somatoform	  
disorder).	  
The	  PHQ-­‐15	  was	  a	  further	  exercise	  in	  reductionism.233	  It	  grouped	  together	  the	  15	  questions	  in	  the	  
PHQ	  that	  examined	  for	  somatisation	  beliefs.	  It	  is	  therefore	  an	  instrument	  that	  focuses	  entirely	  on	  
this	  particular	  disorder.	  It	  is	  limited	  by	  the	  fact	  that	  it	  cannot	  distinguish	  between	  medically	  
explained	  and	  unexplained	  somatic	  symptoms,	  and	  therefore	  must	  be	  used	  as	  a	  measure	  of	  somatic	  
symptom	  severity	  rather	  than	  an	  instrument	  to	  diagnose	  somatoform	  disorders.	  In	  practical	  terms,	  
anyone	  scoring	  highly	  on	  the	  PHQ-­‐15	  should	  be	  assessed	  to	  see	  if	  there	  is	  any	  medical	  pathology	  to	  
explain	  the	  symptoms.	   	  
VISCERAL	  SENSITIVITY	  INDEX	  
The	  Visceral	  Sensitivity	  Index	  (VSI)	  is	  an	  instrument	  that	  was	  designed	  to	  assess	  GI	  symptom-­‐specific	  
anxiety	  (GSA).	  GSA	  is	  though	  thought	  to	  play	  a	  role	  in	  IBS	  symptom	  generation	  and	  propagation,	  and	  
may	  be	  considered	  to	  be	  an	  endogenous	  stressor.234	  Stressors	  that	  affect	  gut	  physiology	  and	  the	  
brain-­‐gut	  axis	  are	  mediated	  by	  the	  emotional	  centres	  which	  mediate	  outputs	  via	  neuroendocrine,	  
autonomic,	  pain	  and	  attentional	  pathways.	  Mayer	  proposed	  a	  stress	  model	  that	  looked	  at	  the	  role	  of	  
stress	  in	  IBS.	  Stressors	  have	  different	  functions	  and	  may	  occur	  at	  different	  time	  points	  in	  the	  cycle	  of	  
symptom	  generation.	  Some	  may	  cause	  permanent	  enhancement	  of	  the	  stress	  response	  
(pathological	  stress),	  some	  precipitate	  transient	  increases	  in	  symptom	  severity,	  and	  some	  cause	  
perpetuation	  of	  symptoms	  (symptom-­‐generated	  stress).	  Figure	  1.3.1	  explains	  this	  relationship.	  
Figure	  1.3.1	  Role	  of	  Stress	  in	  the	  development	  and	  modulation	  of	  IBS	  
	  






In	  trying	  to	  define	  GSA,	  Mayer	  et	  al.	  referred	  to	  earlier	  work	  by	  Spielberger	  and	  Reiss	  in	  terms	  of	  the	  
conceptualisation	  of	  anxiety	  sensitivity	  and	  state	  trait	  anxiety,	  in	  addition	  to	  their	  own	  work	  on	  
biobehavioural	  modelling	  in	  IBS.235-­‐237	   	  
They	  concluded	  that	  GSA	  had	  five	  dimensions:	   	  
1. Worry:	  obsessive,	  negative,	  catastrophic	  thoughts,	  either	  learned	  or	  innate,	  reflecting	  a	  
negative,	  future-­‐oriented	  perspective	  on	  GI	  symptoms	  and	  their	  impact.	  
2. Fear:	  learned	  responses	  to	  previously	  innocuous	  physical	  sensation(s)	  that	  have	  been	  paired	  
with	  a	  painful	  or	  aversive	  stimulus;	  often	  unassociated	  with	  feelings	  of	  anxiety.	  
3. Vigilance:	  an	  increased	  awareness	  of,	  attention	  to,	  and	  increased	  perceived	  relevance	  of	  GI-­‐
specific	  sensations	  resulting	  in	  a	  decreased	  ability	  to	  attend	  to	  other	  internal	  or	  external	  
stimuli.	  
4. Sensitivity:	  heightened	  perception	  of	  GI-­‐specific	  sensations	  and	  symptoms	  under	  a	  variety	  of	  
conditions	  including	  eating	  and	  stress.	  
5. Avoidance:	  increased	  safety	  behaviours,	  rituals,	  and	  seeking	  reassurance	  to	  GI-­‐specific	  
sensations.	  
The	  VSI	  has	  yet	  to	  make	  a	  significant	  impact	  in	  the	  field	  of	  IBS,	  largely	  due	  to	  the	  fact	  that	  it	  is	  such	  a	  
new	  instrument.	  However,	  revalidation	  of	  the	  VSI	  was	  performed	  by	  Labus	  et	  al.	  confirming	  that	  the	  
VSI	  demonstrated	  concurrent,	  divergent	  and	  discriminant	  validity,	  and	  appeared	  to	  explain	  the	  
relationship	  between	  general	  psychological	  distress	  measures	  and	  gastrointestinal	  symptom	  
severity.	  Furthermore,	  the	  VSI	  was	  related	  solely	  to	  gastrointestinal	  (and	  not	  non-­‐gastrointestinal)	  
symptom	  severity.	  
SPIELBERGER	  STATE	  TRAIT	  ANXIETY	  INDEX	  
Cattell	  and	  Scheier	  proposed	  the	  concept	  of	  state	  anxiety	  and	  trait	  anxiety	  in	  1961.238	  However	  this	  
distinction	  could	  not	  be	  made	  without	  reference	  to	  Freud’s	  exposition	  of	  neurotic	  (trait)	  anxiety	  and	  
objective	  anxiety.239	  The	  mantle	  of	  state	  anxiety	  and	  trait	  anxiety	  theory	  was	  readily	  taken	  up	  by	  
Spielberger	  et	  al.	  in	  the	  1970s	  with	  the	  publication	  of	  the	  State	  Trait	  Anxiety	  Inventory	  (STAI).240	  This	  
self-­‐report	  questionnaire	  underwent	  various	  revisions	  (to	  improve	  its	  discrimination	  between	  
anxiety	  and	  depression,	  to	  improve	  the	  psychometric	  potency	  of	  the	  weaker	  questions	  and	  to	  
improve	  the	  factor	  structure	  of	  the	  trait	  anxiety),	  culminating	  in	  the	  definitive	  questionnaire	  in	  






State	  anxiety	  is	  a	  temporary	  up-­‐regulation	  of	  the	  autonomic	  nervous	  system	  caused	  by	  the	  
perception	  of	  impending	  threat.	  State	  anxiety	  is	  context-­‐specific	  i.e.	  situational,	  and	  the	  degree	  of	  
anxiety	  generated	  is	  proportional	  to	  magnitude	  of	  the	  perceived	  threat.	  In	  contrast,	  trait	  anxiety	  is	  a	  
measure	  of	  an	  individual’s	  “anxiety	  proneness”,	  a	  much	  more	  stable	  entity	  akin	  to	  a	  characteristic.	  
Spielberger	  defined	  the	  two	  entities	  as	  follows-­‐	  “State	  and	  trait	  anxiety	  are	  analogous	  in	  certain	  
respects	  to	  kinetic	  and	  potential	  energy.	  State	  anxiety,	  like	  kinetic	  energy,	  refers	  to	  a	  palpable	  
reaction	  or	  process	  taking	  place	  at	  a	  given	  time	  and	  level	  of	  intensity.	  Trait	  anxiety,	  like	  potential	  
energy,	  refers	  to	  individual	  differences	  in	  reactions.	  Potential	  energy	  refers	  to	  differences	  in	  the	  
amount	  of	  kinetic	  energy	  associated	  with	  a	  particular	  physical	  object,	  which	  may	  be	  released	  if	  
triggered	  by	  an	  appropriate	  force.	  Trait	  anxiety	  implies	  differences	  between	  people	  in	  the	  
disposition	  to	  respond	  to	  stressful	  situations	  with	  varying	  amounts	  of	  state	  anxiety.	  But	  whether	  or	  
not	  people	  who	  differ	  in	  trait	  anxiety	  will	  show	  corresponding	  differences	  in	  state	  anxiety	  depends	  
on	  the	  extent	  to	  which	  each	  of	  them	  perceives	  a	  specific	  situation	  as	  psychologically	  dangerous	  or	  
threatening,	  and	  this	  is	  greatly	  influenced	  by	  each	  individual’s	  past	  experience.”	  
The	  STAI	  is	  composed	  of	  two	  separate	  20	  item	  scales	  assessing	  state	  and	  trait	  anxiety	  independently.	  
Each	  item	  is	  answered	  according	  to	  a	  4	  point	  Likert	  scale.	  The	  state	  scale	  questions	  the	  subject	  about	  
how	  they	  are	  feeling	  at	  that	  moment	  whereas	  the	  trait	  scale	  inquires	  about	  how	  they	  generally	  feel.	   	  
The	  STAI	  has	  been	  adopted	  by	  thousands	  of	  research	  studies	  and	  has	  acquired	  substantial	  evidence	  
for	  reliability	  and	  validity.242	  It	  is	  now	  considered	  to	  be	  the	  reference	  standard	  for	  assessing	  state	  
and	  trait	  anxiety.	  Other	  scales	  exist	  but	  they	  have	  not	  achieved	  the	  same	  level	  of	  prominence.	  
QUALITY	  OF	  LIFE	  SCORES	  
IRRITABLE	  BOWEL	  SYNDROME	  IMPACT	  SCALE	  
The	  Irritable	  Bowel	  Syndrome	  Impact	  Scale	  (IBS-­‐IS)	  was	  published	  in	  2005	  by	  Longstreth	  et	  al.243	  Its	  
creation	  was	  fuelled	  by	  a	  desire	  to	  have	  a	  psychometric	  instrument	  that	  could	  assess	  the	  negative	  
impact	  that	  IBS	  symptoms	  have	  on	  patients.	  Previous	  IBS-­‐specific	  quality	  of	  life	  questionnaires	  were	  
not	  powered	  to	  do	  this	  in	  a	  concise,	  self-­‐administered	  format.244-­‐247	   	  
Development	  of	  the	  IBS-­‐IS	  incorporated	  a	  7	  point	  Likert	  scale	  with	  questions	  exploring	  themes	  of	  
anxiety,	  psychological	  distress,	  sleep	  disturbance,	  fatigue,	  interference	  with	  activities	  of	  daily	  living	  






there	  is	  traditionally	  a	  high	  non-­‐completion	  rate	  for	  this	  line	  of	  questioning.248	  Other	  questions	  
involving	  financial	  distress	  and	  IBS	  symptoms	  were	  discarded.	  The	  value	  of	  a	  7	  point	  Likert	  scale	  
(rather	  than	  a	  5	  point	  scale)has	  been	  found	  to	  be	  optimal	  in	  assessing	  responsiveness.249	   	  
The	  pilot	  questions	  devised	  from	  literature	  searches,	  clinical	  observation	  and	  expert	  opinion	  were	  
completed	  by	  155	  IBS	  patients.	  The	  subsequent	  data	  interpretation	  removed	  questions	  that	  had	  a	  
high	  ceiling	  affect,	  questions	  that	  appeared	  to	  be	  assessing	  other	  psychological	  factors,	  and	  those	  
questions	  that	  had	  a	  high	  correlation	  with	  other	  questions	  (to	  reduce	  replication).	  Factor	  analysis	  
further	  distilled	  the	  number	  of	  questions	  into	  its	  final	  form,	  an	  easy	  to	  complete,	  user-­‐friendly	  26	  
item	  questionnaire.	  
Figure	  1.3.2	  Irritable	  Bowel	  Syndrome	  Impact	  Scale	  243	  
	  
	  







CORTICAL	  EVOKED	  POTENTIALS	  
In	  the	  non-­‐cardiac	  chest	  pain	  model,	  CEPs	  differentiated	  a	  seemingly	  homogenous	  patient	  
population	  into	  distinct	  phenotypic	  sub-­‐groups	  according	  to	  subjective	  reporting	  and	  CEP	  waveform	  
analysis.209	  The	  use	  of	  CEPs	  as	  an	  objective	  assessment	  of	  a	  patient’s	  baseline	  visceral	  afferent	  
sensitivity	  can	  be	  harnessed	  to	  interrogate	  sensory	  afferent	  dysfunction	  in	  FGIDs,	  particularly	  in	  IBS.	  
Using	  this	  test,	  patients	  can	  be	  distinguished	  by	  certain	  neurophysiological	  parameters	  according	  to	  
analysis	  of	  the	  individual	  components	  of	  the	  cortical	  response.	  This	  raises	  the	  possibility	  that	  CEPs	  
could	  facilitate	  sub-­‐group	  differentiation	  of	  IBS,	  traditionally	  seen	  as	  a	  homogeneous	  entity.	   	  
Anatomy	  
There	  is	  a	  marked	  contrast	  in	  the	  innervation	  of	  the	  gastrointestinal	  tract	  depending	  on	  whether	  the	  
organ	  has	  developed	  embryologically	  from	  the	  foregut	  or	  the	  hindgut.	  Proximal	  structures	  such	  as	  
the	  oesophagus	  or	  the	  duodenum	  have	  dual	  innervation.	  This	  comes	  from	  both	  vagal	  and	  spinal	  
nerve	  fibres.	  Structures	  that	  are	  located	  more	  distally,	  for	  example	  the	  sigmoid	  colon,	  are	  innervated	  
by	  sacral	  spinal	  afferents.	  The	  types	  of	  nerve	  fibres	  seen	  in	  the	  visceral	  system	  are	  unmyelinated	  and	  
without	  specialized	  receptor	  endings.	  Traditionally	  these	  fibres	  have	  been	  sub-­‐grouped	  according	  to	  
their	  degree	  of	  mechanosensitivity.	   	  
Visceral	  innervation	  
Painful	  stimulation	  of	  the	  viscera	  results	  in	  activation	  of	  both	  spinal	  and	  vagal	  afferents.	  Whilst	  vagal	  
afferent	  activity	  saturates	  at	  innocuous	  stimulation	  intensities,	  spinal	  afferents	  encode	  both	  
innocuous	  and	  noxious	  peripheral	  activity.	  The	  characteristics	  of	  the	  CEP	  suggest	  that	  the	  cortical	  
response	  is	  primarily	  mediated	  via	  spinal	  afferents,	  with	  limited	  contribution	  from	  vagal	  afferents.	  
Current	  thinking	  suggests	  that	  vagal	  afferents	  have	  a	  modulatory	  effect	  on	  pain	  transmission	  and	  
this	  is	  supported	  by	  the	  fact	  that	  vagal	  afferents	  project	  to	  all	  of	  the	  brain-­‐stem	  and	  higher	  cortical	  
regions	  that	  spinal	  afferents	  project	  to.	  The	  complexity	  of	  this	  highly	  integrated	  system	  highlights	  the	  
limitations	  of	  studying	  peripheral	  nerves	  in	  isolation.	  Visceral	  pain	  should	  be	  considered	  to	  be	  one	  
part	  of	  a	  complex	  neurobehavioral	  system.	  Cortical	  Evoked	  Potentials	  provide	  an	  opportunity	  to	  








Cortical	  evoked	  potentials	  (CEPs)	  have	  been	  used	  extensively	  since	  the	  1970s	  for	  clinical	  diagnostic	  
evaluation	  and	  represent	  the	  sequence	  of	  voltage	  changes	  generated	  in	  the	  brain	  in	  response	  to	  an	  
experimental	  stimulus.	  A	  stimulus	  can	  use	  any	  of	  the	  sensory	  modalities.	  For	  example,	  light	  may	  be	  
used	  to	  stimulate	  visual	  evoked	  potentials	  recorded	  in	  the	  occipital	  cortex.	  CEPs	  have	  been	  studied	  
in	  a	  gastroenterological	  context	  since	  1987	  when	  Meunier	  elicited	  evoked	  potentials	  from	  3	  healthy	  
volunteers	  in	  a	  proof	  of	  concept	  study.250	  Research	  from	  the	  same	  group	  the	  following	  year	  
published	  endorectal	  evoked	  potentials	  stimulated	  by	  mechanical	  balloon	  dilatation	  (Figure	  1.3.3).251	  
They	  demonstrated	  that	  the	  absence	  of	  the	  stimulus	  using	  sham	  testing	  did	  not	  elicit	  a	  reproducible	  
cortical	  response.	  
Figure	  1.3.3	  Endo-­‐rectal	  evoked	  response	  
	  
Endo-­‐rectal	  evoked	  response	  from	  a	  single	  subject	  after	  402	  distensions	  of	  the	  rectal	  wall	  compared	  to	  sham	  testing	  in	  the	  
same	  patient.	  Adapted	  from	  Collet,	  L	  et	  al,	  Am	  J	  Physiol	  254:4.	  
Further	  research	  by	  Frieling	  in	  1989252	  and	  Loening-­‐Baucke	  in	  1991253	  using	  electrical	  stimulation	  of	  
the	  rectum	  defined	  and	  categorised	  the	  morphology	  of	  the	  evoked	  potentials,	  and	  assessed	  
reproducibility	  of	  the	  traces.	   	  
CEP	  Morphology	  
The	  cortical	  evoked	  potential	  can	  be	  analysed	  with	  regards	  to	  the	  morphology,	  latency	  and	  
amplitude	  of	  the	  cortical	  responses	  that	  are	  precipitated	  by	  the	  peripheral	  stimulus.	  The	  cortical	  
responses	  take	  the	  form	  of	  electrical	  deflections	  from	  the	  baseline	  level	  of	  (cortical)	  activity.	  A	  series	  







A	  peak	  is	  the	  maximum	  point	  of	  deflection	  on	  the	  CEP	  trace	  (i.e.	  the	  highest	  or	  lowest	  point	  on	  the	  
corresponding	  curve).	  In	  the	  context	  of	  electrical	  rectal	  stimulation,	  5	  discernible	  peaks	  can	  be	  
isolated,	  and	  are	  termed	  as	  such	  (Peaks	  1	  to	  5,	  abbreviated	  to	  P1	  to	  P5).	  With	  increasing	  distance	  
from	  the	  stimulus	  the	  waveforms	  become	  less	  prominent,	  such	  that	  the	  final	  peak	  (Peak	  5)	  can	  be	  
barely	  distinguishable.	  
Earlier	  studies	  have	  named	  the	  various	  CEP	  peaks	  in	  terms	  of	  positive	  or	  negative	  deflections	  e.g.	  P1,	  
N1,	  P2.	  This	  study	  has	  changed	  the	  nomenclature	  to	  make	  it	  more	  accessible.	  As	  a	  result	  “P”	  stands	  
for	  peak	  rather	  than	  positive.	  
The	  first	  part	  of	  the	  cortical	  response	  (Peaks	  1	  to	  3)	  is	  defined	  as	  the	  early	  component	  of	  cortical	  
activity;	  Peaks	  4	  and	  5	  constitute	  the	  late	  response.	  The	  early	  component,	  and	  in	  particular	  Peak	  1	  
represents	  the	  integrity	  of	  the	  neural	  circuit	  that	  sends	  sensory	  information	  from	  the	  periphery	  to	  
the	  brain.	  This	  involves	  activation	  of	  visceral	  sensory	  afferents,	  the	  firing	  of	  paraspinal	  sensory	  nerve	  
pathways	  and	  the	  subsequent	  arousal	  of	  the	  supraspinal	  centres.	  It	  is	  at	  this	  point	  that	  the	  CEP	  
traces	  start	  to	  appear	  on	  the	  monitor.	  
Figure	  1.3.4	  shows	  a	  typical	  evoked	  potential	  following	  rectal	  electrical	  stimulation.	  The	  peaks	  are	  
clearly	  seen.	  It	  is	  therefore	  a	  relatively	  easy	  process	  to	  measure	  the	  latency	  of	  each	  peak-­‐	  this	  is	  the	  
time	  in	  milliseconds	  between	  the	  stimulus	  (@	  0	  seconds)	  and	  the	  peak.	  The	  amplitude	  of	  each	  peak-­‐	  
the	  height	  of	  each	  peak	  from	  baseline-­‐	  is	  calculated	  in	  microvolts.	  
Another	  point	  to	  make	  is	  that	  an	  averaged	  CEP	  trace	  is	  produced	  for	  each	  cycle	  of	  50	  stimulations.	  If	  
you	  were	  to	  analyse	  one	  CEP	  trace	  in	  isolation,	  there	  would	  be	  so	  much	  artefact	  and	  noise	  that	  the	  
results	  would	  be	  unintelligible.	  






Figure	  1.3.4.	  A	  Cortical	  Evoked	  Potential	  recorded	  after	  electrical	  rectal	  stimulation	  in	  
control	  subject	  
	  
Research	  context	  of	  Cortical	  Evoked	  Potentials	  
CEPs	  can	  be	  used	  to	  target	  visceral	  sensory	  afferent	  pathways	  with	  sufficient	  temporal	  resolution	  to	  
discriminate	  between	  primary	  and	  secondary	  processing	  of	  visceral	  afferent	  information.	  In	  other	  
words,	  when	  a	  rectal	  electrical	  stimulus	  is	  administered,	  CEPs	  can	  record	  the	  primary	  cortical	  
response	  to	  the	  stimulus	  followed	  by	  a	  delayed	  secondary	  cortical	  response.	  This	  distinction	  is	  
important	  because	  it	  can	  distinguish	  a	  state	  consistent	  with	  primary	  visceral	  hypersensitivity	  (as	  
defined	  by	  decreased	  latency	  for	  a	  given	  stimulus)	  from	  competing,	  delayed	  central	  contributions	  
influenced	  by	  factors	  such	  as	  psychological	  state	  and	  anxiety.	  Such	  an	  approach	  will	  indicate	  
whether	  IBS	  is	  predominantly	  driven	  by	  primary	  visceral	  hypersensitivity	  as	  previous	  studies	  have	  
suggested	  or	  alternatively	  by	  psychological	  hypersensitivity.	  






Figure	  1.3.5.	  Rectal	  evoked	  potentials	  using	  varying	  stimulus	  intensities	   	  
	  
Adapted	  from	  Harris	  et	  al.	  2006,	  AJP210	  
Figure	  1.3.5	  shows	  rectal	  CEPs	  recorded	  from	  a	  female	  control	  subject	  over	  varying	  stimulus	  
intensities,	  graded	  at	  25%	  intervals	  between	  the	  sensory	  and	  pain	  thresholds.	  With	  increasing	  
stimulus,	  the	  individual	  peaks	  become	  more	  prominent,	  and	  the	  peak	  latencies	  reduce.	  The	  early	  
CEP	  complex	  is	  seen	  in	  the	  shaded	  area,	  and	  represents	  the	  first	  250ms	  of	  cortical	  activity.	  The	  late	  
CEP	  response	  represents	  endogenous	  brain	  activity.	  This	  late	  CEP	  complex	  is	  similar	  to	  the	  P300	  
complexes	  seen	  in	  other	  studies	  such	  as	  the	  Hollerbach	  et	  al.	  (Figure	  1.3.6).	  






Figure	  1.3.6.	  Oesophageal	  evoked	  potentials	  during	  anticipatory	  stimulation	  
	  
Adapted	  from	  Hollerbach	  et	  al,	  Neurogastroenterology	  and	  Motility	  1999.254	  
Figure	  1.3.6	  shows	  oesophageal	  CEPs	  elicited	  during	  electrical	  stimulation	  of	  a	  healthy	  control.	  On	  
the	  left	  hand	  side,	  electrical	  stimulation	  produces	  well-­‐defined,	  reproducible	  morphology	  of	  the	  
early	  CEP	  complex	  (named	  using	  the	  traditional	  terminology,	  the	  P1,	  N1	  and	  P2	  peaks).	  On	  the	  right	  
hand	  side,	  the	  same	  subject	  elicits	  a	  cortical	  response	  in	  anticipation	  of	  an	  electrical	  stimulus	  i.e.	  a	  
sham	  stimulus.	  What	  is	  interesting	  is	  that	  the	  early	  CEP	  complex	  is	  lost,	  but	  the	  late	  complex	  
becomes	  far	  more	  robust.	  This	  indicates	  large	  scale	  non-­‐specific	  cortical	  activity,	  as	  the	  higher	  
cortical	  structures	  prepare	  for	  the	  arrival	  of	  the	  peripheral	  afferent	  stream.	  
In	  summary,	  the	  combination	  of	  CEPs	  with	  subjective	  patient	  reports	  of	  discomfort,	  and	  quantitative	  
assessment	  of	  visceral	  sensation	  (as	  defined	  by	  sensory	  and	  peak	  thresholds	  to	  electrical	  stimulus)	  







CHAPTER	  ONE,	  SECTION	  4:	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
HYPOTHESIS	  &	  AIMS	  
HYPOTHESIS	  
Irritable	  Bowel	  Syndrome	  is	  a	  heterogeneous	  population	  of	  patients	  who	  may	  be	  differentiated	  into	  
discrete	  sub-­‐populations	  based	  on	  neurophysiological,	  psychological	  and	  immunological	  evaluation.	  
Defining	  these	  groups	  allows	  the	  opportunity	  to	  target	  therapy	  depending	  on	  the	  underlying	  
pathogenesis.	  
AIMS	  
To	  compare	  IBS	  patients	  with	  a	  control	  population	  using	  the	  following	  four	  modalities.	  
1.	  Psychological	  Questionnaires	  
• To	  compare	  psychological	  profiles	  of	  IBS	  patients	  with	  controls.	  Previous	  research	  has	  
demonstrated	  numerous	  psychological	  traits	  that	  are	  more	  common	  in	  IBS,	  for	  instance	  
depression.	  This	  study	  is	  powered	  by	  comprehensive	  psychological	  questionnaires	  that	  can	  
discern	  dimensions	  of	  personality	  (e.g.	  neuroticism,	  introversion,	  the	  capacity	  for	  lying	  or	  
criminality),	  and	  assess	  scores	  for	  depression,	  anxiety,	  hypochondriasis	  and	  somatisation.	  
• To	  compare	  the	  Spielberger	  State	  Anxiety	  Index	  (SSAI)	  with	  the	  neurophysiological	  data.	  The	  
SSAI	  assesses	  anxiety	  at	  a	  specific	  time,	  and	  can	  be	  used	  to	  discern	  whether	  a	  subject’s	  
inability	  to	  tolerate	  higher	  electrical	  pain	  thresholds	  is	  due	  to	  the	  anxiety	  of	  moment	  (i.e.	  
those	  anxious	  but	  with	  normal	  sensation)	  or	  due	  to	  genuine	  visceral	  hypersensitivity	  (i.e.	  
those	  relaxed	  but	  with	  genuinely	  increased	  rectal	  sensitivity).	  
2.	  Anorectal	  Sensitivity	  
• To	  use	  electrical	  stimulation	  of	  the	  rectum	  to	  compare	  sensory	  function	  by	  charting	  sensory	  
and	  pain	  thresholds.	  Research	  has	  previously	  focused	  on	  using	  recto-­‐sigmoid	  balloon	  
distension	  as	  a	  surrogate	  for	  visceral	  sensation.	  This	  is	  actually	  a	  marker	  of	  one’s	  tolerance	  
to	  balloon	  distension,	  since	  it	  produces	  symptoms	  of	  impending	  defaecation	  rather	  than	  






is	  perhaps	  more	  physiological	  than	  other	  methods	  of	  interrogating	  visceral	  sensation	  in	  the	  
bowel.	  Electrical	  testing	  may	  endorse	  or	  challenge	  the	  utility	  of	  the	  barostat	  as	  the	  gold	  
standard	  test.	  
3.	  Cortical	  Evoked	  Potentials	  
• To	  document	  the	  morphology,	  amplitude	  and	  latency	  of	  evoked	  potentials	  elicited	  by	  rectal	  
electrical	  stimulation	  in	  a	  control	  population.	  Research	  so	  far	  has	  only	  described	  proof	  of	  
concept	  studies	  and	  suggested	  possibilities	  for	  the	  clinical	  application	  of	  this	  test.	  There	  has	  
been	  no	  attempt	  to	  delineate	  normal	  ranges,	  and	  in	  so	  doing,	  define	  what	  is	  abnormal.	  
• To	  assess	  evoked	  potentials	  over	  3	  separate	  days	  of	  testing	  in	  a	  control	  population.	  
Reproducibility	  of	  data	  on	  intra-­‐day	  or	  between-­‐day	  analysis	  is	  vital	  for	  the	  validity	  of	  a	  
clinical	  test.	  This	  has	  not	  been	  done	  before	  in	  rectal	  evoked	  potentials.	  
• To	  compare	  evoked	  potentials	  in	  an	  IBS	  population	  to	  the	  control	  group.	  Rectal	  evoked	  
potentials	  have	  not	  been	  used	  to	  assess	  a	  disease	  population.	  Evoked	  potentials	  are	  being	  
used	  as	  a	  neurophysiological	  correlate	  of	  visceral	  afferent	  transmission.	  Abnormal	  evoked	  
potentials	  would	  suggest	  altered	  functioning	  of	  this	  pathway-­‐	   	   in	  the	  context	  of	  expressed	  
pain	  at	  low	  stimulus	  intensities,	  a	  neurophysiological	  template	  of	  visceral	  sensitivity	  may	  
become	  apparent.	  
• To	  compare	  intra-­‐day	  and	  between-­‐day	  evoked	  potentials	  in	  IBS	  patients.	  Comparison	  
during	  a	  day’s	  testing	  or	  over	  a	  period	  of	  days	  would	  identify	  whether	  IBS	  patients	  become	  
more	  tolerant	  of	  the	  applied	  stimulus.	  This	  is	  a	  process	  called	  habituation,	  where	  one	  
becomes	  accustomed	  to	  repetitive	  noxious	  stimuli.	  Inability	  to	  habituate	  may	  be	  an	  
important	  mechanism	  in	  sustaining	  visceral	  hypersensitivity,	  due	  to	  the	  failure	  of	  centrally-­‐
mediated	  pain-­‐inhibitory	  pathways.	  
4.	  Cytokine	  Analysis	  
• To	  analyse	  cytokine	  expression	  in	  IBS	  patients	  and	  controls.	  Recent	  data	  has	  proposed	  a	  low-­‐
grade	  inflammatory	  role	  in	  the	  pathogenesis	  of	  IBS.	  This	  study	  will	  use	  a	  broad	  panel	  of	  both	  











IBS	  patients	  were	  identified	  by	  having	  symptoms	  consistent	  with	  the	  Rome	  2	  definition	  of	  IBS,	  and	  
without	  any	  known	  comorbidity	  that	  might	  account	  for	  their	  symptoms.	   	  
Exclusion	  Criteria	  
Patients	  with	  a	  history	  of	  weight	  loss,	  psychiatric	  illness	  (depression,	  mania	  or	  schizophrenia),	  active	  
infection,	  recent	  antibiotics,	  anti-­‐depressants	  or	  anti-­‐inflammatory	  medication	  were	  excluded.	  
Study	  Pathway	  
Each	  study	  participant	  was	  subjected	  to	  three	  non-­‐consecutive	  days	  of	  psychological	  and	  
neurophysiological	  assessment.	  The	  three	  days	  of	  testing	  were	  concluded	  within	  a	  3	  month	  time-­‐
scale.	  
Each	  subject	  underwent	  rectal	  sensitivity	  testing	  to	  determine	  sensory	  and	  pain	  thresholds	  to	  rectal	  
electrical	  stimulation.	  Cortical	  evoked	  potentials	  were	  recorded	  following	  the	  same	  electrical	  
stimulus.	  Psychological	  questionnaires	  were	  completed	  on	  each	  day.	  
Female	  patients	  were	  tested	  during	  the	  follicular	  phase	  of	  the	  menstrual	  cycle	  to	  avoid	  heightened	  
sensory	  perception	  during	  the	  menses.	  
At	  a	  later	  stage	  IBS	  patients	  and	  healthy	  volunteers	  were	  invited	  to	  return	  to	  the	  study	  in	  order	  to	  
give	  blood	  samples	  in	  order	  to	  facilitate	  the	  cytokine	  analysis	  part	  of	  the	  protocol.	  These	  subjects	  
underwent	  further	  clinical	  and	  psychological	  assessment	  in	  addition	  to	  having	  a	  20ml	  sample	  of	  
venous	  blood.	  
Patient	  Recruitment	  
Patients	  with	  IBS	  were	  sourced	  from	  outpatient	  clinics	  at	  St.	  Marks	  Hospital	  and	  Northwick	  Park	  






Some	  of	  the	  healthy	  controls	  worked	  for	  the	  Northwick	  Park	  PCT,	  although	  they	  had	  not	  previously	  
been	  involved	  as	  participants	  in	  other	  research	  trials.	   	   	  
Ethics	  
Ethical	  approval	  was	  granted	  following	  a	  successful	  application	  to	  the	  Brent and Harrow Research 
Ethics Committee.	  
ENDPOINTS	  
1.	  Assessment	  of	  Psychological	  Factors	   	  
Endpoints	  were	  achieved	  with	  reference	  to	  the	  psychological	  questionnaires	  that	  were	  completed.	  
These	  included	  Spielberger	  State-­‐Trait	  Anxiety	  Inventory	  for	  Adults,	  Hospital	  Anxiety	  and	  Depression	  
scale,	  Eysenck	  Personality	  Questionnaire-­‐	  Revised,	  Visceral	  Sensitivity	  Index,	  Patient	  Health	  
Questionnaire,	  Whiteley	  Index	  and	  Irritable	  Bowel	  Syndrome	  Impact	  Scale.	  
2.	  Assessment	  of	  Clinical	  Severity	   	  
The	  Visual	  Descriptor	  Visual	  Analogue	  Scale	  documented	  subjective	  accounts	  of	  the	  unpleasantness	  
and	  intensity	  of	  symptoms.	  The	  Irritable	  Bowel	  Severity	  Scoring	  System	  assessed	  the	  severity	  of	  IBS	  
symptoms.	   	   	  
3.	  Sensory	  and	  pain	  thresholds	  
Rectal	  sensory	  and	  pain	  thresholds	  were	  completed	  on	  each	  day	  of	  testing.	  
4.	  CEP	  Analysis	  
Analysis	  of	  the	  CEP	  waveforms	  assessed	  the	  morphology,	  amplitude	  and	  latency	  of	  the	  individual	  
components	  of	  the	  cortical	  response.	  
5.	  Immunological	  and	  Endocrine	  Endpoints	  
Peripheral	  blood	  mononuclear	  cells	  were	  stimulated	  with	  E.	  coli	  LPS	  (serving	  as	  a	  TLR4	  ligand)	  to	  
investigate	  the	  stimulated	  (and	  non-­‐stimulated)	  expression	  of	  cytokines.	  






Patient	  Flow	  Chart	  
Outpatients	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  2	  Compliance	  for	  Irritable	  Bowel	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No	  exclusion	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Spielberger	  State-­‐Trait	  Anxiety	  Inventory	  for	  Adults	  
Hospital	  Anxiety	  and	  Depression	  scale	  
Eysenck	  Personality	  Questionnaire-­‐	  Revised	  
Visceral	  Sensitivity	  Index	  
Patient	  Health	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Visual	  Descriptor	  Visual	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Whiteley	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  and	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  Potentials	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  scale	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  Action	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Psychological	  Assessment	   	  
The	  questionnaires	  that	  were	  used	  included	  the	  Spielberger	  State-­‐Trait	  Anxiety	  Inventory	  for	  Adults	  
(SSTAI),	  Hospital	  Anxiety	  and	  Depression	  Scale	  (HAD),	  Eysenck	  Personality	  Questionnaire-­‐Revised	  
(EPQ-­‐R),	  Visceral	  Sensitivity	  Index	  (VSI),	  Patient	  Health	  Questionnaire	  (PHQ-­‐15),	  Visual	  Descriptor	  
Visual	  Analogue	  Scale	  (VDVAS),	  Whiteley	  Index	  (WI)	  and	  Irritable	  Bowel	  Syndrome	  Impact	  Scale	  (IBS-­‐
IS).	  
The	  SSTAI,	  HAD	  and	  PHQ-­‐15	  were	  performed	  on	  each	  day	  of	  testing.	  In	  addition,	  the	  EPQ-­‐R,	  VSI	  and	  
WI	  were	  completed	  on	  the	  first	  day	  of	  testing,	  but	  not	  repeated.	   	  








CORTICAL	  EVOKED	  POTENTIAL	  PROTOCOL	  
Rectal	  Sensitivity	  Testing	  
Subject	  Preparation	  
Subjects	  were	  fasted	  overnight	  and	  encouraged	  to	  defaecate	  prior	  to	  starting	  the	  study.	  Bowel	  
preparation	  was	  not	  be	  used,	  thereby	  preventing	  aperient-­‐induced	  anorectal	  sensitisation.	  Subjects	  
were	  positioned	  in	  the	  left	  lateral	  position	  with	  knees	  and	  hips	  flexed	  to	  facilitate	  the	  placement	  of	  
the	  rectal	  catheter.	  After	  its	  insertion,	  subjects	  were	  then	  asked	  to	  adopt	  the	  supine	  position.	   	  
Rectal	  Catheter	   	  
The	  rectal	  catheter	  was	  a	  3mm	  nylon	  tube	  interwoven	  with	  stainless	  steel	  braid	  and	  sheathed	  in	  
silicone	  rubber	  (Gaeltec,	  Dunvegan,	  Isle	  of	  Skye	  IV55	  8GU,	  Scotland,	  UK.).	  It	  featured	  two	  2mm	  
bipolar	  ring	  electrodes	  sited	  1cm	  apart	  from	  each	  other,	  and	  5cm	  from	  the	  distal	  end	  of	  the	  
catheter.	  The	  catheter	  was	  inserted	  into	  the	  rectum	  so	  that	  the	  bipolar	  ring	  electrodes	  were	  
positioned	  10	  cm	  proximal	  to	  the	  anal	  verge.	  The	  catheter	  was	  connected	  to	  a	  constant	  current	  
stimulator	  (model	  DS7A,	  Digitimer	  Ltd,	  UK)	  which	  was	  itself	  controlled	  by	  a	  trigger	  generator	  (model	  
DG2,	  Digitimer	  Ltd,	  UK).	  The	  firing	  of	  the	  trigger	  generator	  and	  subsequent	  discharge	  of	  the	  electrical	  
stimulus	  from	  the	  constant	  current	  stimulator	  was	  delivered	  at	  a	  frequency	  of	  0.5	  Hz	  using	  square	  
wave	  pulses	  of	  500µs	  duration.	  The	  intensity	  of	  the	  stimulus	  was	  manually	  adjusted	  between	  0	  and	  
100mA.	  
Visual	  Analogue	  Scale	  
Subjects	  were	  asked	  to	  subjectively	  grade	  the	  intensity	  of	  the	  stimulus	  using	  a	  visual	  analogue	  scale	  
(VAS)	  scored	  between	  1	  and	  6.	  Word	  anchors	  comprised	  “being	  unaware	  of	  the	  stimulus”	  (1/6),	  or	  
noticing	  a	  “slight	  sensation”	  (2/6),	  “definite	  sensation”	  (3/6),	  slight	  discomfort	  (4/6),	  
“uncomfortable”	  sensation	  (5/6)	  or	  a	  “painful”	  sensation(6/6).	  
Sensory	  and	  Pain	  Thresholds	  
At	  the	  start	  of	  each	  day’s	  testing,	  the	  sensory	  threshold	  (ST)	  and	  pain	  thresholds	  (PT)	  were	  
determined.	  The	  electrical	  testing	  begins	  at	  0mA	  (no	  stimulus).	  The	  current	  is	  then	  progressively	  
increased	  in	  2mA	  increments	  until	  the	  subject	  first	  acknowledges	  the	  electrical	  stimulus	  (defined	  as	  
the	  sensory	  threshold	  or	  2/6	  on	  the	  VAS).	  The	  stimulus	  intensity	  continues	  to	  be	  increased,	  and	  the	  
subject	  is	  encouraged	  to	  communicate	  their	  perception	  of	  the	  increasing	  stimulus	  using	  the	  defined	  






being	  an	  uncomfortable	  sensation	  to	  a	  painful	  sensation	  (defined	  as	  the	  pain	  threshold	  or	  6/6	  on	  the	  
VAS),	  the	  electrical	  current	  is	  terminated.	  This	  cycle	  of	  ascending	  electrical	  stimulation	  is	  repeated	  
two	  more	  times,	  allowing	  one	  to	  calculate	  average	  sensory	  and	  pain	  thresholds	  over	  3	  cycles.	  
Preliminary	  testing	  to	  determine	  sensory	  and	  pain	  thresholds	  facilitates	  the	  calculation	  of	  a	  stimulus	  
intensity	  appropriate	  for	  recording	  CEPs.	  Hobday	  et	  al.255	  used	  a	  CEP	  stimulus	  intensity	  equivalent	  to	  
the	  sensory	  threshold	  plus	  75%	  of	  the	  difference	  between	  the	  sensory	  and	  pain	  thresholds.	  For	  
example,	  if	  the	  sensory	  threshold	  is	  20mA	  and	  the	  pain	  threshold	  is	  80mA,	  then	  the	  test	  stimulation	  
intensity	  is	  65	  mA.	  In	  practice,	  this	  equates	  to	  a	  subjective	  perception	  of	  a	  “slight	  discomfort”	  or	  4/6	  
on	  the	  VAS.	  This	  methodology	  allows	  comparison	  between	  subjects	  because,	  even	  though	  there	  may	  
be	  subtle	  differences	  in	  the	  sensory	  and	  pain	  thresholds	  between	  individuals,	  the	  stimulus	  intensity	  
is	  increased	  by	  the	  same	  factor.	  
Cortical	  Evoked	  Potential	  Testing	  
Electrode	  Placement	  
Silver-­‐silver	  chloride	  surface	  electrodes	  were	  placed	  on	  the	  vertex	  (active	  electrode),	  ear	  lobe	  
(reference	  electrode)	  and	  neck	  (ground	  electrode)	  according	  to	  the	  International	  10–20	  System	  of	  
Electroencephalograph	  (EEG)	  electrode	  placement.	  They	  were	  affixed	  using	  electrode	  gel	  or	  paste	  
(Elefix,	  Nihon	  Kohden,	  Japan)	  after	  the	  underlying	  skin	  had	  been	  gently	  cleaned	  using	  alcohol	  wipes	  
and	  prepared	  with	  a	  mild	  skin	  abrasive	  (Omniprep,	  Weaver	  &	  Aurora).	  Scalp	  impedance	  was	  
maintained	  below	  5kΩ.	   	  
Cortical	  Evoked	  Potential	  Harvesting	  
During	  the	  recording	  of	  CEPs	  the	  subjects	  were	  encouraged	  to	  lie	  still	  and	  silent	  on	  the	  examination	  
couch	  whilst	  fixing	  their	  gaze	  on	  a	  stationary	  object,	  thereby	  minimising	  motor	  artefact.	  The	  rectal	  
stimulus	  was	  delivered	  at	  the	  calculated	  testing	  intensity	  over	  4	  cycles	  of	  50	  electrical	  stimulations	  
spaced	  at	  5	  second	  intervals.	  A	  5	  minute	  pause	  interspersed	  each	  cycle.	  Each	  cycle	  of	  50	  stimulations	  
was	  then	  averaged	  to	  enhance	  signal	  clarity.	  The	  patient	  was	  given	  5	  minutes	  to	  relax	  after	  each	  
cycle,	  and	  then	  the	  testing	  would	  continue.	  Previous	  work	  has	  shown	  this	  approach	  achieved	  the	  
best	  signal-­‐to-­‐noise	  ratio	  and	  optimal	  clarity	  of	  the	  CEP	  components.	  At	  the	  conclusion	  of	  each	  day	  







Cortical	  Evoked	  Potential	  Acquisition	  
Data	  was	  acquired	  using	  a	  CED	  1902	  programmable	  signal	  conditioner	  (Cambridge	  Electronics	  
Design).	  Display	  and	  analysis	  utilised	  the	  SIGAVG	  program	  v.	  6.04	  and	  Signal	  for	  Windows	  v.	  3.08	  
(Cambridge	  Electronic	  Design).	  Amplifier	  gain	  was	  set	  at	  1000	  and	  the	  recording	  sensitivity	  was	  
usually	  between	  25	  and	  100	  μV.	  The	  band	  pass	  filter	  settings	  were	  1–100	  Hz,	  and	  a	  50-­‐Hz	  noise	  
reduction	  unit	  was	  utilised,	  if	  needed,	  to	  reduce	  interference	  from	  the	  main	  electrical	  supply	  
(Humbug	  Noise	  Eliminator,	  Digitimer	  Ltd,	  37	  Hydeway,	  Welwyn	  Garden	  City,	  Hertfordshire,	  AL7	  3BE,	  
UK).	  The	  sampling	  rate	  was	  4	  KHz,	  and	  the	  recording	  epoch	  was	  1.5	  seconds	  in	  duration.	  The	  first	  
200	  ms	  of	  the	  recording	  epoch	  was	  pre-­‐stimulation	  time.	  Each	  individual	  epoch	  was	  saved,	  and	  the	  
average	  of	  the	  run	  can	  be	  viewed	  during	  acquisition.	  An	  artefact	  rejection	  facility	  was	  employed	  to	  
prevent	  contamination	  from	  eye	  blinks	  and	  swallows	  as	  well	  as	  visual	  inspection	  of	  each	  sweep.	   	  
Evoked	  Action	  Potential	  Analysis	  
Rectal	  CEPs	  were	  analysed	  according	  to	  morphology,	  latency	  and	  amplitude	  of	  the	  CEP	  waveforms.	  
CEPs	  were	  averaged	  after	  each	  cycle	  and	  then	  compared	  to	  other	  cycles	  on	  the	  same	  day	  of	  testing	  
(intra-­‐day	  analysis)	  and	  on	  other	  days	  of	  testing	  (inter-­‐day	  analysis).	   	  






CYTOKINE	  PROTOCOL	   	  
Isolation	  and	  Stimulation	  of	  Peripheral	  Blood	  Mononuclear	  Cells	   	  
Peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  were	  prepared	  from	  blood	  samples	  taken	  from	  healthy	  
volunteers	  and	  IBS	  patients.	  20ml	  of	  venous	  blood	  was	  taken	  and	  collected	  in	  standard	  heparinised	  
blood	  bottles.	  Preliminary	  testing	  showed	  that	  even	  short	  durations	  of	  cooling	  in	  a	  refrigerator	  
caused	  cell	  lysis	  and	  destruction,	  rendering	  the	  blood	  samples	  useless.	  As	  a	  result	  the	  blood	  samples	  
were	  maintained	  at	  room	  temperature	  and	  not	  subjected	  to	  a	  cooling	  process	  beforehand.	  The	  
blood	  samples	  were	  processed	  within	  2	  hours	  of	  collection.	  
Materials	  and	  Equipment	  
• 20	  ml	  heparinised	  whole	  blood	  samples	  
• Dulbeco’s	  Phosphate	  Buffered	  Saline	  (PBS),	  Ca++	  and	  Mg++-­‐free,	  sterile	  (Invitrogen)	  
• Ficoll-­‐Paque	  Plus	  (GE	  Healthcare),	  sterile	  
• RPMI	  (Roswell	  Park	  Memorial	  Institute)	  Solution	  combined	  with	  Foetal	  Calf	  Serum	  (FCS),	  L-­‐
glutamine	  and	  Penicillin/Streptomycin.	  
• Standard	  heparinised	  blood	  tubes	  
• 50	  ml	  Accuspin™	  centrifuge	  tubes	  (Sigma-­‐Aldrich)	  
• Sterile	  pipettes	  
• Centrifuge	  
• Incubator	  
• Haemocytometer	  and	  cell	  counter	  
Isolation	  of	  PBMCs	  
1. Whole	  blood	  samples	  were	  diluted	  1	  to	  1	  with	  PBS.	  
2. 20ml	  whole	  blood/PBS	  solution	  was	  layered	  over	  20ml	  of	  Ficoll-­‐Paque	  Plus	  in	  a	  50ml	  
centrifuge	  tube,	  taking	  care	  that	  the	  blood/Ficoll-­‐Paque	  interface	  was	  not	  disturbed	  and	  that	  
there	  was	  a	  clear	  demarcation	  between	  the	  two	  substrates.	  
3. The	  blood	  sample/Ficoll	  was	  centrifuged	  at	  room	  temperature	  for	  20	  minutes.	  The	  
centrifuge	  was	  set	  at	  1500rpm	  with	  the	  brake	  off.	  
4. The	  buffycoat	  formed	  at	  the	  interface	  between	  the	  plasma	  and	  the	  erythrocytes	  was	  






5. The	  buffycoat	  was	  re-­‐diluted	  1	  to	  1	  with	  PBS	  solution	  and	  then	  centrifuged	  for	  15	  minutes.	  
The	  centrifuge	  was	  set	  at	  1100rpm	  with	  the	  brake	  off.	  
6. At	  this	  point	  a	  pellet	  of	  PBMCs	  has	  formed	  at	  the	  bottom	  of	  the	  tube.	  The	  overlying	  
supernatant	  was	  gently	  extracted	  and	  disposed	  of,	  taking	  care	  not	  to	  disturb	  the	  pellet.	  
7. The	  PBMC	  pellet	  was	  re-­‐suspended	  in	  2ml	  of	  RPMI.	  
Cell	  Counting	  and	  PBMC	  dilution	  
1. A	  counting	  chamber	  or	  haemocytometer	  was	  used	  to	  establish	  the	  density	  of	  PBMCs	  in	  a	  
fixed	  10μl	  sample.	  A	  standard	  cell	  counter	  was	  used.	  
2. The	  PBMC	  solution	  was	  diluted	  with	  RPMI	  to	  ensure	  a	  final	  dilution	  of	  1x106	  cells	  per	  ml	  of	  
RPMI.	  
3. The	  PBMC	  solution	  was	  then	  transferred	  to	  standard	  sterile	  96	  well	  plates	  and	  maintained	  at	  
37	  degrees	  Celsius	  in	  an	  incubator,	  pending	  the	  stimulation	  phase	  of	  the	  experiment.	  
LPS	  Stimulation	  and	  Incubation	  
1. 96	  well	  plates	  were	  inoculated	  with	  E.	  coli	  LPS.	  
2. The	  plates	  were	  incubated	  for	  24	  hours,	  and	  then	  frozen	  in	  a	  -­‐20℃	  freezer	  until	  the	  assays	  
were	  ready	  to	  be	  analysed.	  
Cytokine	  Assay	  
96	  Well	  Plate	  Setup	  
Each	  well	  of	  a	  96	  well	  sterile	  culture	  plate	  can	  hold	  250μl	  of	  fluid.	  For	  this	  experiment,	  a	  total	  volume	  
of	  100μl	  of	  PBMCs	  and	  E.	  coli	  LPS	  were	  used	  in	  order	  to	  make	  the	  concentrations	  easier	  to	  calculate.	  
Each	  well	  was	  dispensed	  with:	   	  90μl	  of	  PBMCs	  (1x106	  cells	  per	  ml	  concentration)	  
	   	   	   	   10μl	  of	  E.	  coli	  
Materials	  and	  Equipment	  
• PBMCs	  in	  a	  concentration	  of	  1x106	  cells	  per	  ml	  of	  RPMI	  
• Ultra-­‐pure	  E.	  coli	  0111:B4	  LPS	  (Invivogen,	  Catalogue	  number:	  tlrl-­‐pelps,	  5mg)	  
• Sterile	  96	  well	  tissue	  culture	  plates	  







LPS	  preparation	  from	  Stock	  Powders	  
Concentrations	  required	  for	  the	  experiments:	  0,	  0.1,	  0.3,	  1,	  3,	  10,	  30,	  100	  ng/ml	  
1. 5mg	  dry	  powder	  was	  mixed	  with	  5ml	  of	  sterile	  endotoxin-­‐free	  water	  and	  homogenised	  to	  
make	  a	  solution	  of	  1mg/ml.	  
2. Serial	  dilutions	  were	  performed	  as	  follows:	  
3. Add	  6µl	  LPS	  (1mg/ml)	  to	  594µl	  of	  RPMI=	  10µg/ml	  (600µl	  total)	  
4. Add	  20µl	  of	  10µg/ml	  solution	  to	  180µl	  of	  RPMI=	  1µg/ml	  (200µl	  “stock	  solution”)	  
5. Add	  30µl	  of	  1µg/ml	  stock	  to	  70µl	  of	  RPMI	  =	  300ng/ml	   	  
6. Add	  20µl	  of	  300ng/ml	  solution	  to	  180µl	  of	  RPMI	  =	  30ng/ml	  
7. Add	  20µl	  of	  30ng/ml	  solution	  to	  180µl	  of	  RPMI	  =	  3ng/ml	  
8. Add	  20µl	  of	  1µg/ml	  stock	  to	  180µl	  of	  RPMI	  =	  100ng/ml	  
9. Add	  20µl	  of	  100ng/ml	  solution	  to	  180µl	  of	  RPMI	  =	  10ng/ml	  
10. Add	  20µl	  of	  10ng/ml	  solution	  to	  180µl	  of	  RPMI	  =	  1ng/ml	  
These	  concentrations	  take	  into	  account	  a	  further	  1	  in	  10	  dilution	  when	  added	  to	  the	  RPMI/PBMC	  
solution	  in	  the	  wells.	  
Cytokine	  Analysis	  
MSD	  Multiplex	  Technology	  
The	  MSD	  Pro-­‐inflammatory	  7-­‐Plex	  (MS6000	  7	  Spot	  Plate	  Catalogue	  Number:	  N71008B-­‐1	  from	  
MesoScaleDiscovery,	  www.meso-­‐scale.com)	  was	  used	  for	  analysis	  of	  the	  pro-­‐inflammatory	  
cytokines.	   	  
The	  7-­‐Plex	  in	  its	  title	  refers	  to	  the	  patented	  multiplex	  technology.	  This	  means	  that	  multiple	  cytokines	  
can	  be	  read	  from	  a	  single	  well.	  The	  multiplex	  is	  a	  sandwich	  immunoassay-­‐	  7	  different	  cytokine	  
autoantibodies	  are	  arranged	  in	  a	  discrete	  pattern	  of	  7	  domains	  per	  well.	  Each	  cytokine	  has	  its	  own	  
individual	  domain.	  Therefore	  in	  a	  96	  well	  plate,	  there	  will	  be	  96	  wells	  each	  producing	  data	  from	  7	  
different	  cytokines.	  
The	  technology	  is	  an	  elaboration	  on	  the	  science	  of	  immunofluorescence.	  Mesoscale	  refer	  to	  the	  
technology	  as	  electrochemiluminescence	  detection.	  However,	  the	  principle	  is	  the	  same.	  The	  MSD	  
plates	  are	  pre-­‐coated	  with	  the	  7	  cytokine	  auto-­‐antibodies.	  The	  cytokine	  binds	  to	  its	  capture	  






stimulation	  causes	  light	  to	  be	  emitted	  from	  the	  labelled	  detection	  antibody	  which	  is	  then	  read	  by	  the	  
analysing	  machine	  and	  quantified	  into	  cytokine	  concentrations.	  
The	  7-­‐Plex	  MSD	  plates	  analyse	  these	  pro-­‐inflammatory	  cytokines:	  IL-­‐1B,	  IL-­‐6,	  IL-­‐8,	  IL-­‐10,	  IL-­‐12p70	  and	  
TNF-­‐α.	  An	  anti-­‐inflammatory	  cytokine	  plex	  array	  was	  sourced	  from	  the	  same	  company	  to	  investigate	  
the	  expression	  of	  IFN-­‐γ,	  IL-­‐2,	  IL-­‐4,	  IL-­‐5	  and	  IL-­‐13.	  
Reagent	  Preparation	  
Calibrators	  were	  diluted	  using	  Calibrator	  Diluent	  (CD).	  The	  calibration	  curve	  preparation	  outlined	  
below	  (Figure	  2.1)	  generates	  a	  standard	  curve	  from	  10,000	  pg/ml	  to	  2.4	  pg/ml.	  The	  Calibrator	  
Diluent	  is	  a	  standard	  tissue	  culture	  growth	  medium	  with	  10%	  serum.	   	  
Preparation	  of	  the	  Calibration	  Curve	  
• 10,000	  pg/ml:	   	   Add	  10	  μl	  of	  the	  1	  μg/ml	  stock	  solution	  to	  990	  µL	  of	  CD.	  This	  high	  calibrator	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
(10,000	  pg/ml)	  was	  used	  to	  prepare	  the	  standard	  curve	  following	  a	  1:4	  dilution	  series	  (as	  
shown	  below).	   	  
• 2500	  pg/ml:	   	   Add	  50	  μl	  of	  10,000	  pg/ml	  combined	  high	  calibrator	  (10,000	  pg/ml)	  to	  150	  μl	  
of	  CD.	   	  
• 625	  pg/ml:	   	   Add	  50	  μl	  of	  2500	  pg/ml	  calibrator	  to	  150	  μl	  of	  CD.	   	  
• 156	  pg/ml:	   	   Add	  50	  μl	  of	  625	  pg/ml	  calibrator	  to	  150	  μl	  of	  CD.	   	  
• 39	  pg/ml:	   	   Add	  50	  μl	  of	  156	  pg/ml	  calibrator	  to	  150	  μl	  of	  CD.	   	  
• 9.8	  pg/ml:	   Add	  50	  μl	  of	  39	  pg/ml	  calibrator	  to	  150	  μl	  of	  CD.	   	  
• 2.4	  pg/ml:	   	   Add	  50	  μl	  of	  9.8	  pg/ml	  calibrator	  to	  150	  μl	  of	  CD.	   	   	  
• 0	  pg/ml:	   	   150	  μl	  of	  CD	   	  






Preparation	  of	  the	  Detection	  Antibody	  Solution	  
Detection	  antibody	  solutions	  were	  kept	  refrigerated	  and	  in	  the	  dark	  to	  prevent	  possible	  degradation	  
by	  light.	  The	  detection	  antibodies	  were	  premixed	  in	  solution	  at	  a	  50X	  concentration.	  The	  working	  
detection	  antibody	  solution	  was	  diluted	  down	  to	  1X	  (or	  1.0	  μg/ml).	  For	  each	  plate	  used,	  60	  μl	  aliquot	  
of	  the	  stock	  Detection	  Antibody	  Mix	  was	  diluted	  with	  2.94	  ml	  of	  Antibody	  Diluent	  to	  achieve	  the	  x1	  
dilution	  required	  for	  testing.	  
Preparation	  of	  the	  Read	  Buffer	  
The	  Read	  Buffer	  T	  (at	  a	  x4	  concentration)	  was	  diluted	  1	  in	  2	  in	  deionized	  water	  to	  make	  a	  final	  
concentration	  of	  2X	  Read	  Buffer	  T.	  This	  was	  accomplished	  by	  adding	  10	  ml	  of	  stock	  Read	  Buffer	  T	  
(4X)	  to	  10	  ml	  of	  deionized	  water	  for	  each	  plate.	  
Preparation	  of	  the	  MSD	  plate	  
The	  MSD	  plate	  was	  removed	  from	  the	  refrigerator	  and	  allowed	  to	  reach	  room	  temperature	  before	  
testing	  commenced.	  A	  blocking	  step	  was	  not	  employed	  in	  this	  protocol.	   	   	  
MSD	  Plate	  Setup	  
The	  MSD	  plate	  is	  a	  96	  well	  plate.	  Sixteen	  of	  the	  wells	  were	  allocated	  for	  the	  calibration	  curve	  in	  a	  
manner	  that	  afforded	  two	  separate	  readings	  for	  each	  concentration	  of	  calibrator	  used.	  At	  the	  point	  
of	  analysis,	  these	  two	  signals	  were	  averaged	  by	  the	  Sector	  Imager	  to	  generate	  the	  calibration	  curve.	  
This	  is	  then	  used	  as	  the	  reference	  for	  the	  rest	  of	  the	  wells	  (which	  contained	  the	  patient/healthy	  
volunteer	  samples).	  This	  meant	  that	  each	  96	  well	  plate	  could	  test	  80	  samples.	  Owing	  to	  cost	  and	  
time	  implications,	  there	  was	  no	  redundancy	  in	  the	  samples	  (i.e.	  there	  was	  no	  duplication	  of	  the	  
samples).	  This	  meant	  that	  if	  one	  well	  produced	  unusual	  results	  there	  was	  not	  a	  corresponding	  
duplicate	  to	  compare	  it	  to.	  






Addition	  of	  the	  Sample	  or	  Calibrator	  
25	  µL	  of	  each	  Calibrator	  or	  Sample	  Solution	  was	  dispensed	  into	  a	  separate	  well	  of	  the	  MSD	  plate	  
using	  reverse	  pipetting.	   	  
Reverse	  Pipetting	   	  
This	  is	  a	  technique	  designed	  to	  minimise	  the	  amount	  of	  bubbles	  that	  are	  transferred	  from	  the	  
sample	  source	  into	  the	  96	  well	  plate.	  A	  pipette	  has	  2	  plunger	  settings,	  the	  first	  allowing	  aspiration	  of	  
a	  specific	  volume	  of	  sample,	  and	  the	  second	  deeper	  setting	  that	  expels	  residual	  liquid.	  Reverse	  
pipetting	  requires	  you	  to	  push	  the	  pipet	  plunger	  past	  the	  first	  position	  to	  the	  second	  position	  prior	  
to	  aspirating	  liquid	  into	  the	  tip,	  thereby	  aspirating	  slightly	  more	  liquid	  than	  the	  desired	  volume	  
(overdraw).	  In	  order	  to	  dispense	  the	  liquid	  from	  the	  tip,	  the	  pipet	  plunger	  is	  pushed	  to	  the	  first	  
position	  only.	  Reverse	  pipetting	  results	  in	  a	  much	  more	  controlled	  delivery	  of	  the	  sample	  into	  the	  96	  
well	  plate,	  minimising	  bubbles,	  and	  therefore	  maximising	  the	  signal.	  
Incubation	  of	  the	  MSD	  plate	  
The	  MSD	  plate	  was	  sealed	  with	  an	  adhesive	  plate	  seal	  and	  allowed	  to	  incubate	  for	  2	  hours	  with	  
vigorous	  shaking	  (300-­‐1000	  rpm)	  at	  room	  temperature.	  This	  was	  achieved	  by	  using	  an	  automated	  
shaking	  machine.	  It	  results	  in	  better	  mixing	  and	  more	  rapid	  binding	  of	  the	  sample	  to	  the	  capture	  
antibodies.	   	   	  
Addition	  of	  the	  Detection	  Antibody	  Solution	  
25	  µL	  of	  the	  1X	  Detection	  Antibody	  Solution	  was	  pipetted	  into	  each	  well	  of	  the	  MSD	  plate.	   	  
Incubation	  of	  the	  MSD	  Plate	  
The	  MSD	  plate	  was	  resealed	  and	  then	  incubated	  for	  a	  further	  2	  hours	  with	  vigorous	  shaking	  (300-­‐
1000	  rpm)	  using	  the	  automated	  machine.	  
Washing	  the	  MSD	  plate	  
The	  MSD	  plate	  was	  washed	  three	  times	  using	  an	  automated	  plate	  washer	  that	  was	  fed	  phosphate	  
buffered	  saline	  +	  0.05%	  Tween-­‐20.	   	   	   	  
MSD	  plate	  reading	  
150	  µL	  of	  2X	  Read	  Buffer	  T	  was	  dispensed	  into	  each	  well	  of	  the	  MSD	  plate.	  Analysis	  of	  the	  MSD	  plate	  







Analysis	  using	  the	  Sector	  Imager	  6000	  
The	  Sector	  Imager	  (MesoScaleDiscovery,	  www.meso-­‐scale.com	  )	  was	  configured	  to	  convert	  the	  1	  in	  
2	  dilutions	  of	  the	  PBMC	  assays	  into	  1	  in	  1	  dilutions.	  In	  other	  words,	  it	  doubled	  the	  analysed	  cytokine	  
signal	  to	  account	  for	  the	  fact	  that	  the	  PBMC	  assays	  had	  been	  diluted	  down	  by	  a	  factor	  of	  2	  using	  
RPMI.	  The	  data	  was	  exported	  into	  pdf	  and	  Excel	  formats,	  and	  then	  manipulated	  into	  the	  patient	  
database.	  






CHAPTER	  THREE,	  SECTION	  ONE:	   	  
CEP	  STUDY	  RESULTS	  
The	  results	  are	  presented	  under	  two	  major	  headings-­‐	  data	  from	  the	  cortical	  evoked	  potential	  
analysis	  (termed	  CEP	  Study),	  and	  data	  from	  the	  cytokine	  analysis	  (termed	  Cytokine	  Study).	  Each	  of	  
these	  distinct	  studies	  is	  further	  sub-­‐divided	  into	  demographic,	  psychological,	  neurophysiological	  and	  
immunological	  sections.	  
Conventions	  
Graphs	  are	  presented	  using	  a	  hybrid	  scattergram/box	  and	  whisker	  plot	  i.e.	  the	  same	  data	  is	  
represented	  in	  both	  forms	  side	  by	  side.	  The	  box	  and	  whisker	  plot	  is	  defined	  according	  to	  Tukey’s	  
original	  specification	  (Tukey,	  J.	  W.	  "Box-­‐and-­‐Whisker	  Plots."	  Exploratory	  Data	  Analysis.	  Reading,	  MA:	  
Addison-­‐Wesley,	  pp.	  39-­‐43,	  1977).	  Statistical	  significance	  is	  defined	  as	  a	  p	  value	  <	  0.05.	  
Patient	  Recruitment	  
Cortical	  evoked	  potentials	  were	  harvested	  from	  33	  IBS	  patients	  and	  21	  controls.	  All	  CEP	  testing	  was	  
completed	  within	  a	  3	  month	  timeframe.	   	  
Table	  3.1.1a	  Study	  Demographics	  
	   Controls	   IBS	  
Sex	   7	  Males,	  14	  Females	   6	  Males,	  27	  Females	  
Mean	  age	   31.4	   40.1	  
Median	  age	   30	   38	  
Mode	  age	   30	   30	  
Age	  range	   21	  to	  46	   20	  to	  63	  
	  
Controls	  were	  recruited	  from	  local	  advertisement	  at	  St.	  Marks	  and	  Northwick	  Park	  hospitals,	  and	  
were	  healthy	  volunteers	  i.e.	  disease-­‐free.	  The	  IBS	  population	  were	  recruited	  contemporaneously	  
from	  the	  outpatient	  clinics	  of	  the	  very	  same	  hospitals.	  They	  were	  recruited	  consecutively	  (i.e.	  in	  a	  
non-­‐randomised	  fashion)	  from	  secondary	  and	  tertiary	  referrals	  to	  these	  clinics,	  and	  serve	  as	  a	  









The	  clinical	  subtypes	  of	  the	  33	  IBS	  patients	  comprised	  8	  mixed-­‐type,	  6	  constipation-­‐predominant,	  16	  
diarrhoea-­‐predominant	  and	  3	  unsubtyped	  IBS	  patients.	  This	  is	  seen	  graphically	  on	  Figure	  3.1.1.	  
Diarrhoea-­‐predominance	  was	  the	  most	  common	  IBS	  subtype	  in	  our	  sample.	  This	  is	  contrary	  to	  some	  
population-­‐based	  studies	  which	  suggest	  that	  the	  IBS-­‐Mixed	  subtype	  is	  more	  prevalent.	  
Figure	  3.1.1	  IBS	  subtypes	  for	  the	  CEP	  study	  
Table	  3.1.1b	  CEP	  Study	  Completion	  
	   Controls	   IBS	  
Day	  1	   21	   33	  
Day	  2	   19	   31	  
Day	  3	   19	   29	  
	  
All	  IBS	  patients	  and	  Control	  subjects	  completed	  the	  first	  day	  of	  CEP	  testing.	  Over	  the	  next	  two	  days	  
of	  testing	  there	  was	  some	  diminution	  in	  numbers,	  but	  not	  as	  much	  as	  one	  might	  have	  expected	  
given	  the	  nature	  of	  the	  testing.	  One	  IBS	  patient	  was	  lost	  to	  follow-­‐up	  after	  the	  1st	  day;	  corruption	  of	  
the	  CEP	  data	  removed	  a	  second	  IBS	  patient	  from	  further	  CEP	  analysis	  on	  days	  2	  and	  3;	  a	  third	  IBS	  
patient	  was	  lost	  to	  follow-­‐up	  after	  the	  2nd	  day;	  finally,	  the	  4th	  IBS	  patient	  did	  not	  complete	  the	  last	  
day	  of	  testing	  since	  she	  was	  due	  to	  undergo	  cosmetic	  surgery,	  and	  fell	  out	  of	  the	  3	  month	  window	  of	  
testing.	  
Of	  the	  2	  control	  subjects	  who	  did	  not	  complete	  the	  3	  days	  of	  testing,	  the	  first	  became	  pregnant	  and	  
had	  to	  withdraw	  from	  the	  study;	  the	  second	  found	  it	  increasing	  difficult	  to	  fit	  the	  testing	  into	  her	  















It	  is	  important	  to	  note	  that	  there	  were	  no	  withdrawals	  from	  the	  study	  on	  account	  of	  the	  invasiveness	  
or	  discomfort	  of	  the	  CEP	  testing.	  Both	  groups	  quickly	  became	  comfortable	  with	  the	  testing	  protocol,	  
evident	  even	  during	  the	  1st	  day	  of	  testing.	  This	  appeared	  to	  validate	  the	  testing	  protocol	  in	  a	  
practical	  sense-­‐	  the	  protocol	  was	  not	  perceived	  as	  being	  too	  traumatic.	  
Study	  Power	  
As	  this	  was	  an	  exploratory	  study,	  we	  arrived	  at	  a	  sample	  number	  by	  considering	  the	  results	  of	  the	  
Hobson	  et	  al.	  non-­‐cardiac	  chest	  pain	  (NCCP)	  disease	  model.209	  This	  employed	  a	  sample	  size	  of	  29	  
NNCP	  patients,	  and	  had	  sufficient	  power	  to	  define	  clinical	  subtypes.	  The	  data	  from	  this	  study	  for	  the	  
discrimination	  of	  sensory	  and	  pain	  thresholds	  between	  healthy	  controls	  and	  patients	  with	  non-­‐
cardiac	  chest	  pain	  is	  tabulated	  in	  Table	  3.1.1c.	  
Table	  3.1.1c	  Sensory	  Thresholds	  and	  Pain	  Thresholds	  to	  Oesophageal	  Stimulation	  
	  
Post-­‐priori	  analysis	  of	  the	  pain	  threshold	  (PT)	  data	  computes	  a	  required	  sample	  size	  of	  21,	  a	  power	  
of	  64%	  and	  a	  minimal	  detectable	  difference	  of	  15.17mA.	   	   	  
Statistics	  
One	  way	  ANOVA	  was	  used	  to	  examine	  for	  inter-­‐	  and	  intra-­‐	  group	  differences	  between	  the	  3	  days	  and	  
repeated	  measures	  ANOVA	  assessed	  the	  repeatability	  of	  observations	  between	  separate	  days.	  The	  
mean	  3	  day	  difference	  between	  IBS	  and	  control	  groups	  was	  analysed	  by	  the	  Mann-­‐Whitney	  test.	  







Psychological	  analysis	  was	  performed	  using	  a	  variety	  of	  psychological	  instruments.	  These	  were	  
performed	  before	  the	  anorectal	  physiology	  and	  CEP	  harvesting.	  Each	  study	  volunteer	  was	  left	  alone	  
in	  a	  quiet	  room	  to	  allow	  sufficient	  time	  to	  reflect	  and	  answer	  the	  questionnaires.	  






DAY	  1	  PSYCHOLOGICAL	  TESTS	   	  
Figure	  3.1.2	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Psychoticism	  
	  
Table	  3.1.2	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Psychoticism	  
Unpaired	  t	  test	   	  	  
P	  value	   0.4636	  
Mean	  ±	  SEM	  of	  Controls	   5.952	  ±	  0.6152	  N=21	  
Mean	  ±	  SEM	  of	  IBS	   5.273	  ±	  0.6205	  N=33	  
Difference	  between	  means	   0.6797	  ±	  0.9205	  
95%	  confidence	  interval	   -­‐1.169	  to	  2.528	  
	  























Figure	  3.1.3	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Extraversion	  
	  
	  
Table	  3.1.3	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Extraversion	  
Unpaired	  t	  test	   	  	  
P	  value	   0.0047	  
Mean	  ±	  SEM	  of	  Controls	   17.76	  ±	  0.9950	  N=21	  
Mean	  ±	  SEM	  of	  IBS	   13.70	  ±	  0.8966	  N=33	  
Difference	  between	  means	   4.065	  ±	  1.377	  
95%	  confidence	  interval	   1.300	  to	  6.830	  
	  
























Figure	  3.1.4	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Neuroticism	  
	  
	  
Table	  3.1.4	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Neuroticism	  
Unpaired	  t	  test	   	  	  
P	  value	   0.0001	  
Mean	  ±	  SEM	  of	  Controls	   8.905	  ±	  0.9484	  N=21	  
Mean	  ±	  SEM	  of	  IBS	   14.81	  ±	  0.9677	  N=32	  
Difference	  between	  means	   -­‐5.908	  ±	  1.422	  
95%	  confidence	  interval	   -­‐8.764	  to	  -­‐3.051	  
	  

























Figure	  3.1.5	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Lie	  
	  
Table	  3.1.5	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Lie	  
Unpaired	  t	  test	   	  	  
P	  value	   0.0225	  
Mean	  ±	  SEM	  of	  Controls	   8.095	  ±	  0.8133	  N=21	  
Mean	  ±	  SEM	  of	  IBS	   10.67	  ±	  0.7013	  N=33	  
Difference	  between	  means	   -­‐2.571	  ±	  1.093	  
95%	  confidence	  interval	   -­‐4.766	  to	  -­‐0.3764	  
	  
























Figure	  3.1.6	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Addiction	  
Table	  3.1.6	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Addiction	  
Unpaired	  t	  test	   	  	  
P	  value	   0.5039	  
Mean	  ±	  SEM	  of	  Controls	   3.619	  ±	  0.4854	  N=21	  
Mean	  ±	  SEM	  of	  IBS	   3.242	  ±	  0.3228	  N=33	  
Difference	  between	  means	   0.3766	  ±	  0.5596	  
95%	  confidence	  interval	   -­‐0.7474	  to	  1.501	  
	  
























Figure	  3.1.7	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Criminality	  
Table	  3.1.7	  Eysenck	  Personality	  Questionnaire-­‐	  Revised:	  Criminality	  
Unpaired	  t	  test	   	  	  
P	  value	   0.1280	  
Mean	  ±	  SEM	  of	  Controls	   4.619	  ±	  0.4336	  N=21	  
Mean	  ±	  SEM	  of	  IBS	   5.333	  ±	  0.2449	  N=33	  
Difference	  between	  means	   -­‐0.7143	  ±	  0.4618	  
95%	  confidence	  interval	   -­‐1.642	  to	  0.2131	  
	  
Analysis	  
The	  EPQ-­‐R	  demonstrated	  statistical	  significance	  between	  groups	  for	  extraversion,	  neuroticism	  and	  
lie.	  IBS	  patients	  were	  more	  introverted	  (i.e.	  less	  extrovert).	  Introversion	  is	  a	  state	  of	  chronic	  over-­‐
arousal	  in	  which	  one	  actively	  seeks	  a	  more	  relaxed,	  serene	  environment.	  IBS	  patients	  were	  more	  
neurotic,	  which	  reflects	  a	  state	  of	  emotional	  instability,	  constant	  worrying	  and	  a	  tendency	  towards	  
depression	  and	  anxiety.	  The	  lie	  scale	  is	  the	  concept	  of	  dissimulation,	  in	  which	  one	  pretends	  that	  
things	  are	  better	  than	  they	  actually	  are.	   	  
The	  value	  of	  using	  the	  EPQ-­‐R	  in	  this	  study	  is	  that	  few	  investigators	  have	  researched	  the	  personality	  
traits	  of	  people	  with	  IBS.	  The	  EPQ-­‐R	  has	  not	  been	  used	  before	  in	  an	  IBS	  study.	  Another	  point	  to	  make	  
is	  that	  the	  increased	  neuroticism	  scores	  (with	  the	  inherent	  implication	  of	  increased	  tendencies	  to	  
anxiety	  and	  depression)	  show	  good	  correlation	  with	  the	  Hospital	  Anxiety	  and	  Depression	  scores	  and	  






















Figure	  3.1.8	  Visceral	  Sensitivity	  Index	  






15	  questions	  with	  a	  maximum	  of	  5	  points	  per	  question,	  making	  a	  combined	  total	  of	  75.	  
Analysis	  
The	  Visceral	  Sensitivity	  Index	  assesses	  anxiety	  related	  to	  specific	  gastrointestinal	  symptoms.	  
Examples	  include	  being	  anxious	  about	  going	  into	  a	  new	  restaurant,	  being	  frightened	  about	  
abdominal	  discomfort	  and	  being	  aware	  of	  abdominal	  symptoms	  during	  periods	  of	  stress	  etc.	  As	  a	  
consequence,	  the	  IBS	  population	  was	  always	  going	  to	  score	  more	  highly	  the	  control	  population,	  as	  
seen	  by	  the	  level	  of	  statistical	  significance	  that	  was	  attained.	  Of	  the	  21	  controls,	  3	  subjects	  scored	  
over	  10.	  In	  the	  IBS	  group,	  only	  3	  out	  of	  33	  scored	  less	  than	  20,	  the	  average	  was	  41.5	  and	  the	  range	  
spanned	  from	  10	  to	  73.	  It	  is	  obvious	  that	  anxiety	  related	  to	  gastrointestinal	  symptoms,	  and	  the	  fear	  
of	  losing	  control	  of	  one’s	  bodily	  function	  (its	  ultimate	  expression	  being	  faecal	  incontinence)	  causes	  
significant	  distress	  in	  IBS	  patients.	  Anecdotally,	  many	  of	  the	  IBS	  patients	  described	  how	  they	  always	  
needed	  to	  know	  exactly	  where	  a	  toilet	  was	  when	  they	  were	  out,	  and	  some	  felt	  almost	  paralysed	  by	  
the	  thought	  of	  having	  to	  leave	  their	  own	  homes.	  
Unpaired	  t	  test	   	  	  
P	  value	   <	  0.0001	  
Mean	  ±	  SEM	  of	  Controls	   6.762	  ±	  1.765	  N=21	  
Mean	  ±	  SEM	  of	  IBS	   41.52	  ±	  3.169	  N=33	  
Difference	  between	  means	   -­‐34.75	  ±	  4.226	  
























Figure	  3.1.9	  Patient	  Health	  Questionnaire	  15	  
Table	  3.1.9	  Patient	  Health	  Questionnaire	  15	  
Unpaired	  t	  test	   	  	  
P	  value	   <	  0.0001	  
Mean	  ±	  SEM	  of	  Controls	   5.238	  ±	  0.6543	  N=21	  
Mean	  ±	  SEM	  of	  IBS	   11.52	  ±	  0.8418	  N=33	  
Difference	  between	  means	   -­‐6.277	  ±	  1.179	  
95%	  confidence	  interval	   -­‐8.646	  to	  -­‐3.909	  
	  
Scoring	  
15	  questions	  with	  a	  maximum	  score	  of	  2	  per	  question,	  giving	  a	  combined	  maximum	  of	  30.	  A	  case	  is	  
considered	  to	  have	  a	  score	  of	  6	  or	  more.	  
Analysis	  
The	  PHQ-­‐15	  data	  shows	  an	  increase	  in	  somatisation	  in	  IBS	  patients.	  The	  Control	  group	  mean	  was	  
5.24,	  within	  the	  normal	  range.	  This	  compared	  to	  a	  mean	  of	  11.52	  in	  the	  IBS	  group.	  High	  PHQ	  values	  
cannot	  diagnose	  somatoform	  disorders,	  but	  measure	  somatic	  symptom	  severity.	  An	  interesting	  
observation	  in	  studies	  which	  have	  used	  the	  PHQ-­‐15	  is	  that	  high	  scores	  are	  associated	  with	  excessive	  
consumption	  of	  health	  care	  resources.	  Of	  course,	  IBS	  patients	  (like	  most	  other	  medical	  conditions)	  
are	  divided	  into	  those	  cases	  that	  present	  to	  their	  doctors	  for	  investigation	  of	  their	  symptoms,	  and	  
those	  that	  do	  not.	  However,	  in	  tertiary	  gastroenterology	  centres,	  it	  is	  not	  difficult	  to	  find	  a	  subgroup	  
of	  IBS	  patients	  who	  are	  not	  satisfied	  until	  they	  have	  been	  subjected	  to	  every	  investigation	  to	  exclude	  
organic	  pathology,	  and	  even	  then	  they	  find	  it	  difficult	  to	  accept	  the	  idea	  that	  their	  symptoms	  have	  a	  
functional	  aetiology.	  Certainly,	  somatisation	  or	  the	  transference	  of	  internal	  psychological	  conflict	  

























Figure	  3.1.10	  Whiteley	  Index	  
	  
Table	  3.1.10	  Whiteley	  Index	  
Unpaired	  t	  test	   	  	  
P	  value	   0.0014	  
Mean	  ±	  SEM	  of	  Controls	   22.75	  ±	  1.852	  N=20	  
Mean	  ±	  SEM	  of	  IBS	   31.36	  ±	  1.639	  N=33	  
Difference	  between	  means	   -­‐8.614	  ±	  2.554	  
95%	  confidence	  interval	   -­‐13.74	  to	  -­‐3.482	  
	  
Scoring	  
14	  questions	  with	  between	  1	  and	  5	  scored	  per	  question	  to	  make	  a	  combined	  total	  of	  70.	  Healthy	  
people	  without	  health	  anxiety	  generally	  have	  a	  score	  of	  21	  +/-­‐	  7	  (14	  to	  28).	  Patients	  with	  
hypochondria	  are	  found	  to	  have	  a	  score	  of	  44	  +/-­‐	  11	  (32	  to	  55).	  
Analysis	  
The	  Whiteley	  Index	  demonstrates	  good	  statistical	  significance	  between	  the	  groups.	  With	  reference	  
to	  the	  control	  population	  3	  subjects	  had	  scores	  at	  or	  above	  the	  threshold	  of	  32	  to	  imply	  some	  degree	  
of	  hypochondriasis.	  The	  control	  range	  was	  16	  to	  45.	  Sixteen	  of	  33	  IBS	  scored	  32	  with	  a	  group	  range	  
of	  19	  to	  51.	  The	  IBS	  group	  mean	  was	  31.36	  just	  short	  of	  this	  threshold.	  In	  addition	  to	  disease	  
conviction	  and	  disease	  phobia,	  the	  Whiteley	  Index	  explores	  somatic	  preoccupation,	  thereby	  tying	  in	  























DAY	  1	  TO	  3	  PSYCHOLOGICAL	  TESTS	  
The	  following	  psychological	  tests	  were	  completed	  on	  each	  of	  the	  3	  days	  of	  CEP	  testing.	  They	  were	  
chosen	  because	  they	  were	  powered	  to	  observe	  volatile	  psychological	  factors	  i.e.	  those	  factors	  that	  
change	  over	  short	  periods	  of	  time	  e.g.	  situational	  anxiety.	   	   	   	  






Figure	  3.1.11	  Hospital	  Anxiety	  and	  Depression:	  Anxiety	  Score	  
	  
Table	  3.1.11	  Hospital	  Anxiety	  and	  Depression:	  Anxiety	  Score	   	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0002	   0.0008	   0.0017	  
Mean	  ±	  SEM	  of	  Controls	   5.190	  ±	  0.6818	  N=21	   4.850	  ±	  0.5632	  N=20	   4.526	  ±	  0.6595	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   9.333	  ±	  0.7186	  N=33	   8.581	  ±	  0.7589	  N=31	   8.448	  ±	  0.8446	  N=29	  
Difference	  between	  means	   -­‐4.143	  ±	  1.053	   -­‐3.731	  ±	  1.049	   -­‐3.922	  ±	  1.174	  
95%	  confidence	  interval	   -­‐6.259	  to	  -­‐2.027	   -­‐5.842	  to	  -­‐1.620	   -­‐6.287	  to	  -­‐1.557	  
	  
Scoring	  
7	  questions	  with	  scores	  between	  0	  and	  3	  producing	  a	  combined	  total	  of	  21.	  Non-­‐cases	  score	  
between	  0	  &	  7;	  possible	  cases	  score	  between	  8	  &	  10;	  probable	  cases	  score	  between	  11	  &	  21.	  
Analysis	  
The	  HAD-­‐Anxiety	  scores	  recorded	  in	  the	  IBS	  group	  were	  repeatedly	  and	  significantly	  more	  than	  the	  
Control	  group.	  The	  IBS	  mean	  3	  day	  averages	  spanned	  between	  8.4	  and	  9.3,	  identifying	  possible	  
anxiety	  cases.	  The	  Control	  group	  mean	  was	  5.19	  on	  Day	  1,	  dropping	  to	  4.52	  by	  Day	  3.	  Interestingly,	  2	  
Controls	  on	  Day	  1	  were	  identified	  as	  possible	  cases,	  and	  2	  more	  were	  identified	  as	  probable	  cases.	  



























Figure	  3.1.12	  Hospital	  Anxiety	  and	  Depression:	  Depression	  Score	  
Table	  3.1.12	  Hospital	  Anxiety	  and	  Depression:	  Depression	  Score	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0002	   0.0095	   0.0082	  
Mean	  ±	  SEM	  of	  Controls	   1.333	  ±	  0.3541	  N=21	   1.800	  ±	  0.4451	  N=21	   1.579	  ±	  0.5091	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   4.394	  ±	  0.5673	  N=33	   4.032	  ±	  0.6090	  N=31	   4.414	  ±	  0.7584	  N=29	  
Difference	  between	  means	   -­‐3.061	  ±	  0.7670	   -­‐2.232	  ±	  0.8271	   -­‐2.835	  ±	  1.026	  
95%	  confidence	  interval	   -­‐4.601	  to	  -­‐1.520	   -­‐3.895	  to	  -­‐0.5695	   -­‐4.902	  to	  -­‐0.7681	  
	  
Scoring	  
7	  questions	  with	  scores	  between	  0	  and	  3	  producing	  a	  combined	  total	  of	  21.	  Non-­‐cases	  score	  
between	  0	  &	  7;	  possible	  cases	  score	  between	  8	  &	  10;	  probable	  cases	  score	  between	  11	  &	  21.	  
Analysis	  
The	  HAD-­‐Depression	  looks	  for	  depressive	  tendencies,	  and	  shares	  the	  same	  scoring	  system	  as	  the	  
HAD-­‐Anxiety.	  Both	  group	  means	  fell	  within	  the	  range	  of	  normality	  (i.e.	  less	  than	  8),	  but	  even	  so,	  the	  
IBS	  patients	  were	  found	  to	  have	  more	  depressive	  tendencies	  than	  their	  healthy	  counterparts.	  No	  
possible	  or	  probable	  cases	  were	  identified	  in	  the	  Control	  group	  over	  the	  3	  days.	  The	  range	  of	  scores	  
in	  the	  IBS	  group	  was	  0	  and	  12	  (Days	  1	  and	  2),	  and	  0	  and	  14	  (Day	  3)	  proving	  that	  certain	  individuals	  



























Figure	  3.1.13	  Spielberger	  State	  Trait	  Anxiety	  Inventory:	  State	  Anxiety	  
Table	  3.1.13	  Spielberger	  State	  Trait	  Anxiety	  Inventory:	  State	  Anxiety	   	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0062	   0.0014	   0.0297	  
Mean	  ±	  SEM	  of	  Controls	   31.90	  ±	  1.489	  N=21	   28.95	  ±	  1.274	  N=20	   31.63	  ±	  2.265	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   38.85	  ±	  1.691	  N=33	   37.61	  ±	  1.884	  N=31	   39.69	  ±	  2.494	  N=29	  
Difference	  between	  means	   -­‐6.944	  ±	  2.434	   -­‐8.663	  ±	  2.564	   -­‐8.058	  ±	  3.590	  
95%	  confidence	  interval	   -­‐11.83	  to	  -­‐2.056	   -­‐13.82	  to	  -­‐3.505	   -­‐15.29	  to	  -­‐0.8247	  
	  
Scoring	  
20	  questions	  scored	  between	  1	  and	  4,	  making	  a	  combined	  total	  of	  80.	  Cases	  score	  more	  than	  35.	  
Analysis	  
The	  Spielberger	  State	  Anxiety	  Index	  is	  powered	  to	  detect	  situational	  anxiety.	  It	  offers	  to	  identify	  
those	  subjects	  who	  demonstrate	  ongoing	  anxiety.	  Its	  inclusion	  was	  brought	  about	  by	  the	  desire	  to	  
see	  if	  there	  was	  any	  difference	  between	  the	  study	  groups	  when	  both	  were	  faced	  with	  the	  same	  
unknown	  entity,	  namely	  rectal	  electrical	  stimulation	  and	  CEP	  harvesting.	  Surprisingly	  statistical	  
significance	  was	  achieved	  even	  at	  Day	  1with	  a	  mean	  IBS	  score	  of	  38.8	  (compared	  to	  31.9	  in	  the	  
Controls).	  At	  no	  point	  did	  the	  State	  Anxiety	  drop	  below	  the	  case	  threshold	  of	  35	  in	  the	  IBS	  group.	  
This	  suggests	  that	  IBS	  patients	  mount	  a	  greater	  anxiety	  response	  to	  the	  same	  perceived	  threat	  (the	  
electrical	  stimulation),	  and	  that	  this	  does	  not	  diminish	  over	  time	  even	  with	  increasing	  familiarity	  of	  


























Figure	  3.1.14	  Spielberger	  State	  Trait	  Anxiety	  Inventory:	  Trait	  Anxiety	  
	  
Table	  3.1.14	  Spielberger	  State	  Trait	  Anxiety	  Inventory:	  Trait	  Anxiety	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0002	   0.0051	   0.0004	  
Mean	  ±	  SEM	  of	  Controls	   33.90	  ±	  1.496	  N=21	   32.60	  ±	  1.588	  N=20	   32.16	  ±	  1.714	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   44.48	  ±	  1.882	  N=33	   40.71	  ±	  1.966	  N=31	   43.96	  ±	  2.285	  N=28	  
Difference	  between	  means	   -­‐10.58	  ±	  2.648	   -­‐8.110	  ±	  2.765	   -­‐11.81	  ±	  3.118	  
95%	  confidence	  interval	   -­‐15.90	  to	  -­‐5.261	   -­‐13.67	  to	  -­‐2.548	   -­‐18.09	  to	  -­‐5.522	  
	  
Scoring	  
20	  questions	  scored	  between	  1	  and	  4,	  making	  a	  combined	  total	  of	  80.	  Cases	  score	  more	  than	  35.	  
Analysis	  
The	  Spielberger	  Trait	  Anxiety	  Index	  examines	  for	  one’s	  general	  propensity	  to	  anxiety,	  essentially	  
defining	  an	  anxiety	  characteristic.	  The	  Control	  group	  scored	  persistently	  below	  the	  case	  threshold	  of	  
35,	  whereas	  the	  IBS	  group	  did	  not	  fall	  below	  40	  over	  the	  3	  days.	  The	  Trait	  Anxiety	  score	  is	  more	  time	  
independent	  than	  the	  State	  Anxiety.	  However	  both	  indexes	  showed	  little	  variation	  in	  either	  group	  
over	  the	  3	  separate	  days.	   	  


























Figure	  3.1.15	  Visual	  Descriptor	  Visual	  Analogue	  Scale:	  Unpleasantness	  of	  Symptoms	  
	  
Table	  3.1.15	  Visual	  Descriptor	  Visual	  Analogue	  Scale:	  Unpleasantness	  of	  Symptoms	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   <	  0.0001	   <	  0.0001	   <	  0.0001	  
Mean	  ±	  SEM	  of	  Controls	   1.619	  ±	  0.4220	  N=21	   1.145	  ±	  0.4025	  N=20	   1.200	  ±	  0.4106	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   11.78	  ±	  0.7361	  N=33	   10.02	  ±	  0.6769	  N=31	   9.631	  ±	  0.7841	  N=29	  
Difference	  between	  means	   -­‐10.17	  ±	  0.9847	   -­‐8.871	  ±	  0.9049	   -­‐8.431	  ±	  1.027	  
95%	  confidence	  interval	   -­‐12.14	  to	  -­‐8.188	   -­‐10.69	  to	  -­‐7.051	   -­‐10.50	  to	  -­‐6.362	  
	  
Scoring	  
The	  VDVAS	  is	  a	  20cm	  vertical	  column	  with	  various	  descriptors	  outlined	  at	  defined	  distances	  from	  the	  
baseline	  at	  0cm.	  Increasing	  distance	  from	  baseline	  indicates	  increased	  severity	  of	  the	  
unpleasantness	  of	  gastrointestinal	  symptoms.	   	  
Analysis	  
The	  VDVAS	  for	  the	  unpleasantness	  of	  gastrointestinal	  symptoms	  produces	  a	  clear	  demarcation	  
between	  IBS	  and	  Control	  groups.	  This	  is	  hardly	  surprising	  given	  the	  fact	  the	  Control	  group	  by	  
definition	  is	  asymptomatic.	  However	  it	  afforded	  a	  snapshot	  of	  the	  perception	  of	  gastrointestinal	  


























Figure	  3.1.16	  Visual	  Descriptor	  Visual	  Analogue	  Scale:	  Intensity	  of	  Symptoms	  
	  
Table	  3.1.16	  Visual	  Descriptor	  Visual	  Analogue	  Scale:	  Intensity	  of	  Symptoms	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   <	  0.0001	   <	  0.0001	   <	  0.0001	  
Mean	  ±	  SEM	  of	  Controls	   1.752	  ±	  0.6115	  N=21	   1.675	  ±	  0.6089	  N=20	   1.358	  ±	  0.5163	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   13.73	  ±	  0.6943	  N=33	   12.29	  ±	  0.6890	  N=31	   11.97	  ±	  0.8123	  N=29	  
Difference	  between	  means	   -­‐11.98	  ±	  0.9991	   -­‐10.62	  ±	  0.9888	   -­‐10.61	  ±	  1.090	  
95%	  confidence	  interval	   -­‐13.99	  to	  -­‐9.974	   -­‐12.60	  to	  -­‐8.626	   -­‐12.80	  to	  -­‐8.412	  
	  
Scoring	  
The	  VDVAS	  is	  a	  20cm	  vertical	  column	  with	  various	  descriptors	  outlined	  at	  defined	  distances	  from	  the	  
baseline	  at	  0cm.	  Increasing	  distance	  from	  baseline	  indicates	  increased	  severity	  of	  the	  intensity	  of	  
gastrointestinal	  symptoms.	   	  
Analysis	  
The	  VDVAS	  for	  gastrointestinal	  intensity	  is	  constructed	  in	  an	  identical	  fashion	  to	  the	  VDVAS	  for	  
unpleasantness,	  with	  the	  exception	  that	  different	  visual	  descriptors	  are	  used.	  Like	  its	  sibling,	  the	  
VDVAS	  for	  intensity	  of	  gastrointestinal	  symptoms	  produces	  a	  clear	  separation	  between	  the	  two	  


























ANORECTAL	  SENSITIVITY	  AND	  CORTICAL	  EVOKED	  POTENTIALS	  
The	  following	  section	  comprises	  the	  anorectal	  physiology	  data,	  featuring	  the	  sensory	  and	  pain	  
thresholds;	  analysis	  of	  the	  morphology	  of	  the	  CEPs;	  the	  assessment	  of	  the	  CEPs	  peaks	  with	  regards	  
to	  latency	  and	  amplitude;	  and	  Tables	  3.1.22b	  to	  d	  show	  the	  comparison	  of	  the	  peak	  latencies	  and	  
amplitudes	  for	  the	  Control	  group	  over	  the	  3	  days	  of	  testing.	  






Figure	  3.1.17	  Sensory	  Thresholds	  
	  
Table	  3.1.17	  Sensory	  Thresholds	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.8347	   0.0139	   0.8717	  
Mean	  ±	  SEM	  of	  Controls	   18.06	  ±	  1.360	  N=21	   14.73	  ±	  0.9137	  N=20	   15.82	  ±	  1.767	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   18.70	  ±	  2.277	  N=33	   21.29	  ±	  2.000	  N=30	   16.24	  ±	  1.772	  N=29	  
Difference	  between	  means	   -­‐0.6418	  ±	  3.061	   -­‐6.560	  ±	  2.568	   -­‐0.4252	  ±	  2.618	  
95%	  confidence	  interval	   -­‐6.789	  to	  5.505	   -­‐11.73	  to	  -­‐1.392	   -­‐5.699	  to	  4.849	  
	  
Analysis	  
Mean	  values	  for	  sensory	  thresholds	  were	  similar	  in	  both	  groups	  over	  Days	  1	  and	  3.	  Day	  2	  produced	  a	  
separation	  between	  the	  groups	  with	  an	  IBS	  mean	  of	  21.29mA	  and	  a	  Control	  mean	  of	  14.73mA.	  With	  
reference	  to	  the	  scattergrams,	  it	  is	  quite	  clear	  that	  there	  were	  a	  few	  IBS	  outliers	  who	  were	  skewing	  
the	  distribution	  to	  the	  right.	  Even	  so	  a	  higher	  sensory	  threshold	  reflects	  either	  a	  hyposensitive	  state	  


































Figure	  3.1.18	  Pain	  Thresholds	  
	  
Table	  3.1.18	  Pain	  Thresholds	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0735	   0.2463	   0.0058	  
Mean	  ±	  SEM	  of	  Controls	   70.21	  ±	  4.793	  N=21	   71.61	  ±	  4.814	  N=20	   79.45	  ±	  4.839	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   57.72	  ±	  4.513	  N=33	   63.19	  ±	  4.893	  N=30	   58.23	  ±	  5.011	  N=29	  
Difference	  between	  means	   12.48	  ±	  6.833	   8.420	  ±	  7.173	   21.22	  ±	  7.334	  
95%	  confidence	  interval	   -­‐1.241	  to	  26.20	   -­‐6.017	  to	  22.86	   6.440	  to	  35.99	  
	  
Analysis	  
The	  pain	  threshold	  denotes	  the	  stimulus	  intensity	  that	  confers	  a	  painful	  response.	  Comparison	  of	  the	  
2	  groups	  shows	  a	  lower	  pain	  threshold	  in	  IBS	  patients	  over	  the	  three	  days,	  reaching	  statistical	  
significance	  on	  Day	  3.	  This	  is	  due	  to	  an	  increase	  in	  the	  pain	  thresholds	  in	  the	  Control	  group	  rather	  
than	  a	  corresponding	  drop	  in	  the	  pain	  thresholds	  in	  the	  IBS	  group.	  The	  IBS	  thresholds	  stay	  largely	  
unchanged	  over	  the	  three	  days.	  There	  is	  a	  much	  larger	  range	  of	  thresholds	  in	  the	  IBS	  patients,	  with	  
values	  recorded	  between	  10.83mA	  and	  99mA	  on	  the	  first	  day,	  contrasting	  with	  34mA	  and	  99mA	  in	  
the	  control	  group.	  The	  rise	  in	  pain	  thresholds	  by	  the	  Control	  group	  on	  Day	  3	  may	  be	  explained	  by	  the	  
fact	  that	  the	  Control	  group	  has	  started	  to	  habituate	  to	  the	  testing	  protocol	  allowing	  a	  greater	  
current	  to	  be	  applied.	  Symptom-­‐generation	  and	  propagation	  in	  IBS	  may	  be	  partially	  driven	  by	  the	  


































CORTICAL	  EVOKED	  POTENTIALS	  
Figure	  3.1.19	  A	  Cortical	  evoked	  potential	  recorded	  after	  a	  single	  stimulation	  from	  a	  
Control	  subject	  
	  








Figure	  3.1.21	  Cortical	  evoked	  potentials	  recorded	  over	  4	  cycles	  of	  50	  electrical	  
stimulations	  from	  a	  Control	  subject	  
	  
	  










Figure	  3.1.19	  shows	  how	  difficult	  it	  is	  to	  analyse	  a	  CEP	  in	  isolation.	  Each	  trace	  is	  readily	  susceptible	  to	  
movement	  artefact,	  and	  it	  is	  only	  after	  the	  averaging	  of	  multiple	  frames	  that	  the	  true	  morphology	  of	  
the	  cortical	  response	  is	  seen	  (Figure	  3.1.20).	  The	  vertical	  dotted	  lines	  in	  this	  figure	  reveal	  the	  
distribution	  of	  the	  separate	  peaks	  so	  that	  the	  latencies	  and	  amplitudes	  can	  be	  calculated.	   	   	   	  
The	  intra-­‐day	  reproduction	  of	  the	  cortical	  response	  over	  a	  series	  of	  4	  separate	  cycles	  of	  50	  
stimulations	  is	  clearly	  evident	  in	  Figure	  3.1.21.	  The	  inter-­‐day	  comparisons	  are	  seen	  in	  Figure	  3.1.22.	  
The	  black	  and	  green	  graphs	  represent	  testing	  on	  Day	  1	  and	  2.	  The	  Day	  3	  graph	  is	  coloured	  in	  red.	  For	  
this	  particular	  control	  subject,	  the	  Spielberger	  State	  Anxiety	  steadily	  fell	  from	  the	  initial	  peak	  of	  33	  
on	  Day	  1	  to	  27	  on	  Day	  2	  and	  26	  on	  Day	  3.	  The	  stimulus	  intensity	  increased	  from	  33.25mA	  on	  Day	  1	  to	  
58.6mA	  on	  Day	  3.	  This	  suggests	  that	  increased	  familiarity	  with	  the	  testing	  produced	  a	  more	  relaxed	  
subject,	  and	  the	  opportunity	  to	  increase	  the	  stimulus	  intensity	  resulting	  in	  a	  more	  prominent	  cortical	  
response.	  
	  
INTRA-­‐DAY	  AND	  INTER-­‐DAY	  VARIABILITY	  OF	  CORTICAL	  EVOKED	  POTENTIALS	  IN	  THE	  CONTROL	  
GROUP	  
Table	  3.1.22b	  One	  Way	  ANOVA	  of	  the	  mean	  difference	  of	  anorectal	  sensitivities,	  CEP	  peak	  
latencies	  and	  CEP	  peak	  amplitudes	  between	  Day	  2	  and	  Day	  1	  in	  the	  Control	  group	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Sensory	  Threshold	  (mA)	   -­‐3.33	   (-­‐7.18,	  0.52)	   0.089	  
Pain	  Threshold	   1.41	   (-­‐12.07,	  14.89)	   0.8351	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Peak	  1	  Latency	  (ms)	   0.64	   (-­‐9.72,	  11.00)	   0.9018	  
Peak	  2	  Latency	   -­‐5.14	   (-­‐18.05,	  7.78)	   0.4288	  
Peak	  3	  Latency	   -­‐5.27	   (-­‐19.83,	  9.28)	   0.471	  
Peak	  4	  Latency	   -­‐11.71	   (-­‐39.42,	  16.01)	   0.4011	  
Peak	  5	  Latency	   -­‐9.58	   (-­‐75.45,	  56.28)	   0.7717	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Peak	  1	  Amplitude	  (mV)	   0.63	   (-­‐2.45,	  3.72)	   0.6821	  
Peak	  2	  Amplitude	   2.65	   (-­‐4.82,	  10.12)	   0.4803	  
Peak	  3	  Amplitude	   3.52	   (-­‐2.47,	  9.51)	   0.2439	  








Table	  3.1.22c	  One	  Way	  ANOVA	  of	  the	  mean	  difference	  of	  anorectal	  sensitivities,	  CEP	  peak	  
latencies	  and	  CEP	  peak	  amplitudes	  between	  Day	  3	  and	  Day	  1	  in	  the	  Control	  group	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Sensory	  Threshold	  (mA)	   -­‐2.24	   (-­‐6.15,	  1.66)	   0.2545	  
Pain	  Threshold	   9.24	   (-­‐4.42,	  22.91)	   0.1808	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Peak	  1	  Latency	  (ms)	   -­‐0.75	   (-­‐11.11,	  9.61)	   0.8855	  
Peak	  2	  Latency	   -­‐6.56	   (-­‐19.47,	  6.35)	   0.3133	  
Peak	  3	  Latency	   -­‐8.71	   (-­‐23.27,	  5.85)	   0.2357	  
Peak	  4	  Latency	   -­‐16.84	   (-­‐44.56,	  10.87)	   0.2286	  
Peak	  5	  Latency	   0.45	   (-­‐65.42,	  66.32)	   0.9892	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Peak	  1	  Amplitude	  (mV)	   -­‐0.05	   (-­‐3.14,	  3.04)	   0.9744	  
Peak	  2	  Amplitude	   3.77	   (-­‐3.69,	  11.24)	   0.3155	  
Peak	  3	  Amplitude	   5.56	   (-­‐0.43,	  11.54)	   0.0683	  
Peak	  4	  Amplitude	   1.46	   (-­‐1.43,	  4.35)	   0.3146	  
	  
Table	  3.1.22d	  One	  Way	  ANOVA	  of	  the	  mean	  difference	  of	  anorectal	  sensitivities,	  CEP	  peak	  
latencies	  and	  CEP	  peak	  amplitudes	  between	  Day	  3	  and	  Day	  2	  in	  the	  Control	  group	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Sensory	  Threshold	  (mA)	   1.08	   (-­‐2.89,	  5.06)	   0.5834	  
Pain	  Threshold	   7.84	   (-­‐6.00,	  21.67)	   0.2586	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Peak	  1	  Latency	  (ms)	   -­‐1.39	   (-­‐12.01,	  9.23)	   0.7922	  
Peak	  2	  Latency	   -­‐1.42	   (-­‐14.97,	  12.13)	   0.8328	  
Peak	  3	  Latency	   -­‐3.44	   (-­‐16.81,	  9.93)	   0.6054	  
Peak	  4	  Latency	   -­‐5.14	   (-­‐32.68,	  22.40)	   0.7074	  
Peak	  5	  Latency	   10.03	   (-­‐61.05,	  81.11)	   0.7764	  
	   Mean	  difference	   95%	  CI	   P-­‐value	  
Peak	  1	  Amplitude	  (mV)	   -­‐0.68	   (-­‐4.01,	  2.65)	   0.6793	  
Peak	  2	  Amplitude	   1.13	   (-­‐6.98,	  9.23)	   0.7797	  
Peak	  3	  Amplitude	   2.04	   (-­‐4.33,	  8.40)	   0.5205	  




Tables	  3.1.22b,	  3.1.22c	  and	  3.1.22d	  compare	  control	  data	  pertaining	  to	  sensory	  and	  pain	  thresholds,	  
and	  CEP	  peak	  amplitudes	  and	  latencies.	  One	  Way	  ANOVA	  could	  supported	  the	  null	  hypothesis	  
concluding	  that	  the	  CEP	  protocol	  produced	  reproducible	  and	  reliable	  data	  over	  different	  days	  of	  
testing	  in	  the	  control	  group	  i.e.	  the	  CEP	  data	  was	  no	  different	  on	  different	  days	  of	  testing	  .	  Without	  







Analysis	  of	  the	  Cortical	  Evoked	  Potentials	  between	  Controls	  and	  IBS	  
The	  following	  series	  of	  graphs	  shows	  the	  comparison	  of	  the	  individual	  CEP	  components	  between	  the	  
Control	  and	  IBS	  groups.	  
Figure	  3.1.23	  Peak	  1	  Latency	  over	  3	  days	  
	  
	  
Table	  3.1.23	  Peak	  1	  Latency	  over	  3	  days	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0012	   0.0067	   0.1443	  
Mean	  ±	  SEM	  of	  Controls	   73.49	  ±	  3.641	  N=21	   74.13	  ±	  3.987	  N=19	   72.74	  ±	  3.393	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   96.35	  ±	  4.797	  N=33	   99.52	  ±	  6.550	  N=31	   107.8	  ±	  18.90	  N=29	  
Difference	  between	  means	   -­‐22.86	  ±	  6.691	   -­‐25.38	  ±	  8.954	   -­‐35.05	  ±	  23.60	  
































Figure	  3.1.24	  Peak	  2	  Latency	  over	  3	  days	  
	  
Table	  3.1.24	  Peak	  2	  Latency	  over	  3	  days	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0311	   0.0100	   0.0461	  
Mean	  ±	  SEM	  of	  Controls	   119.8	  ±	  4.347	  N=21	   114.7	  ±	  5.170	  N=19	   113.3	  ±	  4.234	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   138.8	  ±	  6.211	  N=33	   143.6	  ±	  7.801	  N=31	   133.6	  ±	  7.503	  N=29	  
Difference	  between	  means	   -­‐18.93	  ±	  8.540	   -­‐28.92	  ±	  10.78	   -­‐20.31	  ±	  9.908	  




































Figure	  3.1.25	  Peak	  3	  Latency	  over	  3	  days	  
	  
Table	  3.1.25	  Peak	  3	  Latency	  over	  3	  days	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.1828	   0.0346	   0.0229	  
Mean	  ±	  SEM	  of	  Controls	   224.2	  ±	  5.903	  N=21	   218.9	  ±	  4.641	  N=19	   215.5	  ±	  4.682	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   239.2	  ±	  8.004	  N=33	   243.1	  ±	  8.183	  N=31	   243.3	  ±	  9.051	  N=29	  
Difference	  between	  means	   -­‐14.99	  ±	  11.10	   -­‐24.14	  ±	  11.10	   -­‐27.87	  ±	  11.84	  


































Figure	  3.1.26	  Peak	  4	  Latency	  over	  3	  days	  
	  
Table	  3.1.26	  Peak	  4	  Latency	  over	  3	  days	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.6833	   0.2806	   0.2584	  
Mean	  ±	  SEM	  of	  Controls	   397.4	  ±	  10.22	  N=21	   385.7	  ±	  7.297	  N=19	   380.6	  ±	  11.45	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   405.8	  ±	  14.84	  N=33	   402.5	  ±	  11.09	  N=31	   396.1	  ±	  8.015	  N=29	  
Difference	  between	  means	   -­‐8.348	  ±	  20.35	   -­‐16.71	  ±	  15.32	   -­‐15.51	  ±	  13.55	  

































Figure	  3.1.27	  Peak	  5	  Latency	  over	  3	  days	  
	  
Table	  3.1.27a	  Peak	  5	  Latency	  over	  3	  days	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.2023	   0.8319	   0.4858	  
Mean	  ±	  SEM	  of	  Controls	   633.0	  ±	  20.92	  N=21	   623.4	  ±	  19.03	  N=19	   633.4	  ±	  29.43	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   674.3	  ±	  21.72	  N=33	   629.7	  ±	  19.75	  N=31	   612.1	  ±	  15.30	  N=29	  
Difference	  between	  means	   -­‐41.28	  ±	  31.96	   -­‐6.264	  ±	  29.34	   21.32	  ±	  30.35	  
































Table	  3.1.27b	  Summary	  of	  CEP	  Peak	  Latency	  Data	  
One	  Way	  ANOVA	  Comparison	  of	  Means:	  IBS	  vs.	  Controls	  
	   Day	  1	   Day	  2	   Day	  3	  











73.5	   96.35	   22.8	   0.0012	   74.1	   99.5	   25.38	   0.006	   72.7	   107.8	   35.5	   0.14	  
Peak	  
2	  L	  
119.85	   138.7	   18.9	   0.031	   114.7	   143.6	   28.9	   0.01	   113.3	   133.6	   20.3	   0.04	  
Peak	  
3	  L	  
224.2	   239.2	   14.99	   0.18	   218.9	   243.1	   24.1	   0.03	   215.5	   243.3	   27.9	   0.022	  
Peak	  
4	  A	  
397.4	   405.8	   8.35	   0.68	   385.7	   402.4	   16.7	   0.28	   380.6	   396.1	   15.5	   0.25	  
Peak	  
5	  A	  
633	   674.3	   41.3	   0.2	   623.4	   629.7	   6.3	   0.83	   633.4	   612.2	   -­‐21.3	   0.48	  
	  
Statistical	  significance	  is	  achieved	  in	  the	  early	  components	  of	  the	  cortical	  response.	  Latencies	  are	  
attenuated	  in	  the	  IBS	  population	  compared	  to	  the	  controls	  over	  3	  days.	  The	  difference	  is	  always	  in	  
the	  same	  direction,	  namely	  that	  the	  IBS	  CEP	  traces	  are	  more	  delayed,	  causing	  a	  right-­‐shift	  in	  the	  CEP	  
traces.	  This	  is	  contrary	  to	  what	  was	  expected-­‐	  the	  hypothesis	  proposed	  that	  latencies	  would	  be	  
reduced	  in	  IBS.	  
	  






Figure	  3.1.28	  Peak	  1	  Amplitude	  
	  
Table	  3.1.28	  Peak	  1	  Amplitude	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0750	   0.1864	   0.2908	  
Mean	  ±	  SEM	  of	  Controls	   7.529	  ±	  0.9821	  N=21	   8.163	  ±	  1.110	  N=19	   7.479	  ±	  1.210	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   5.110	  ±	  0.8580	  N=33	   6.026	  ±	  1.045	  N=31	   6.043	  ±	  0.7472	  N=29	  
Difference	  between	  means	   2.419	  ±	  1.331	   2.137	  ±	  1.595	   1.436	  ±	  1.344	  




































Figure	  3.1.29	  Peak	  2	  Amplitude	  
	  
	  
Table	  3.1.29	  Peak	  2	  Amplitude	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0459	   0.0272	   0.0078	  
Mean	  ±	  SEM	  of	  Controls	   19.36	  ±	  2.340	  N=21	   22.01	  ±	  2.995	  N=19	   23.14	  ±	  2.645	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   13.26	  ±	  1.857	  N=33	   14.45	  ±	  1.844	  N=31	   14.85	  ±	  1.679	  N=29	  
Difference	  between	  means	   6.101	  ±	  2.984	   7.563	  ±	  3.319	   8.286	  ±	  2.977	  




































Figure	  3.1.30	  Peak	  3	  Amplitude	  
	  
	  
Table	  3.1.30	  Peak	  3	  Amplitude	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0065	   0.0019	   0.0006	  
Mean	  ±	  SEM	  of	  Controls	   19.58	  ±	  1.963	  N=21	   23.10	  ±	  2.355	  N=19	   25.14	  ±	  2.075	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   12.51	  ±	  1.549	  N=33	   14.20	  ±	  1.563	  N=31	   15.87	  ±	  1.524	  N=29	  
Difference	  between	  means	   7.070	  ±	  2.494	   8.901	  ±	  2.716	   9.268	  ±	  2.522	  



































Figure	  3.1.31	  Peak	  4	  Amplitude	  
	  
Table	  3.1.31	  Peak	  4	  Amplitude	  
Unpaired	  t	  test	   Day	  1	  	   Day	  2	   Day	  3	  
P	  value	   0.0130	   0.0689	   0.1653	  
Mean	  ±	  SEM	  of	  Controls	   7.905	  ±	  0.8499	  N=21	   8.395	  ±	  0.9238	  N=19	   9.368	  ±	  1.288	  N=19	  
Mean	  ±	  SEM	  of	  IBS	   5.310	  ±	  0.5959	  N=33	   6.336	  ±	  0.6559	  N=31	   7.525	  ±	  0.6428	  N=29	  
Difference	  between	  means	   2.595	  ±	  1.008	   2.058	  ±	  1.106	   1.843	  ±	  1.307	  


































Table	  3.1.31b	  Summary	  of	  CEP	  Peak	  Amplitude	  Data	  
One	  Way	  ANOVA	  Comparison	  of	  Means:	  IBS	  vs.	  Controls	  
	   Day	  1	   Day	  2	   Day	  3	  
(𝛍V)	   Controls	   IBS	   Mean	  Δ	   P-­‐value	   Controls	   IBS	   Mean	  Δ	   P-­‐value	   Controls	   IBS	   Mean	  Δ	   P-­‐value	  
Peak	  1	  
A	   7.5	   5.1	   -­‐2.42	   0.07	   8.16	   6.03	   -­‐2.14	   0.18	   7.5	   6	   -­‐1.4	   0.29	  
Peak	  2	  
A	   19.4	   13.3	   -­‐6.1	   0.045	   22	   14.4	   -­‐7.56	   0.02	   23.1	   14.9	   -­‐8.3	   0.007	  
Peak	  3	  
A	   19.58	   12.51	   -­‐7.07	   0.006	   23.1	   14.5	   -­‐8.9	   0.001	   25.1	   15.9	   -­‐9.3	   0.0006	  
Peak	  4	  
A	   7.9	   5.3	   -­‐2.59	   0.01	   8.4	   6.3	   -­‐2.1	   0.068	   9.4	   7.5	   -­‐1.84	   0.165	  
	  
Again	  the	  data	  confounded	  the	  proposed	  hypothesis	  of	  rectal	  hypersensitivity.	  Group	  analysis	  of	  the	  
CEP	  amplitudes	  show	  that	  IBS	  patients	  produced	  smaller	  amplitude	  traces	  compared	  to	  Controls,	  
and	  that	  this	  was	  independent	  of	  the	  amount	  of	  electricity	  used	  (stimulus	  intensity	  on	  Visits	  1	  and	  2	  
was	  not	  statistically	  different).	  






CORRELATIONS	  OF	  THE	  CEP	  STUDY	  DATA	  
Table	  3.1.32	  Spearman	  Correlation	  Coefficients	  of	  the	  IBS	  Group	  
Key	  
P-­‐	  Psychoticism	  Scale	  of	  the	  EPQR	  
E-­‐	  Extroversion	  Scale	  of	  the	  EPQR	  
N-­‐	  Neuroticism	  scale	  of	  the	  EPQR	  
L-­‐	  Lie	  Scale	  of	  the	  EPQR	  
A-­‐	  Addiction	  Scale	  of	  the	  EPQR	   	  
C-­‐	  Criminality	  Scale	  of	  the	  EPQR	  
VSI-­‐	  Visceral	  Sensitivity	  Index	   	  
PHQ-­‐	  Patient	  Health	  
Questionnaire	  
Whiteley-­‐	  Whiteley	  Index	  
HAD	  A-­‐	  Anxiety	  scale	  of	  the	  HAD	  
HAD	  D-­‐	  Depression	  scale	  of	  the	  
HAD	  
SSTAI-­‐S-­‐	  State	  anxiety	  of	  the	  
Spielberger	  State	  Trait	  Anxiety	  
Inventory	   	  
SSTAI-­‐T-­‐	  Trait	  Anxiety	  of	  the	  
Spielberger	  State	  Trait	  Anxiety	  
Inventory	  
VDVASU-­‐	  Unpleasantness	  scale	  of	  
the	  Visual	  Descriptor	  Visual	  
Analogue	  Scale	  
VDVASI-­‐	  Intensity	  scale	  of	  the	  
Visual	  Descriptor	  Visual	  Analogue	  
Scale	  
ST-­‐	  Sensory	  threshold	  
	  
Spearman	  Correlation	  Coefficients	   	  
Prob	  >	  |r|	  under	  H0:	  Rho=0	   	  
	  
	   C	   SSTAI-­‐T	   	   	   	   	   	   	   	   	   	  
P	   0.37247	   0.36715	   	   	   	   	   	   	   	   	   	  
	   0.0328	   0.0356	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   A	   	   	   	   	   	   	   	   	   	   	  
E	   -­‐0.41201	   	   	   	   	   	   	   	   	   	   	  
	   0.0172	   	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   C	   SSTAI-­‐T	   HAD	  A	   HAD	  D	   VDVASU	   VDVAS	  I	   PHQ	   VSI	   Whiteley	   	   	  
N	   0.61553	   0.5835	   0.76783	   0.34422	   0.54057	   0.44507	   0.55436	   0.48272	   0.49252	   	   	  
	   0.0001	   0.0004	   <.0001	   0.0498	   0.0012	   0.0094	   0.0008	   0.0044	   0.0036	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   A	   C	   	   	   	   	   	   	   	   	   	  
L	   -­‐0.6453	   -­‐0.0678	   	   	   	   	   	   	   	   	   	  
	   <.0001	   0.7077	   	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   E	   L	   PHQ	   	   	   	   	   	   	   	   	  
A	   -­‐0.41201	   -­‐0.6453	   0.37629	   	   	   	   	   	   	   	   	  
	   0.0172	   <.0001	   0.0309	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   N	   L	   P	   HAD	  A	   PHQ	   Whiteley	   	   	   	   	   	  
C	   0.61553	   -­‐0.0678	   0.37247	   0.52365	   0.45061	   0.43997	   	   	   	   	   	  
	   0.0001	   0.7077	   0.0328	   0.0018	   0.0085	   0.0104	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   N	   SSTAI-­‐T	   HAD	  A	   HAD	  D	   VDVASU	   VDVAS	  I	   PHQ	   Whiteley	   ST	   	  
VSI	   0.48272	   0.39704	   0.37085	   0.42135	   0.48114	   0.50155	   0.46713	   0.55978	   0.38714	   	   	  
	   0.0044	   0.0221	   0.0336	   0.0146	   0.0046	   0.0029	   0.0061	   0.0007	   0.026	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	              






	   N	   A	   C	   SSTAI-­‐S	   SSTAI-­‐T	   HAD	  A	   HAD	  D	   VDVASU	   VDVAS	  I	   VSI	   Whiteley	  
PHQ	   0.55436	   0.37629	   0.45061	   0.34836	   0.67089	   0.38868	   0.66543	   0.56999	   0.67615	   0.46713	   0.50269	  
	   0.0008	   0.0309	   0.0085	   0.0469	   <.0001	   0.0254	   <.0001	   	   	   	   	   0.0005	   <.0001	   0.0061	   0.0029	  
	   	   	   	   	   	   	   	   	   	   	   	              
	   N	   C	   SSTAI-­‐T	   HAD	  A	   HAD	  D	   VDVASU	   VDVAS	  I	   PHQ	   VSI	   	   	  
Whiteley	   0.49252	   0.43997	   0.44766	   0.53542	   0.56976	   0.49318	   0.44376	   0.50269	   0.55978	   	   	  
	   0.0036	   0.0104	   0.009	   0.0013	   0.0005	   0.0035	   0.0097	   0.0029	   0.0007	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   N	   SSTAI-­‐S	   SSTAI-­‐T	   C	   VDVASU	   PHQ	   VSI	   Whiteley	   	   	   	  
HAD	  A	   0.76783	   0.36388	   0.57662	   0.52365	   0.34935	   0.38868	   0.37085	   0.53542	   	   	   	  
	   <.0001	   0.0374	   0.0004	   0.0018	   0.0463	   0.0254	   0.0336	   0.0013	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   N	   SSTAI-­‐T	   VDVASU	   VDVAS	  I	   PHQ	   VSI	   Whiteley	   	   	   	   	  
HAD	  D	   0.34422	   0.62891	   0.57476	   0.56411	   0.66543	   0.42135	   0.56976	   	   	   	   	  
	   0.0498	   <.0001	   0.0005	   0.0006	   <.0001	   	   	   	   	   0.0146	   0.0005	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   SSTAI-­‐T	   HAD	  A	   PHQ	   	   	   	   	   	   	   	   	  
SSTAI-­‐S	   0.57193	   0.36388	   0.34836	   	   	   	   	   	   	   	   	  
	   0.0005	   0.0374	   0.0469	   	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   N	   SSTAI-­‐S	   P	   HAD	  A	   HAD	  D	   VDVASU	   VDVAS	  I	   PHQ	   VSI	   Whiteley	   	  
SSTAI-­‐T	   0.5835	   0.57193	   0.36715	   0.57662	   0.62891	   0.54086	   0.38273	   0.67089	   0.39704	   0.44766	   	  
	   0.0004	   0.0005	   0.0356	   0.0004	   <.0001	   0.0012	   0.0279	   <.0001	   0.0221	   0.009	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   N	   SSTAI-­‐T	   HAD	  A	   HAD	  D	   VDVASI	   PHQ	   VSI	   Whiteley	   	   	   	  
VDVAU	   0.54057	   0.54086	   0.34935	   0.57476	   0.78928	   0.56999	   0.48114	   0.49318	   	   	   	  
	   0.0012	   0.0012	   0.0463	   0.0005	   <.0001	   0.0005	   0.0046	   0.0035	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   N	   SSTAI-­‐T	   HAD	  D	   VDVASU	   PHQ	   VSI	   Whiteley	   	   	   	   	  
VDVASI	   0.44507	   0.38273	   0.56411	   0.78928	   0.67615	   0.50155	   0.44376	   	   	   	   	  
	   0.0094	   0.0279	   0.0006	   <.0001	   <.0001	   0.0029	   0.0097	   	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	   	  	   VSI	   	   	   	   	   	   	   	   	   	   	  
ST	   0.38714	   	   	   	   	   	   	   	   	   	   	  
	   0.026	   	   	   	   	   	   	   	   	   	   	  






CHAPTER	  THREE,	  SECTION	  TWO:	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  
CYTOKINE	  STUDY	  RESULTS	  
The	  patients	  assembled	  for	  the	  blood	  test	  were	  drawn	  from	  the	  initial	  group	  of	  IBS	  patients	  who	  had	  
the	  CEP	  testing.	  There	  was	  only	  one	  IBS	  patient	  who	  was	  the	  exception	  to	  this,	  preferring	  just	  to	  give	  
blood	  and	  not	  go	  through	  with	  CEP	  testing.	  Similarly,	  a	  subset	  of	  controls	  (9	  in	  total)	  emerged	  from	  
the	  parent	  CEP	  group	  for	  blood	  testing.	  
Table	  3.2.1	  IBS/Control	  Demographics	  
	   Controls	   IBS	  
Sex	   1	  Males,	  8	  Females	   4	  Males,	  21	  Females	  
Mean	  age	   36.4	   40.1	  
Median	  age	   37	   41	  
Mode	  age	   n/a	   28	  
Age	  range	   25	  to	  46	   18	  to	  64	  
	  
Figure	  3.2.1	  IBS	  subtypes	  for	  the	  Cytokine	  study	  
	  
	  
















Figure	  3.2.2	  Irritable	  Bowel	  Severity	  Scoring	  System	  
	  
Table	  3.2.2	  Irritable	  Bowel	  Severity	  Scoring	  System	  
Unpaired	  t	  test	   	  
P	  value	   <	  0.0001	  
Mean	  ±	  SEM	  of	  Controls	   30	  ±	  10	  N=9	  
Mean	  ±	  SEM	  of	  IBS	   203	  ±	  22	  N=24	  
Difference	  between	  means	   -­‐172	  ±	  37	  
95%	  confidence	  interval	   -­‐248	  to	  -­‐96	  
	  
Scoring	  
IBS	  in	  remission:	  <75;	  Mild	  IBS:	  75	  to	  175;	  Moderate	  IBS:	  175	  to	  300;	  Severe	  IBS:	  >300	  ;	   	   	   	  
(Maximum	  score	  of	  500)	  
Analysis	  
The	  Irritable	  Bowel	  Severity	  Scoring	  System	  was	  a	  late	  addition	  to	  the	  study	  protocol.	  Its	  inclusion	  
was	  brought	  about	  because	  of	  the	  need	  for	  a	  quantitative	  marker	  of	  IBS	  clinical	  severity.	  It	  assesses	  
symptoms	  in	  the	  preceding	  10	  days.	  According	  to	  the	  scoring	  system	  the	  IBS	  mean	  value	  of	  202.5	  fell	  
within	  the	  category	  of	  moderate	  IBS.	  Two	  of	  the	  25	  IBS	  patients	  fell	  within	  the	  category	  of	  being	  in	  
clinical	  remission,	  scoring	  less	  than	  75.	  The	  range	  of	  severity	  was	  broad	  with	  values	  recorded	  


























Figure	  3.2.3	  Irritable	  Bowel	  Syndrome	  Impact	  Scale	  
Table	  3.2.3	  Irritable	  Bowel	  Syndrome	  Impact	  Scale	  
Unpaired	  t	  test	   Daily	  Activities	   Emotional	  Distress	   Sleep	  Disturbance	  
P	  value	   <	  0.0001	   <	  0.0001	   0.0173	  
Mean	  ±	  SEM	  of	  Controls	   6.730	  ±	  0.1224	  N=9	   6.822	  ±	  0.09095	  N=9	   6.861	  ±	  0.09420	  N=9	  
Mean	  ±	  SEM	  of	  IBS	   4.607	  ±	  0.2747	  N=24	   4.450	  ±	  0.3147	  N=24	   5.375	  ±	  0.3567	  N=24	  
Difference	  between	  means	   2.123	  ±	  0.4589	   2.372	  ±	  0.5218	   1.486	  ±	  0.5911	  
95%	  confidence	  interval	   1.187	  to	  3.059	   1.308	  to	  3.437	   0.2804	  to	  2.692	  
	  
Unpaired	  t	  test	   Eating	  Habits	   Fatigue	   	  
P	  value	   <	  0.0001	   0.0003	   	  
Mean	  ±	  SEM	  of	  Controls	   6.806	  ±	  0.1002	  N=9	   6.833	  ±	  0.1111	  N=9	   	  
Mean	  ±	  SEM	  of	  IBS	   3.635	  ±	  0.2998	  N=24	   4.438	  ±	  0.3562	  N=24	   	  
Difference	  between	  means	   3.170	  ±	  0.4981	   2.396	  ±	  0.5913	   	  
95%	  confidence	  interval	   2.154	  to	  4.186	   1.190	  to	  3.602	   	  
	  
Analysis	  
Interpretation	  of	  the	  results	  is	  based	  on	  the	  understanding	  that	  the	  maximum	  score	  per	  category	  is	  
7,	  and	  that	  this	  score	  indicates	  normality	  (see	  Figure	  1.3.2)	  Deflections	  towards	  the	  value	  of	  zero	  are	  
associated	  with	  increasing	  symptom	  severity.	  The	  IBS-­‐IS	  is	  useful	  because	  it	  gives	  an	  idea	  of	  impaired	  
quality	  of	  life,	  disruption	  with	  daily	  affairs	  and	  food	  intolerance.	   	  
The	  IBS-­‐IS	  delivers	  statistical	  significance	  across	  all	  domains.	  The	  graphic	  below	  is	  taken	  from	  the	  





















































The	  following	  section	  features	  the	  cytokine	  data.	  Each	  cytokine	  is	  presented	  individually.	  6	  point	  
dose-­‐response	  curves	  show	  the	  amount	  of	  cytokine	  produced	  following	  the	  administration	  of	  E.coli	  
LPS.	  The	  initial	  point	  on	  each	  graph	  is	  an	  unstimulated	  sample,	  i.e.	  LPS	  concentration	  of	  zero.	  The	  
cytokines	  are	  separated	  into	  the	  two	  groups	  according	  to	  their	  pro	  and	  anti-­‐inflammatory	  roles.	  






PRO-­‐INFLAMMATORY	  CYTOKINE	  DATA	  
Figure	  3.2.4	  TNF-­‐α	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.4	  TNF-­‐α	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   57.93	   77.84	   -­‐19.91	   (-­‐105.73,	  65.91)	   0.6398	  
0.1	   2496.46	   4683.95	   -­‐2187.5	   (-­‐3901.27,	  -­‐473.72)	   0.014	  
0.3	   3161.3	   7389.24	   -­‐4227.94	   (-­‐5973.10,	  -­‐2482.77)	   <0.0001	  
1	   3701.43	   8758.32	   -­‐5056.88	   (-­‐7110.81,	  -­‐3002.96)	   <0.0001	  
3	   3718.72	   8328.48	   -­‐4609.76	   (-­‐6634.06,	  -­‐2585.47)	   <0.0001	  
10	   2970.33	   8433.07	   -­‐5462.75	   (-­‐7526.47,	  -­‐3399.03)	   <0.0001	  
	  
Analysis	  
Figure	  3.2.4	  demonstrates	  a	  consistent	  grouping	  of	  TNF-­‐Alpha	  expression	  in	  the	  IBS	  group.	  Notably	  
there	  is	  no	  separation	  between	  the	  control	  and	  IBS	  groups	  in	  the	  unstimulated	  samples.	  The	  Control	  
group	  produces	  significantly	  more	  TNF-­‐Alpha	  during	  LPS	  stimulation.	  However	  there	  is	  a	  larger	  range	  
in	  the	  control	  group	  compared	  to	  the	  IBS	  group.	  	   	  
TNF$α































Figure	  3.2.5	  IFN-­‐γ	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.5	  IFN-­‐γ	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  -­‐	  One	  Way	  ANOVA	   	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   137.61	   111.71	   25.9	   (-­‐43.60,	  95.40)	   0.4534	  
0.1	   910.52	   1620.96	   -­‐710.44	   (-­‐1342.46,	  -­‐78.42)	   0.0288	  
0.3	   1484.17	   2134.29	   -­‐650.11	   (-­‐2121.53,	  821.30)	   0.3736	  
1	   1293.04	   2501	   -­‐1207.96	   (-­‐2152.62,	  -­‐263.29)	   0.0139	  
3	   1406.77	   2897.64	   -­‐1490.88	   (-­‐2464.42,	  -­‐517.33)	   0.0039	  
10	   921.22	   2177.73	   -­‐1256.5	   (-­‐2105.76,	  -­‐407.25)	   0.005	  
	  
Analysis	  
Statistical	  significance	  is	  reached	  at	  various	  LPS	  concentrations	  (0.1,	  1,	  3	  and	  10ng/ml).	  However,	  the	  
scattergrams	  clearly	  identify	  Control	  outliers	  which	  skew	  the	  data.	  Removal	  of	  these	  outliers	  



































Figure	  3.2.6	  IL-­‐1-­‐βrelease	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.6	  IL-­‐1-­‐βrelease	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   9.4	   4.18	   5.22	   (0.23,	  10.20)	   0.0408	  
0.1	   2195.63	   2229.82	   -­‐34.18	   (-­‐1419.87,	  1351.51)	   0.9602	  
0.3	   3945.87	   3383.88	   561.99	   (-­‐1310.01,	  2433.99)	   0.5452	  
1	   5433.18	   4279.81	   1153.37	   (-­‐1253.15,	  3559.90)	   0.3363	  
3	   5653.68	   4625.97	   1027.72	   (-­‐1913.85,	  3969.28)	   0.4818	  
10	   3469.87	   4497.45	   -­‐1027.58	   (-­‐2988.26,	  933.10)	   0.2937	  
	  
Analysis	  
IL-­‐1β	  expression	  is	  not	  shown	  to	  be	  different	  in	  the	  LPS-­‐stimulated	  samples	  between	  the	  two	  groups.	   	  
	  
IL1$β






























	   Figure	  3.2.7	  IL-­‐2	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.7	  IL-­‐2	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   20.5	   22.5	   -­‐2	   (-­‐11.46,	  7.45)	   0.6688	  
0.1	   49.47	   76.87	   -­‐27.4	   (-­‐53.95,	  -­‐0.84)	   0.0436	  
0.3	   61.24	   99.79	   -­‐38.54	   (-­‐63.18,	  -­‐13.90)	   0.0032	  
1	   64.16	   101.22	   -­‐37.06	   (-­‐62.10,	  -­‐12.01)	   0.005	  
3	   61.06	   94.88	   -­‐33.82	   (-­‐59.27,	  -­‐8.37)	   0.0108	  
10	   41.81	   86.31	   -­‐44.51	   (-­‐66.27,	  -­‐22.74)	   0.0002	  
	  
Analysis	   	  
IL-­‐2	  release	  is	  statistically	  different	  between	  the	  two	  groups	  in	  the	  LPS-­‐stimulated	  samples.	  The	  IBS	  
group	  demonstrates	  a	  much	  tighter	  range	  of	  cytokine	  expression	  compared	  to	  the	  IBS	  group.	  A	  few	  
































Figure	  3.2.8	  IL-­‐6	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.8	  IL-­‐6	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   29.39	   16.81	   12.57	   (-­‐4.93,	  30.07)	   0.1531	  
0.1	   11946.56	   12823.69	   -­‐877.12	   (-­‐5847.41,	  4093.17)	   0.7216	  
0.3	   16898.62	   11573.36	   5325.26	   (-­‐63.55,	  10714.07)	   0.0526	  
1	   18875.22	   11269.47	   7605.74	   (2890.51,	  12320.98)	   0.0025	  
3	   19723.86	   10167.8	   9556.06	   (3829.76,	  15282.36)	   0.0018	  
10	   15105.89	   10242.13	   4863.76	   (383.76,	  9343.75)	   0.0343	  
	  
Analysis	  
This	  data	  demonstrates	  good	  separation	  between	  the	  two	  groups	  for	  LPS-­‐stimulated	  IL-­‐6	  expression.	  
This	  becomes	  more	  marked	  with	  higher	  concentrations	  of	  LPS,	  reaching	  statistical	  significance	  at	  
concentrations	  greater	  than	  0.3ng/ml.	   	  
	  
IL6






























Figure	  3.2.9	  IL-­‐8	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.9	  IL-­‐8	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   3215.21	   2019.75	   1195.46	   (-­‐920.98,	  3311.89)	   0.2584	  
0.1	   15966.99	   2829.47	   13137.52	   (8834.91,	  17440.13)	   <0.0001	  
0.3	   13259.12	   2217.8	   11041.32	   (7438.46,	  14644.18)	   <0.0001	  
1	   13017.76	   2129.75	   10888.01	   (6774.28,	  15001.74)	   <0.0001	  
3	   13165.73	   2126	   11039.73	   (6878.61,	  15200.84)	   <0.0001	  
10	   15296.58	   1979.57	   13317.01	   (8873.03,	  17761.00)	   <0.0001	  
	  
Analysis	  
Figure	  3.2.9	  shows	  marked	  differences	  in	  IL-­‐8	  expression	  between	  the	  two	  groups.	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Figure	  3.2.10	  IL-­‐12	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.10	  IL-­‐12	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   18.99	   16.57	   2.42	   (-­‐10.73,	  15.57)	   0.7101	  
0.1	   129.78	   125.05	   4.73	   (-­‐53.13,	  62.60)	   0.8686	  
0.3	   177.76	   153.5	   24.26	   (-­‐44.26,	  92.78)	   0.476	  
1	   187.71	   202.02	   -­‐14.32	   (-­‐85.51,	  56.88)	   0.6842	  
3	   175.33	   172.38	   2.95	   (-­‐68.84,	  74.74)	   0.9337	  
10	   118.62	   167.93	   -­‐49.31	   (-­‐100.72,	  2.09)	   0.0595	  
	  
Analysis	  
IL-­‐12	  expression	  in	  IBS	  patients	  produces	  a	  broad	  range	  of	  data.	  This	  is	  in	  contrast	  to	  the	  tight	  
grouping	  of	  results	  in	  the	  control	  group.	  Statistical	  significance	  is	  not	  reached	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ANTI-­‐INFLAMMATORY	  CYTOKINE	  DATA	  
Figure	  3.2.11	  IL-­‐4	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.11	  IL-­‐4	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   10.49	   4	   6.5	   (1.42,	  11.57)	   0.0137	  
0.1	   50.48	   62.19	   -­‐11.71	   (-­‐54.16,	  30.73)	   0.578	  
0.3	   59.63	   92.1	   -­‐32.47	   (-­‐58.10,	  -­‐6.84)	   0.0147	  
1	   67.82	   91.48	   -­‐23.65	   (-­‐50.31,	  3.00)	   0.0801	  
3	   67.11	   85.23	   -­‐18.12	   (-­‐46.03,	  9.79)	   0.1955	  
10	   44.95	   77.47	   -­‐32.51	   (-­‐54.08,	  -­‐10.95)	   0.0043	  
	  
Analysis	  
Table	  3.2.11	  suggests	  a	  statistical	  separation	  of	  the	  two	  groups,	  but	  the	  scattergram	  indicates	  that	  
both	  groups	  produce	  broadly	  similar	  data.	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Figure	  3.2.12	  IL-­‐5	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
	  
Table	  3.2.12	  IL-­‐5	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   4.5	   3.25	   1.25	   (-­‐1.34,	  3.83)	   0.3337	  
0.1	   12.21	   19.57	   -­‐7.35	   (-­‐13.69,	  -­‐1.02)	   0.0243	  
0.3	   18.24	   29.75	   -­‐11.52	   (-­‐19.50,	  -­‐3.54)	   0.006	  
1	   20.69	   30.5	   -­‐9.81	   (-­‐17.53,	  -­‐2.09)	   0.0144	  
3	   19.93	   31.37	   -­‐11.44	   (-­‐19.46,	  -­‐3.41)	   0.0067	  
10	   13.4	   28.66	   -­‐15.26	   (-­‐21.68,	  -­‐8.83)	   <0.0001	  
	  
Analysis	  
LPS-­‐stimulated	  PBMCs	  in	  the	  control	  group	  produced	  more	  IL-­‐5	  than	  in	  the	  IBS	  group.	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Figure	  3.2.13	  IL-­‐10	  release	  from	  LPS-­‐stimulated	  PBMCs 
	  
Table	  3.2.13	  IL-­‐10	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   73.8	   53.97	   19.83	   (-­‐21.37,	  61.02)	   0.3342	  
0.1	   481.03	   889.41	   -­‐408.38	   (-­‐731.18,	  -­‐85.59)	   0.0148	  
0.3	   711.5	   1160.58	   -­‐449.08	   (-­‐957.09,	  58.94)	   0.0812	  
1	   822.35	   1146.91	   -­‐324.56	   (-­‐825.83,	  176.72)	   0.1966	  
3	   810.31	   1557.42	   -­‐747.11	   (-­‐1267.27,	  -­‐226.94)	   0.0063	  
10	   519.55	   1492.97	   -­‐973.42	   (-­‐1477.83,	  -­‐469.00)	   0.0004	  
	  
Analysis	  


































Figure	  3.2.14	  IL-­‐13	  release	  from	  LPS-­‐stimulated	  PBMCs	  
	  
Table	  3.2.14	  IL-­‐13	  release	  from	  LPS-­‐stimulated	  PBMCs-­‐	  One	  Way	  ANOVA	   	   	   	   	   	  




IBS	  Mean	   Control	  Mean	   Difference	  Of	  
The	  Means	  
95%	  CI	   P	  Value	  
0	   25.44	   33.47	   -­‐8.03	   (-­‐18.93,	  2.87)	   0.1434	  
0.1	   60.63	   94.71	   -­‐34.08	   (-­‐63.01,	  -­‐5.16)	   0.0224	  
0.3	   78.85	   132.53	   -­‐53.68	   (-­‐87.05,	  -­‐20.30)	   0.0025	  
1	   84.11	   133.22	   -­‐49.11	   (-­‐81.64,	  -­‐16.57)	   0.0043	  
3	   78.72	   124.68	   -­‐45.96	   (-­‐77.89,	  -­‐14.03)	   0.0062	  
10	   55.65	   115.98	   -­‐60.33	   (-­‐85.16,	  -­‐35.50)	   <0.0001	  
	  
Analysis	  
IL-­‐13	  release	  is	  consistently	  and	  significantly	  increased	  in	  control	  subjects	  following	  LPS-­‐stimulation.	  
	  

































CORRELATIONS	  OF	  THE	  CYTOKINE	  DATA	  
Table	  3.2.15	  Spearman	  Correlation	  Coefficients	  of	  the	  IBS	  Group	  
Key	  
P-­‐	  Psychoticism	  Scale	  of	  the	  EPQR	  
A-­‐	  Addiction	  Scale	  of	  the	  EPQR	   	  
C-­‐	  Criminality	  Scale	  of	  the	  EPQR	  
VSI-­‐	  Visceral	  Sensitivity	  Index	   	  
HAD	  A-­‐	  Anxiety	  scale	  of	  the	  HAD	  
HAD	  D-­‐	  Depression	  scale	  of	  the	  
HAD	  
SSTAI-­‐S-­‐	  State	  anxiety	  of	  the	  
Spielberger	  State	  Trait	  Anxiety	  
Inventory	   	  
SSTAI-­‐T-­‐	  Trait	  Anxiety	  of	  the	  
Spielberger	  State	  Trait	  Anxiety	  
Inventory	  
VDVASU-­‐	  Unpleasantness	  scale	  of	  
the	  Visual	  Descriptor	  Visual	  
Analogue	  Scale	  
VDVASI-­‐	  Intensity	  scale	  of	  the	  
Visual	  Descriptor	  Visual	  Analogue	  
Scale	  
IBSSS-­‐	  Irritable	  Bowel	  Severity	  
Scoring	  System	  
IBSIS	  DA-­‐	  Daily	  Activities	  scale	  
IBSIS	  ED-­‐	  Emotional	  Distress	  scale	  
IBSIS	  EH-­‐	  Eating	  Habits	  scale	  
IBSIS	  SD-­‐	  Sleeping	  Dysfunction	  
IBSIS	  F-­‐	  Fatigue	  Scale
	  
Spearman	  Correlation	  Coefficients	   	  
Prob	  >	  |r|	  under	  H0:	  Rho=0	   	  
 
	   IL6	   TNF	  α	   	   	   	   	   	  
P	   -­‐0.43417	   -­‐0.50002	   	   	   	   	   	  
	   0.034	   0.0128	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   IL13	   IL2	   	   	   	   	   	  
A	   -­‐0.45475	   -­‐0.46009	   	   	   	   	   	  
	   0.0256	   0.0237	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   IL8	   	   	   	   	   	   	  
C	   -­‐0.41465	   	   	   	   	   	   	  
	   0.0439	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   IFN	  γ	   	   	   	   	   	   	  
VSI	   0.45551	   	   	   	   	   	   	  
	   0.0253	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   SSTAI-­‐S	   SSTAI-­‐T	   HAD	  D	   IFN	  γ	   IL10	   	   	  
HAD	  A	   0.48486	   0.68163	   0.55896	   0.55433	   0.40744	   	   	  
	   0.019	   0.0003	   0.0056	   0.0049	   0.0481	   	   	  
	   	   	   	   	   	   	   	  	   SSTAI-­‐S	   SSTAI-­‐T	   HAD	  A	   TNF	  α	   IL	  13	   	   	  
HAD	  D	   0.67264	   0.64604	   0.55896	   -­‐0.44428	   -­‐0.43215	   	   	  
	   0.0004	   0.0009	   0.0056	   0.0337	   0.035	   	   	  
	   	   	   	   	   	   	   	  	   SSTAI-­‐T	   HAD	  A	   HAD	  D	   VDVAS	  U	   TNF	  α	   	   	  






	   <.0001	   0.019	   0.0004	   0.0472	   0.0449	   	   	  
	   	   	   	   	   	   	   	  	   SSTAI-­‐S	   HAD	  A	   HAD	  D	   VDVAS	  U	   IBSIS	  ED	   	   IBSIS	  SD	   	  
SSTAI-­‐T	   0.83313	   0.68163	   0.64604	   0.54641	   -­‐0.4434	   -­‐0.4222	   	  
	   <.0001	   0.0003	   0.0009	   0.0085	   0.0341	   0.0448	   	  
	   	   	   	   	   	   	   	  	   IBSSS	   SSTAI-­‐S	   SSTAI-­‐T	   VDVAS	  I	   IBSIS	  DA	   IBSIS	  ED	   IBSIS	  F	  
VDVAS	  U	   0.5661	   0.42756	   0.54641	   0.82881	   -­‐0.56346	   -­‐0.47775	   -­‐0.42627	  
	   0.006	   0.0472	   0.0085	   <.0001	   0.0063	   0.0245	   0.0479	  
	   	   	   	   	   	   	   	  	   IBSSS	   VDVAS	  U	   IBSIS	  DA	   IBSIS	  F	   IL5	   IL13	   IL2	  
VDVAS	  I	   0.60248	   0.82881	   -­‐0.47509	   -­‐0.43168	   -­‐0.41159	   -­‐0.44285	   -­‐0.42064	  
	   0.003	   <.0001	   0.0255	   0.0448	   0.0457	   0.0302	   0.0407	  
	   	   	   	   	   	   	   	  	   VDVAS	  U	   VDVAS	  I	   IBSIS	  DA	   IBSIS	  ED	   IBSIS	  SD	   	   IBSIS	  F	   	  
IBSSS	   0.5661	   0.60248	   -­‐0.58594	   -­‐0.56371	   -­‐0.53981	   -­‐0.43801	   	  
	   0.006	   0.003	   0.0033	   0.0051	   0.0078	   0.0366	   	  
	   	   	   	   	   	   	   	  	   IBSSS	   VDVAS	  U	   VDVAS	  I	   IBSIS	  ED	   IBSIS	  F	   	   	  
IBSIS	  DA	   -­‐0.58594	   -­‐0.56346	   -­‐0.47509	   0.87028	   0.76681	   	   	  
	   0.0033	   0.0063	   0.0255	   <.0001	   <.0001	   	   	  
	   	   	   	   	   	   	   	  	   IBSSS	   SSTAI-­‐T	   IBSIS	  DA	   IBSIS	  F	   	   	   	  
IBSIS	  ED	   -­‐0.56371	   -­‐0.4434	   0.87028	   0.82245	   	   	   	  
	   0.0051	   0.0341	   <.0001	   <.0001	   	   	   	  
	   	   	   	   	   	   	   	  	   IBSIS	  DA	   IBSIS	  F	   	   	   	   	   	  
IBSIS	  EH	   0.49578	   0.41917	   	   	   	   	   	  
	   0.0161	   0.0465	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   IBSSS	   SSTAI-­‐T	   IBSIS	  F	   	   	   	   	  
IBSIS	  SD	   	   -­‐0.53981	   -­‐0.4222	   0.4248	   	   	   	   	  
	   0.0078	   0.0448	   0.0433	   	   	   	   	  
	   	   	   	   	   	   	   	  	   IBSSS	   VDVAS	  U	   VDVAS	  I	   IBSIS	  DA	   IBSIS	  ED	   IBSIS	  SD	   IBSIS	  EH	  
IBSIS	  F	   -­‐0.43801	   -­‐0.42627	   -­‐0.43168	   0.76681	   0.82245	   0.4248	   0.41917	  
	   0.0366	   0.0479	   0.0448	   <.0001	   <.0001	   0.0433	   0.0465	  
	   	   	   	   	   	   	   	  	   SSTAI-­‐S	   HAD	  D	   P	   	   	   	   	  
TNF	  α	   -­‐0.42189	   -­‐0.44428	   -­‐0.50002	   	   	   	   	  
	   0.0449	   0.0337	   0.0128	   	   	   	   	  
	   	   	   	   	   	   	   	  	   HAD	  A	   VSI	   	   	   	   	   	  
IFN	  γ	   0.55433	   0.45551	   	   	   	   	   	  
	   0.0049	   0.0253	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   A	   VDVAS	  I	   	   	   	   	   	  
IL2	   -­‐0.46009	   -­‐0.42064	   	   	   	   	   	  
	   0.0237	   0.0407	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   P	   	   	   	   	   	   	  
IL6	   -­‐0.43417	   	   	   	   	   	   	  
	   0.034	   	   	   	   	   	   	  






IL8	   -­‐0.41465	   	   	   	   	   	   	  
	   0.0439	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   VDVAS	  I	   	   	   	   	   	   	  
IL2	   -­‐0.42064	   	   	   	   	   	   	  
	   0.0407	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   VDVAS	  I	   	   	   	   	   	   	  
IL5	   -­‐0.41159	   	   	   	   	   	   	  
	   0.0457	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   HAD	  A	   	   	   	   	   	   	  
IL10	   0.40744	   	   	   	   	   	   	  
	   0.0481	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  	   A	   VDVAS	  I	   HAD	  D	   	   	   	   	  
IL13	   -­‐0.45475	   -­‐0.44285	   -­‐0.43215	   	   	   	   	  
	   0.0256	   0.0302	   0.035	   	   	   	   	  
	  






Table	  3.2.16	  Summary	  of	  the	  Cytokine	  Correlations	  
Assessment	  Parameter	   Negative	  correlation	   Positive	  correlation	  
Spielberger	  –	  State	  anxiety	   TNF-­‐α	   	  
HAD	  –	  Anxiety	   	   IFN-­‐γ,	  IL-­‐10	  
HAD	  –	  Depression	   TNF-­‐α,	  IL-­‐13	   	  
EPQ	  R–	  Psychoticism	   IL-­‐6,	  TNF-­‐α	   	  
EPQ	  R–	  Addiction	   IL-­‐2,	  IL-­‐13	   	  
EPQ	  R	   	   –Criminality	   IL-­‐8	   	  
VSI	   	   	   IFN-­‐γ	  
VDVAS-­‐I	  –	  Intensity	   IL-­‐2,	  IL-­‐5,	  IL-­‐13	   	  
	  














Interest	  in	  the	  psychosocial	  aspect	  of	  IBS	  is	  fuelled	  by	  the	  high	  prevalence	  of	  functional	  disease,	  the	  
ambiguity	  surrounding	  the	  pathogenesis	  of	  symptoms	  and	  the	  lack	  of	  compelling	  treatment	  options.	  
Symptom	  generation	  and	  propagation	  is	  likely	  to	  be	  influenced	  by	  many	  factors.	  Indeed	  the	  
biopsychosocial	  model	  of	  disease	  proposed	  by	  Engel	  informs	  us	  that	  the	  phenotype	  of	  disease	  is	  a	  
product	  of	  the	  synthesis	  of	  three	  domains	  affecting	  Self-­‐	  the	  biological,	  the	  psychological	  and	  the	  
social.256	  
The	  Study	  Dataset	  
Data	  produced	  from	  this	  study	  has	  demonstrated	  considerable	  psychological	  comorbidity	  in	  the	  IBS	  
group.	  Most	  of	  the	  psychological	  parameters	  that	  the	  protocol	  employed	  produced	  significant	  
differentiation	  between	  the	  study	  and	  control	  groups.	  This	  study	  was	  comprehensive	  in	  its	  breadth	  
of	  psychological	  analysis.	  Most	  studies	  use	  1	  or	  2	  different	  psychometric	  devices.	  In	  contrast,	  our	  
study	  protocol	  scrutinised	  symptom	  specific	  anxiety	  (Visceral	  Sensitivity	  Index),	  generalised	  anxiety	  
(Hospital	  Anxiety	  and	  Depression	  Scale),	  contextual	  anxiety	  (Spielberger	  State	  Trait	  Anxiety	  Index),	  
depression	  (Hospital	  Anxiety	  and	  Depression	  Scale;	  Spielberger	  State	  Trait	  Anxiety	  Index),	  
somatisation	  (Patient	  Health	  Questionnaire-­‐15),	  and	  hypochondriasis	  (Whiteley	  Index).	  
The	  study	  data	  showed	  that	  IBS	  patients	  were	  more	  introverted	  (Figure	  3.1.3);	  neurotic	  (Figure	  
3.1.4);	  displayed	  a	  tendency	  to	  dissimulate	  (Figure	  3.1.5);	  demonstrated	  more	  GI	  symptom-­‐specific	  
anxiety	  (Figure	  3.1.8),	  generalised	  anxiety	  (Figure	  3.1.11,	  Figure	  3.1.14)	  and	  situational	  anxiety	  
(Figure	  3.1.);	  had	  a	  greater	  tendency	  towards	  depression	  (Figure	  3.1.12);	  were	  scored	  more	  highly	  
for	  hypochondriasis	  (Figure	  3.1.10)	  and	  somatisation	  (Figure	  3.1.9).	  There	  was	  a	  significant	  
impairment	  in	  their	  day-­‐to-­‐day	  functioning	  (Figure	  3.2.3).	  This	  data	  seems	  to	  be	  consistent	  with	  the	  








Psychological	  Co-­‐Morbidity	  in	  IBS	  
Psychological	  symptoms	  and	  coexisting	  psychiatric	  disease	  are	  common	  in	  IBS.257	  The	  prevalence	  of	  
depressive	  or	  anxiety	  disorders	  in	  FGIDs	  is	  remarkably	  high	  (estimated	  to	  being	  between	  42%	  and	  
61%.258-­‐263).	  This	  relationship	  is	  even	  more	  pronounced	  in	  IBS	  patients	  seeking	  medical	  services.	   	  
Panic	  disorder,	  generalized	  anxiety	  disorder,	  major	  depression,	  social	  phobia	  and	  post-­‐traumatic	  
stress	  disorder	  were	  the	  most	  common	  anxiety-­‐related	  psychiatric	  comorbidities	  associated	  with	  IBS	  
patients	  who	  seek	  treatment.264	  Community-­‐based	  studies	  dismiss	  the	  suggestion	  that	  treatment-­‐
seeking	  is	  a	  function	  of	  psychiatric	  disease-­‐	  IBS	  anxiety-­‐related	  psychiatric	  comorbidity	  in	  the	  non-­‐
treatment	  seekers	  appears	  to	  have	  similar	  prevalence	  rates	  compared	  to	  IBS	  treatment	  seekers.265	   	  
However,	  it	  should	  also	  be	  noted	  that	  psychiatric	  disease	  on	  its	  own	  is	  prevalent	  in	  community	  
populations.	  Standard	  psychiatric	  interviews	  (using	  the	  Present	  State	  Examination)	  of	  new	  referrals	  
presenting	  to	  a	  general	  medical	  outpatients	  revealed	  a	  15%	  prevalence	  of	  psychiatric	  disorders	  in	  
those	  with	  medically-­‐explainable	  symptoms	  and	  between	  38%	  and	  45%	  prevalence	  in	  those	  patients	  
with	  either	  poorly	  or	  unexplainable	  symptoms.266	  A	  Belgium	  study	  randomly	  selected	  2316	  patients	  
in	  a	  primary	  care	  setting,	  identifying	  threshold	  or	  sub-­‐threshold	  psychiatric	  disease	  in	  42.5%,	  the	  
most	  common	  conditions	  being	  major	  depression,	  anxiety	  and	  somatoform	  disorders.267	  
Life	  Stressors	  
Life	  stressors	  are	  reported	  more	  frequently	  in	  IBS	  patients.268	  Exacerbations	  of	  stress	  can	  be	  
positively	  linked	  to	  increased	  symptomatology,	  health-­‐seeking	  behaviour	  and	  illness-­‐related	  
absenteeism.268	  Recurrent	  or	  chronic	  stress	  produces	  a	  damaging	  sequence	  of	  physiological	  sequelae	  
arising	  from	  heightened	  and	  persistent	  neuroendocrine	  arousal.	  Sterling	  and	  Eyer	  coined	  the	  phase	  
allostatic	  load	  in	  1988	  to	  describe	  this.269	   	  
Allostasis	  
Allostasis	  is	  an	  adaptive	  mechanism	  designed	  to	  preserve	  physiological	  homeostasis	  in	  response	  to	  
stress	  or	  threat.	  Therefore	  in	  the	  short-­‐term	  its	  manipulation	  of	  various	  body	  systems	  (such	  as	  the	  
immune	  system,	  the	  nervous	  system	  or	  the	  HPA	  axis)	  confers	  an	  advantage	  to	  the	  individual.	  Yet	  the	  
inability	  to	  turn	  off	  this	  system	  promotes	  abnormal	  illness	  behaviour	  and	  disease.	  The	  concept	  of	  
allostasis	  was	  refined	  by	  further	  work	  by	  McEwan	  and	  colleagues.270,271	  Clinical	  symptoms	  suggesting	  







Early	  life	  events	  
Early	  life	  events	  may	  contribute	  to	  the	  development	  of	  disordered	  stress	  management.	  Such	  events	  
may	  include	  emotional	  neglect,	  unstable	  relationships	  between	  parent	  and	  child	  or	  abuse	  in	  any	  of	  
its	  forms.	  At	  an	  early	  age,	  this	  can	  lead	  to	  maladaptive	  stress	  responses	  leading	  to	  life-­‐long	  
psychosocial	  and	  medical	  dysfunction.272,273	  Dube	  et	  al.	  demonstrated	  that	  adverse	  childhood	  
trauma	  increases	  the	  lifetime	  risk	  of	  attempted	  suicide	  between	  2	  and	  5	  times,	  and	  that	  it	  was	  also	  
associated	  with	  the	  development	  of	  alcoholism,	  depression,	  illicit	  drug	  use	  and	  other	  high	  risk	  
behaviour.274	  Other	  adult-­‐onset	  medical	  conditions	  associated	  with	  early	  life	  events	  include	  COPD,	  
autoimmune	  disorders,	  asthma,	  mood	  disorders,	  prescription	  drug	  use	  and	  obesity.275-­‐277	  
Early	  life	  events	  and	  abuse	  have	  been	  documented	  with	  increased	  frequency	  in	  patients	  with	  IBS	  and	  
functional	  disease.67-­‐70,75,278	  Even	  if	  one	  disregards	  the	  ultimate	  diagnosis,	  patients	  reporting	  to	  GI	  
clinics	  with	  functional	  symptoms	  experience	  greater	  pain	  severity,	  psychological	  distress,	  daily	  
dysfunction	  and	  days	  off	  sick	  if	  an	  abuse	  history	  is	  present.	  From	  a	  clinician’s	  point	  of	  view	  it	  is	  
important	  to	  make	  a	  rapid	  diagnosis	  (for	  example,	  of	  a	  child	  presenting	  with	  recurrent	  abdominal	  
pain)	  to	  allow	  the	  timely	  intervention	  of	  cognitive	  therapy	  (and	  parent	  re-­‐education)	  to	  prevent	  life-­‐
long	  maladaptive	  illness	  behaviour.279	  Creed	  et	  al.	  offered	  a	  measure	  of	  consolation	  to	  this	  subject-­‐	  
IBS	  patients	  with	  a	  history	  of	  self-­‐reported	  sexual	  abuse	  were	  more	  likely	  to	  respond	  to	  psychological	  
therapy.149	   	   	  
Chronic	  Stress	  and	  Symptom	  Severity	  
Bennet	  et	  al.	  studied	  the	  relationship	  between	  chronic	  stress	  and	  the	  severity	  of	  IBS	  symptoms.280	  
Life	  stress	  and	  symptom	  intensity	  measures	  were	  recorded	  over	  a	  16	  month	  period.	  They	  concluded	  
that	  chronic	  highly	  threatening	  stressors	  influenced	  symptom	  severity.	  Those	  IBS	  patients	  faced	  with	  
just	  one	  of	  said	  stressors	  did	  not	  display	  any	  clinical	  improvement	  during	  the	  testing	  period	  whereas	  
all	  of	  those	  IBS	  patients	  without	  stress	  had	  a	  50%	  improvement	  in	  symptoms.	  The	  relationship	  
between	  stress	  and	  symptom	  generation	  was	  so	  strong	  that	  for	  the	  majority	  of	  IBS	  patients	  one	  
could	  predict	  that	  if	  a	  critical	  stress	  threshold	  was	  breached,	  symptomatic	  improvement	  would	  be	  
unlikely.	  
Previous	  research	  has	  shown	  that	  psychological	  factors	  are	  responsible	  for	  the	  development	  of	  






independent	  predictors	  of	  the	  development	  of	  PI-­‐IBS	  twelve	  months	  before	  the	  primary	  
gastroenteritic	  insult.281	  
The	  relationship	  between	  self-­‐reported	  stress,	  psychological	  distress	  and	  GI	  symptoms	  has	  been	  
repeatedly	  assessed	  by	  Heitkemper’s	  group.282,283	  They	  documented	  positive	  correlations	  between	  
mean	  daily	  stress	  and	  GI	  symptom	  distress,	  and	  an	  association	  between	  stress,	  anxiety	  and	  
depression.	  Further	  work	  by	  the	  same	  group	  concluded	  that	  stress	  is	  a	  predictor	  of	  GI-­‐related	  
symptom	  severity,	  and	  that	  day-­‐to-­‐day	  fluctuations	  in	  the	  physiological	  response	  to	  stress	  are	  a	  
component	  of	  symptom	  generation.284	   	  
Even	  in	  a	  population	  of	  healthy	  volunteers,	  studies	  have	  shown	  a	  positive	  correlation	  between	  
symptoms	  consistent	  with	  functional	  GI	  disorders	  and	  the	  admission	  of	  perceived	  chronic	  stress,	  and	  
the	  presence	  of	  dispositional	  stress	  reactivity	  and	  maladaptive	  coping	  strategies.285	   	  
Conversely	  the	  appropriate	  management	  of	  stress,	  and	  the	  introduction	  of	  new	  coping	  mechanisms	  
to	  deal	  with	  chronic	  stress	  produce	  an	  improvement	  in	  the	  level	  of	  GI	  symptoms.286-­‐288	  
Hypothalamic-­‐Pituitary-­‐Adrenal	  Axis	  
From	  a	  neuroendocrine	  perspective,	  the	  dysregulation	  of	  the	  HPA	  axis	  is	  implicated	  in	  the	  
generation	  and	  propagation	  of	  IBS	  symptoms.289-­‐292	  As	  an	  example,	  Dinan	  et	  al.	  demonstrated	  
elevated	  basal	  cortisol	  levels	  and	  an	  exaggerated	  response	  to	  CRH	  injection	  in	  IBS	  patients	  compared	  
to	  controls.290	  
Of	  the	  many	  HPA	  axis	  studies	  that	  have	  been	  performed	  in	  IBS	  patients,	  there	  remains	  some	  
disagreement	  about	  basal	  cortisol	  levels	  between	  IBS	  patients	  and	  controls,	  and	  the	  stimulated	  
stress	  response.293	  These	  differences	  may	  be	  attributable	  to	  study	  design,	  methodological	  
differences	  or	  patient	  selection.	  However,	  the	  consensus	  appears	  to	  be	  that	  HPA	  axis	  dysregulation	  
is	  a	  feature	  of	  IBS,	  and	  that	  most	  investigators	  report	  higher	  baseline	  and	  hormone-­‐stimulated	  
cortisol	  levels	  but	  variable	  HPA	  axis	  responses	  to	  physical	  or	  emotional	  stressors.293	  
Chang’s	  group	  questioned	  the	  relationship	  between	  the	  HPA	  axis	  and	  early	  adverse	  life	  events.294	  
They	  divided	  a	  group	  of	  IBS	  patients	  into	  those	  that	  had	  childhood	  maltreatment,	  and	  those	  that	  did	  
not.	  They	  subjected	  both	  groups	  (plus	  a	  control	  arm)	  to	  the	  visceral	  trauma	  of	  sigmoidoscopy	  whilst	  
serially	  measuring	  salivary	  cortisol	  levels.	  Their	  analysis	  concluded	  that	  HPA	  axis	  overactivity	  was	  






cortisol	  levels	  to	  baseline	  was	  associated	  with	  improved	  quality	  of	  life	  and	  less	  symptoms	  severity	  in	  
the	  IBS	  group.	  
Maternal	  Deprivation	  Model	  
The	  maternal	  deprivation	  model	  is	  employed	  in	  animal	  studies	  to	  stimulate	  early	  life	  stress.295	  
Although	  other	  models	  have	  been	  used	  (such	  as	  prenatal	  stress	  or	  early	  post-­‐natal	  handling	  
paradigms),	  the	  separation	  of	  a	  pup	  from	  the	  mother	  is	  the	  most	  widely	  used	  model	  to	  mimic	  early	  
life	  stress	  and	  stimulate	  stress-­‐related	  adult-­‐onset	  disease.	  Maternal	  separation	  of	  murine	  neonates	  
predisposes	  them	  to	  stress-­‐induced	  colonic	  epithelial	  dysfunction	  (with	  increased	  intestinal	  
permeability)	  and	  visceral	  hypersensitivity	  mediated	  by	  acetylcholine	  and	  CRF.191,296,297	  
An	  explanation	  of	  the	  link	  between	  early	  life	  conditioning	  and	  the	  subsequent	  response	  to	  stress	  
(and	  the	  reactivity	  of	  the	  HPA	  axis)	  can	  be	  inferred	  from	  animal	  studies.	  Liu	  et	  al.	  used	  a	  murine	  
model	  to	  show	  that	  the	  offspring	  of	  maternal	  rats	  who	  exhibited	  more	  licking	  and	  grooming	  of	  her	  
puppies	  demonstrated	  reduced	  ACTH	  and	  cortisol	  responses	  to	  acute	  stress,	  and	  decreased	  levels	  of	  
hypothalamic	  CRH	  transcription.	  Cross-­‐fostering	  studies	  conclude	  that	  it	  is	  the	  nurturing	  of	  the	  
mother	  rat	  (regardless	  of	  whether	  she	  has	  given	  birth	  to	  the	  baby	  rat)	  that	  produces	  this	  protective	  
effect	  on	  HPA	  axis	  responses.298	  This	  introduces	  the	  concept	  of	  epigenetics-­‐	  this	  is	  the	  idea	  that	  
changes	  to	  phenotype	  or	  gene	  expression	  are	  not	  necessarily	  related	  to	  changes	  in	  DNA	  
sequencing.299	  Changes	  in	  epigenetic	  programming	  are	  realised	  by	  changes	  in	  chromatin	  structure	  
and	  methylation	  of	  DNA	  sequences,	  resulting	  in	  phenotypic	  plasticity.	  
In	  the	  context	  of	  the	  maternal	  separation	  studies,	  the	  suckling	  behaviour	  of	  the	  mother	  rat	  appears	  
to	  program	  HPA	  axis	  reactivity	  in	  the	  newborn.300-­‐302	  Furthermore,	  the	  unpredictability	  of	  early	  life	  
trauma	  is	  paramount	  to	  the	  development	  of	  visceral	  hypersensitivity	  in	  later	  life.	  
Startle	  Responses	  
Other	  evidence	  linking	  the	  emotional	  state	  and	  centrally-­‐driven	  over-­‐arousability	  can	  be	  found	  in	  
research	  using	  startle	  responses.303	  In	  this	  paradigm,	  the	  startle	  response	  is	  used	  as	  a	  non-­‐invasive	  
measure	  of	  the	  central	  defence	  response	  to	  threat.	  Naliboff	  et	  al.	  subjected	  IBS	  patients	  and	  controls	  
to	  either	  abdominal	  or	  non-­‐abdominal	  (bicipital)	  aversive	  stimuli	  during	  cued	  periods	  of	  safety	  (no	  
stimulation	  given),	  imminent	  threat	  (possible	  stimulation),	  anticipated	  threat	  (a	  rest	  period	  before	  






connections	  would	  be	  used	  to	  administer	  threat	  but	  that	  no	  stimulations	  would	  be	  given	  during	  this	  
phase)	  whilst	  at	  the	  same	  time	  monitoring	  the	  acoustic	  startle	  responses.304	   	  
The	  data	  revealed	  that	  IBS	  patients	  mounted	  a	  larger	  startle	  response	  during	  anticipation	  and	  
imminent	  threat	  (after	  an	  initial	  stimulation	  had	  been	  given).	  Psychometric	  analysis	  demonstrated	  
that	  neuroticism	  (as	  defined	  by	  Eysenck	  Neuroticism	  scale)	  was	  associated	  with	  larger	  startle	  
responses	  during	  periods	  of	  safety	  and	  anticipatory	  threat	  than	  during	  imminent	  threat,	  and	  that	  
anxiety	  was	  negatively	  correlated	  with	  startle	  responses	  during	  imminent	  threat.	  The	  importance	  of	  
this	  work	  is	  that	  even	  though	  peripheral	  visceral	  hypersensitivity	  is	  an	  important	  pathological	  
mechanism	  in	  IBS,	  central	  structures,	  circuits	  involved	  in	  the	  emotional	  response	  to	  aversive	  or	  non-­‐
aversive	  stimuli	  and	  one’s	  psychological	  constitution	  are	  intrinsically	  linked	  to	  the	  perception	  of	  pain.	   	   	   	   	  
The	  Limbic	  System	  
The	  central	  pathway	  that	  is	  responsible	  for	  integrating	  sensory	  perception	  and	  emotion	  is	  the	  limbic	  
system,	  and	  in	  particular	  the	  amygdala.305	  This	  structure	  determines	  the	  emotional	  context	  of	  
afferent	  sensory	  nerve	  transmission,	  and	  serves	  to	  acquire	  and	  maintain	  memories	  pertaining	  to	  said	  
sensory	  stimulation.	  As	  a	  result	  the	  amygdala	  is	  a	  key	  pathway	  in	  forming	  the	  fight	  or	  flight	  response,	  
and	  for	  the	  creation	  of	  anxiety	  and	  fear.	  Its	  role	  in	  the	  conditioned	  response	  is	  undisputed.306,307	  The	  
advent	  of	  more	  advanced	  imaging	  techniques	  such	  as	  functional	  MRI	  confirms	  its	  importance	  in	  the	  
modulation	  of	  pain.308	   	  
Manipulation	  of	  the	  limbic	  system	  can	  be	  performed	  using	  simple	  laboratory	  paradigms.309	  Healthy	  
volunteers	  were	  asked	  to	  review	  various	  unpalatable	  and	  disturbing	  images	  to	  induce	  a	  state	  of	  
negative	  affect.	  Subsequent	  testing	  demonstrated	  enhanced	  startle	  responses,	  and	  diminished	  
inhibitory	  pain	  pathways.310	   	  
The	  Role	  of	  the	  Amygdala	  
A	  recent	  study	  by	  Choi	  et	  al.	  devised	  a	  system	  of	  dynamic	  fear	  arousal	  in	  which	  rats	  were	  subjected	  
to	  the	  emotional	  trauma	  of	  a	  having	  a	  predatory	  robot	  programmed	  to	  lunge	  at	  them	  whilst	  they	  
were	  foraging	  for	  food.311	  The	  initial	  behaviour	  was	  that	  of	  fleeing	  to	  the	  nest	  or	  freezing.	  Chemical	  
disinhibition	  of	  the	  amygdala	  (using	  an	  intra-­‐amygdalar	  infusion	  of	  a	  GABAA	  receptor	  antagonist)	  
prompted	  heightened	  fear	  responses	  in	  the	  rats.	  Conversely	  the	  chemical	  inactivation	  of	  the	  
amygdala	  (using	  a	  GABAA	  receptor	  agonist	  infusion)	  caused	  the	  rats	  to	  abandon	  any	  escape	  response	  






This	  study	  gives	  a	  valuable	  insight	  into	  the	  bidirectional	  role	  of	  the	  amygdala	  in	  risk-­‐taking	  
behaviours.	  Further	  support	  for	  this	  can	  be	  seen	  by	  studying	  patients	  with	  bilateral	  lesions	  of	  the	  
amygdala-­‐	  De	  Martino	  et	  al.	  subjected	  two	  such	  individuals	  to	  various	  experimental	  economic	  tasks,	  
asking	  them	  to	  gamble,	  thereby	  exposing	  them	  to	  the	  risks	  of	  losses	  in	  the	  pursuit	  of	  gains.312	  
Compared	  to	  controls,	  they	  demonstrated	  a	  remarkable	  reduction	  in	  loss	  aversion,	  the	  concept	  of	  
forgoing	  the	  opportunity	  of	  substantial	  reward	  due	  to	  the	  fear	  of	  realising	  a	  loss.	   	  
Dysregulation	  of	  the	  Amygdala	  
Dysregulation	  of	  the	  amygdala	  and	  its	  connection	  with	  the	  ventromedial	  prefrontal	  cortex,	  a	  central	  
structure	  involved	  in	  sympathetic	  arousal,	  is	  associated	  with	  altered	  regulation	  of	  affect.	  Anxiety	  
states	  such	  as	  Post-­‐traumatic	  Stress	  Disorder	  have	  been	  shown	  to	  have	  enhanced	  reactivity	  of	  the	  
amygdala	  to	  affect-­‐inducing	  stimuli	  with	  concomitant	  suppression	  of	  the	  ventromedial	  prefrontal	  
cortex	  (indicating	  increased	  physiological	  arousal).313,314	  This	  has	  led	  to	  the	  hypothesis	  that	  altered	  
activity	  in	  the	  amygdala	  and	  associated	  pre-­‐frontal	  structures	  is	  the	  pathological	  foundation	  for	  the	  
development	  of	  anxiety	  states.	   	   	   	   	  
In	  the	  context	  of	  IBS,	  Naliboff	  et	  al.	  demonstrated	  enhanced	  responses	  in	  the	  amygdala	  and	  the	  
dorsal	  anterior	  cingulate	  cortex	  in	  response	  to	  anticipated	  and	  delivered	  rectal	  balloon	  distension.315	  
The	  same	  group	  published	  a	  companion	  study	  which	  documented	  that	  repeated	  visceral	  stimulation	  
with	  the	  barostat	  (six	  sessions	  over	  a	  12	  month	  follow-­‐up)	  produced	  habituation	  of	  the	  visceral	  
perception	  of	  rectal	  distension-­‐316	  PET	  scanning	  elucidated	  that	  this	  correlated	  with	  decreased	  
activity	  of	  the	  amygdala,	  the	  dorsal	  anterior	  cingulate	  cortex	  and	  the	  dorsal	  brainstem.	   	  
Emotional	  Over-­‐arousal	  
Petrovic	  et	  al.	  suggested	  that	  when	  the	  body	  is	  faced	  with	  an	  imminent	  painful	  threat,	  suppression	  
of	  the	  amygdala	  and	  its	  connections	  is	  part	  of	  a	  cognitive	  coping	  strategy.317	  The	  failure	  to	  down-­‐
regulate	  the	  activity	  of	  the	  amygdala	  during	  anticipated	  pain,	  and	  to	  maintain	  a	  state	  of	  emotional	  
over-­‐arousal	  may	  be	  a	  hallmark	  of	  IBS	  and	  other	  chronic	  pain	  states.318	  Mayer	  et	  al.	  characterised	  
this	  as	  “ineffective	  cortico-­‐limbic-­‐pontine	  inhibition	  of	  visceral	  afferent	  input	  within	  the	  homeostatic	  
afferent	  processing	  network”.319	  How	  this	  then	  translates	  to	  IBS	  GI	  symptomatology	  can	  be	  inferred	  
from	  animal	  studies	  which	  show	  that	  a	  conditioned	  fear	  environment	  produces	  increased	  colonic	  








Many	  studies	  report	  an	  association	  between	  functional	  disease	  and	  somatisation.321-­‐324	  The	  
increasing	  number	  of	  functional	  diagnoses	  made	  in	  any	  one	  individual	  should	  give	  rise	  to	  
consideration	  for	  the	  presence	  of	  somatoform	  disorders.	  The	  criteria	  for	  the	  diagnosis	  of	  
Somatisation	  Disorder	  (SD)	  has	  features	  which	  complement	  the	  diagnosis	  of	  IBS.	  Again	  mirroring	  IBS,	  
SD	  uses	  subjective	  patient	  reports	  to	  arrive	  at	  a	  diagnosis.	  Using	  DSM	  IV	  classification,325	  
Somatisation	  Disorder	  is	  defined	  as	  a	  persistence	  of	  physical	  symptoms	  in	  the	  absence	  of	  a	  medical	  
explanation.	  There	  are	  five	  features:	  a	  history	  of	  somatic	  symptoms	  prior	  to	  the	  age	  of	  30,	  two	  GI-­‐
related	  symptoms	  e.g.	  diarrhoea,	  pain	  in	  at	  least	  4	  different	  parts	  of	  the	  body,	  one	  
pseudoneurological	  symptom	  e.g.	  fainting	  and	  one	  symptom	  of	  sexual	  dysfunction	  e.g.	  erectile	  
dysfunction.	   	  
Somatisation	  and	  IBS	  
Clearly	  the	  overlap	  between	  SD	  and	  IBS	  is	  obvious.	  A	  study	  by	  North	  et	  al.	  was	  designed	  to	  tease	  
apart	  the	  strands	  of	  functional	  disease	  from	  primary	  somatoform	  disorder	  and	  other	  psychiatric	  
illness	  in	  a	  female	  IBS	  population	  attending	  outpatients323	  SD	  was	  confidently	  diagnosed	  in	  25%	  of	  
patients	  with	  another	  5%	  being	  labelled	  as	  having	  a	  high	  probability	  of	  having	  the	  disorder.	  This	  has	  
significant	  implications	  in	  the	  construction	  of	  clinical	  trials,	  and	  perhaps	  SD	  DSM	  IV-­‐positivity	  should	  
be	  screened	  in	  future	  research	  models.	   	   	   	   	  
Somatoform	  disorders	  were	  traditionally	  assumed	  to	  be	  an	  external	  manifestation	  of	  psychological	  
disharmony.326,327	  However,	  other	  theories	  such	  as	  visceral	  and	  somatic	  hypersensitivity	  or	  a	  cascade	  
of	  catastrophic	  cognitions	  and	  overemphasised	  fears	  (i.e.	  thinking	  that	  a	  transient	  episode	  of	  chest	  
pain	  is	  synonymous	  with	  having	  a	  heart	  attack)	  may	  act	  as	  mechanistic	  drivers	  of	  disease.	  It	  is	  
important	  to	  note	  that	  the	  strict	  criteria	  for	  diagnosis	  does	  not	  make	  reference	  to	  psychological	  
comorbidity.	  
Another	  interesting	  observation	  is	  that	  even	  though	  SD	  is	  not	  defined	  by	  psychological	  parameters,	  
patients	  with	  SD	  may	  describe	  psychiatric	  symptoms	  more	  frequently	  than	  patients	  with	  known	  non-­‐
somatoform	  psychiatric	  disease.	  Lenze	  et	  al.	  documented	  a	  wide	  variety	  of	  psychotic,	  manic,	  
depressive	  and	  anxiety-­‐related	  symptoms	  in	  a	  group	  of	  SD	  patients	  that	  was	  not	  attributable	  to	  
other	  psychiatric	  comorbidity.328	  Indeed	  patients	  with	  SD	  were	  found	  to	  have	  increased	  frequency	  of	  






(comprising	  the	  Histrionic,	  Narcissistic,	  Antisocial	  and	  Borderline	  Personality	  Disorders).	  Again	  the	  
caveat	  to	  this	  study	  was	  that	  SD	  should	  be	  an	  important	  differential	  diagnosis	  for	  someone	  
presenting	  with	  wide-­‐ranging	  psychiatric	  symptomatology.	  
Irritable	  Bowel	  Syndrome	  patients	  with	  the	  comorbidity	  of	  a	  somatoform	  disorder	  tend	  to	  have	  
more	  marked	  abnormal	  illness	  behaviours	  e.g.	  increased	  utilisation	  of	  healthcare	  resources,	  days	  off	  
work,	  changes	  to	  medications,	  and	  display	  more	  psychiatric	  symptoms.323	   	   	  
Diagnostic	  uncertainty	  arises	  when	  one	  has	  to	  make	  a	  diagnosis	  of	  IBS	  in	  the	  presence	  of	  
somatoform	  symptomatology,	  especially	  if	  the	  patient	  does	  not	  meet	  the	  precise	  criteria	  for	  
Somatisation	  Disorder	  or	  one	  of	  the	  other	  somatoform	  disorders	  (undifferentiated	  somatoform	  
disorder	  or	  somatoform	  disorder	  not	  otherwise	  specified).	  Or	  if	  a	  patient	  with	  known	  psychiatric	  
disease	  presents	  with	  medically	  ambiguous	  symptoms.	  Furthermore,	  the	  magnitude	  of	  somatoform	  
symptoms	  may	  not	  be	  discernible	  from	  a	  single	  doctor/patient	  consultation,	  and	  the	  diagnosis	  or	  
diagnoses	  may	  involve	  a	  considerable	  amount	  of	  time	  and	  effort	  on	  the	  part	  of	  the	  clinician.	  
Conclusion	  
Our	  study	  endorses	  the	  well-­‐documented	  associations	  of	  psychological	  comorbidity	  in	  Irritable	  
Bowel	  Syndrome.	  Knowledge	  of	  these	  associations,	  and	  the	  differentiation	  of	  a	  primary	  psychogenic	  
process	  from	  a	  functional	  gastrointestinal	  process	  with	  multifaceted	  psychological	  dimensions	  are	  
crucial	  to	  the	  management	  of	  the	  patient.	  The	  use	  of	  psychometric	  questionnaires	  should	  be	  
considered	  a	  vital	  core	  of	  any	  future	  clinical	  trials	  involving	  IBS.	  Finally,	  the	  observation	  of	  more	  
centrally	  driven	  psychologically-­‐mediated	  symptoms	  in	  refractory	  IBS	  should	  alert	  the	  physician	  that	  
psychological	  manipulation,	  for	  example	  with	  hypnotherapy	  or	  cognitive	  behavioural	  therapy,	  may	  
be	  a	  worthwhile	  consideration.	   	   	   	  







The	  Study	  Dataset	  
The	  results	  from	  our	  data	  have	  shown	  that	  rectal	  electrical	  stimulation	  produces	  a	  robust	  cortical	  
response	  that	  is	  stable	  and	  reproducible	  over	  time	  (Tables	  3.1.22b	  to	  d).	  This	  is	  the	  first	  study	  to	  
demonstrate	  such	  findings	  in	  the	  IBS	  population.	  As	  shown	  in	  Figures	  3.1.19	  to	  3.1.22,	  the	  evoked	  
potentials	  were	  compared	  at	  many	  time	  points-­‐	  during	  each	  cycle	  of	  testing,	  during	  separate	  cycles	  
(intra-­‐day),	  and	  during	  different	  days	  of	  testing	  (inter-­‐day).	  There	  was	  no	  statistical	  difference	  
between	  data	  collected	  from	  either	  patient	  or	  control	  subject	  during	  intra-­‐day	  comparisons.	  In	  other	  
words,	  when	  someone	  is	  being	  tested	  on	  a	  particular	  day	  the	  first	  cycle	  of	  evoked	  potentials	  will	  be	  
comparable	  to	  the	  last	  cycle	  of	  evoked	  potentials.	  This	  has	  important	  implications	  in	  that	  one	  could	  
dramatically	  shorten	  the	  test	  protocol	  from	  4	  cycles	  to	  2	  cycles	  (or	  even	  less).	  
Anorectal	  Sensitivity	  
Testing	  both	  IBS	  patients	  and	  controls	  over	  3	  separate	  days	  allowed	  for	  serial	  assessment	  of	  
neurophysiological	  function.	  Examination	  of	  the	  sensory	  threshold	  data	  showed	  that	  the	  IBS	  group	  
appeared	  to	  be	  less	  sensitive	  on	  Day	  2	  compared	  to	  controls.	  However,	  the	  data	  from	  Days	  1	  and	  
Days	  3	  is	  similar,	  and	  my	  assumption	  is	  that	  the	  sensory	  threshold	  data	  is	  an	  anomaly	  produced	  from	  
a	  few	  outlying	  results.	  
Pain	  threshold	  testing	  on	  the	  first	  two	  days	  did	  not	  show	  any	  statistical	  difference	  between	  controls	  
and	  cases.	  This	  echoes	  previous	  studies	  that	  show	  that	  in	  a	  pre-­‐excited	  state	  it	  can	  be	  very	  difficult	  
to	  separate	  IBS	  patients	  and	  controls.329	  A	  difference	  in	  pain	  thresholds	  was	  noted	  on	  Day	  3.	  This	  
showed	  that	  whilst	  the	  IBS	  group	  maintained	  a	  fixed	  pain	  threshold,	  the	  control	  group	  became	  more	  
disinhibited,	  allowing	  a	  greater	  electrical	  stimulus	  to	  be	  applied.	  This	  is	  the	  concept	  of	  habituation,	  in	  
which	  one	  becomes	  conditioned	  to	  a	  repetitive	  aversive	  stimulus.	  Once	  more	  this	  raises	  speculation	  
that	  IBS	  patients	  may	  lack	  the	  ability	  to	  disinhibit	  themselves,	  or	  conversely,	  to	  activate	  descending	  
inhibitory	  pathways	  leading	  to	  symptom	  persistence	  and	  reinforcement.	  Perhaps	  the	  manipulation	  
of	  descending	  inhibitory	  pathways	  and	  the	  stimulation	  of	  the	  endogenous	  opioid	  system	  is	  a	  
potential	  therapeutic	  target.	  
CEP	  Morphology	  
The	  morphology	  of	  the	  evoked	  potentials	  (Figures	  1.3.4,	  3.1.19	  to	  3.1.22),	  as	  defined	  by	  the	  principle	  






morphology	  in	  all	  subjects	  tested.	  In	  some	  individuals,	  the	  evoked	  potentials	  were	  almost	  
indistinguishable	  between	  separate	  days	  of	  testing.	  Of	  course,	  different	  people	  produced	  different	  
CEP	  traces.	  This	  arises	  from	  many	  factors-­‐	  for	  instance,	  the	  variation	  in	  the	  amount	  of	  electricity	  
used,	  changes	  in	  the	  integrity	  of	  the	  visceral	  sensory	  neural	  pathways,	  the	  preparation	  of	  the	  bowel,	  
and	  the	  degree	  of	  anxiety	  experienced	  in	  the	  run	  up	  to	  the	  procedure.	  
CEP	  Response	  to	  Increased	  Stimulus	  
The	  evoked	  potentials	  were	  exquisitely	  sensitive	  to	  the	  amount	  of	  stimulus	  applied.	  As	  the	  stimulus	  
intensity	  increased,	  the	  P1	  amplitude	  increased	  and	  the	  P1	  latency	  decreased.	  This	  is	  a	  commentary	  
on	  the	  increasing	  recruitment	  of	  sensory	  afferents	  and	  the	  more	  dominant	  cortical	  representation	  of	  
the	  stimulus	  as	  it	  increases.	  It	  also	  reflects	  the	  fact	  that	  different	  nerve	  fibres	  have	  different	  myelin	  
configurations.	   	  
Those	  afferents	  that	  are	  not	  myelinated,	  such	  as	  C	  fibres,	  have	  a	  higher	  activation	  threshold	  than	  
their	  myelinated	  counterparts,	  e.g.	  Aδ	  fibres.	  As	  a	  result	  there	  is	  preferential	  activation	  of	  Aδ	  fibres	  
at	  low	  stimulus	  intensities	  with	  increasing	  C	  fibre	  depolarization	  at	  the	  higher	  stimulus	  intensities.330	  
Further	  evidence	  of	  the	  preferential	  firing	  of	  Aδ	  fibres	  is	  supplied	  by	  Bromm	  et	  al.	  This	  group	  
demonstrated	  that	  C	  fibre	  afferent	  transmission	  was	  much	  slower	  than	  Aδ	  fibre	  transmission,	  and	  
accounted	  for	  a	  late	  and	  ultra-­‐late	  CEP	  response	  (>1000ms).331-­‐333	  
P1	  
Hobson	  et	  al.’s	  comparison	  of	  the	  cortical	  representation	  of	  MEG	  and	  CEP	  data	  following	  painful	  
(visceral)	  oesophageal	  stimulation	  predicts	  that	  the	  P1	  wave	  seen	  in	  our	  own	  data	  represents	  the	  
firing	  of	  the	  primary	  (S1)	  and	  secondary	  (S2)	  somatosensory	  cortex	  and	  the	  posterior	  insula.334	  Their	  
data	  showed	  P1	  activation	  at	  around	  85ms,	  and	  increased	  activity	  of	  the	  anterior	  insula	  and	  the	  
cingulate	  cortex	  at	  around	  105ms.	  Our	  data	  has	  a	  P1	  latency	  of	  73.5ms	  in	  controls	  and	  96.35ms	  in	  
IBS	  patients	  on	  the	  first	  day	  of	  testing,	  suggesting	  that	  there	  is	  a	  consistency	  between	  the	  two	  
studies.	   	  
The	  Hobson	  paper	  also	  reflected	  on	  the	  fact	  that	  neural	  activity	  was	  maintained	  for	  a	  longer	  period	  
of	  time	  on	  the	  CEP	  tracings	  than	  the	  MEG.	  This	  may	  explain	  why	  a	  discrete	  peak	  following	  P1	  (and	  







Early	  and	  Late	  CEP	  Complexes	  
The	  rectal	  evoked	  potential	  has	  been	  described	  in	  terms	  of	  its	  morphology	  and	  the	  number	  of	  peak	  
deflections	  from	  the	  baseline,	  but	  also	  in	  terms	  of	  latency.	  The	  early	  CEP	  complex	  occurs	  within	  
250ms,	  and	  represents	  the	  initial	  cortical	  activity	  following	  the	  applied	  stimulus.	  This	  is	  said	  to	  be	  the	  
exogenous	  response	  of	  the	  stimulus-­‐induced	  neural	  activity.	   	  
Subsequent	  CEP	  activity	  beyond	  250ms	  reflects	  the	  endogenous	  processing	  of	  the	  stimulus-­‐	  this	  is	  
the	  late	  CEP	  complex.	  It	  represents	  the	  analysis	  of	  the	  stimulus	  amongst	  higher	  cortical	  domains	  of	  
pain	  perception,	  perhaps	  invoking	  the	  emotional,	  behavioural	  or	  attentional	  centres.	   	  
P2	  and	  P3	  
Peak	  2	  and	  Peak	  3	  produce	  a	  large	  scale	  explosion	  of	  neural	  activity	  following	  the	  stimulus.	  In	  the	  
Hobson	  paper,	  this	  activity	  was	  seen	  across	  all	  the	  topographical	  areas	  of	  testing,	  including	  the	  
somatosensory	  cortex	  (S1,	  S2),	  and	  the	  anterior	  and	  posterior	  insula	  cortex.	  334	   	   Given	  that	  CEPs	  can	  
only	  record	  the	  volume	  of	  neural	  activity	  (i.e.	  amplitude)	  rather	  than	  any	  anatomical	  differentiation,	  
the	  large	  P3	  peaks	  represent	  combined	  neural	  activity	  of	  all	  these	  areas.	  In	  both	  controls	  and	  IBS	  
patients	  the	  P3	  latency	  occurred	  with	  250ms.	  The	  decay	  of	  the	  P3	  potential	  marks	  the	  transition	  of	  
the	  early	  CEP	  complex	  into	  the	  late	  CEP	  complex.	  
Late	  CEP	  Complex	  
The	  late	  CEP	  complex	  is	  interesting	  because	  research	  has	  shown	  that	  cortical	  evoked	  potentials	  can	  
be	  seen	  even	  in	  the	  anticipation	  of	  a	  visceral	  stimulus.	  Hollerbach	  et	  al.	  demonstrated	  that	  
anticipatory	  evoked	  potentials	  with	  peak	  latencies	  of	  around	  280ms	  were	  produced	  in	  control	  
subjects	  experiencing	  oesophageal	  visceral	  stimulation	  with	  intermittently	  (and	  randomly)	  non-­‐firing	  
pauses.254	  The	  authors	  concluded	  that	  this	  late	  phase	  of	  cortical	  activity	  may	  be	  a	  surrogate	  marker	  
for	  the	  cognitive	  processing	  attached	  to	  visceral	  perception.	  Our	  data	  suggests	  that	  this	  
neurophysiological	  profile	  is	  consistent	  with	  a	  hypervigilant	  phenotype.	  Clues	  to	  this	  phenotype	  
during	  testing	  would	  be	  an	  IBS	  patient	  with	  high	  STAI	  scores,	  low	  stimulus	  intensity,	  protracted	  
latencies	  but	  robust	  late	  CEP	  complex	  tracings.	  
Combining	  Pain	  Threshold	  with	  Peak	  Latency	  
Hobson	  et	  al.	  used	  CEPs	  to	  differentiate	  in	  neurophysiological	  terms	  a	  group	  of	  patients	  with	  non-­‐






had	  similarly	  negative	  workups	  for	  oesophageal	  manometry	  and	  pH	  testing,	  the	  use	  of	  CEPs	  was	  
instrumental	  in	  delineating	  three	  discrete	  sub-­‐populations.	   	  
The	  first	  group	  had	  reduced	  pain	  thresholds	  to	  electrical	  oesophageal	  stimulation	  and	  
normal/reduced	  P1	  latencies.	  The	  second	  group	  had	  reduced	  pain	  thresholds	  with	  increased	  P1	  
latencies.	  The	  final	  group	  had	  normal	  pain	  thresholds	  with	  normal	  (or	  increased)	  P1	  latencies.	  They	  
concluded	  that	  the	  first	  group	  were	  demonstrating	  a	  phenotype	  with	  enhanced	  oesophageal	  
afferent	  sensitivity.	  The	  second	  group	  of	  patients	  reported	  pain	  or	  discomfort	  with	  delayed	  P1	  
latencies,	  indicating	  an	  absence	  of	  afferent	  hypersensitivity.	  Symptom	  generation	  in	  the	  latter	  group	  
was	  most	  likely	  secondary	  to	  cortical	  amplification	  of	  a	  normal	  afferent	  stream.	  
Sub-­‐Group	  Analysis	  of	  the	  IBS	  Dataset	  
The	  pairing	  of	  anorectal	  sensitivity	  with	  CEP	  latency	  can	  be	  applied	  to	  our	  own	  dataset.	  This	  allows	  
sub-­‐differentiation	  of	  the	  IBS	  group.	  It	  should	  be	  noted	  that	  this	  differentiation	  is	  not	  possible	  
without	  the	  use	  of	  a	  subjective	  record	  of	  patient	  pain	  perception-­‐	  CEPs	  viewed	  in	  isolation	  could	  do	  
nothing	  more	  that	  demonstrate	  whether	  there	  is	  normal	  or	  delayed	  afferent	  transmission	  for	  a	  given	  
stimulus.	  The	  additional	  of	  an	  individual’s	  experience	  of	  the	  applied	  stimulus	  informs	  one	  how	  to	  
interpret	  the	  CEP	  traces.	  
Proposing	  a	  Reference	  Range	  for	  Pain	  Threshold	  and	  CEP	  Latency	  
In	  order	  to	  identify	  in	  neurophysiological	  terms	  what	  is	  abnormal,	  one	  has	  to	  define	  what	  is	  normal.	  
P1	  latency	  was	  taken	  as	  the	  reference	  latency.	  Conceptually	  it	  seemed	  more	  logical	  that	  the	  first	  
representation	  of	  the	  cortical	  response	  should	  be	  used	  as	  the	  defining	  variable.	  However,	  using	  P2	  
latency	  would	  have	  been	  equally	  appropriate.	   	  
The	  control	  3	  day	  mean	  P1	  latency	  was	  73.4ms	  with	  a	  standard	  deviation	  of	  16.1ms.	  Two	  standard	  
deviations	  above	  this	  is	  106ms.	  Values	  above	  106ms	  were	  considered	  to	  be	  attenuated.	  The	  cut	  off	  
for	  pain	  threshold	  was	  defined	  as	  being	  less	  than	  50mA	  since	  all	  healthy	  controls	  had	  levels	  above	  
this	  value	  (range	  50	  to	  90mA).	  
Determining	  an	  appropriate	  value	  for	  the	  pain	  threshold	  was	  more	  difficult	  than	  for	  the	  P1	  latency.	  1	  
SD	  below	  the	  control	  pain	  threshold	  was	  48.19mA,	  and	  2	  SDs	  below	  the	  control	  pain	  threshold	  was	  
26.33mA.	  If	  we	  had	  used	  the	  same	  system-­‐	  projecting	  2	  SDs	  below	  the	  control	  mean	  pain	  threshold-­‐	  






decision	  to	  define	  the	  pain	  threshold	  as	  being	  less	  than	  50mA,	  whilst	  not	  as	  statistically	  robust,	  still	  
identified	  a	  small	  sub-­‐group	  of	  IBS	  patients	  that	  had	  thresholds	  below	  that	  of	  their	  control	  
counterparts.	   	  
Identifying	  the	  IBS	  Subgroups	  
Twelve	  IBS	  patients	  had	  a	  mean	  three	  day	  PT	  ≤50mA:	  four	  patients	  had	  P1	  latency	  >106ms,	  and	  eight	  
patients	  had	  a	  P1	  latency	  ≤106ms.	  Twenty-­‐one	  patients	  had	  a	  mean	  three	  day	  PT	  ≤50mA:	  five	  
patients	  had	  had	  P1	  latency	  >106ms,	  and	  sixteen	  patients	  had	  a	  P1	  latency	  ≤106ms.	  This	  data	  is	  
summarised	  in	  Figure	  4.1.	  
Figure	  4.1	  Patient	  Stratification	  using	  Pain	  Threshold	  and	  Peak	  1	  Latency	  
	  
Extrapolation	  of	  this	  data	  suggests	  that	  of	  the	  IBS	  patients	  that	  were	  tested,	  16	  of	  the	  33	  IBS	  patients	  
had	  normal	  visceral	  afferent	  function	  (normal	  P1	  latency	  and	  normal	  sensory	  thresholds),	  4	  patients	  
were	  hypervigilant	  (decreased	  sensory	  thresholds	  with	  delayed	  P1	  latency),	  5	  patients	  were	  
hyposensitive	  (raised	  sensory	  thresholds	  with	  delayed	  P1	  latency)	  and	  8	  patients	  demonstrated	  
visceral	  afferent	  hypersensitivity	  (decreased	  pain	  thresholds	  with	  decreased	  P1	  latencies).	   	   This	  
data	  is	  summarised	  in	  Figure	  4.2.	  






Figure	  4.2	  Identifying	  the	  IBS	  Subgroups	  using	  Pain	  Threshold	  and	  Peak	  1	  Latency	  
	  
Neuropsychophysiological	  Patterns	  
While	  it	  would	  be	  difficult	  to	  present	  all	  the	  CEP	  traces	  for	  21	  Controls	  and	  34	  IBS	  patients	  spanning	  
3	  days,	  three	  CEP	  patterns	  emerged.	  These	  patterns	  must	  be	  viewed	  in	  the	  context	  of	  the	  amount	  of	  
electrical	  stimulus	  used,	  and	  the	  prevailing	  anxiety	  state.	  
The	  first	  pattern	  is	  what	  would	  be	  considered	  the	  normal	  pattern.	  This	  can	  be	  seen	  in	  Figure	  4.3.,	  
labelled	  Control.	   	   The	  Control	  demonstrates	  a	  good	  cortical	  response	  over	  2	  separate	  days	  using	  
stimulus	  intensities	  of	  61	  and	  77mA	  respectively.	  The	  anxiety	  state	  is	  defined	  by	  the	  Spielberger	  
State	  Anxiety	  Index.	  In	  this	  subject,	  anxiety	  drops	  from	  Day	  1	  to	  Day	  2	  as	  might	  be	  expected	  of	  
someone	  becoming	  more	  relaxed	  about	  the	  testing	  process.	  
The	  second	  subject,	  labelled	  IBS	  1,	  produces	  high	  amplitude,	  short	  latency	  evoked	  potentials	  in	  the	  
context	  of	  dropping	  anxiety	  levels	  and	  tiny	  amounts	  of	  electrical	  stimulus	  (27	  and	  26	  milliamps	  on	  
separate	  days).	  This	  is	  very	  much	  the	  pattern	  that	  we	  expected	  to	  see	  in	  primary	  rectal	  afferent	  
hypersensitivity.	  It	  reflects	  an	  upregulation	  of	  visceral	  afferent	  transmission,	  one	  of	  the	  putative	  
driving	  mechanisms	  of	  IBS	  symptomatology.	   	  
The	  third	  subject,	  termed	  IBS	  2,	  produces	  ill-­‐defined	  CEP	  traces	  on	  the	  first	  day.	  Only	  31mA	  of	  
electricity	  was	  applied.	  By	  Day	  2,	  the	  subject	  manages	  to	  tolerate	  a	  much	  higher	  electrical	  stimulus	  
even	  in	  the	  context	  of	  increasing	  anxiety	  levels.	  The	  distinction	  here	  is	  that	  the	  patient	  can	  tolerate	  
high	  electrical	  stimulations	  (someone	  with	  visceral	  hypersensitivity	  would	  not	  tolerate	  such	  a	  jump	  
in	  electricity),	  but	  was	  not	  able	  to	  do	  so	  on	  Day	  1.	  This	  is	  independent	  of	  any	  dysfunction	  in	  the	  






the	  ether	  of	  background	  cortical	  electricity.	  This	  kind	  of	  IBS	  patient	  personifies	  the	  chronically	  
aroused,	  hypervigilant	  phenotype.	  
Figure	  4.3	  Cortical	  Evoked	  Potentials	  from	  a	  Control	  subject	  and	  two	  IBS	  patients	   	   	   	   	   	  
on	  Day	  1	  and	  2	  
	  
	  
Summary	  of	  CEP	  data	  
In	  summary	  the	  study	  protocol	  has	  managed	  to	  define	  4	  distinct	  subgroups	  based	  on	  objective	  
neurophysiological	  and	  anorectal	  parameters.	  The	  fact	  that	  only	  8	  of	  the	  33	  (approximately	  25%)	  
have	  been	  found	  to	  have	  rectal	  afferent	  hypersensitivity	  may	  appear	  somewhat	  less	  than	  the	  
prevalence	  described	  in	  other	  IBS	  literature.	  Some	  studies	  calculate	  the	  prevalence	  of	  
hypersensitivity	  to	  balloon	  distension	  in	  IBS	  patients	  at	  around	  60%.335,336.	  The	  presence	  of	  rectal	  
afferent	  hyposensitivity	  at	  around	  15%	  is	  consistent	  with	  established	  data.	  Observations	  from	  
Professor	  Whorwell’s	  group	  (and	  other	  research	  groups)	  demonstrated	  that	  a	  small	  minority	  of	  
constipation-­‐predominant	  IBS	  patients	  (between	  6	  and	  19%)	  had	  rectal	  hyposensitivity	  to	  balloon	  
distension.138,337	   	  
This	  does	  not	  discredit	  either	  the	  technology	  of	  CEPs	  (and	  sensory	  threshold	  testing)	  to	  identify	  






hallmark	  of	  IBS.	  It	  can	  be	  explained	  by	  the	  fact	  that	  IBS	  reflects	  a	  heterogeneous	  population,	  that	  
previous	  research	  using	  the	  barostat	  introduces	  confounding	  factors	  at	  every	  step	  of	  the	  way	  from	  
the	  peripheral	  receptor	  to	  the	  cortex	  (thereby	  embellishing	  the	  prevalence	  of	  visceral	  
hypersensitivity),	  and	  because	  visceral	  hypersensitivity	  is	  the	  final	  expression	  of	  a	  complicated	  
pathway	  that	  involves	  the	  modulation	  of	  the	  afferent	  sensory	  stream	  by	  spinal,	  sub-­‐cortical	  and	  
cortical	  processes.	  
In	  order	  to	  scrutinise	  the	  role	  of	  visceral	  hypersensitivity	  in	  IBS,	  it	  is	  important	  to	  observe	  its	  
conceptual	  development,	  and	  to	  identify	  each	  step	  of	  the	  afferent	  pathway	  towards	  the	  S1/S2	  
cortex.	  
Dismissing	  Old	  Theories	  
Many	  studies	  now	  conclude	  that	  visceral	  hypersensitivity	  is	  an	  important	  pathological	  mechanism	  in	  
Irritable	  Bowel	  Syndrome.338	  However,	  before	  the	  concept	  of	  visceral	  hypersensitivity	  became	  
popular,	  other	  theories	  on	  the	  development	  of	  symptoms	  in	  IBS	  were	  prevalent.	   	   The	  most	  notable	  
was	  the	  theory	  of	  colonic	  dysmotility	  leading	  to	  symptom	  generation.	  However	  research	  designed	  to	  
investigate	  colonic	  dysmotility	  failed	  to	  correlate	  changes	  in	  colonic	  motility	  with	  the	  onset	  of	  
pain.339	  As	  a	  result,	  the	  theory	  of	  visceral	  hypersensitivity	  started	  to	  become	  more	  conceptually	  
relevant.	  
The	  Era	  of	  the	  Barostat	  
The	  demise	  of	  the	  theory	  of	  dysmotility	  introduced	  the	  era	  of	  the	  barostat	  in	  which	  the	  tolerance	  to	  
rectosigmoid	  balloon	  distension	  was	  seen	  as	  a	  biomarker	  for	  colonic	  sensitivity.336	   	   Many	  research	  
groups	  documented	  increased	  colonic	  sensitivity	  in	  IBS	  groups	  compared	  to	  controls	  using	  the	  
barostat,	  or	  have	  shown	  that	  repetitive	  stimulation	  precipitates	  a	  sensitised	  state.329	   	  
Some	  investigators	  suggested	  that	  the	  aberrant	  referral	  of	  pain	  to	  non-­‐sacral	  sites	  during	  barostat	  
testing	  was	  a	  characteristic	  of	  dysregulated	  sensory	  function.	  This	  has	  been	  termed	  aberrant	  
viscerosomatic	  referral.340	  Other	  groups	  have	  demonstrated	  visceral	  hypersensitivity	  in	  other	  parts	  
of	  the	  gastrointestinal	  tract	  in	  the	  absence	  of	  rectal	  hypersensitivity.	  This	  may	  reflect	  regional	  and/or	  
temporal	  changes	  in	  visceral	  hypersensitivity.	  
Taken	  in	  isolation,	  hypersensitivity	  to	  rectal	  balloon	  distension	  can	  identify	  the	  majority	  of	  IBS	  






referral	  and	  the	  intensity	  of	  perceived	  sensations	  improves	  the	  sensitivity	  of	  barostat	  testing.	  94%	  of	  
IBS	  patients	  were	  identified	  in	  Mertz	  et	  al.’s	  IBS	  cohort	  using	  this	  methodology.336	  However,	  
regardless	  of	  the	  barostat	  test	  paradigm,	  it	  is	  impossible	  to	  remove	  the	  psychological	  and	  emotional	  
processing	  associated	  with	  having	  an	  inflatable	  balloon	  inserted	  in	  the	  rectum.	   	  
Subjective	  Sensory	  Perception	   	  
Whitehead	  et	  al.	  scrutinised	  the	  phenomenon	  of	  subjective	  sensory	  perception	  during	  balloon	  
distension.341	  They	  noted	  that	  IBS	  patients	  reported	  more	  pain	  even	  during	  sham	  balloon	  
distensions;	  in	  addition,	  laboratory	  measures	  taken	  to	  reduce	  psychological	  factors	  during	  balloon	  
distension	  caused	  a	  shift	  of	  the	  IBS	  hypersensitive	  state	  to	  that	  of	  normal	  visceral	  sensitivity.	  
Furthermore,	  psychological	  remodelling,	  for	  instance	  via	  hypnotherapy,	  has	  been	  shown	  to	  reduce	  
rectal	  sensitivity,	  clearly	  demonstrating	  the	  involvement	  of	  central	  processes	  in	  the	  functioning	  of	  
ostensibly	  peripheral	  mechanisms	  in	  pain	  perception.138	  
Visceral	  Afferent	  Sensory	  Transmission	  
It	  is	  quite	  clear	  that	  it	  is	  difficult	  to	  separate	  peripheral	  visceral	  signalling	  from	  the	  emotional	  or	  
environmental	  context	  of	  the	  stimulus.	  Visceral	  afferents	  travel	  towards	  the	  dorsal	  horn	  in	  
association	  with	  sympathetic	  fibres	  via	  the	  splanchnic	  nerves	  passing	  through	  the	  mesenteric	  ganglia	  
and	  the	  prevertebral	  ganglia.	  The	  exceptions	  to	  this	  are	  the	  visceral	  afferents	  supplying	  the	  
anorectum	  that	  travel	  via	  the	  pudendal	  nerves,	  and	  those	  of	  the	  proximal	  gut	  (from	  the	  oesophagus	  
to	  the	  jejunum)	  that	  ascend	  via	  the	  vagus	  nerve,	  terminating	  in	  the	  Nucleus	  Tractus	  Solitarius.	  Any	  
exaggeration	  or	  inhibition	  of	  any	  part	  of	  this	  sequence	  may	  provoke	  a	  hypersensitive	  (or	  
hyposensitive)	  state.	  In	  effect,	  changes	  to	  peripheral	  nerve	  transmission,	  central	  sensory	  processing	  
or	  descending	  efferent	  nerve	  transmission	  may	  alter	  the	  perception	  of	  pain.	  
Visceral	  Noiciceptors	  
A	  widespread	  yet	  low	  density	  network	  of	  noiciceptors	  populates	  the	  mucosa	  of	  the	  gut.	  Visceral	  
afferents	  do	  not	  populate	  the	  gastrointestinal	  tract	  in	  isolation-­‐	  they	  also	  innervate	  the	  mesentery,	  
heart	  and	  other	  viscera,	  and	  serve	  as	  a	  communication	  pathway	  between	  the	  central	  and	  enteric	  
nervous	  systems.	  Furthermore	  the	  proximity	  of	  afferent	  fibres	  to	  inflammatory	  cells	  e.g.	  mast	  cells	  








Visceral	  Afferent	  Receptors	  
When	  a	  peripheral	  stimulus	  is	  applied,	  many	  different	  types	  of	  receptor	  may	  be	  instructed	  to	  convey	  
the	  signal.	  Visceral	  afferent	  receptors	  are	  divided	  into	  3	  classes-­‐	  intensity-­‐encoding	  
mechanoreceptors,	  high	  threshold	  mechanoreceptors	  and	  mechanically-­‐insensitive	  
mechanoreceptors	  (the	  so-­‐called	  “silent	  fibres”).343,344	  The	  first	  group	  of	  mechanoreceptors	  have	  a	  
low	  threshold	  for	  firing,	  and	  operate	  under	  normal	  physiological	  conditions.	  They	  encode	  both	  non-­‐
noxious	  (physiological)	  and	  noxious	  stimulus	  intensities.	  The	  second	  group	  have	  a	  high	  threshold	  for	  
firing,	  and	  only	  encode	  noxious	  stimuli	  i.e.	  at	  intensities	  approximating	  to	  the	  pain	  threshold.	  The	  
mechanically-­‐insensitive	  receptors	  have	  very	  poor	  response	  to	  mechanical	  stimulus	  but	  are	  sensitive	  
to	  chemical,	  metabolic,	  inflammatory	  or	  thermal	  stimuli.345-­‐348	   	  
In	  the	  context	  of	  the	  barostat,	  balloon	  distension	  produces	  a	  barrage	  of	  sensory	  information	  that	  
involves	  multiple	  visceral	  receptors,	  ranging	  from	  those	  that	  are	  mechanically-­‐sensitive	  to	  those	  that	  
are	  not.	  In	  terms	  of	  being	  a	  discrete	  assessment	  of	  visceral	  hypersensitivity,	  there	  are	  many	  
disadvantages	  to	  its	  use.	   	  
In	  contrast	  our	  study	  protocol	  employed	  a	  short-­‐lived	  electrical	  stimulus	  that	  was	  programmed	  so	  
that	  the	  stimulus	  was	  delivered	  at	  slightly	  different	  successive	  time	  points,	  thereby	  reducing	  
anticipatory	  bias.	   	  
Disruption	  of	  the	  Peripheral	  Signal	  
Disruption	  or	  manipulation	  of	  peripheral	  sensory	  mechanisms	  highlight	  their	  importance	  in	  the	  
perception	  of	  pain.	  For	  instance,	  the	  rectal	  mucosa	  can	  be	  artificially	  sensitised	  by	  agents	  such	  as	  
glycerol349	  or	  desensitised	  by	  lidocaine.350	  In	  a	  more	  obvious	  clinical	  setting,	  bacterial	  sensitisation	  of	  
the	  bowel	  produces	  an	  IBS	  symptom	  complex	  following	  gastroenteritis.	  It	  is	  also	  important	  to	  point	  
out	  that	  IBS	  is	  characterised	  by	  visceral	  hypersensitivity	  but	  not	  somatic	  hypersensitivity.	  Accarino	  et	  
al.	  went	  so	  far	  as	  to	  show	  that	  IBS	  patients	  had	  increased	  somatic	  pain	  tolerances	  compared	  to	  
controls.351	  Fukudo	  et	  al.	  demonstrated	  exaggerated	  colonic	  motility	  in	  IBS	  patients	  using	  a	  barostat	  
distension	  paradigm	  that	  fell	  below	  the	  sensory	  threshold,	  suggesting	  an	  abnormal	  pre-­‐cortical	  
reflex.352	  
Visceral	  Pain	  
The	  perception	  of	  visceral	  pain	  is	  ambiguous,	  ill-­‐defined	  and	  non-­‐specific.	  In	  the	  clinical	  context,	  






These	  symptoms	  may	  be	  difficult	  to	  distinguish	  from	  other	  clinical	  conditions.	  This	  is	  due	  to	  the	  
anatomy	  of	  the	  visceral	  neural	  pathways.	   	  
Visceral	  Receptor	  Convergence	  
1st	  order	  neurons	  have	  diffuse	  connections	  over	  multiple	  segments	  of	  the	  spine.353	  Visceral	  
noiciceptors	  converge	  with	  spinothalamic	  projection	  neurones	  in	  lamina	  I,	  II	  and	  V	  of	  the	  dorsal	  
horn.354	  The	  spinothalamic	  neurones	  receive	  concurrent	  innervation	  from	  somatic	  afferents	  from	  
both	  deep	  and	  superficial	  somatic	  structures	  in	  the	  same	  dermatome.	  This	  anatomical	  arrangement	  
explains	  the	  phenomenon	  of	  referred	  somatic	  pain.355	  This	  occurs	  when	  noxious	  stimulation	  of	  
visceral	  afferents	  co-­‐stimulates	  viscero-­‐somatic	  neurones	  at	  the	  level	  of	  the	  dorsal	  horn	  precipitating	  
dermatomal	  pain.	  It	  may	  also	  explain	  why	  people	  who	  complain	  of	  symptoms	  from	  non-­‐
gastrointestinal	  viscera	  (e.g.	  dysmenorrhoea)	  demonstrate	  heightened	  sensitivities	  during	  colonic	  
distension	  testing.	  
Other	  patterns	  of	  convergence	  occur	  at	  the	  dorsal	  horn	  between	  visceral	  afferents	  and	  autonomic	  
(vagal)	  and	  enteric	  fibres	  leading	  to	  further	  blurring	  of	  the	  clinical	  picture-­‐	  for	  example	  the	  onset	  of	  
visceral	  discomfort	  may	  invite	  an	  autonomic	  response,	  such	  as	  nausea,	  sweating	  and	  vasomotor	  
flushing.	  
Subliminal	  Processing	  of	  Visceral	  Signals	  
Most	  visceral	  afferent	  sensory	  flow	  does	  not	  reach	  the	  level	  of	  cognitive	  processing,	  i.e.	  the	  
background	  level	  of	  visceral	  activity	  is	  filtered	  out	  before	  reaching	  the	  consciousness.	  This	  allows	  the	  
individual	  to	  concentrate	  on	  more	  pressing	  cognitive	  demands.	  The	  exceptions	  to	  this	  are	  the	  
sensations	  of	  fullness	  required	  to	  alert	  the	  body	  that	  the	  point	  of	  satiety	  has	  been	  reached	  or	  that	  it	  
is	  time	  to	  void.	  However,	  during	  times	  of	  pain,	  biochemical	  stress	  or	  inflammation,	  there	  is	  an	  
increased	  firing	  of	  the	  high-­‐threshold	  receptors	  (and/or	  chemoreceptors)	  to	  signal	  distress.	   	  
Homeostatic	  Afferent	  Processing	  Network	   	  
Visceral	  signals	  ascend	  in	  the	  CNS	  where	  their	  information	  is	  processed	  by	  sub-­‐cortical	  and	  cortical	  
structures.	  Lamina	  I	  neurons	  in	  the	  dorsal	  horn	  project	  to	  those	  centres	  involved	  in	  visceral	  
homeostasis.	  These	  structures	  include	  brainstem	  sites,	  parabrachial	  nucleus,	  periaqueductal	  grey,	  
the	  caudal	  and	  rostral	  venterolateral	  medulla,	  hypothalamus	  and	  amygdala.	  Mayer	  et	  al.	  termed	  this	  






processed	  initially	  by	  a	  hierarchical	  framework	  of	  modality-­‐specific	  sub-­‐cortical	  reflexes,	  both	  
autonomic	  and	  somatic,	  designed	  to	  preserve	  homeostasis.356	   	  
In	  addition	  to	  sub-­‐cortical	  processing,	  the	  Lamina	  1	  outflow	  is	  directed	  towards	  the	  cortex	  via	  the	  
posteromedial	  aspect	  of	  the	  thalamus,	  designated	  the	  ventral	  caudal	  part	  of	  the	  medial	  dorsal	  
nucleus	  (MDvc).	  This	  circuit	  activates	  the	  dorsal	  anterior	  cingulate	  cortex	  (dACC)	  which	  has	  a	  role	  in	  
the	  cognitive	  affective	  appraisal	  of	  visceral	  (and	  somatic)	  sensation.	  It	  also	  serves	  to	  regulate	  
autonomic	  function,	  emotional	  responses	  and	  behavioural	  motivations	  such	  as	  reward-­‐anticipation.	   	  
Another	  discrete	  neural	  circuit	  projects	  visceral	  information	  to	  the	  Dorsal	  Posterior	  Insular	  Cortex	  
(via	  the	  postero-­‐lateral	  thalamus,	  termed	  the	  VMpo)	  which	  has	  responsibilities	  for	  temperature	  
regulation,	  pain,	  hunger	  etc.357	  
Figure	  4.4	  Neuroanatomy	  of	  the	  Ascending	  Visceral	  Afferents	  
	  
Figure	  A	  demonstrates	  the	  ascending	  projections	  from	  homeostatic	  afferents	  from	  the	  spine	  via	  Lamina	  1,	  and	  from	  
parasympathetic	  nerve	  fibres	  via	  the	  Nucleus	  Tractus	  Solitarius	  (NTS).	  This	  information	  convenes	  at	  the	  Parabrachial	  
Nucleus	  before	  projecting	  to	  the	  venteromedial	  thalamic	  nuclei	  (VMpo	  and	  VMb)	  or	  the	  medial	  dorsal	  nucleus	  (MDvc).	  
Subsequent	  projections	  activate	  the	  dorsal	  anterior	  cingulate	  cortex	  (dACC),	  dorsal	  posterior	  insula	  and	  area	  3a	  of	  the	  
cortex,	  part	  of	  the	  sensorimotor	  cortex.	  Figure	  B	  demonstrates	  ascending	  projections	  from	  homeostatic	  afferents	  towards	  






Sensory	  information	  passing	  through	  the	  dorsal	  posterior	  insula	  is	  relayed	  to	  the	  middle	  insula	  and	  
(non-­‐dominant)	  right	  anterior	  insula.	  The	  right	  anterior	  insula	  has	  intimate	  connections	  with	  the	  
dorsal	  anterior	  cingulate	  cortex	  and	  the	  right	  orbito-­‐frontal	  cortex,	  and	  mediates	  interoceptive	  
awareness	  and	  the	  emotional	  response.	  The	  right	  anterior	  insula	  cortex	  is	  sensitive	  to	  homeostatic	  
emotions	  (the	  awareness	  of	  the	  “physiological	  self”)	  such	  as	  hunger,	  thirst,	  libido	  and	  temperature	  
and	  affords	  them	  their	  subjective	  emotional	  context	  (e.g.	  happiness,	  anger,	  fear	  etc.).	  As	  a	  result,	  it	  
is	  possible	  to	  define	  in	  neuroanatomical	  terms	  how	  a	  distant	  visceral	  signal	  can	  pass	  through	  layers	  
of	  sub-­‐cortical	  and	  cortical	  brain	  networks,	  culminating	  in	  a	  subjective,	  integrated	  emotional	  
response.	   	  
Visceral	  Perception	  
The	  perception	  of	  visceral	  discomfort	  or	  pain	  is	  the	  translation	  of	  visceral	  sensory	  input	  by	  
supraspinal	  structures	  into	  a	  subjective	  form	  that	  is	  influenced	  by	  memory,	  context,	  emotion,	  
motivational	  factors	  and	  the	  level	  of	  cognitive	  processing.	  Dysregulation	  of	  any	  of	  these	  networks	  
may	  cause	  altered	  perception	  of	  the	  visceral	  signal.	  
Other	  Research	  Modalities	  
The	  holy	  grail	  of	  visceral	  sensitivity	  testing	  in	  IBS	  is	  to	  mate	  an	  optimal	  method	  of	  stimulating	  the	  
gastrointestinal	  tract	  with	  an	  optimal	  method	  of	  assessing	  the	  physiological	  response	  to	  the	  applied	  
stimulus,	  preferably	  at	  multiple	  levels-­‐	  the	  periphery,	  the	  spine	  and	  the	  brain.	  Of	  course	  this	  is	  
unlikely	  to	  materialise.	  Many	  testing	  modalities	  have	  been	  put	  forward	  as	  being	  superior	  to	  their	  
counterparts-­‐	  these	  include	  functional	  MRI	  (fMRI),	  positron	  emission	  tomography	  (PET),	  single	  
photon	  emission	  computerized	  tomography	  (SPECT),	  magnetoencephalography	  (MEG)	  and,	  of	  
course,	  cortical	  evoked	  potentials	  (CEPs).	  
Functional	  Brain	  Imaging	  
The	  combination	  of	  functional	  brain	  imaging	  and	  visceral	  stimulation	  (regardless	  of	  modality)	  creates	  
an	  anatomical	  representation	  of	  the	  regional	  areas	  of	  the	  brain	  responsible	  for	  the	  processing	  of	  
visceral	  sensory	  information.359	  Functional	  MRI	  uses	  cerebral	  blood	  flow	  as	  a	  marker	  for	  neuronal	  
activity	  i.e.	  activated	  areas	  of	  the	  brain	  stimulate	  increased	  blood	  flow.	  In	  contrast	  CEPs	  can	  show	  
the	  magnitude	  of	  a	  cortical	  response,	  but	  cannot	  differentiate	  which	  parts	  of	  the	  cortex	  are	  being	  






complex)	  can	  highlight	  any	  delay	  in	  afferent	  transmission	  to	  the	  sensory	  cortex.	  The	  value	  of	  using	  
either	  fMRI	  or	  MEG	  is	  that	  one	  can	  then	  see	  which	  specific	  areas	  of	  the	  cortex	  are	  being	  targeted.	   	  
Functional	  MRI	  and	  Subliminal	  Distension	  
Lawal	  et	  al.	  used	  functional	  MRI	  (fMRI)	  and	  subliminal	  distension	  pressures	  to	  test	  visceral	  
processing	  in	  IBS	  patients.360	  The	  reason	  for	  using	  sub-­‐threshold	  pressures	  was	  reduce	  the	  degree	  of	  
stimulus-­‐induced	  cognitive	  bias.	  Their	  data	  demonstrated	  increased	  activity	  in	  five	  cortical	  domains-­‐	  
the	  cingulate	  gyrus,	  the	  sensory/motor	  cortex,	  the	  parietal/occipital	  cortex,	  the	  pre-­‐frontal	  cortex	  
and	  the	  insular	  cortex-­‐	  compared	  to	  controls.	  The	  mechanism	  for	  this	  is	  unclear-­‐	  Azpiroz	  et	  al.	  
suggested	  that	  it	  was	  either	  due	  to	  increased	  signalling	  from	  the	  peripheral	  afferent	  receptors,	  
amplification	  of	  a	  normal	  peripheral	  signal	  in	  the	  spinal	  cord	  or	  due	  to	  central	  amplification	  of	  the	  
signal.361	  
Pain-­‐facilitating	  and	  Pain-­‐inhibitory	  pathways	  
Mayer	  et	  al.	  sought	  to	  assess	  the	  contribution	  of	  central	  pathways	  to	  the	  development	  of	  visceral	  
hypersensitivity	  by	  comparing	  IBS	  patients	  with	  quiescent	  colitics	  and	  controls.362	  Using	  the	  barostat	  
and	  fMRI,	  they	  discovered	  that	  IBS	  patients	  showed	  enhanced	  activation	  of	  the	  limbic	  and	  paralimbic	  
systems	  (comprising	  the	  amygdala,	  hypothalamus,	  dorsomedial	  pre-­‐frontal	  cortex	  and	  
ventral/rostral	  anterior	  cingulate	  cortex)	  compared	  to	  disease	  and	  non-­‐disease	  control	  groups.	  
Furthermore	  there	  was	  suppression	  of	  the	  periaqueductal	  grey	  in	  IBS	  patients,	  a	  descending	  
pathway	  involved	  in	  pain	  inhibition.	  This	  study	  proposed	  that	  IBS	  patients	  had	  up-­‐regulated	  pain-­‐
facilitatory	  pathways	  and	  diminished	  pain-­‐inhibitory	  pathways.	  This	  finding	  was	  echoed	  in	  later	  work	  
by	  the	  same	  research	  group.	  They	  discovered	  that	  IBS	  patients	  failed	  to	  activate	  pain-­‐inhibitory	  
pathways	  in	  the	  dorsal	  brainstem,	  namely	  the	  locus	  ceruleus	  and	  parabrachial	  nuclei,	  in	  response	  to	  
an	  anticipated	  visceral	  stimulus.318	  
Whilst	  fMRI	  (and	  PET)	  has	  dramatically	  enhanced	  our	  knowledge	  of	  the	  neuroanatomical	  and	  
neurometabolic	  representation	  of	  cortical	  pain	  processing,	  its	  use	  in	  IBS	  research	  is	  confined	  to	  the	  
larger	  research	  houses.	  This	  is	  due	  to	  the	  capital	  expense	  of	  the	  equipment,	  and	  the	  associated	  costs	  
of	  running	  the	  scanner.	  However,	  apart	  from	  the	  expense	  involved,	  fMRI	  is	  limited	  by	  the	  
claustrophobic	  confines	  of	  the	  scanner	  and	  its	  sensitivity	  to	  artefact,	  anticipation	  and	  habituation.316	  
The	  principle	  failure	  of	  fMRI	  is	  its	  delayed	  temporal	  resolution	  (approximately	  4	  to	  8	  seconds).	  A	  






However,	  because	  cortical	  pain	  processing	  is	  an	  instantaneous	  and	  dynamic	  process,	  it	  cannot	  
differentiate	  between	  stimulus-­‐specific	  activity	  and	  stimulus-­‐independent	  activity.333	   	  
Magnetoencephalography	  
Magnetoencephalography	  records	  minute	  magnetic	  depolarisations	  that	  occur	  in	  the	  cortex	  
following	  electrical	  neuronal	  activity.	  This	  occurs	  in	  real-­‐time.363	  In	  many	  ways	  it	  is	  the	  best	  method	  
to	  investigate	  cortical	  processing	  because	  of	  its	  temporal	  and	  spatial	  resolution.	  However,	  there	  are	  
few	  centres	  in	  the	  UK	  that	  offer	  it.	  Furthermore,	  there	  is	  good	  evidence	  to	  show	  that	  CEPs	  
demonstrate	  cortical	  responses	  with	  temporal	  resolution	  that	  match	  that	  of	  MEGs.334	   	   	  
Cortical	  Evoked	  Potentials	  
Our	  study	  chose	  to	  use	  CEPs	  because	  we	  identified	  a	  clinical	  need	  in	  being	  able	  to	  differentiate	  IBS	  
patients	  with	  pain-­‐amplifying	  peripheral	  sensitisation	  from	  those	  with	  more	  centrally-­‐driven	  
processes.	  This	  has	  a	  clear	  cut	  utility	  in	  altering	  patient	  management-­‐	  the	  clinician	  may	  consider	  to	  
use	  psychological	  therapy	  as	  opposed	  to	  anti-­‐spasmodics	  or	  analgesics	  if	  there	  is	  compelling	  
evidence	  that	  the	  central	  over-­‐interpretation	  of	  visceral	  information	  (as	  evidenced	  by	  a	  hypervigilant	  
anxiety-­‐driven	  profile)	  dominates	  the	  clinical	  picture.	  The	  reliance	  on	  the	  subjective	  reporting	  of	  pain	  
and	  discomfort	  cannot	  be	  used	  alone	  since	  it	  is	  under	  constant	  threat	  from	  response	  bias,	  the	  
tendency	  to	  over-­‐report	  pain	  in	  patients	  with	  functional	  gastrointestinal	  disorders,341,364	  and	  the	  
increased	  perception	  of	  visceral	  stimuli	  during	  stress	  in	  IBS	  patients.	   	  
Advantages	  of	  Cortical	  Evoked	  Potentials	  
Cortical	  evoked	  potentials	  have	  been	  thoroughly	  tested	  in	  the	  discipline	  of	  neuroscience.	  Their	  use	  
as	  neurophysiological	  markers	  of	  visceral	  afferent	  nerve	  transmission	  and	  subsequent	  cortical	  
processing	  has	  been	  recently	  described	  in	  a	  study	  on	  non-­‐cardiac	  chest	  pain.365	  Evoked	  potentials	  
have	  exquisite	  temporal	  resolution	  (recorded	  in	  milliseconds),	  the	  equipment	  is	  inexpensive	  and	  
testing	  can	  be	  easily	  performed	  in	  a	  standard	  clinical	  setting.	  Reproducibility	  of	  the	  data	  can	  be	  seen	  
instantaneously	  on	  a	  stimulus	  to	  stimulus	  basis.	  The	  learning	  curve	  to	  achieve	  competency	  in	  
harvesting	  CEPs	  is	  short-­‐	  this	  makes	  the	  training	  of	  technicians	  an	  expedient	  process.	  Furthermore,	  
even	  in	  the	  presence	  of	  an	  electrical	  visceral	  stimulus,	  the	  testing	  paradigm	  is	  not	  perceived	  to	  be	  as	  








Disdvantages	  of	  Cortical	  Evoked	  Potentials	  
Disadvantages	  to	  using	  CEPs	  are	  the	  time-­‐consuming	  nature	  of	  the	  test	  protocol,	  and	  the	  importance	  
of	  having	  at	  least	  2	  separate	  days	  of	  testing	  to	  allow	  for	  the	  initial	  novelty	  and	  associated	  
apprehension	  of	  the	  procedure	  to	  subside	  (as	  evidenced	  by	  high	  anxiety	  scores	  for	  both	  controls	  and	  
cases	  on	  the	  first	  day	  of	  testing).	  
Conclusion	  
In	  summary,	  our	  data	  shows	  that	  CEP	  testing	  in	  IBS	  produces	  reliable	  and	  reproducible	  data,	  and	  
when	  twined	  with	  psychological	  evaluation	  and	  subjective	  responses	  to	  the	  applied	  stimulus,	  can	  
give	  valuable	  insights	  into	  the	  putative	  mechanisms	  at	  play.	  
	  
	  












Cytokine	  analysis	  in	  IBS	  has	  come	  under	  increasing	  scrutiny	  in	  the	  field	  of	  IBS.	  Recent	  studies	  have	  
demonstrated	  that	  differentiation	  can	  be	  made	  between	  IBS	  patients	  and	  control	  groups	  at	  an	  
immune	  level.182,186,187	  It	  is	  postulated	  that	  IBS	  patients	  have	  a	  low	  grade	  inflammatory	  process	  that	  
may	  contribute	  to	  the	  sensitisation	  of	  the	  GI	  tract,	  and	  contribute	  to	  the	  development	  and	  
maintenance	  of	  the	  symptom	  complex.	  
The	  study	  by	  Gonsalkorale	  et	  al.	  acknowledged	  that	  the	  immune	  system	  was	  a	  delicate	  balance	  of	  
pro-­‐inflammatory	  and	  anti-­‐inflammatory	  cytokine	  cascades.	  Their	  data	  suggested	  that	  in	  IBS	  this	  
balance	  has	  become	  imbalanced,	  giving	  a	  more	  pro-­‐inflammatory	  expression.189	  This	  aroused	  the	  
prospect	  of	  being	  able	  to	  identify	  IBS	  patients	  from	  an	  immunohistochemical	  profile.	  The	  concept	  
seemed	  to	  be	  attractive	  given	  that	  in	  other	  disease	  states	  such	  as	  inflammatory	  bowel	  disease	  or	  
rheumatoid	  arthritis,	  the	  targeted	  use	  of	  cytokine	  antagonists	  e.g.	  TNF-­‐α	  have	  revolutionised	  
treatment	  and	  subverted	  the	  natural	  history	  of	  the	  disease.	  
Spiller	  et	  al.	  identified	  that	  in	  the	  post-­‐infectious	  model	  of	  IBS,	  the	  duration	  and	  severity	  of	  the	  insult	  
from	  an	  acute	  presentation	  of	  gastroenteritis	  were	  significant	  risk	  factors	  in	  the	  development	  of	  the	  
persistence	  of	  IBS	  symptoms.	  The	  up-­‐regulation	  of	  the	  pro-­‐inflammatory	  state	  (and	  its	  quantification	  
by	  immunohistochemical	  means)	  could	  feasibly	  identify	  predictors	  for	  the	  development	  of	  post-­‐
infectious	  IBS.366	  This	  has	  obvious	  ramifications	  for	  clinical	  practice.	  
Study	  Methodology	   	  
The	  methodological	  framework	  upon	  which	  this	  study	  was	  designed	  came	  largely	  from	  Liebregts	  et	  
al.367	  This	  study	  identified	  a	  population	  of	  IBS	  patients	  using	  Rome	  2	  criteria	  and	  negative	  findings	  at	  
colonoscopy	  and	  stool	  testing.	  IBS	  subtyping	  discriminated	  into	  diarrhoea,	  constipation	  and	  mixed-­‐
picture	  phenotypes.	   	  
Further	  inspection	  of	  the	  diarrhoea-­‐predominant	  patients	  (numbering	  20	  in	  all)	  identified	  5	  patients	  
with	  post-­‐infectious	  IBS	  (confirmed	  with	  previous	  positive	  testing	  for	  Campylobacter	  or	  Salmonella).	  
Controls	  were	  healthy	  and	  without	  previous	  comorbidity.	  Psychological	  assessment	  comprised	  the	  






Immunological	  assessment	  comprised	  the	  harvesting	  of	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  
using	  conventional	  techniques-­‐	  blood	  sampling,	  centrifugation	  and	  suspension	  in	  an	  appropriate	  
medium	  (RPMI	  with	  a	  cell	  density	  of	  1x106	  cells/ml).	  The	  PBMCs	  were	  then	  stimulated	  with	  E.	  coli	  
LPS	  at	  a	  dose	  of	  1ng/ml,	  and	  then	  incubated	  over	  a	  24-­‐hour	  period.	  Cytokine	  analysis	  of	  TNF-­‐α	  ,	  IL-­‐1β	  
and	  IL-­‐6	  were	  performed	  using	  ELISA	  techniques.	  Their	  data	  is	  presented	  in	  Figure	  4.5.	  
Comparison	  of	  Cytokine	  Production	  Between	  The	  Studies	   	  
Figure	  4.5	  TNF-­‐α	  Production	  from	  Controls	  and	  IBS	  patients	  with	  and	  without	  LPS	  
stimulation	  (Liebgrets	  et	  al.)	  
	  
(A)	  TNF-­‐α	  production	  (pg/ml)	  by	  PBMCs	  from	  healthy	  controls	  (HCs)	  and	  IBS	  patients	  before	  (baseline)	  and	  (B)	  after	  
stimulation	  with	  1	  ng/ml	  of	  E	  coli	  LPS.	  Adapted	  from	  Liebregts	  et	  al.367	   	   	  
The	  boxed	  area	  represents	  the	  interquartile	  range	  of	  HCs.	  Under	  baseline	  conditions,	  subjects	  with	  D-­‐IBS	  showed	  
significantly	  (P<0.05)	  higher	  TNF-­‐α	  levels	  compared	  with	  HCs.	  LPS	  co-­‐incubation	  caused	  a	  significant	  increase	  of	  TNF-­‐α	  in	  all	  
subjects	  compared	  with	  non-­‐stimulated	  PBMCs.	  The	  LPS-­‐induced	  TNF-­‐α	  production	  was	  significantly	  (P	  =.005)	  higher	  in	  D-­‐
IBS	  patients	  compared	  with	  HCs.	  No	  significant	  differences	  were	  observed	  in	  M-­‐IBS	  and	  C-­‐IBS,	  whereas	  PI-­‐IBS	  showed	  
significantly	  higher	  baseline	  and	  LPS-­‐stimulated	  TNF-­‐α	  levels	  compared	  with	  HCs.	  Patients	  with	  PI-­‐IBS	  did	  not	  differ	  
significantly	  from	  patients	  with	  D-­‐IBS.	  
This	  data	  compares	  striking	  with	  our	  own	  data.	  The	  data	  from	  our	  TNF-­‐α	  analysis	  shows	  a	  significant	  
difference	  between	  controls	  and	  IBS	  in	  the	  LPS-­‐stimulated	  dose-­‐response	  graph	  (Figure	  4.6).	  When	  
the	  LPS	  concentration	  was	  0	  pg/ml	  (i.e.	  non-­‐stimulated)	  there	  was	  no	  difference	  between	  groups.	  






Figure	  4.6	  TNF-­‐α	  Production	  from	  Controls	  and	  IBS	  patients	  with	  and	  without	  LPS	  
stimulation	  
	  
The	  IL-­‐1	  β	  data	  from	  the	  Liebgrets	  et	  al.	  paper	  is	  presented	  in	  Figure	  4.7.	  
Figure	  4.7	  IL-­‐1	  β	  Production	  from	  Controls	  and	  IBS	  patients	  with	  and	  without	  LPS	  
stimulation	  (Liebgrets	  et	  al.)	  
	  
(A)	  IL-­‐1	  β	  production	  (pg/ml)	  by	  PBMCs	  from	  HCs	  and	  IBS	  patients	  before	  (baseline)	  and	  (B)	  after	  stimulation	  with	  1	  ng/ml	  
of	  E	  coli	  LPS.	  Under	  baseline	  conditions,	  subjects	  with	  D-­‐IBS	  showed	  significantly	  (P=.004)	  higher	  IL-­‐1	  β	  levels	  compared	  
with	  HCs.	  Co-­‐incubation	  with	  LPS	  significantly	  enhanced	  IL-­‐1	  β	  production	  in	  all	  subjects	  compared	  with	  baseline.	  The	  LPS-­‐
induced	  increase	  of	  IL-­‐1	  β	  was	  significantly	  higher	  in	  DIBS	  (P	  =	  .01)	  and	  C-­‐IBS	  (P	  =	  .012)	  patients	  compared	  with	  HCs,	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whereas	  there	  were	  no	  significant	  alterations	  in	  M-­‐IBS.	  PI-­‐IBS	  patients	  showed	  significantly	  (P	  <.05)	  higher	  baseline	  and	  
LPS-­‐induced	  IL-­‐1	  β	  levels	  compared	  with	  HCs	  without	  a	  significant	  difference	  vs.	  D-­‐IBS.367	   	   	  
As	  a	  comparison,	  our	  IL-­‐1	  β	  data	  is	  presented	  in	  Figure	  4.8.	  
Figure	  4.8	  IL-­‐1	  β	  Production	  from	  Controls	  and	  IBS	  patients	  with	  and	  without	  LPS	  
stimulation	  
	  
The	  IL-­‐6	  data	  from	  the	  Liebgrets	  et	  al.	  paper	  is	  presented	  in	  Figure	  4.9.	  
Figure	  4.9	  IL-­‐6	  Production	  from	  Controls	  and	  IBS	  patients	  with	  and	  without	  LPS	  stimulation	  
(Liebgrets	  et	  al.)	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(A)	  IL-­‐6	  production	  (pg/ml)	  by	  PBMCs	  from	  HCs	  and	  IBS	  patients	  before	  (baseline)	  and	  (B)	  after	  stimulation	  with	  1	  ng/ml	  of	  
E	  coli	  LPS.	  Compared	  with	  controls,	  baseline	  (P	  =	  .005)	  and	  LPS-­‐stimulated	  (P	  =	  .011)	  IL-­‐6	  production	  was	  significantly	  
higher	  in	  D-­‐IBS	  and	  (P	  <	  .05)	  PI-­‐IBS	  patients.	  There	  were	  no	  significant	  differences	  in	  M-­‐IBS	  and	  C-­‐IBS.	  
As	  a	  comparison,	  our	  IL-­‐6	  data	  is	  presented	  in	  Figure	  4.10.	  
Figure	  4.10	  IL-­‐6	  Production	  from	  Controls	  and	  IBS	  patients	  with	  and	  without	  LPS	  
stimulation	  
	  
Side	  by	  side	  comparison	  of	  these	  two	  studies	  is	  fascinating.	  The	  original	  cocktail	  of	  TNF-­‐α,	  IL-­‐1	  β	  and	  
IL-­‐6	  was	  chosen	  because	  they	  represent	  pro-­‐inflammatory	  cytokines.	  Liebregts	  et	  al.	  wanted	  to	  test	  
their	  hypothesis	  that	  IBS	  patients	  expressed	  an	  augmented	  pro-­‐inflammatory	  state.	  Their	  data	  
showed	  that	  the	  diarrhoea-­‐predominant	  IBS	  patients	  expressed	  significantly	  higher	  levels	  of	  all	  three	  
cytokines	  both	  at	  baseline	  and	  after	  LPS	  stimulation.	  This	  difference	  was	  even	  more	  prominent	  in	  the	  
5	  PI-­‐IBS	  patients	  that	  were	  isolated	  from	  the	  larger	  group	  of	  20	  diarrhoea-­‐predominant	  patients.	  
Our	  data	  has	  contrasting	  results.	  TNF-­‐	  α	  was	  expressed	  more	  in	  controls	  in	  the	  LPS-­‐stimulated	  
experiments,	  IL-­‐1	  β	  did	  not	  produce	  a	  statistical	  difference	  between	  the	  two	  groups,	  and	  IL-­‐6	  was	  the	  
only	  cytokine	  (of	  the	  three)	  to	  demonstrate	  an	  advantage	  in	  favour	  of	  the	  IBS	  group.	  
Methodological	  Differences	  Between	  The	  Two	  Studies	  
It	  is	  something	  of	  a	  challenge	  to	  explain	  the	  differences	  seen	  in	  cytokine	  production	  between	  our	  
study	  and	  the	  Liebgrets	  et	  al.	  study.	  The	  first	  point	  of	  enquiry	  lies	  with	  the	  methodology	  of	  the	  two	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studies.	  As	  far	  as	  possible,	  we	  tried	  to	  emulate	  the	  methodology	  of	  Liebregts	  et	  al.	  However	  
important	  (and	  is	  some	  cases	  deliberate)	  differences	  arose.	   	  
Inclusion	  criteria	  was	  based	  on	  the	  Rome	  2	  criteria	  for	  both	  studies,	  but	  Liebregts	  et	  al.	  also	  used	  
colonoscopy	  and	  stool	  analysis	  to	  exclude	  competing	  diagnoses.	  In	  the	  IBS	  literature	  and	  according	  
to	  the	  Rome	  Foundation,	  a	  diagnosis	  of	  IBS	  can	  be	  reasonably	  made	  when	  there	  is	  adherence	  and	  
conformity	  to	  the	  Rome	  criteria	  in	  the	  absence	  of	  any	  red	  flag	  symptoms	  or	  any	  other	  more	  obvious	  
diagnosis.	  Traditionally	  IBS	  research	  has	  not	  insisted	  on	  invasive	  testing	  before	  a	  subject	  is	  
considered	  fit	  for	  eligibility	  to	  a	  study.	  As	  a	  result,	  this	  was	  not	  incorporated	  into	  our	  study	  design	  
although	  it	  was	  considered	  but	  dismissed	  as	  adding	  complexity	  to	  the	  study	  design,	  adding	  
unnecessary	  invasive	  testing	  to	  a	  group	  of	  patients	  who	  were	  already	  involved	  in	  CEP	  analysis,	  and	  
increasing	  the	  cost	  and	  duration	  of	  the	  enterprise.	  
Patient	  Recruitment	  
Patient	  recruitment	  was	  run	  through	  a	  tertiary	  referral	  centre	  in	  our	  trial.	  This	  meant	  that	  the	  clinical	  
symptom	  severity	  of	  the	  IBS	  patients	  was	  far	  greater	  than	  one	  would	  expect	  from	  a	  community-­‐
based	  or	  GP-­‐based	  study.	  I	  am	  sure	  that	  this	  accounts	  for	  the	  marked	  differences	  in	  the	  
psychological	  assessments	  seen	  between	  the	  controls	  and	  the	  IBS	  patients.	  The	  Liebregts	  et	  al.	  study	  
recruited	  from	  the	  Outpatient	  clinics	  at	  the	  Royal	  Adelaide	  which	  is	  a	  secondary	  care	  facility.	   	  
In	  terms	  of	  the	  numbers	  recruited,	  the	  Liebregts	  et	  al.	  study	  was	  far	  more	  comprehensive	  in	  its	  
scope	  to	  attract	  patients	  and	  controls.	  Fifty-­‐five	  IBS	  patients	  and	  36	  control	  patients	  were	  included.	  
This	  is	  sharply	  contrasted	  with	  our	  own	  study,	  which	  could	  only	  assemble	  25	  IBS	  patients	  and	  9	  
controls.	  This	  is	  a	  major	  fault	  of	  our	  study,	  since	  it	  is	  easy	  to	  conclude	  that	  the	  study	  was	  
underpowered,	  producing	  data	  unrepresentative	  of	  either	  IBS	  patients	  or	  controls.	  Reasons	  for	  why	  
the	  study	  had	  so	  few	  numbers	  stem	  from	  the	  fact	  that	  the	  immunology	  testing	  was	  part	  of	  a	  larger	  
test	  protocol	  that	  included	  CEP	  analysis	  and	  comprehensive	  psychological	  assessment.	  Furthermore,	  
the	  intricacy	  and	  the	  complexity	  of	  the	  immunology	  experiments	  meant	  that	  there	  were	  insufficient	  
resources	  to	  expand	  the	  study	  sample.	  
IBS	  Sub-­‐type	  Analysis	  
A	  further	  point	  to	  make	  about	  the	  recruitment	  process	  was	  that	  the	  larger	  numbers	  in	  the	  Liebregts	  
et	  al.	  study	  allowed	  them	  to	  perform	  subtype	  analysis,	  differentiating	  cytokine	  expression	  between	  






phenotype,	  and	  in	  particular	  the	  post-­‐infectious	  variant,	  was	  pretty	  much	  an	  entity	  distinct	  from	  all	  
other	  subtypes.	  The	  data	  suggests	  that	  an	  up-­‐regulated	  immune	  system	  in	  PI-­‐IBS	  patients	  could	  be	  
an	  important	  pathogenetic	  mechanism	  in	  maintaining	  symptoms.	  To	  do	  that	  in	  our	  IBS	  population	  of	  
25	  would	  have	  produced	  data	  of	  questionable	  accuracy.	  Even	  so,	  it	  should	  be	  noted	  that	  12	  of	  the	  25	  
(48%)	  IBS	  patients	  in	  our	  study	  were	  diarrhoea-­‐predominant	  compared	  to	  20	  out	  of	  55	  (36%)	  in	  the	  
Liebregts	  et	  al.	  study.	  If	  diarrhoea-­‐predominance	  does	  indeed	  reflect	  a	  pro-­‐inflammatory	  state	  then	  
our	  data	  should	  have	  reflected	  this.	  
ELISA	  vs	  MSD	  Plex	  Technology	  
The	  preparation	  of	  the	  PBMCs	  was	  conducted	  using	  typical	  laboratory	  conventions,	  as	  outlined	  
previously.	  Our	  protocol	  followed	  the	  Liebregts	  et	  al.	  study	  as	  closely	  as	  possible.	  The	  exception	  to	  
this	  was	  the	  way	  that	  the	  cytokine	  concentrations	  were	  calculated.	  Their	  approach	  was	  to	  use	  an	  
ELISA-­‐based	  system	  for	  the	  three	  cytokines.	  Our	  approach	  was	  to	  use	  the	  MSD	  Plex	  multi-­‐array	  
system.	  This	  is	  a	  commercial,	  automated	  system	  which	  according	  to	  the	  type	  of	  cytokine	  plates	  used	  
can	  produce	  concurrent	  readings	  of	  multiple	  cytokines.	  Its	  makers,	  MSD,	  refer	  to	  the	  term	  
“Electrochemiluminescence	  Detection”	  (ECL),	  which	  is	  an	  awkward	  commercial	  term	  to	  describe	  an	  
updated	  version	  of	  the	  ELISA	  technology.	   	  
In	  ELISA	  testing,	  an	  unknown	  solution	  of	  antigen	  is	  immobilised	  on	  a	  microtitre	  plate,	  and	  then	  an	  
enzyme-­‐linked	  antibody	  is	  added	  which	  effects	  a	  colour	  change.	  The	  degree	  of	  colour	  change	  is	  
proportionate	  to	  the	  concentration	  of	  the	  antigen,	  in	  this	  case	  a	  cytokine.	  Electrochemiluminescence	  
adds	  the	  extra	  dimension	  of	  using	  electron-­‐transfer	  reactions	  to	  excite	  chemical	  intermediates	  that	  
emit	  light.	  This	  degree	  of	  light	  emitted	  is	  proportional	  to	  the	  amount	  of	  cytokine	  present.	  
The	  benefit	  of	  using	  MSD	  technology	  is	  that	  multiple	  cytokines	  can	  be	  assessed	  in	  each	  well	  (of	  a	  96-­‐
well	  plate).	  Furthermore	  it	  is	  a	  much	  easier	  and	  faster	  system	  to	  use-­‐	  once	  the	  96	  well	  plates	  are	  
prepared,	  they	  are	  simply	  slotted	  into	  the	  machine,	  and	  the	  data	  is	  then	  produced	  by	  the	  computer.	  
The	  downside	  to	  them	  is	  the	  exorbitant	  cost	  per	  96	  well	  plate.	  
Magnitude	  of	  Cytokine	  Production	   	  
The	  cytokine	  quantification	  between	  the	  2	  studies	  is	  out	  by	  an	  order	  of	  magnitude.	  For	  a	  1ng/ml	  
stimulation	  of	  E.	  coli	  LPS	  the	  mean	  cytokine	  reading	  for	  TNF-­‐α	  was	  324.8	  pg/ml	  for	  the	  Liebregts	  et	  
al.	  study	  and	  3701.43	  pg/ml	  in	  our	  study.	  This	  is	  a	  significantly	  different	  figure.	  Perhaps	  it	  can	  be	  






Another	  factor	  would	  be	  the	  method	  of	  cytokine	  quantification,	  namely	  the	  difference	  in	  sensitivities	  
between	  standard	  ELISA	  and	  electrochemiluminescence.	   	  
ELISA	  vs	  MSD	  Plex	  Antigen	  Sensitivity	   	  
Differences	  between	  standard	  ELISA	  testing	  and	  electrochemiluminescence	  (ECL)	  have	  been	  studied	  
by	  various	  research	  groups	  concerned	  with	  immunology-­‐related	  laboratory	  techniques.	  A	  French	  
group	  compared	  ELISA	  to	  ECL	  for	  the	  detection	  of	  a	  Ricin	  antigen.368	  They	  found	  that	  the	  ELISA	  
detected	  antibody	  at	  levels	  of	  400pg/ml	  of	  Ricin	  whereas	  the	  newer	  technique	  had	  a	  limit	  of	  
detection	  at	  50pg/ml.	  Furthermore	  the	  ELISA	  assay	  was	  completed	  in	  7	  hours	  whereas	  the	  ECL	  
completed	  in	  2.5	  hours.	  The	  disparity	  of	  4.5	  hours	  between	  completing	  the	  two	  tests	  with	  an	  
eminently	  degradable	  substrate	  cannot	  be	  ignored.	  The	  conclusion	  was	  that	  ECL	  was	  8	  times	  more	  
sensitive	  that	  ELISA,	  3	  times	  faster	  and	  allowed	  the	  convenience	  of	  using	  a	  96	  well	  plate.	   	  
The	  use	  of	  ECL	  compared	  to	  ELISA	  is	  sufficient	  to	  explain	  some	  of	  the	  difference	  in	  results.	  Despite	  
the	  aspiration	  to	  emulate	  the	  methodology	  of	  the	  Liebregts	  et	  al.	  study,	  it	  would	  have	  been	  quite	  
impossible	  to	  clone	  and	  replicate	  it	  without	  some	  obfuscation	  of	  the	  original.	  Certainly	  the	  choice	  
between	  ELISA	  and	  ECL	  was	  born	  out	  of	  the	  fact	  that	  the	  superior	  technology	  was	  at	  our	  disposal,	  
and	  that	  it	  was	  a	  much	  more	  efficient	  technique.	   	  
Psychological	  Parameters	  
In	  terms	  of	  psychological	  analysis,	  the	  Liebregts	  et	  al.	  study	  used	  the	  Bowel	  Disease	  Questionnaire	  
and	  the	  Hospital	  Anxiety	  and	  Depression	  Scale	  (HAD).	  The	  HAD	  scores	  showed	  that	  IBS	  patients	  had	  
significantly	  higher	  scores	  for	  anxiety	  (8.4	  +/-­‐	  3.0)	  and	  depression	  (7.6	  +/-­‐	  3.6)	  compared	  with	  
controls	  (anxiety,	  2.9	  +/-­‐	  2.7;	  depression,	  2.7	  +/-­‐	  2.5).	  This	  data	  fits	  nicely	  with	  our	  own	  data	  that	  
demonstrates	  an	  increased	  psychological	  comorbidity	  in	  IBS	  patients	  across	  a	  spectrum	  of	  domains.	  
The	  Liebregts	  et	  al.	  study	  reviewed	  the	  correlations	  between	  cytokine	  expression	  and	  HAD-­‐anxiety	  
states.	  They	  observed	  a	  positive	  correlation	  between	  LPS-­‐induced	  TNF-­‐α	  expression	  and	  anxiety	  (r	  =	  
0.59,	  P	  <.001).	  This	  data	  is	  presented	  in	  Figure	  4.11.	  Our	  own	  correlation	  data	  (Table	  3.2.15)	  
demonstrates	  positive	  correlations	  between	  HAD-­‐anxiety	  and	  both	  IFN-­‐γ	  and	  IL-­‐10.	  TNF-­‐α	  is	  







Figure	  4.11	  Correlation	  of	  E	  coli	  LPS-­‐induced	  TNF-­‐α	  production	  and	  HAD-­‐Anxiety	  Scores	  
(Liebregts	  et	  al.)	  
	  
Overall,	  LPS-­‐induced	  TNF-­‐α	  release	  is	  associated	  significantly	  with	  anxiety	  scores	  (r	  =	  0.59,	  P	  <	  .001)	  in	  patients	  with	  IBS,	  
although	  it	  did	  not	  reach	  statistical	  significance	  for	  the	  IBS	  subgroups.	  
Cytokine	  Dose	  Response	  Curves	  
The	  Liebregts	  et	  al.	  study	  used	  a	  single	  dose	  of	  E.	  coli	  LPS.	  PBMCs	  were	  either	  stimulated	  using	  this	  
dose	  or	  not	  stimulated,	  left	  for	  24	  hours	  of	  incubation	  and	  then	  analysed	  using	  an	  ELISA.	  In	  practical	  
terms	  this	  was	  a	  relatively	  simplistic	  design.	  To	  expand	  upon	  their	  work,	  our	  cytokine	  protocol	  used	  a	  
6	  point	  concentration	  of	  LPS	  to	  enable	  dose	  response	  curves.	  This	  was	  important	  since	  it	  is	  relatively	  
easy	  to	  see	  that	  even	  at	  the	  smaller	  doses	  e.g.	  0.1	  or	  0.3	  ng/ml	  of	  LPS,	  significant	  evolution	  of	  
cytokines	  from	  the	  PBMCS	  occurs.	  In	  the	  cytokine	  assays	  for	  TNF-­‐α,	  and	  IL	  2,	  IL-­‐4,	  IL-­‐8,	  IL-­‐10,	  IL-­‐13	  
and	  IFN-­‐γ,	  LPS	  stimulation	  even	  at	  an	  LPS	  dose	  of	  0.1ng/ml	  is	  enough	  to	  cause	  statistically	  significant	  
separation	  between	  the	  two	  groups.	  
At	  baseline	  in	  the	  non-­‐stimulated	  samples,	  only	  IL-­‐1-­‐	  β	  and	  IL-­‐4	  demonstrated	  significantly	  different	  
data	  between	  control	  and	  IBS	  populations.	  This	  contrasts	  again	  with	  the	  Liebregts	  et	  al.	  study	  which	  
found	  statistical	  difference	  for	  their	  3	  chosen	  cytokines-­‐	  TNF-­‐α,	  IL-­‐1β	  and	  IL-­‐6-­‐	  even	  at	  baseline.	  
Expanding	  the	  Cytokine	  Panel	  
TNF-­‐α,	  IL-­‐1β	  and	  IL-­‐6	  were	  chosen	  by	  Liebregts	  et	  al.	  specifically	  because	  of	  their	  role	  as	  pro-­‐
inflammatory	  cytokines.	  Since	  the	  MSD	  multi-­‐array	  technology	  was	  available,	  our	  study	  allowed	  






inflammatory	  cytokines	  comprise	  TNF-­‐α,	  IFN-­‐γ,	  IL-­‐1β,	  IL-­‐2,	  IL-­‐6,	  IL-­‐8,	  and	  IL-­‐12.	  The	  anti-­‐inflammatory	  
cytokines	  are	  represented	  by	  IL-­‐4,	  IL-­‐5,	  IL-­‐10,	  and	  IL-­‐13.	  
Pro-­‐Inflammatory	  and	  Anti-­‐Inflammatory	  Cytokines	  
Even	  casual	  observation	  of	  our	  data	  shows	  that	  there	  is	  a	  mixed	  pro-­‐inflammatory	  profile	  in	  IBS.	  Of	  
the	  pro-­‐inflammatory	  cytokines,	  IBS	  patients	  produce	  significantly	  less	  TNF-­‐α	  and	  IL-­‐2;	  the	  data	  from	  
IFN-­‐γ,	  IL-­‐1-­‐β	  and	  IL-­‐12	  is	  equivocal,	  yet	  there	  is	  a	  large	  production	  of	  IL-­‐6	  and	  IL-­‐8.	  Of	  the	  anti-­‐
inflammatory	  cytokines,	  broadly	  speaking	  IBS	  patients	  produce	  less	  than	  their	  healthy	  counterparts.	  
With	  reference	  to	  previous	  immune	  studies	  in	  IBS,	  and	  particularly	  the	  Liebregts	  et	  al.	  study,	  our	  
data	  does	  not	  support	  the	  hypothesis	  that	  IBS	  patients	  exist	  in	  a	  state	  of	  heightened	  immune	  
regulation.	  In	  order	  to	  explain	  the	  results	  that	  our	  study	  has	  produced,	  it	  is	  important	  to	  look	  at	  the	  
interaction	  between	  the	  pro-­‐inflammatory	  immune	  state	  and	  the	  anti-­‐inflammatory	  immune	  state.	  
This	  has	  conventionally	  been	  seen	  as	  the	  balance	  between	  the	  TH1	  or	  TH2	  systems.	  
The	  Immune	  System	  and	  the	  Brain	  
The	  immune	  system	  serves	  as	  a	  defensive	  mechanism	  to	  protect	  against	  invading	  pathogens.	  The	  
balance	  between	  the	  innate	  and	  the	  adaptive	  systems	  is	  influenced	  by	  the	  nature	  of	  the	  pathogen,	  
prior	  exposure	  to	  said	  pathogen	  and	  environmentary	  pressures.	  The	  common	  language	  of	  peptide	  
hormones	  and	  neurotransmitters	  shared	  between	  the	  immune	  system	  and	  the	  central	  nervous	  
system	  has	  fathered	  the	  concept	  of	  bidirectional	  communication	  between	  these	  two	  systems.369	  Not	  
only	  can	  the	  immune	  system	  exert	  influence	  on	  the	  brain	  (for	  example	  the	  action	  of	  IL-­‐1β	  on	  the	  
hypothalamus	  to	  produce	  CRH	  and	  ACTH)	  but	  also	  the	  brain	  can	  reciprocate	  by	  altering	  immune	  
function	  (for	  example,	  vagal	  acetylcholine	  down-­‐regulates	  macrophage	  pro-­‐inflammatory	  cytokine	  
function).	   	  
The	  classic	  experiment	  to	  show	  the	  link	  between	  the	  brain	  and	  the	  immune	  system	  was	  that	  
performed	  by	  Ader	  and	  Cohen	  in	  1975.370	  They	  selected	  a	  group	  of	  rats	  that	  had	  been	  conditioned	  
with	  saccharin-­‐infused	  water	  and	  the	  immunosuppressant	  cyclophosphamide	  to	  produce	  an	  illness-­‐
induced	  taste	  aversion.	  They	  injected	  both	  conditioned	  and	  unconditioned	  rats	  with	  sheep	  
erythrocytes	  to	  promote	  an	  immune	  response.	  Both	  groups	  of	  rats	  were	  exposed	  to	  the	  saccharin	  
water	  (without	  the	  immunosuppressant).	  The	  conditioned	  rats	  demonstrated	  significantly	  less	  






triggered	  the	  conditioned	  nervous	  system	  to	  down-­‐regulate	  the	  immune	  response.	  This	  landmark	  
study	  coined	  the	  term	  Psychoneuroimmunology.	  
The	  Shifting	  Balance	  between	  TH1	  and	  TH2	  Immune	  Responses	  
Environmental	  pressures	  such	  as	  stress	  can	  therefore	  have	  a	  profound	  effect	  on	  immune	  function	  
with	  preferential	  stimulation	  of	  either	  the	  TH1	  or	  TH2	  systems.371	  Animal	  models	  have	  observed	  that	  
when	  an	  animal	  is	  presented	  with	  an	  acute	  stressor,	  for	  instance	  the	  arrival	  of	  an	  aggressive	  animal,	  
a	  TH1	  mediated	  immune	  response	  is	  up-­‐regulated.	  This	  confers	  rapid	  cellular-­‐based	  immunity	  to	  the	  
host	  who	  is	  under	  threat,372	  thus	  equipping	  it	  to	  deal	  with	  bacterial	  infection	  after	  attack	  more	  
efficiently.	  
The	  Immune	  System	  and	  Stress	  
The	  human	  correlation	  to	  such	  a	  model,	  termed	  the	  social	  disruption	  model,	  in	  which	  an	  acute	  
predatory	  threat	  is	  present,	  is	  fortunately	  not	  as	  common	  as	  it	  used	  to	  be.	  Stress	  in	  its	  various	  forms	  
has	  been	  defined	  by	  various	  investigators.373	  There	  are	  thought	  to	  be	  5	  types	  of	  stress-­‐	  acute	  time-­‐
limited	  stressors	  such	  as	  public	  speaking;	  brief	  naturalistic	  stressors	  that	  involve	  the	  confrontation	  of	  
a	  short-­‐term	  challenge,	  such	  as	  examinations;	  stressful	  event	  sequences	  in	  which	  a	  single,	  isolated	  
event	  gives	  rise	  to	  its	  sequelae	  (e.g.	  losing	  your	  spouse)	  but	  with	  the	  individual	  harbouring	  the	  
insight	  or	  understanding	  that	  the	  stressor	  will	  start	  to	  disappear;	  chronic	  stressors	  which	  absorb	  a	  
person’s	  life	  such	  that	  he	  or	  she	  has	  no	  idea	  whether	  the	  stress	  will	  go	  away;	  and	  finally,	  distant	  
stressors	  which	  are	  traumatic	  experiences	  in	  the	  past	  that	  still	  cause	  emotional	  and	  cognitive	  distress	  
(e.g.	  rape	  as	  a	  child).	  
Stress-­‐induced	  Immunosuppression	  
The	  relevance	  of	  this	  is	  that	  the	  immune	  system	  is	  influenced	  by	  the	  type	  and	  chronicity	  of	  the	  
stressor	  it	  is	  subjected	  to.	  From	  a	  historical	  perspective,	  a	  model	  of	  immunosuppression	  was	  
originally	  proposed	  by	  Selye	  in	  1975	  that	  stated	  that	  stress	  leads	  to	  a	  globally	  suppressed	  immune	  
system.374-­‐376	  This	  gave	  way	  to	  the	  concept	  of	  a	  biphasic	  response	  in	  which	  cell-­‐mediated	  immunity	  
was	  enhanced	  by	  acute	  stress	  and	  dampened	  by	  chronic	  stress.	  The	  innate	  system	  is	  much	  more	  
rapid	  in	  its	  deployment	  of	  immune	  response	  than	  the	  adaptive	  system,	  and	  is	  less	  energy-­‐
dependent.	  During	  the	  fight	  or	  flight	  response,	  the	  host	  preferentially	  choses	  to	  amplify	  the	  innate	  






A	  year	  later	  Marshal	  et	  al.	  proposed	  that	  chronic	  stress	  causes	  a	  dysregulation	  in	  the	  balance	  of	  the	  
immune	  response	  and	  a	  shift	  in	  the	  TH1	  /TH2	  axis.379	  Chronic	  stress	  leads	  to	  a	  more	  TH2-­‐weighted	  
environment,	  such	  that	  the	  individual	  is	  more	  liable	  to	  infection	  and	  neoplastic	  disease	  (reduced	  TH1	  
activity)	  and	  more	  prone	  to	  allergic	  and	  autoimmune	  phenomena	  (increased	  TH2	  activity).	  
When	  considering	  immune	  changes	  with	  reference	  to	  the	  specific	  type	  of	  stressor,	  a	  large	  meta-­‐
analysis	  of	  over	  300	  studies	  looking	  at	  immune	  function	  and	  stress	  in	  in-­‐vivo	  studies	  was	  performed	  
by	  Segerstrom	  et	  al.371	   	  
The	  meta-­‐analysis	  identified	  that	  TH1-­‐mediated	  immunity	  is	  boosted	  during	  acute	  time-­‐limited	  stress.	  
Among	  the	  observations	  seen	  were	  an	  abrupt	  increase	  in	  the	  number	  of	  natural	  killer	  cells	  and	  
granular	  lymphocytes	  in	  the	  peripheral	  blood,	  a	  redistribution	  of	  T	  cells	  towards	  the	  skin	  (as	  part	  of	  a	  
compartmentalisation	  of	  immune	  cells	  to	  areas	  where	  they	  may	  be	  most	  effective),	  an	  increase	  in	  
the	  cytotoxicity	  of	  natural	  killers	  cells,	  and	  a	  rise	  in	  the	  production	  of	  IL-­‐6	  and	  IFN-­‐γ.	   	  
Brief	  naturalistic	  stressors	  did	  not	  seem	  to	  change	  the	  population	  densities	  of	  the	  cells	  in	  the	  
immune	  system,	  but	  seemed	  to	  have	  an	  effect	  on	  the	  functioning	  of	  those	  cells	  following	  changes	  in	  
cytokine	  production.	  The	  net	  result	  was	  a	  shift	  to	  a	  TH2	  weighted	  system	  (IFN-­‐γ	  was	  suppressed;	  IL-­‐6	  
and	  IL-­‐10	  were	  increased;	  natural	  killer	  cell	  cytotoxicity	  was	  diminished).	  
Stressful	  event	  sequences	  did	  not	  produce	  a	  uniform	  pattern	  of	  immune	  changes.	  This	  can	  also	  be	  
said	  of	  distant	  stressors.	   	  
Chronic	  stressors-­‐	  such	  as	  living	  with	  handicap	  or	  financial	  embarrassment-­‐	  caused	  a	  global	  down-­‐
regulation	  of	  both	  TH1	  and	  TH2	  systems.	  
The	  Sick	  Role	  
Stress-­‐induced	  changes	  in	  an	  individual’s	  immunophenotype	  leads	  to	  alterations	  in	  other	  areas	  of	  
one’s	  functioning.	  This	  includes	  alterations	  of	  pain	  sensitivity,	  psychological	  state,	  sleep	  patterns,	  
appetite	  and	  physical	  activity	  levels.	  The	  complicated	  reaction	  to	  infection	  or	  injury,	  involving	  
immunological,	  neurological,	  psychological	  and	  philosophical	  factors	  promotes	  the	  (correct)	  
adoption	  of	  the	  sick	  role.380	  This	  is	  a	  mechanism	  designed	  to	  confer	  a	  biological	  advantage	  to	  an	  
individual381	  and	  to	  conserve	  energy.382	  However	  this	  process	  can	  become	  maladaptive,	  the	  sick	  role	  







Stress	  and	  the	  Hypothalamic-­‐Pituitary-­‐Adrenal	  Axis	  
Stress	  in	  IBS	  has	  been	  assessed	  by	  manipulation	  of	  the	  Hypothalamic-­‐Pituitary-­‐Adrenal	  axis.	  Dinan	  et	  
al.	  observed	  an	  exaggerated	  release	  of	  ACTH	  and	  cortisol	  in	  IBS	  patients	  in	  response	  to	  CRH	  
infusion.290	  Furthermore	  baseline	  levels	  of	  IL-­‐6	  and	  IL-­‐8	  and	  cortisol	  were	  significantly	  raised,	  and	  a	  
positive	  correlation	  between	  ACTH	  release	  and	  IL-­‐6	  reached	  statistical	  significance.	  
Taché’s	  group	  has	  been	  pivotal	  in	  researching	  CRF1	  signalling	  pathways	  in	  functional	  disease.383,384	  
Stress-­‐induced	  stimulation	  of	  colonic	  motility,	  diarrhoea	  and	  defaecation	  with	  concomitant	  mast	  cell	  
degranulation,	  PGE2	  synthesis	  and	  increased	  mucosal	  permeability	  can	  imitated	  by	  the	  injection	  of	  
CRF	  in	  rats.385	   	  
With	  regard	  to	  the	  IBS	  population,	  stress	  has	  an	  important	  pathophysiological	  role.	  Using	  a	  concept	  
similar	  to	  Tache’s	  study,	  Fukodo	  et	  al.	  demonstrated	  that	  the	  biochemical	  induction	  of	  the	  stress	  
response	  by	  intravenous	  injection	  of	  CRH	  stimulated	  increased	  colonic	  motility,	  duration	  of	  
abdominal	  pain	  and	  ACTH	  response	  in	  IBS	  patients	  compared	  to	  controls,	  suggesting	  an	  exaggerated	  
role	  of	  the	  HPA	  axis	  in	  symptom	  generation.386	  Sagami	  proved	  the	  opposite	  point-­‐	  that	  the	  
administration	  of	  a	  CRH	  receptor	  antagonist	  produced	  an	  improvement	  in	  abdominal	  pain	  scores,	  
colonic	  motility	  and	  visceral	  perception	  after	  gut	  stimulation	  in	  IBS	  patients	  compared	  to	  controls.387	   	  
The	  importance	  of	  CRH	  is	  not	  purely	  confined	  to	  IBS	  and	  functional	  disease-­‐	  other	  studies	  have	  
demonstrated	  elevated	  CRH	  in	  conditions	  as	  diverse	  as	  childhood	  trauma,	  anxiety	  states,	  obsessive	  
compulsive	  disorders,	  depressions	  and	  post-­‐traumatic	  stress.388-­‐390	   	  
Immune	  Function	  and	  Stress	  
In	  our	  study,	  comprehensive	  psychological	  analysis	  has	  shown	  a	  heavy	  burden	  of	  psychological	  
comorbidity	  and	  symptomatology.	  Increased	  pro-­‐inflammatory	  IL-­‐8	  levels	  were	  positively	  correlated	  
with	  unpleasantness	  of	  symptoms	  and	  somatisation	  whilst	  the	  anti-­‐inflammatory	  cytokines	  IL-­‐4	  and	  
IL-­‐5	  were	  negatively	  correlated	  with	  the	  same	  measures.	  With	  increasing	  symptom	  severity	  and	  
psychological	  comorbidity,	  our	  data	  demonstrated	  a	  global	  immune	  suppression	  of	  both	  the	  TH1	  and	  
TH2	  pathways.	  As	  reflected	  by	  Segerstrom	  et	  al.	  this	  would	  be	  consistent	  with	  the	  immune	  changes	  









The	  two	  cytokines	  that	  were	  increased	  in	  the	  IBS	  group	  in	  our	  data	  were	  IL-­‐6	  and	  IL-­‐8.	  IL-­‐6	  promotes	  
T	  cell	  differentiation	  and	  drives	  the	  maturation	  of	  the	  TReg	  and	  TH17	  cell	  lines.	  It	  is	  possible	  that	  the	  
over-­‐expression	  of	  IL-­‐6	  is	  driving	  a	  TH17	  pathway.	  
TH17	  is	  a	  recently	  discovered	  subset	  of	  T	  helper	  cells,	  sitting	  beside	  the	  classical	  TH1	  and	  TH2	  pathways.	  
It	  was	  first	  proposed	  in	  2000	  by	  Infante-­‐Duarte	  et	  al391	  who	  demonstrated	  a	  novel	  non-­‐TH1	  non-­‐TH2	  
CD4+	  cell	  which	  evolved	  IL-­‐17	  rather	  than	  IFN-­‐γ	  or	  Il-­‐4.	  Subsequent	  studies	  demonstrated	  that	  the	  
TH17	  cell	  line	  develops	  in	  response	  to	  TGF-­‐β,	  IL-­‐6,	  IL-­‐1	  and	  IL-­‐21,	  and	  that	  TH17	  cells	  also	  produce	  IL-­‐21	  
and	  IL-­‐22.392.	  The	  TH17	  pathway	  is	  seen	  in	  Figure	  4.12.	  
Figure	  4.12	  The	  TH17	  Pathway	  
	  
Adapted	  from	  A	  brief	  history	  of	  TH17,	  the	  first	  major	  revision	  in	  the	  TH1/TH2	  hypothesis	  of	  T	  cell-­‐mediated	  tissue	  damage	  by	  
Steinman,	  L	  and	  Steinman,	  L393	  
The	  TH17	  subset	  serves	  to	  target	  Gram-­‐negative	  bacteria,	  fungi	  and	  certain	  protozoa.	  TH17	  over-­‐
expression	  has	  been	  associated	  with	  autoimmune	  and	  inflammatory	  diseases.	  These	  include	  






TH17	  cells	  facilitate	  neutrophil	  recruitment,	  activation	  and	  migration	  and	  are	  thought	  to	  be	  an	  
important	  part	  of	  mucosal	  defence.396	  They	  predominate	  in	  mucosal	  and	  epithelial	  junctions,	  for	  
example	  the	  GI	  tract.	   	  
An	  increased	  TH17	  profile	  as	  suggested	  by	  our	  data	  would	  stimulate	  mucosal	  immunity	  and	  a	  pro-­‐
inflammatory	  cytokine	  profile.	  TH17	  differentiation	  is	  at	  its	  most	  potent	  when	  both	  TH1	  and	  TH2	  
effector	  functions	  are	  suppressed.395,397,398	  Furthermore	  an	  enhanced	  TH17	  response	  causes	  an	  
upregulation	  in	  the	  production	  of	  IL-­‐6,	  IL-­‐8	  and	  metalloproteinases	  (MMPs)	  in	  major	  target	  cells	  such	  
as	  sub-­‐epithelial	  myofibroblasts.399	  
Conclusion	  
Our	  cytokine	  data	  demonstrates	  TH1	  and	  TH2	  immune	  suppression	  with	  elevated	  IL-­‐6	  and	  IL-­‐8	  levels	  in	  
IBS.	  This	  is	  consistent	  with	  the	  immunophenotype	  of	  chronic	  stress,	  and	  perhaps	  represents	  a	  shift	  
to	  a	  TH17	  profile.	  The	  follow-­‐up	  to	  this	  study	  would	  be	  to	  reconstruct	  the	  protocol	  with	  specific	  
reference	  to	  quantifying	  Il-­‐17,	  IL-­‐23	  and	  TGF-­‐β	  since	  this	  would	  give	  substance	  to	  the	  novel	  
hypothesis	  of	  a	  TH17	  profile	  in	  IBS.	  
	  







This	  study	  has	  used	  4	  modalities	  of	  testing	  to	  separate	  IBS	  patients	  from	  their	  control	  counterparts.	  
The	  psychological	  data	  has	  been	  consistent	  with	  the	  established	  literature	  about	  the	  depth	  of	  
psychological	  comorbidity	  found	  in	  IBS	  patients.	  It	  has	  identified	  certain	  character	  traits	  that	  may	  be	  
more	  common	  in	  this	  condition,	  e.g.	  neuroticism	  and	  introversion.	  The	  clinical	  challenge	  is	  being	  
able	  to	  tease	  apart	  the	  psychological	  comorbidity	  associated	  with	  IBS	  from	  a	  primary	  psychological	  
process	  that	  shares	  the	  outward	  manifestation	  of	  gastrointestinal	  symptomatology.	  Needless	  to	  say	  
the	  prompt	  identification	  of	  psychological	  comorbidity	  is	  imperative	  for	  the	  appropriate	  
management	  of	  the	  patient.	  
The	  use	  of	  electrical	  stimulation	  of	  the	  rectum	  did	  not	  discriminate	  between	  the	  two	  groups	  in	  terms	  
of	  pain	  threshold	  until	  the	  final	  day	  of	  testing.	  This	  is	  in	  contrast	  to	  previous	  studies	  that	  
differentiated	  patients	  and	  controls	  using	  balloon	  distension	  paradigms.	  Perhaps	  by	  removing	  the	  
emotional	  context	  of	  the	  stimulus	  (i.e.	  a	  rapidly	  inflating	  and	  deflating	  balloon	  in	  the	  rectum	  with	  the	  
incipient	  sensation	  of	  impending	  defaecation),	  renders	  the	  hypersensitive	  rectum	  normosensitive	  by	  
minimising	  subjective	  sensory	  perception.	  Conversely,	  the	  disinhibition	  of	  a	  control	  subject	  through	  
habituation	  produces	  an	  increase	  in	  pain	  threshold.	   	  
CEP	  analysis	  in	  conjunction	  with	  anorectal	  sensitivity	  produced	  4	  sub-­‐groups	  of	  IBS	  patients-­‐	  those	  
with	  normal	  CEPs	  and	  pain	  threshold,	  those	  with	  afferent	  hyper	  or	  hyposensitivity,	  and	  those	  who	  
were	  hypervigilant.	  Further	  work,	  and	  much	  larger	  studies,	  will	  need	  to	  assess	  whether	  this	  has	  a	  
useful	  clinical	  context.	  The	  identification	  of	  sub-­‐groups	  potentially	  offers	  targeted	  therapy	  to	  the	  
individual.	  
The	  immunology	  of	  IBS	  has	  become	  a	  popular	  area	  of	  research	  over	  the	  last	  decade.	  Many	  studies	  
have	  demonstrated	  a	  pro-­‐inflammatory	  state	  in	  IBS,	  either	  by	  quantifying	  cytokine	  expression	  in	  
peripheral	  blood	  cells	  or	  colonic	  mucosal	  samples.	  Our	  own	  data	  did	  not	  support	  this,	  instead	  
suggesting	  that	  other	  pathways,	  namely	  the	  TH17	  pathway,	  may	  be	  important.	  Further	  work	  needs	  to	  
agree	  on	  a	  uniform	  methodology	  for	  investigating	  cytokine	  expression	  in	  IBS,	  to	  look	  at	  novel	  
pathways	  beyond	  the	  established	  TH1	  /TH2	  axis,	  to	  expand	  the	  samples	  sizes,	  and	  to	  replicate	  
previous	  studies	  to	  make	  sure	  that	  the	  differences	  seen	  in	  earlier	  work	  are	  universal	  and	  
reproducible.	   	   	  













BRITISH	  SOCIETY	  OF	  GASTROENTEROLOGY	  POSTER,	  13.03.08	  
Clinical	  phenotyping	  of	  Irritable	  Bowel	  Syndrome	  in	  a	  prospective	  controlled	  trial	  using	  













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































NEUROGASTROENTEROLOGY	  &	  MOTILITY	  POSTER,	  07.11.08	  
Test	  re-­‐test	  reproducibility	  of	  rectal	  cortical	  evoked	  potentials	  in	  patients	  with	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Neurophysiological	  assessment	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  rectal	  afferent	  sensitivity	  in	  patients	  with	  Irritable	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  SOCIETY	  OF	  GASTROENTEROLOGY	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Objective	  assessment	  of	  rectal	  afferent	  sensitivity	  and	  primary	  cortical	  processing	  in	  





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































NEUROGASTROENTEROLOGY	  &	  MOTILITY	  POSTER,	  28.08.09	  
Psychological	  comorbidity	  and	  symptom	  intensity	  do	  not	  correlate	  with	  rectal	  afferent	  
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































UEGW/WCOG	  GASTRO	  2009	  POSTER,	  23.11.09,	  LONDON	  
High	  depression	  and	  anxiety	  scores	  in	  a	  systematic	  review	  of	  Psychological	  Questionnaires	  
in	  Irritable	  Bowel	  Syndrome	  
C.	  Elliott,	  M.	  A.	  Kamm,	  D.	  Bullas,	  S.	  R.	  Gurmany,	  N.	  Arebi	  
INTRODUCTION	  
Irritable	  bowel	  syndrome	  (IBS)	  is	  associated	  with	  psychological	  co-­‐morbidity	  (PCM).	  Specific	  
psychological	  questionnaires	  (PQ)	  have	  been	  used	  to	  define	  PCM	  prevalence	  and	  applied	  in	  
therapeutic	  trials.	  Numerous	  questionnaires	  are	  available	  with	  emphasis	  on	  different	  psychological	  
domains.	  PCM	  may	  indicate	  the	  need	  for	  psychological	  therapy	  
AIMS	  &	  METHODS	  
1)	  to	  determine	  types	  and	  frequency	  of	  PQ	  used	  to	  record	  PCM	  in	  IBS	  2)	  to	  compare	  score	  
differences	  between	  IBS	  and	  controls.	  A	  PubMed	  literature	  search	  (1980	  to	  2008)	  used	  search	  terms	  
questionnaire/scores	  with	  a	  list	  of	  psychological	  conditions	  and	  IBS.	  Excluded	  studies:	  population	  
with	  primary	  psychological	  or	  psychiatric	  disorder,	  IBS	  treatment	  studies	  or	  quality	  of	  life	  or	  well-­‐
being	  PQ.	  For	  aim	  2	  only	  studies	  that	  reported	  controls	  scores	  were	  assessed.	  Results	  are	  expressed	  
as	  mean	  scores	  and	  95%	  confidence	  intervals	  (CI).	  
RESULTS	  
From	  a	  total	  371	  studies,	  68	  studies	  met	  the	  inclusion	  criteria.	  Fifty-­‐three	  studies	  were	  analysed.	  A	  
total	  of	  46	  different	  PQ	  were	  identified.	  The	  number	  of	  studies	  using	  each	  PQ	  is	  shown	  in	  
parenthesis:	  Scl-­‐90(14),	  Hospital	  Anxiety	  and	  Depression	  Scale	  (HADS)(10),	  Eysenck	  Personality	  
Inventory	  (EPI)(8),	  Diagnostic	  Interview	  Schedule	  (DIS-­‐	  DSM-­‐III-­‐R)(8),	  Minnesota	  Multiphasic	  
Personality	  Inventory	  (MMPI)	  (8),	  Short	  Form	  (SF-­‐36)(7),	  Beck	  Depression	  Inventory	  (BDI)(7)	  
Hamilton	  Depression	  Scale	  (HDS)	  (6)	  Spielberger	  State/trait	  Anxiety	  (SSTAI)	  (5).	  The	  PQ	  in	  remaining	  
36	  studies	  was	  infrequently	  used	  (1-­‐3).	  Mean	  score	  differences	  between	  controls	  and	  IBS	  were	  
greatest	  for	  depression	  (7.0)	  and	  anxiety	  (8.3)irrespective	  of	  PQ	  type	  (table).	  DIS-­‐	  DSM-­‐III-­‐R	  reported	  
%	  of	  patients	  above	  a	  threshold.	  Scores	  for	  somatisation,	  obsessive	  compulsive,	  interpersonal	  
sensitivity,	  phobic	  anxiety,	  paranoid	  ideation	  and	  personality	  by	  MMPI	  and	  EPI	  were	  only	  marginally	  
greater	  for	  IBS	  compared	  to	  controls.	   	  
	  
CONCLUSION	  
46	  PQ	  have	  been	  used	  to	  describe	  IBS	  PCM.	  Control	  PQ	  scores	  are	  marginally	  lower	  than	  IBS	  patients	  
for	  all	  domains	  except	  for	  depression	  and	  anxiety.	  These	  indicate	  that	  whilst	  PCM	  is	  common,	  
depression	  and	  anxiety	  are	  the	  more	  marked	  manifestations	  of	  IBS.	  Psychological	  assessment	  in	  






BRITISH	  SOCIETY	  OF	  GASTROENTEROLOGY	  POSTER,	  LIVERPOOL	  ACC,	  25TH	  MARCH	  2010	  
Stress-­‐induced	  immunomodulation	  in	  Irritable	  Bowel	  Syndrome	  suppresses	   	   	   	   	   	   	   	   	  




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































AGA	  INSTITUTE,	  DIGESTIVE	  DISEASE	  WEEK,	  NEW	  ORLEANS,	  LA,	  MAY	  4TH	  2010	   	   	   	   	   	   	   	   	  
Suppression	  of	  TH1	  and	  TH2	  cytokines	  in	  patients	  with	  Irritable	  Bowel	  Syndrome-­‐	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  2011	  
Distinct	  Neurophysiological	  Profiles	  In	  Irritable	  Bowel	  Syndrome	  
	  
Distinct neurophysiological profiles in irritable bowel syndrome
Naila Arebi,1* Dominic C. Bullas,1* George E. Dukes,2 Salma Gurmany,1 Kirsty J. Hicks,2
Michael A. Kamm,4,5 and Anthony R. Hobson2,3
1Gastrointestinal Physiology Department, St. Mark’s Hospital Campus, Imperial College, Harrow, Middlesex,
2GlaxoSmithKline Research and Development, Stevenage, 3The Neurogastroenterology Diagnostic Centre, Princess Grace
Hospital, 5Imperial College, London, United Kingdom; and 4St. Vincent’s Hospital and University of Melbourne,
Melbourne, Australia
Submitted 20 December 2010; accepted in final form 23 February 2011
Arebi N, Bullas DC, Dukes GE, Gurmany S, Hicks KJ,
Kamm MA, Hobson AR. Distinct neurophysiological profiles in
irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol
300: G1086 –G1093, 2011. First published February 24, 2011;
doi:10.1152/ajpgi.00553.2010.—The objective of this study was to
determine whether cortical evoked potentials (CEPs) can define neu-
rophysiological patterns in irritable bowel syndrome (IBS). In this
prospective study of consecutive patients attending secondary and
tertiary centers, patients with Rome II-defined IBS underwent rectal
sensory and pain threshold (RST and RPT, respectively) testing with
electrical stimulation on three separate visits. CEPs were collated for
75% pain thresholds, and anxiety [Spielberger State-Trait Anxiety
Inventory (SSTAI)] questionnaires were completed. Subjects were 33
IBS patients (27 female, mean age 40.1 yr) and 21 healthy controls
(14 female, mean age 31.4 yr). At visit 3, RPT was significantly lower
[mean (95% CI)] in IBS patients than in control subjects: 58.2 mA
(48.0–68.5) vs. 79.5 mA (69.3–89.6) (P ! 0.01). No significant
differences were observed in CEP latencies and amplitudes between
visits 1, 2, and 3 within each group, except P2 latency for controls
(P " 0.04) and N2 latency (P " 0.04) and N2 amplitude (P " 0.02)
for IBS patients. Group comparisons showed significant differences in
3-day mean RPT, CEP amplitudes, and CEP latencies between IBS
patients and controls. RPT !50 mA and P1 latency #106 ms were
identified four IBS subgroups: 24% were hypersensitive, 12% were
hypervigilant, 15% were hyposensitive, and 49% exhibited normal P1
latency and pain threshold. CEPs are reliable and reproducible mea-
sures of early sensory processing. Identification of four IBS neuro-
physiological patterns highlights its heterogeneous nature. These find-
ings mark the first step toward personalized medicine in IBS, whereby
therapy may be directed at the underlying physiological process.
brain-gut interaction; visceral sensitivity; gastrointestinal physiology
ABDOMINAL PAIN IS THE CARDINAL symptom of irritable bowel
syndrome (IBS), with associated diagnostic symptoms such as
alterations in stool frequency or consistency (7). Visceral
hypersensitivity is a recognized physiological process associ-
ated with pain in IBS (20). Several mechanisms may contribute
to the low pain threshold observed in this condition. Peripheral
sensitization of visceral afferent nerves activated by previous
injury or infection, mediated via inflammatory mediators such
as prostaglandins, is closely integrated with central sensitiza-
tion of spinal afferents (21, 26). Once chronic sensitization is
established, the two processes become indistinguishable, as
they contribute to the development of visceral hypersensitivity
in functional gut disorders (5, 21, 25, 26). More recently,
perception of gut stimuli and postprandial symptoms in IBS
were shown to be enhanced during stressful conditions (10,
22). As the treatment and management strategies deployed to
ameliorate these different aberrant mechanisms are distinct
(i.e., analgesics vs. psychological therapy), identifying the
predominant underlying pathophysiology remains an important
clinical objective.
The subjective end point of pain or discomfort when assess-
ing visceral sensation remains inadequate because of suscep-
tibility to response bias related to the psychological state, with
a higher tendency of patients with functional gut disorders to
report pain (4, 31). The lack of a single robust objective clinical
marker to quantify visceral hypersensitivity has hindered prog-
ress in IBS drug development. Much of this difficulty lies in
the complex multifaceted nature of the condition, compounded
by the strong emotional and neurobehavioral components of
pain.
Surrogate measurements of visceral pain can be obtained
from visceral function studies, such as the barostat, or meta-
bolic neuroimaging techniques, such as PET and functional
MRI (1, 18). Evaluation of pain using these tools had several
limitations, including anticipation, habituation, and lack of
non-stimulus-specific activity (23, 33). Some of the limitations
were overcome by magnetoencephalography (MEG) (15).
However, as MEG is available in only a few centers world-
wide, extrapolation of MEG data to EEG recording of cerebral
evoked potentials (CEPs) was subsequently developed as a
possible clinical tool with an objective evaluation of visceral
pain. CEPs are measurements of electrical potentials, generated
by cortical neurons following a series of repeated sensory
stimuli, recorded using scalp surface electrodes. Stimulus-
specific CEPs occur at a fixed time after each stimulus, while
other brain activity does not; stimulus-specific CEPs may be
“extracted” from the brain’s background as a distinct wave-
form.
CEPs have been used to understand pain transmission in the
noncardiac chest pain (NCCP) disease model, where CEPs
represent objective neurophysiological correlates of afferent
transmission and processing within the brain (27). With esoph-
ageal stimulation, as stimulation intensity and sensory percep-
tion increases toward pain, P1 latency decreases, and wave
amplitude increases (14). This phenomenon reflects the recruit-
ment of an increasing number of afferents. The relationship
between amplitude, latency, and intensity of sensory percep-
tion favors visceral CEP as an objective neurophysiological
correlate of gastrointestinal sensory processing (14). Subse-
quent studies with CEP have shown that a homogeneous NCCP
group could be differentiated into three distinct neurophysio-
logical phenotypes (16).
* N. Arebi and D. C. Bullas contributed equally to this work.
Address for reprint requests and other correspondence: N. Arebi, St. Mark’s
Hospital, Watford Rd., Harrow, London HA1 3UJ, UK (e-mail: naila.arebi@imperial.
ac.uk).
Am J Physiol Gastrointest Liver Physiol 300: G1086–G1093, 2011.
First published February 24, 2011; doi:10.1152/ajpgi.00553.2010.












The purpose of the present study was to determine whether
distinct neurophysiological phenotypes occur in IBS. The pri-
mary aim was to test the reliability of CEPs in response to
rectal electrical stimulation over time in IBS. Secondary aims
were to correlate these profiles with sensory and psychological
measures.
MATERIALS AND METHODS
Consecutive IBS patients were recruited from the outpatient clinics
at a tertiary and a secondary care hospital. Patients were included if
they fulfilled the Rome II criteria for IBS. Investigations were under-
taken at the discretion of the attending physician. Exclusion criteria
included unexplained weight loss, psychiatric disorder, acute infec-
tion, recent antibiotic treatment, antidepressant therapy, anxiolytics,
and anti-inflammatory or pain medication. Healthy volunteers were
recruited concomitantly as the control group by local advertisement.
All participants gave informed consent. The study was approved by
the Harrow Ethics Committee.
Protocol
Each participant underwent 3 nonconsecutive days of neurophysi-
ological assessment within a 3-mo period. At each visit, subjects
underwent rectal electrical stimulation to determine sensory and pain
thresholds; CEPs to the rectal stimulus were subsequently recorded.
Female patients were tested during the follicular phase of the men-
strual cycle.
Assessment of Rectal Sensitivity
Rectal stimulation. The rectal catheter (Gaeltec, Dunvegan, Isle of
Skye, Scotland, UK) featured two 2-mm bipolar ring electrodes sited
1 cm apart. The electrodes were positioned 10 cm proximal to the anal
verge. The catheter was connected to a constant-current stimulator
(model DS7A, Digitimer), which was controlled by a trigger generator
(model DG2, Digitimer). The stimulus frequency was 0.5 Hz using
500-!s square-wave pulses. The intensity of the stimulus was manu-
ally adjusted between 0 and 100 mA.
Visual analog scale. Subjects graded the stimulus intensity using a
visual analog scale (VAS) scored between 1 and 6 as follows:
“unaware of the stimulus” was scored as 1, “slight sensation” as 2,
“definite sensation” as 3, “slight discomfort” as 4 “uncomfortable” as
5, and “painful” as 6. This scale has been used previously in CEP
studies and showed correlation between stimulation intensity and CEP
responses (16).
Rectal sensory and pain thresholds. Rectal sensory and pain thresh-
olds (RST and RPT, respectively) were determined by assessing
response in 2-mA increments. The first electrical stimulus perception
was defined as the sensory threshold, or VAS " 2. Further stimulus
intensity increases were recorded via VAS until sensation was per-
ceived as painful (defined as the pain threshold, or VAS " 6). This
ascending electrical stimulation cycle was repeated twice to calculate
average RST and RPT over three cycles. The stimulus intensity used
to elicit CEP was equivalent to the RST plus 75% of the difference
between the RST and RPT (75% RPT) and has been validated in
previous studies (13).
Assessment of CEPs
Placement of cortical electrodes. Silver-silver chloride surface
electrodes were placed on the vertex (active electrode), earlobe
(reference electrode), and neck (ground electrode) according to the
International 10-20 System of EEG electrode placement. The elec-
trodes were fixed using electrode gel or paste (Elebix, Nihon Kohden)
after the skin was scrubbed with a mild abrasive (Omniprep, Weaver
& Aurora) to maintain scalp impedance at #5 k$.
CEP recordings. CEPs were recorded with subjects lying still and
their gaze fixed on a stationary object to minimize motor artifacts. The
rectal stimulus was delivered at the calculated testing intensity over
four cycles of 50 electrical stimulations spaced at 5-s intervals. A
5-min pause interspersed each cycle. Each cycle of 50 stimulations
was averaged to enhance signal clarity. The patient was given 5 min
to relax after each cycle before testing resumed. At the conclusion of
each day of testing, four averaged CEP waveforms were calculated.
CEP acquisition and analysis. Data were acquired using a pro-
grammable signal conditioner (model 1902, Cambridge Electronics
Design), as previously described (13). Rectal CEPs were analyzed
according to morphology, latency, and amplitude of the waveforms.
CEPs were averaged after each cycle and then compared with other
cycles on the same day of testing (intraday analysis) and on other days
of testing (interday analysis). Four main CEP components were
recognized in previous studies.
Definition of terms. The main CEP peak components are P1, N1,
P2, and N2. Neurophysiological convention describes negative poten-
tials as upward deflections (N1 and N2) and positive potentials as
downward deflections (P1 and P2). Latency refers to time (in ms)
from the stimulus trigger to the peak component. Amplitude is defined
as the voltage difference between consecutive CEP peaks (Fig. 1).
Early recorded CEP complex represents stimulus-specific activa-
tion of the primary or secondary somatosensory cortex and insula and
depends on transmitted afferent signal strength intensity. Cortical
activity of %250 ms or more after stimulation reflects brain endoge-
nous processing of the afferent information and represents a more
general “arousal”-type response. The relationship between CEP mor-
phology and pain thresholds was examined in a previous study (16)
and defined as follows. 1) Afferent hypersensitivity refers to pain
perception at relatively low stimulus intensity with a normal-latency
P1 component. 2) Hypervigilance refers to pain perception at low
stimulation intensity, but with prolonged-latency P1 responses (indi-
cating that afferent signaling pathways are not sensitized, instead
patients were “amplifying” normal-intensity stimuli once the stimulus
reached the brain). 3) Hyposensitivity refers to maximum stimulus
application (limited by the stimulator and safety reasons) without
eliciting a normal CEP response.
Withdrawals. All participants completed the first day of CEP
testing (visit 1). At visit 2, two IBS patients and two controls dropped
out for the following reasons: failure to attend, technical failure of
electronic CEP data capture, pregnancy, and difficulty in attending
hospital. At visit 3, a further two IBS patients withdrew: one failed to
attend, and the other underwent unrelated surgery.
Reference values. The results from the healthy controls were used
to define reference values for normal pain threshold and P1 latency.
Fig. 1. Diagrammatic representation of rectal cortical evoked potential (CEP)
components. Diagram shows positive and negative deflections following a
stimulus. Neurophysiological convention describes negative potentials as up-
ward deflections (N1 and N2) and positive potentials as downward deflections
(P1 and P2). Latency refers to time (in ms) from stimulus trigger to peak
component. Amplitude is defined as voltage difference between consecutive
CEP peaks. Markers for P1 latency (P1L) and P1 amplitude (P1A) are shown.
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Differences in anxiety between study groups faced with the same
unknown testing situation were examined using the Spielberger State-
Trait Anxiety Inventory (SSTAI), which measures state (SSTAI-state)
and trait (SSTAI-trait) anxiety and overall anxiety levels. Scores range
from 20 to 80, with higher scores indicating greater anxiety (29). Each
questionnaire has 20 questions, with 4 possible Likert-type responses
scored between 1 and 4. Scores !35 in either test were considered to
be pathological.
Data Collection and Statistics
The RST and RPT (mA) are presented as means with 95% confi-
dence intervals [means (95% CI)]. CEPs demonstrated characteristic
morphology with P1, N1, P2, N2, and N3 peaks. The latency (ms) and
amplitude ("V) of P1, P2, P3, N1, and N2 waves were measured for
75% RPT. Data are presented as mean differences between visits 1, 2,
and 3, with 95% CI to highlight the reproducibility of the measure-
ments. Absolute values are also expressed as means (95% CI). As this
was an exploratory study, we decided on sample number by consid-
ering the results of the NCCP disease model, where a sample size of
32 was sufficient to define phenotypes (16). One-way ANOVA was
used to examine for inter- and intragroup differences between visits 1,
2, and 3, and repeated-measures ANOVA assessed the repeatability of
observations between visits. The mean 3-day difference between IBS
patients and controls was analyzed by the Mann-Whitney test.
RESULTS
Demographics
Thirty-three Rome II IBS patients (27 female, mean age 40
yr) and 21 healthy controls (14 female, mean age 31 yr) were
recruited. Demographic data are shown in Table 1. There were
no significant differences in age and sex between the two
groups.
Pain and Sensory Thresholds
RST and RPT. CONTROLS. At visits 1, 2, and 3, RSTs [means
(95% CI)] were 18.1 mA (15.2–20.9), 14.7 mA (12.8–16.7),
and 15.8 mA (12.1–19.5), respectively, and RPTs were 70.2
mA (60.2–80.2), 71.61 mA (61.5–81.7), and 79.5 mA (69.3–
89.6), respectively. Mean differences between visits 1, 2, and 3
are shown in Table 2. There were no statistical differences
between visits 1, 2, and 3.
IBS PATIENTS. At visits 1, 2, and 3, RSTs were 18.7 mA
(14.1–23.3), 21.3 mA (17.2–25.4), and 16.2 mA (12.6–19.9),
respectively, and RPTs were 57.7 mA (48.5–66.9), 63.2 mA
(53.2–73.2), and 58.2 mA (47.9–68.5), respectively. There
were no significant differences between visits 1, 2, and 3 for the
IBS patients (Table 2).
75% RPT. For 75% RPT, there were no differences between
visits 1, 2, and 3 for the controls and IBS patients (data not
shown).
IBS patients vs. controls. At visit 2, RST [mean (95% CI)]
was 6.6 mA (1.4–11.7) lower for IBS patients than controls
(P # 0.01; Fig. 2A). At visit 3, RPTs were significantly
different between the IBS patients and controls, with a differ-
ence of $21.2 ($36.0 to $6.5) (P % 0.01; Fig. 2B). The mean
3-day RST was 16.2 mA (14.6–17.9) for controls and 18.8 mA
(16.4–21.1) for the IBS patients; the difference was not sig-
nificant. There was, however, a significant difference in RPT:
73.6 mA (68–79.2) for controls and 59.7 mA (54.2–65.1) for
IBS patients (P % 0.001).
CEPs
CEP peak latency in controls. At visit 1, peak latencies were
73.5 ms (65.9–81.1) for P1, 119.9 ms (110.8–128.9) for N1,
224.2 ms (211.9–236.5) for P2, 397.4 ms (376.1–418.8) for
N2, and 633.0 ms (589.4–676.6) for N3. The differences
between visits 1, 2, and 3 are shown in Table 3. Only P2
latency was significantly different between visits 1, 2, and 3
(P# 0.04). P1 latency values for each subject at visits 1, 2, and
3 are shown in Fig. 3A.
CEP peak amplitudes in controls. At visit 1, peak amplitudes
[mean (95% CI)] were 7.5 "V (5.5–9.6) for P1, 19.4 "V
(14.5–24.2) for N1, 19.6 "V (15.5–23.7) for P2, and 7.9 "V
(6.1–9.7) for N2. There was no statistically significant differ-
ence between the 3-day measurements (Table 3).
CEP peak latency in IBS patients. At visit 1, peak latencies
[mean (95% CI)] were 96.4 ms (86.6–106.1) for P1, 138.8 ms
(126.1–151.4) for N1, 239.2 ms (222.9–255.5) for P2, 405.8
Table 1. Demographics of study participants
Controls (n # 21) IBS Patients (n # 33)
Age, yr [mean (range)] 31.4 (21–46) 40.1 (20–63)
Sex, M/F [n (%)] 7/14 (33/67) 6/27 (18/82)





Mean ages and sex distribution were similar in each group. Most irritable
bowel syndrome (IBS) patients had diarrhea-predominant IBS.
Table 2. Sensory and pain thresholds in controls and IBS patients
Visit 2 vs. Visit 1 Visit 3 vs. Visit 1 Visit 3 vs. Visit 2
Controls
RST $3.3 ($7.2 to 0.5) $2.2 ($6.2 to 1.7) 1.1 ($2.9 to 5.1)
RPT 1.4 ($12.1 to 4.9) 9.2 ($4.4 to 22.9) 7.8 ($6.0 to 21.7)
75% RPT 0.13 ($10.8 to 11.1) 6.2 ($4.9 to 17.3) 6.1 ($5.2 to 17.3)
IBS patients
RST 2.6 ($3.1 to 8.3) $2.5 ($8.2 to 3.3) $5.05 ($10.4 to 0.3)
RPT 5.5 ($7.8 to 18.8) 0.5 ($12.9 to 13.9) $5.0 ($19.0 to 9.1)
75% RPT 4.7 ($6.3 to 15.6) $0.3 ($11.3 to 10.7) $5.0 ($16.4 to 6.4)
Values are means [95% confidence interval (CI)]. Data are shown as mean differences between IBS patients and controls for visits 1, 2, and 3. There were
no significant differences in rectal pain threshold (RPT) and rectal sensory threshold (RST) between visits 1, 2, and 3 in controls and IBS patients.
Repeated-measures ANOVA was used for statistical analysis on participants who attended all 3 visits.
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ms (375.6–436.0) for N2, and 674.3 ms (630.0–718.5) for N3.
Differences between visits 1, 2, and 3 are shown in Table 4; the
only significant difference between visits 1, 2, and 3 was for N2
latency (P ! 0.04). Individual P1 latency values for visits 1, 2,
and 3 are shown in Fig. 3B.
CEP peak amplitude in IBS patients. At visit 1, peak ampli-
tude [mean (95% CI)] was 5.1 "V (3.4–6.9) for P1, 13.3 "V
(9.5–17.0) for N1, 12.5 "V (9.4–15.7) for P2, and 5.3 "V
(4.1–6.5) for N2. For P1, N1, and P2 amplitudes, there was no
intervisit variation; N2 amplitude showed a significant differ-
ence between visits 1, 2, and 3 (P ! 0.02; Table 4).
Comparative Profiles of IBS Patients and Controls
CEPs characteristics. LATENCY. Mean 3-day latencies
[means (95% CI)] were longer for the IBS patients than
controls for P1, N1, and P2 (P # 0.001): 101 ms (88.1–113.8)
vs. 73.5 ms (69.3 - 77.6) for P1, 138.8 ms (130.6–147.0) vs.
116.1 ms (110.8–121.4) for N1, and 241.8 ms (232.2–251.3)
vs. 219.7 ms (213.7–225.6) for P2. There was no significant
difference for N2 latency between the two groups: 401.66 ms
(388.1–415.3) and 388.3 ms (376.9–399.6) for IBS patients
and controls, respectively (P ! 0.08).
The mean differences in peak latencies between IBS patients
and controls at visits 1, 2, and 3 are shown in Supplemental
Table S1 (see Supplemental Material for this article, available
online at the Journal website). N1 latency was consistently
prolonged in the IBS patients compared with controls at visits
1, 2, and 3. In addition, P1 latency was significantly longer in
the IBS patients at visits 1 and 2, and P2 latency was prolonged
in the IBS patients at visits 2 and 3.
Amplitude. Comparison of 3-day mean amplitudes revealed
lower amplitudes [mean (95% CI)] for the IBS patients than
controls for the four components (P # 0.005): 5.7 "V (4.7–
6.7) and 7.7 "V (6.5–9.0) for P1, 14.2 "V (12.1–16.2) and
21.4 "V (18.4–24.5) for N1, 14.1 "V (12.3–15.9) and 22.5 "V
(20.0–25.0) for P2, and 6.3 "V (5.6–7.1) and 8.5 "V (7.4–9.7)
for N2 for the IBS patients and controls, respectively. When P1
amplitudes in IBS patients and controls were comparable for
each visit, no significant differences were noted. N1 and P2
amplitudes were consistently lower at visits 1, 2, and 3 for the
IBS patients than controls. N2 amplitude was only significantly
lower at visit 1 (see Supplemental Table S1).
Psychological Profile
SSTAI-state scores [means (95% CI)] for the IBS patients
were 38.9 (35.4–42.3), 37.6 (33.8–41.5), and 39.7 (34.6–
44.8) for visits 1, 2, and 3, respectively. In comparison, the
scores for controls were 31.9 (28.8–35.0), 28.9 (26.3–31.6),
and 31.6 (26.9–36.4). For each group, there were no significant
interday differences for these scores (Fig. 4A; see Supplemen-
tal Table S2).
Fig. 2. Rectal sensory threshold (RST) and rectal pain threshold (RPT) for
control subjects and patients with irritable bowel syndrome (IBS). A: RST was
significantly greater [by 6.6 mA (95% CI 1.4–11.7)] for IBS patients than
controls at visit 2. *P ! 0.01. B: RPT was significantly less [by $21.2 mA
($36.0 to $6.5)] in IBS patients than controls at visit 3. **P # 0.01 (1-way
ANOVA).
Table 3. Mean differences between visits 1, 2, and 3 for CEP components in controls
Visit 2 vs. Visit 1 Visit 3 vs. Visit 1 Visit 3 vs. Visit 2 P Value
Latency
P1 (peak 1) 0.6 ($9.7 to 11.0) $0.8 ($11.1 to 9.6) $1.4 ($12.0 to 9.2) NS
N1 (peak 2) $5.1 ($18.1 to 7.8) $6.6 ($19.5 to 6.4) $1.4 ($15.0 to 12.1) NS
P2 (peak 3) $5.3 ($19.8 to 9.3) $8.7 ($23.3 to 5.9) $3.4 ($16.8 to 9.9) 0.04
N2 (peak 4) $11.7 ($39.4 to 6.0) $16.8 ($44.6 to 10.9) $5.1 ($32.7 to 22.4) NS
Amplitude
P1 (peak 1) 0.6 ($2.5 to 3.7) $0.1 ($3.1 to 3.0) $0.7 ($4.0 to 2.7) NS
N1 (peak 2) 2.7 ($4.8 to 10.1) 3.8 ($3.7 to 11.2) 1.1 ($7.0 to 9.2) NS
P2 (peak 3) 3.5 ($2.5 to 9.5) 5.6 ($0.4 to 11.5) 2.0 ($4.3 to 8.4) NS
N2 (peak 4) 0.5 ($2.4 to 3.4) 1.5 ($1.4 to 4.4) 1.0 ($2.2 to 4.2) NS
Values are means (95% CI); n ! 21. Five cortical evoked potentials (CEPs) were observed. There were no significant differences between amplitude
components at visits 1, 2, and 3. Repeated-measures ANOVA was used for statistical analysis on participants who attended all 3 visits (n ! 19). There was a
significant difference in P2 latency between visits (P ! 0.04). NS, not significant.
G1089CEP PROFILES IN IBS














SSTAI-trait scores [means (95% CI)] for the IBS patients
were 44.5 (40.7–48.3), 40.7 (36.7–44.7), and 44.0 (39.3–48.7)
at visits 1, 2, and 3, respectively. Comparative scores for
controls were 33.9 (30.8–37.0), 32.6 (29.3–35.9), and 32.2
(28.6 –35.8) (Fig. 4B). There were no differences in the
scores at visits 1, 2, and 3 for each group (see Supplemental
Table S2).
IBS patients vs. controls. At each visit, state and trait scores
were significantly greater for IBS patients than controls. This
suggests that IBS patients mount a greater anxiety response to
the same perceived threat of electrical stimulation that does not
diminish over time with increasing familiarity of the test
protocol.
Reference Values to Identify Phenotypes
Healthy controls were used to define the control reference
values for P1 latency. The 3-day mean was 73.4 ms with a
standard deviation (SD) of 16.1 ms. Therefore, P1 latencies
!106 ms (2 SDs above the reference mean P1 latency) were
considered abnormal. Hypersensitivity to rectal stimulation
was defined as RPT !50 mA, as all healthy controls had
levels above this value (range for RPT was 50 –92).
IBS Phenotypes: Subgroup Analysis
Low (!50 mA) RPT. In 12 IBS patients, mean 3-day RPT
was !50 mA. P1 latency was !106 ms in four of these IBS
patients and !106 ms in eight IBS patients. Eight of these IBS
patients had visceral hypersensitivity, as defined by RPT "50
mA, with a normal-latency P1 !106 ms, and four showed
features of hypervigilance, with low pain thresholds (!50 mA)
and high P1 latency (!106 ms; Figs. 5 and 6).
Normal (!50 mA) RPT. A 3-day mean pain threshold !50
mA was observed in 21 IBS patients. Five of these IBS patients
exhibited prolonged (!106 ms) latency, and 16 exhibited
normal latency. Hyposensitivity, as defined by high or normal
pain threshold !50 mA and prolonged P1 latency !106 ms,
was therefore noted in five IBS patients. The greatest propor-
tion of IBS patients (49%) showed normal RPT !50 mA and
normal P1 latency (Figs. 5 and 6).
Normal, hypervigilant, and hypersensitive profiles. The dif-
ference between CEP, pain threshold, and anxiety state em-
phasizing the above profiles is shown for three subjects in
Supplemental Fig. S1.
DISCUSSION
This study is the first to use rectal CEP over time to examine
IBS neurophysiological profiles. We show that rectal CEPs
generate a reproducible, objective assessment of rectal afferent
sensitivity and are consistent for interday testing in healthy
controls and IBS patients. The rectal CEP recordings were also
morphologically similar between visits 1, 2, and 3 for the four
major components of the early primary afferent cortical re-
sponse.
CEP Interpretation
We, and others, previously showed that the early CEP
complex in response to visceral stimulation is stimulus-depen-
dent and represents activation of the primary or secondary
somatosensory cortex and insula (15). In esophageal studies,
cortical activity after #150 ms following electrical stimulation
relates to brain endogenous processing of afferent information.
Unlike early CEP components, which depend on the intensity
of the transmitted afferent signal strength, later components
appear to represent a more general arousal-type response to the
stimulus. These later responses may be heightened in response
to a low level of stimulation if a subject’s arousal or attention
is altered and may provide an objective measure of hypervigi-
lance.
Fig. 3. Individual data points for P1 latency at visits 1, 2, and 3 for controls (A)
and IBS patients (B). §P1 latency $ 608.6 ms.
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P1 latency represents the time interval between stimulation
and activation of these sensory discriminatory brain regions. In
healthy subjects, as the perceived stimulus intensity increases,
there is a concurrent reduction in latency and an increase in
amplitude of the CEP components (14). This provides an
objective measure that correlates strongly with a subjective end
point. In our previous NCCP work, we identified a group of
patients expressing pain at relatively low stimulation levels but
with normal P1 latency (16), indicative of afferent sensitiza-
tion. A second group that also reported pain at low stimulation
intensities showed prolonged-latency P1 responses. As these
responses were similar to those expected when CEPs were
acquired around the subject’s perception threshold, we sur-
mised that the afferent signaling pathway was not sensitized;
instead, the subjects were amplifying normal-intensity stimuli
once these stimuli had reached the brain, with hypervigilance
being a possible process by which this could happen. We
acknowledge that stress-induced rectal hyperalgesia may also
be a mechanism by which this kind of central amplification
may occur, but until this is proven, the term “hypervigilance”
has been used to distinguish between these two groups.
CEP as a Cortical Sensory Processing Tool
CEP techniques have been used by neurophysiologists to
investigate visual, auditory, and somatosensory pathways,
leading to adaptations to study visceral sensation (3, 9). In
rectal studies, different visceral stimuli, namely, electrical and
mechanical modalities, generated identical CEP waveforms,
except for a slight latency difference due to a 50-ms delay in
the balloon inflation (11). We chose an electric modality,
because it provides distinct painful stimulation, which may be
more applicable in pain studies. Rectal distension responses are
mediated by unmyelinated C-fibers and thinly myelinated A!-
fibers through the pelvic nerve (19, 24, 28). A previous study
Table 4. CEP components in IBS patients
Visit 2 vs. Visit 1 Visit 3 vs. Visit 1 Visit 3 vs. Visit 2 P Value
Latency
P1 (peak 1) 3.2 ("28.0 to 34.3) 11.4 ("20.3 to 43.2) 8.3 ("30.7 to 47.3) NS
N1 (peak 2) 4.9 ("15.0 to 24.7) "5.2 ("25.3 to 15.0) "10.0 ("31.8 to 11.7) NS
P2 (peak 3) 3.9 ("19.3 to 27.1) 4.2 ("19.5 to 27.8) 0.3 ("24.1 to 24.7) NS
N2 (peak 4) "3.3 ("36.4 to 29.8) "9.7 ("43.4 to 24.0) "6.3 ("34.1 to 21.4) 0.04
Amplitude
P1 (peak 1) 0.9 ("1.6 to 3.4) 0.9 ("1.6 to 3.5) 0.02 ("2.6 to 2.6) NS
N1 (peak 2) 1.2 ("3.8 to 6.2) 1.6 ("3.5 to 6.7) 0.4 ("4.6 to 5.4) NS
P2 (peak 3) 1.7 ("2.6 to 6.0) 3.4 ("1.0 to 7.7) 1.7 ("2.7 to 6.1) NS
N2 (peak 4) 1.0 ("0.7 to 2.8) 2.2 (0.4 to 4.0) 1.2 ("0.7 to 3.0) 0.02
Values [means (95% CI)] are mean differences between visits 1, 2, and 3 for each cortical evoked potential (CEP) component (n # 33). Five potentials were
observed. There were significant differences in N2 latency and N2 amplitude between visits 1, 2, and 3 in IBS patients. Repeated-measures ANOVA was used
for statistical analysis on participants who attended all 3 visits (n # 29).
Fig. 4. Spielberger State and Trait Anxiety Index (SSTAI-state and SSTAI-
trait) scores [mean (95% CI)] at visits 1, 2, and 3 in controls (A) and IBS
patients (B). Score was $35 (the level for diagnosis of anxiety) in all controls.
There were no significant differences between visits 1, 2, and 3. Scores were
higher (%35) for IBS patients than controls, but there were no differences
between visits 1, 2, and 3.
Fig. 5. Definition of profiles according to pain thresholds (PT) and P1 latency.
Patients with RPT !50 mA were considered hypersensitive. Hypersensitive
group was further subclassified according to P1 latency, which represents time
taken for stimulus to reach cortex; 24% had latency !106 ms, indicative of
true visceral hypersensitivity. Those with a prolonged latency were hypervig-
ilant. Within the group with normal rectal sensation, 15% showed prolonged
latency, indicative of hyposensitivity.
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showed shorter-than-expected CEP latencies for C-fiber stim-
ulation (2), suggesting that electrical and mechanical rectal
CEPs are mediated via A!-fibers.
Rectal CEP morphology exhibits some differences from
CEP morphology of other gut segments; for example, P1
latency is shorter than duodenal and esophageal CEP latency
(13, 17). The reason for the shorter P1 latency is unclear;
further studies on conduction velocities may clarify whether
this may represent faster-conducting afferent pathways con-
veying rectal sensation, reflecting prominence given to conti-
nence mechanisms.
CEPs have sufficient temporal resolution to discriminate
between primary (stimulus-specific cortical response) and sec-
ondary (non-stimulus-specific cortical response) processing of
visceral afferent activity. The latter contains endogenous pain
components affected by attention, cognition, and behavior.
This distinction is important, as it differentiates primary vis-
ceral hypersensitivity (increased CEP amplitude for a given
stimulus) from competing delayed central contributions influ-
enced by factors such as psychological state. Previous research
on esophageal cortical sensory processing revealed that evoked
potential (EP) activity up to 150 ms after stimulation represents
the primary component (14–16). Activity occurring after"250
ms represents endogenous cortical activity, as observed by
measurement of EP latency to anticipated esophageal stimulus
(17). Studying visceral sensation with CEPs should identify
whether IBS is driven by primary visceral hypersensitivity or
psychological hypersensitivity.
Drewes et al. (6) took this concept of temporal resolution
further by incorporating regional brain activation to map net-
works involved in EPs to sensory stimuli. Activity from EEGs
in response to painful esophageal stimuli showed sequential
activation of the thalamus, insula, cingulate, and somatosen-
sory cortex. Using grouped CEP responses, Drewes et al. also
showed subtle differences in the cingulate cortex activation
region in IBS patients. Different cortical topography may
explain partly the differences in latency and amplitude between
various CEP components between IBS patients and controls in
our study.
CEP Components Identify Distinct IBS Phenotypes
Individual components of rectal CEP were used to define
normal population reference ranges for subgroup analysis in
our IBS population to explore the prevalence of primary
visceral hypersensitivity. We found that IBS represents a
heterogeneous patient group with different neurophysiological
profiles. Most patients with IBS (49%) had a normal pain
threshold and normal sensory afferent transmission. Only a
minority of IBS patients (24%) had afferent visceral hypersen-
sitivity with pain threshold #50 mA and normal latency. A
similar number showed hyposensitivity or hypervigilance, with
a low pain threshold and increased latency.
Pain thresholds in IBS patients were significantly different
from those in controls at visit 3. This was mainly due to
habituation of RPT over time in controls, whereas values for
IBS patients remained consistent. Habituation to painful stim-
ulation is mediated via descending inhibitory mechanisms,
which have been shown to be defective in IBS patients in
several studies (23, 32). This might suggest that the treatment
strategy for attenuating visceral afferent transmission (via an-
algesics) would differ from boosting endogenous pain mecha-
nisms, for example, endogenous opioids, such as $-endorphin.
A recent preclinical study with probiotics showed that attenu-
ation of experimental visceral hypersensitivity was associated
with upregulation of peripheral opioid receptors (30).
In previous work from our department, Murray et al. (22)
demonstrated little difference in sensory thresholds between
IBS patients and controls until experimental stress was applied
(22). The wide range of sensory response from hyper- to
hyposensitivity seen in our cohort most likely skews the
sensory threshold data upward. Pain thresholds differed be-
Fig. 6. Profile for each IBS patient determined by RPT-P1 latency relationship.
Top: 3-day mean results for patients with RPT !50 mA. In 4 patients, P1
latency was"106 ms, indicative of hypervigilance; in remaining 8 patients, P1
latency was !106 ms, indicative of visceral hypersensitivity. Bottom: 3-day
mean results for patients with RPT "50 mA. Only 5 patients showed a
prolonged ("106 ms) P1 latency, indicative of hyposensitivity; remaining 16
patients showed a normal P1 latency. *Very high (289 ms) P1 latency in 1
patient.
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tween controls and IBS patients only because of an increase in
pain threshold in controls over time; this appears to be atten-
uated in some IBS patients.
We also looked at potential confounders, such as state and
trait anxiety. Of the five studies that previously used SSTAI for
IBS patients, only three recorded mean SSTAI-state scores
with an overall mean of 47.7 (8). Only one study recorded a
mean SSTAI-state score of 35.5 for a control group. The mean
SSTAI-trait score was 47.2 for IBS patients (in 4 studies) and
41.2 for controls (in 2 studies) (8). The SSTAI-trait score is
more time-independent than the SSTAI-state score, but both
indexes showed little variation in either group over visits 1, 2,
and 3. At no point did the state score drop below the case
threshold of 35 in the IBS group.
Conclusions
This is the first study to validate CEP testing in IBS. Testing
was reproducible and robust. Early CEP responses and pain
thresholds defined distinct neurophysiological groups, support-
ing the concept of IBS as a heterogeneous syndrome. Local and
central mechanisms are likely to contribute to each profile;
defining each contribution may allow effective drug therapy.
The abundant CEP data generated from this study can be used
in future therapeutic studies.
GRANTS
This work was funded by an educational grant from GlaxoSmithKline
Research and Development.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the authors.
REFERENCES
1. Bernstein CN, Frankenstein UN, Rawsthorne P, Pitz M, Summers R,
McIntyre MC. Cortical mapping of visceral pain in patients with GI
disorders using functional magnetic resonance imaging. Am J Gastroen-
terol 97: 319–327, 2002.
2. Bromm B, Treede RD. Human cerebral potentials evoked by CO2 laser
stimuli causing pain. Exp Brain Res 67: 153–162, 1987.
3. Collet L, Meunier P, Duclaux R, Chery-Croze S, Falipou P. Cerebral
evoked potentials after endorectal mechanical stimulation in humans. Am
J Physiol Gastrointest Liver Physiol 254: G477–G482, 1988.
4. Dorn SD, Palsson OS, Thiwan SI, Kanazawa M, Clark WC, van
Tilburg MA, Drossman DA, Scarlett Y, Levy RL, Ringel Y, Crowell
MD, Olden KW, Whitehead WE. Increased colonic pain sensitivity in
irritable bowel syndrome is the result of an increased tendency to report
pain rather than increased neurosensory sensitivity. Gut 56: 1202–1209,
2007.
5. Drewes AM, Gregersen H. Multimodal pain stimulation of the gastroin-
testinal tract. World J Gastroenterol 12: 2477–2486, 2006.
6. Drewes AM, Sami SA, Dimcevski G, Nielsen KD, Funch-Jensen P,
Valeriani M, Arendt-Nielsen L. Cerebral processing of painful oesoph-
ageal stimulation: a study based on independent component analysis of the
EEG. Gut 55: 619–629, 2006.
7. Drossman DA. Introduction: The Rome Foundation and Rome III. Neu-
rogastroenterol Motil 19: 783–786, 2007.
8. Elliott C, Kamm MA, Bullas D, Gurmany S, Arebi N. High depression
and anxiety scores in a systematic review of psychological questionnaires
in irritable bowel syndrome (Abstract). Gut 58 Suppl II: A185, 2010.
9. Frieling T, Enck P, Wienbeck M. Cerebral responses evoked by elec-
trical stimulation of rectosigmoid in normal subjects. Dig Dis Sci 34:
202–205, 1989.
10. Fukudo S, Nomura T, Muranaka M, Taguchi F. Brain-gut response to
stress and cholinergic stimulation in irritable bowel syndrome. A prelim-
inary study. J Clin Gastroenterol 17: 133–141, 1993.
11. Harris ML, Hobson AR, Hamdy S, Thompson DG, Akkermans LM,
Aziz Q. Neurophysiological evaluation of healthy human anorectal sen-
sation. Am J Physiol Gastrointest Liver Physiol 291: G950–G958, 2006.
12. Hobday DI, Hobson A, Furlong PL, Thompson DG, Aziz Q. Compar-
ison of cortical potentials evoked by mechanical and electrical stimulation
of the rectum. Neurogastroenterol Motil 12: 547–554, 2000.
13. Hobday DI, Hobson AR, Sarkar S, Furlong PL, Thompson DG, Aziz
Q. Cortical processing of human gut sensation: an evoked potential study.
Am J Physiol Gastrointest Liver Physiol 283: G335–G339, 2002.
14. Hobson AR, Sarkar S, Furlong PL, Thompson DG, Aziz Q. A cortical
evoked potential study of afferents mediating human esophageal sensa-
tion. Am J Physiol Gastrointest Liver Physiol 279: G139–G147, 2000.
15. Hobson AR, Furlong PL, Worthen SF, Hillebrand A, Barnes GR,
Singh KD, Aziz Q. Real-time imaging of human cortical activity evoked
by painful esophageal stimulation. Gastroenterology 128: 610–619, 2005.
16. Hobson AR, Furlong PL, Sarkar S, Matthews PJ, Willert RP,
Worthen SF, Unsworth BJ, Aziz Q. Neurophysiologic assessment of
esophageal sensory processing in noncardiac chest pain. Gastroenterology
130: 80–88, 2006.
17. Hollerbach S, Fitzpatrick D, Shine G, Kamath MV, Upton AR,
Tougas G. Cognitive evoked potentials to anticipated oesophageal stim-
ulus in humans: quantitative assessment of the cognitive aspects of
visceral perception. Neurogastroenterol Motil 11: 37–46, 1999.
18. Kern MK, Shaker R. Cerebral cortical registration of subliminal visceral
stimulation. Gastroenterology 122: 290–298, 2002.
19. Mayer EA, Raybould HE. Role of visceral afferent mechanisms in
functional bowel disorders. Gastroenterology 99: 1688–1704, 1990.
20. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal
perception is a biological marker of patients with irritable bowel syn-
drome. Gastroenterology 109: 40–52, 1995.
21. Munakata J, Naliboff B, Harraf F, Kodner A, Lembo T, Chang L,
Silverman DH, Mayer EA. Repetitive sigmoid stimulation induces rectal
hyperalgesia in patients with irritable bowel syndrome. Gastroenterology
112: 55–63, 1997.
22. Murray CD, Flynn J, Ratcliffe L, Jacyna MR, Kamm MA, Emmanuel
AV. Effect of acute physical and psychological stress on gut autonomic
innervation in irritable bowel syndrome. Gastroenterology 127: 1695–
1703, 2004.
23. Naliboff BD, Berman S, Suyenobu B, Labus JS, Chang L, Stains J,
Mandelkern MA, Mayer EA. Longitudinal change in perceptual and
brain activation response to visceral stimuli in irritable bowel syndrome
patients. Gastroenterology 131: 352–365, 2006.
24. Ness TJ, Metcalf AM, Gebhart GF. A psychophysiological study in
humans using phasic colonic distension as a noxious visceral stimulus.
Pain 43: 377–386, 1990.
25. Price DD, Zhou Q, Moshiree B, Robinson ME, Verne GN. Peripheral
and central contributions to hyperalgesia in irritable bowel syndrome. J
Pain 7: 529–535, 2006.
26. Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution
of central sensitisation to the development of non-cardiac chest pain.
Lancet 356: 1154–1159, 2000.
27. Sarkar S, Hobson AR, Furlong PL, Woolf CJ, Thompson DG, Aziz Q.
Central neural mechanisms mediating human visceral hypersensitivity. Am
J Physiol Gastrointest Liver Physiol 281: G1196–G1202, 2001.
28. Sengupta JN, Gebhart GF. Characterization of mechanosensitive pelvic
nerve afferent fibers innervating the colon of the rat. J Neurophysiol 71:
2046–60, 1994.
29. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait
Anxiety Inventory. Palo Alto, CA: Consulting Psychologist Press, 1970.
30. Verdu EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P,
Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic
therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut
55: 182–90, 2006.
31. Whitehead WE, Palsson OS. Is rectal pain sensitivity a biological marker
for irritable bowel syndrome: psychological influences on pain perception.
Gastroenterology 115: 1263–71, 1998.
32. Wilder-Smith CH, Schindler D, Lovblad K, Redmond SM, Nirkko A.
Brain functional magnetic resonance imaging of rectal pain and activation
of endogenous inhibitory mechanisms in irritable bowel syndrome patient
subgroups and healthy controls. Gut 53: 1595–601, 2004.
33. Yaguez L, Coen S, Gregory LJ, Amaro E Jr, Altman C, Brammer MJ,
Bullmore ET, Williams SC, Aziz Q. Brain response to visceral aversive
conditioning: a functional magnetic resonance imaging study. Gastroen-
terology 128: 1819–29, 2005.
G1093CEP PROFILES IN IBS












1.	  Neal	  KR,	  Barker	  L,	  Spiller	  RC.	  Prognosis	  in	  post-­‐infective	  irritable	  bowel	  syndrome:	  A	  six	  year	  follow	  
up	  study.	  British	  Medical	  Journal	  2002;51(3):410.	  
2.	  Spiegel	  BM,	  Gralnek	  IM,	  Bolus	  R,	  Chang	  L,	  Dulai	  GS,	  Naliboff	  B,	  Mayer	  EA.	  Is	  a	  negative	  
colonoscopy	  associated	  with	  reassurance	  or	  improved	  health-­‐related	  quality	  of	  life	  in	  irritable	  bowel	  
syndrome?	  Gastrointest	  Endosc	  2005,	  Dec;62(6):892-­‐9.	  
3.	  Wilson	  S,	  Roberts	  L,	  Roalfe	  A,	  Bridge	  P,	  Singh	  S.	  Prevalence	  of	  irritable	  bowel	  syndrome:	  A	  
community	  survey.	  Br	  J	  Gen	  Pract	  2004,	  Jul;54(504):495-­‐502.	  
4.	  Drossman	  DA,	  Li	  Z,	  Andruzzi	  E,	  Temple	  RD,	  Talley	  NJ,	  Thompson	  WG,	  et	  al.	  U.S.	  Householder	  
survey	  of	  functional	  gastrointestinal	  disorders.	  Prevalence,	  sociodemography,	  and	  health	  impact.	  Dig	  
Dis	  Sci	  1993,	  Sep;38(9):1569-­‐80.	  
5.	  O'Keefe	  E,	  Talley	  NJ.	  Irritable	  bowel	  syndrome	  in	  the	  elderly.	  Clin	  Geriatr	  Med	  1991,	  May;7(2):265-­‐
86.	  
6.	  Bennett	  G,	  Talley	  NJ.	  Irritable	  bowel	  syndrome	  in	  the	  elderly.	  Best	  Practice	  &	  Research	  Clinical	  
Gastroenterology	  2002;16(1):63-­‐76.	  
7.	  Talley	  NJ,	  O'Keefe	  EA,	  Zinsmeister	  AR,	  Melton	  LJ.	  Prevalence	  of	  gastrointestinal	  symptoms	  in	  the	  
elderly:	  A	  population-­‐based	  study.	  Gastroenterology	  1992,	  Mar;102(3):895-­‐901.	  
8.	  Talley	  NJ,	  Zinsmeister	  AR,	  Van	  Dyke	  C,	  Melton	  LJ.	  Epidemiology	  of	  colonic	  symptoms	  and	  the	  
irritable	  bowel	  syndrome.	  Gastroenterology	  1991,	  Oct;101(4):927-­‐34.	  
9.	  van	  der	  Horst	  HE,	  van	  Dulmen	  AM,	  Schellevis	  FG,	  van	  Eijk	  JT,	  Fennis	  JF,	  Bleijenberg	  G.	  Do	  patients	  
with	  irritable	  bowel	  syndrome	  in	  primary	  care	  really	  differ	  from	  outpatients	  with	  irritable	  bowel	  
syndrome?	  Gut	  1997,	  Nov;41(5):669-­‐74.	  
10.	  Simrén	  M,	  Abrahamsson	  H,	  Svedlund	  J,	  Björnsson	  ES.	  Quality	  of	  life	  in	  patients	  with	  irritable	  
bowel	  syndrome	  seen	  in	  referral	  centers	  versus	  primary	  care:	  The	  impact	  of	  gender	  and	  






11.	  Corney	  RH,	  Stanton	  R.	  Physical	  symptom	  severity,	  psychological	  and	  social	  dysfunction	  in	  a	  series	  
of	  outpatients	  with	  irritable	  bowel	  syndrome.	  J	  Psychosom	  Res	  1990;34(5):483-­‐91.	  
12.	  Lee	  OY,	  Mayer	  EA,	  Schmulson	  M,	  Chang	  L,	  Naliboff	  B.	  Gender-­‐Related	  differences	  in	  IBS	  
symptoms.	  Am	  J	  Gastroenterol	  2001,	  Jul;96(7):2184-­‐93.	  
13.	  Heitkemper	  MM,	  Cain	  KC,	  Jarrett	  ME,	  Burr	  RL,	  Hertig	  V,	  Bond	  EF.	  Symptoms	  across	  the	  menstrual	  
cycle	  in	  women	  with	  irritable	  bowel	  syndrome.	  Am	  J	  Gastroenterol	  2003,	  Feb;98(2):420-­‐30.	  
14.	  Crowell	  MD,	  Dubin	  NH,	  Robinson	  JC,	  Cheskin	  LJ,	  Schuster	  MM,	  Heller	  BR,	  Whitehead	  WE.	  
Functional	  bowel	  disorders	  in	  women	  with	  dysmenorrhea.	  Am	  J	  Gastroenterol	  1994,	  
Nov;89(11):1973-­‐7.	  
15.	  Houghton	  LA,	  Lea	  R,	  Jackson	  N,	  Whorwell	  PJ.	  The	  menstrual	  cycle	  affects	  rectal	  sensitivity	  in	  
patients	  with	  irritable	  bowel	  syndrome	  but	  not	  healthy	  volunteers.	  Gut	  2002,	  Apr;50(4):471-­‐4.	  
16.	  Wigington	  WC,	  Johnson	  WD,	  Minocha	  A.	  Epidemiology	  of	  irritable	  bowel	  syndrome	  among	  
african	  americans	  as	  compared	  with	  whites:	  A	  population-­‐based	  study.	  Clin	  Gastroenterol	  Hepatol	  
2005,	  Jul;3(7):647-­‐53.	  
17.	  Minocha	  A,	  Johnson	  WD,	  Wigington	  WC.	  Prevalence	  of	  abdominal	  and	  pelvic	  surgeries	  in	  
patients	  with	  irritable	  bowel	  syndrome:	  Comparison	  between	  caucasian	  and	  african	  americans.	  Am	  J	  
Med	  Sci	  2008,	  Feb;335(2):82-­‐8.	  
18.	  Ng	  B,	  Dimsdale	  JE,	  Rollnik	  JD,	  Shapiro	  H.	  The	  effect	  of	  ethnicity	  on	  prescriptions	  for	  patient-­‐
controlled	  analgesia	  for	  post-­‐operative	  pain.	  Pain	  1996,	  Jul;66(1):9-­‐12.	  
19.	  Dimsdale	  JE.	  Stalked	  by	  the	  past:	  The	  influence	  of	  ethnicity	  on	  health.	  Psychosom	  Med	  
2000;62(2):161-­‐70.	  
20.	  Hahn	  BA,	  Yan	  S,	  Strassels	  S.	  Impact	  of	  irritable	  bowel	  syndrome	  on	  quality	  of	  life	  and	  resource	  
use	  in	  the	  united	  states	  and	  united	  kingdom.	  Digestion	  1999,	  Jan;60(1):77-­‐81.	  
21.	  Akehurst	  RL,	  Brazier	  JE,	  Mathers	  N,	  O'Keefe	  C,	  Kaltenthaler	  E,	  Morgan	  A,	  et	  al.	  Health-­‐Related	  







22.	  Gralnek	  IM,	  Hays	  RD,	  Kilbourne	  A,	  Naliboff	  B,	  Mayer	  EA.	  The	  impact	  of	  irritable	  bowel	  syndrome	  
on	  health-­‐related	  quality	  of	  life.	  Gastroenterology	  2000,	  Sep;119(3):654-­‐60.	  
23.	  Creed	  F,	  Ratcliffe	  J,	  Fernandez	  L,	  Tomenson	  B,	  Palmer	  S,	  Rigby	  C,	  et	  al.	  Health-­‐Related	  quality	  of	  
life	  and	  health	  care	  costs	  in	  severe,	  refractory	  irritable	  bowel	  syndrome.	  Ann	  Intern	  Med	  2001,	  May	  
1;134(9	  Pt	   	   2):860-­‐8.	  
24.	  Spiegel	  BM,	  Gralnek	  IM,	  Bolus	  R,	  Chang	  L,	  Dulai	  GS,	  Mayer	  EA,	  Naliboff	  B.	  Clinical	  determinants	  of	  
health-­‐related	  quality	  of	  life	  in	  patients	  with	  irritable	  bowel	  syndrome.	  Arch	  Intern	  Med	  2004,	  Sep	  
13;164(16):1773-­‐80.	  
25.	  Hungin	  AP,	  Whorwell	  PJ,	  Tack	  J,	  Mearin	  F.	  The	  prevalence,	  patterns	  and	  impact	  of	  irritable	  bowel	  
syndrome:	  An	  international	  survey	  of	  40,000	  subjects.	  Aliment	  Pharmacol	  Ther	  2003,	  Mar	  
1;17(5):643-­‐50.	  
26.	  Cain	  KC,	  Jarrett	  ME,	  Burr	  RL,	  Rosen	  S,	  Hertig	  VL,	  Heitkemper	  MM.	  Gender	  differences	  in	  
gastrointestinal,	  psychological,	  and	  somatic	  symptoms	  in	  irritable	  bowel	  syndrome.	  Dig	  Dis	  Sci	  2008,	  
Nov	  1.	  
27.	  Koloski	  NA,	  Talley	  NJ,	  Boyce	  PM.	  Does	  psychological	  distress	  modulate	  functional	  gastrointestinal	  
symptoms	  and	  health	  care	  seeking?	  A	  prospective,	  community	  cohort	  study.	  Am	  J	  Gastroenterol	  
2003,	  Apr;98(4):789-­‐97.	  
28.	  Longstreth	  GF,	  Yao	  JF.	  Irritable	  bowel	  syndrome	  and	  surgery:	  A	  multivariable	  analysis.	  
Gastroenterology	  2004,	  Jun;126(7):1665-­‐73.	  
29.	  Kennedy	  TM,	  Jones	  RH.	  Epidemiology	  of	  cholecystectomy	  and	  irritable	  bowel	  syndrome	  in	  a	  UK	  
population.	  Br	  J	  Surg	  2000,	  Dec;87(12):1658-­‐63.	  
30.	  Miller	  V,	  Hopkins	  L,	  Whorwell	  PJ.	  Suicidal	  ideation	  in	  patients	  with	  irritable	  bowel	  syndrome.	  Clin	  
Gastroenterol	  Hepatol	  2004,	  Dec;2(12):1064-­‐8.	  
31.	  Spiegel	  B,	  Schoenfeld	  P,	  Naliboff	  B.	  Systematic	  review:	  The	  prevalence	  of	  suicidal	  behaviour	  in	  







32.	  Maxion-­‐Bergemann	  S,	  Thielecke	  F,	  Abel	  F,	  Bergemann	  R.	  Costs	  of	  irritable	  bowel	  syndrome	  in	  the	  
UK	  and	  US.	  Pharmacoeconomics	  2006;24(1):21-­‐37.	  
33.	  sandler	  RS,	  Everhart	  JE,	  Donowitz	  M,	  Adams	  E,	  Cronin	  K,	  Goodman	  C,	  et	  al.	  The	  burden	  of	  
selected	  digestive	  diseases	  in	  the	  united	  states.	  Gastroenterology	  2002;122(5):1500-­‐11.	  
34.	  Bentkover	  JD,	  Field	  C,	  Greene	  EM,	  Plourde	  V,	  Casciano	  JP.	  The	  economic	  burden	  of	  irritable	  
bowel	  syndrome	  in	  canada.	  Can	  J	  Gastroenterol	  1999,	  Mar;13	  Suppl	  A:89A-­‐96A.	  
35.	  Sandler	  RS,	  Everhart	  JE,	  Donowitz	  M,	  Adams	  E,	  Cronin	  K,	  Goodman	  C,	  et	  al.	  The	  burden	  of	  
selected	  digestive	  diseases	  in	  the	  united	  states.	  Gastroenterology	  2002,	  May;122(5):1500-­‐11.	  
36.	  Drossman	  DA.	  The	  functional	  gastrointestinal	  disorders	  and	  the	  rome	  III	  process.	  
Gastroenterology	  2006;130(5):1377-­‐90.	  
37.	  Kruis	  W,	  Thieme	  C,	  Weinzierl	  M,	  Schüssler	  P,	  Holl	  J,	  Paulus	  W.	  A	  diagnostic	  score	  for	  the	  irritable	  
bowel	  syndrome.	  Its	  value	  in	  the	  exclusion	  of	  organic	  disease.	  Gastroenterology	  1984,	  Jul;87(1):1-­‐7.	  
38.	  Manning	  AP,	  Thompson	  WG,	  Heaton	  KW,	  Morris	  AF.	  Towards	  positive	  diagnosis	  of	  the	  irritable	  
bowel.	  Br	  Med	  J	  1978,	  Sep	  2;2(6138):653-­‐4.	  
39.	  Mearin	  X	  Bad&	  x	  000	  ED	  a	  A	  Balboa	  F.	  Irritable	  bowel	  syndrome	  prevalence	  varies	  enormously	  
depending	  on	  the	  employed	  diagnostic	  criteria:	  Comparison	  of	  rome	  II	  versus	  previous	  criteria	  in	  a	  
general	  population.	  Scand	  J	  Gastroenterol	  2001;36(11):1155-­‐61.	  
40.	  Boyce	  PM,	  Koloski	  NA,	  Talley	  NJ.	  Irritable	  bowel	  syndrome	  according	  to	  varying	  diagnostic	  
criteria:	  Are	  the	  new	  rome	  II	  criteria	  unnecessarily	  restrictive	  for	  research	  and	  practice?	  Am	  J	  
Gastroenterol	  2000,	  Nov;95(11):3176-­‐83.	  
41.	  Sperber	  AD,	  Shvartzman	  P,	  Friger	  M,	  Fich	  A.	  Unexpectedly	  low	  prevalence	  rates	  of	  IBS	  among	  
adult	  israeli	  jews.	  Neurogastroenterol	  Motil	  2005,	  Apr;17(2):207-­‐11.	  
42.	  Hammer	  J,	  Eslick	  GD,	  Howell	  SC,	  Altiparmak	  E,	  Talley	  NJ.	  Diagnostic	  yield	  of	  alarm	  features	  in	  






43.	  Vanner	  SJ,	  Depew	  WT,	  Paterson	  WG,	  DaCosta	  LR,	  Groll	  AG,	  Simon	  JB,	  Djurfeldt	  M.	  Predictive	  
value	  of	  the	  rome	  criteria	  for	  diagnosing	  the	  irritable	  bowel	  syndrome.	  Am	  J	  Gastroenterol	  1999,	  
Oct;94(10):2912-­‐7.	  
44.	  Stewart	  M,	  Brown	  JB,	  Donner	  A,	  McWhinney	  IR,	  Oates	  J,	  Weston	  WW,	  Jordan	  J.	  The	  impact	  of	  
patient-­‐centered	  care	  on	  outcomes.	  J	  Fam	  Pract	  2000,	  Sep;49(9):796-­‐804.	  
45.	  Roter	  DL,	  Hall	  JA,	  Merisca	  R,	  Nordstrom	  B,	  Cretin	  D,	  Svarstad	  B.	  Effectiveness	  of	  interventions	  to	  
improve	  patient	  compliance:	  A	  meta-­‐analysis.	  Med	  Care	  1998,	  Aug;36(8):1138-­‐61.	  
46.	  Drossman	  DA,	  Morris	  CB,	  Hu	  Y,	  Toner	  BB,	  Diamant	  N,	  Leserman	  J,	  et	  al.	  A	  prospective	  assessment	  
of	  bowel	  habit	  in	  irritable	  bowel	  syndrome	  in	  women:	  Defining	  an	  alternator.	  Gastroenterology	  
2005,	  Mar;128(3):580-­‐9.	  
47.	  Garrigues	  V,	  Mearin	  F,	  Badía	  X,	  Balboa	  A,	  Benavent	  J,	  Caballero	  A,	  et	  al.	  Change	  over	  time	  of	  
bowel	  habit	  in	  irritable	  bowel	  syndrome:	  A	  prospective,	  observational,	  1-­‐year	  follow-­‐up	  study	  
(RITMO	  study).	  Aliment	  Pharmacol	  Ther	  2007,	  Feb	  1;25(3):323-­‐32.	  
48.	  Waller	  SL,	  Misiewicz	  JJ.	  Prognosis	  in	  the	  irritable-­‐bowel	  syndrome.	  A	  prospective	  study.	  Lancet	  
1969,	  Oct	  11;2(7624):754-­‐6.	  
49.	  Talley	  NJ,	  Weaver	  AL,	  Zinsmeister	  AR,	  Melton	  LJ.	  Onset	  and	  disappearance	  of	  gastrointestinal	  
symptoms	  and	  functional	  gastrointestinal	  disorders.	  Am	  J	  Epidemiol	  1992,	  Jul	  15;136(2):165-­‐77.	  
50.	  Lembo	  T,	  Fullerton	  S,	  Diehl	  D,	  Raeen	  H,	  Munakata	  J,	  Naliboff	  B,	  Mayer	  EA.	  Symptom	  duration	  in	  
patients	  with	  irritable	  bowel	  syndrome.	  Am	  J	  Gastroenterol	  1996,	  May;91(5):898-­‐905.	  
51.	  Locke	  GR,	  Zinsmeister	  AR,	  Fett	  SL,	  Melton	  LJ,	  Talley	  NJ.	  Overlap	  of	  gastrointestinal	  symptom	  
complexes	  in	  a	  US	  community.	  Neurogastroenterol	  Motil	  2005,	  Feb;17(1):29-­‐34.	  
52.	  Agréus	  L,	  Svärdsudd	  K,	  Nyrén	  O,	  Tibblin	  G.	  Irritable	  bowel	  syndrome	  and	  dyspepsia	  in	  the	  general	  
population:	  Overlap	  and	  lack	  of	  stability	  over	  time.	  Gastroenterology	  1995,	  Sep;109(3):671-­‐80.	  
53.	  Halder	  SL,	  Locke	  GR,	  Schleck	  CD,	  Zinsmeister	  AR,	  Melton	  LJ,	  Talley	  NJ.	  Natural	  history	  of	  
functional	  gastrointestinal	  disorders:	  A	  12-­‐year	  longitudinal	  population-­‐based	  study.	  






54.	  Whorwell	  PJ,	  McCallum	  M,	  Creed	  FH,	  Roberts	  CT.	  Non-­‐Colonic	  features	  of	  irritable	  bowel	  
syndrome.	  Gut	  1986,	  Jan;27(1):37-­‐40.	  
55.	  Whitehead	  WE,	  Palsson	  O,	  Jones	  KR.	  Systematic	  review	  of	  the	  comorbidity	  of	  irritable	  bowel	  
syndrome	  with	  other	  disorders:	  What	  are	  the	  causes	  and	  implications?	  Gastroenterology	  2002,	  
Apr;122(4):1140-­‐56.	  
56.	  MacDonald	  AJ,	  Bouchier	  IA.	  Non-­‐Organic	  gastrointestinal	  illness:	  A	  medical	  and	  psychiatric	  study.	  
Br	  J	  Psychiatry	  1980,	  Mar;136:276-­‐83.	  
57.	  Colgan	  S,	  Creed	  F,	  Klass	  H.	  Symptom	  complaints,	  psychiatric	  disorder	  and	  abnormal	  illness	  
behaviour	  in	  patients	  with	  upper	  abdominal	  pain.	  Psychol	  Med	  1988,	  Nov;18(4):887-­‐92.	  
58.	  Craig	  TK,	  Brown	  GW.	  Goal	  frustration	  and	  life	  events	  in	  the	  aetiology	  of	  painful	  gastrointestinal	  
disorder.	  J	  Psychosom	  Res	  1984;28(5):411-­‐21.	  
59.	  Ford	  MJ,	  Miller	  PM,	  Eastwood	  J,	  Eastwood	  MA.	  Life	  events,	  psychiatric	  illness	  and	  the	  irritable	  
bowel	  syndrome.	  Gut	  1987,	  Feb;28(2):160-­‐5.	  
60.	  Toner	  BB,	  Garfinkel	  PE,	  Jeejeebhoy	  KN.	  Psychological	  factors	  in	  irritable	  bowel	  syndrome.	  Can	  J	  
Psychiatry	  1990,	  Mar;35(2):158-­‐61.	  
61.	  Drossman	  DA,	  McKee	  DC,	  Sandler	  RS,	  Mitchell	  CM,	  Cramer	  EM,	  Lowman	  BC,	  Burger	  AL.	  
Psychosocial	  factors	  in	  the	  irritable	  bowel	  syndrome.	  A	  multivariate	  study	  of	  patients	  and	  
nonpatients	  with	  irritable	  bowel	  syndrome.	  Gastroenterology	  1988,	  Sep;95(3):701-­‐8.	  
62.	  Sandler	  RS,	  Drossman	  DA,	  Nathan	  HP,	  McKee	  DC.	  Symptom	  complaints	  and	  health	  care	  seeking	  
behavior	  in	  subjects	  with	  bowel	  dysfunction.	  Gastroenterology	  1984,	  Aug;87(2):314-­‐8.	  
63.	  Kettell	  J,	  Jones	  R,	  Lydeard	  S.	  Reasons	  for	  consultation	  in	  irritable	  bowel	  syndrome:	  Symptoms	  
and	  patient	  characteristics.	  Br	  J	  Gen	  Pract	  1992,	  Nov;42(364):459-­‐61.	  







65.	  Whitehead	  WE,	  Crowell	  MD,	  Robinson	  JC,	  Heller	  BR,	  Schuster	  MM.	  Effects	  of	  stressful	  life	  events	  
on	  bowel	  symptoms:	  Subjects	  with	  irritable	  bowel	  syndrome	  compared	  with	  subjects	  without	  bowel	  
dysfunction.	  Gut	  1992,	  Jun;33(6):825-­‐30.	  
66.	  Bennett	  EJ,	  Tennant	  CC,	  Piesse	  C,	  Badcock	  CA,	  Kellow	  JE.	  Level	  of	  chronic	  life	  stress	  predicts	  
clinical	  outcome	  in	  irritable	  bowel	  syndrome.	  Gut	  1998,	  Aug;43(2):256-­‐61.	  
67.	  Drossman	  DA,	  Leserman	  J,	  Nachman	  G,	  Li	  ZM,	  Gluck	  H,	  Toomey	  TC,	  Mitchell	  CM.	  Sexual	  and	  
physical	  abuse	  in	  women	  with	  functional	  or	  organic	  gastrointestinal	  disorders.	  Ann	  Intern	  Med	  1990,	  
Dec	  1;113(11):828-­‐33.	  
68.	  Talley	  NJ,	  Fett	  SL,	  Zinsmeister	  AR,	  Melton	  LJ.	  Gastrointestinal	  tract	  symptoms	  and	  self-­‐reported	  
abuse:	  A	  population-­‐based	  study.	  Gastroenterology	  1994,	  Oct;107(4):1040-­‐9.	  
69.	  Talley	  NJ,	  Fett	  SL,	  Zinsmeister	  AR.	  Self-­‐Reported	  abuse	  and	  gastrointestinal	  disease	  in	  
outpatients:	  Association	  with	  irritable	  bowel-­‐type	  symptoms.	  Am	  J	  Gastroenterol	  1995,	  
Mar;90(3):366-­‐71.	  
70.	  Leroi	  AM,	  Bernier	  C,	  Watier	  A,	  Hémond	  M,	  Goupil	  G,	  Black	  R,	  et	  al.	  Prevalence	  of	  sexual	  abuse	  
among	  patients	  with	  functional	  disorders	  of	  the	  lower	  gastrointestinal	  tract.	  Int	  J	  Colorectal	  Dis	  
1995;10(4):200-­‐6.	  
71.	  Gwee	  KA,	  Graham	  JC,	  McKendrick	  MW,	  Collins	  SM,	  Marshall	  JS,	  Walters	  SJ,	  Read	  NW.	  
Psychometric	  scores	  and	  persistence	  of	  irritable	  bowel	  after	  infectious	  diarrhoea.	  Lancet	  1996,	  Jan	  
20;347(8995):150-­‐3.	  
72.	  Neal	  KR,	  Barker	  L,	  Spiller	  RC.	  Prognosis	  in	  post-­‐infective	  irritable	  bowel	  syndrome:	  A	  six	  year	  
follow	  up	  study.	  Gut	  2002,	  Sep;51(3):410-­‐3.	  
73.	  Whitehead	  WE,	  Bosmajian	  L,	  Zonderman	  AB,	  Costa	  PT,	  Schuster	  MM.	  Symptoms	  of	  psychologic	  
distress	  associated	  with	  irritable	  bowel	  syndrome.	  Comparison	  of	  community	  and	  medical	  clinic	  
samples.	  Gastroenterology	  1988,	  Sep;95(3):709-­‐14.	  
74.	  Abell	  TL,	  Cutts	  TF,	  Cooper	  T.	  Effect	  of	  cisapride	  therapy	  for	  severe	  dyspepsia	  on	  gastrointestinal	  






75.	  Talley	  NJ,	  Boyce	  PM,	  Jones	  M.	  Is	  the	  association	  between	  irritable	  bowel	  syndrome	  and	  abuse	  
explained	  by	  neuroticism?	  A	  population	  based	  study.	  Gut	  1998,	  Jan;42(1):47-­‐53.	  
76.	  Chang	  L.	  Review	  article:	  Epidemiology	  and	  quality	  of	  life	  in	  functional	  gastrointestinal	  disorders.	  
Aliment	  Pharmacol	  Ther	  2004,	  Nov;20	  Suppl	  7:31-­‐9.	  
77.	  Paganelli	  R,	  Quinti	  I,	  D'Offizi	  GP,	  Papetti	  C,	  Carini	  C,	  Aiuti	  F.	  Immune	  complexes	  in	  food	  allergy:	  A	  
critical	  reappraisal.	  Annals	  of	  Allergy	  1987;59(5	  Pt	  2):157.	  
78.	  Chandra	  RK.	  Food	  hypersensitivity	  and	  allergic	  disease:	  A	  selective	  review.	  Am	  J	  Clin	  Nutr	  1997,	  
Aug;66(2):526S-­‐9S.	  
79.	  Burr	  ML,	  Merrett	  TG.	  Food	  intolerance:	  A	  community	  survey.	  British	  Journal	  of	  Nutrition	  
1983;49(02):217-­‐.	  
80.	  Farup	  PG,	  Monsbakken	  KW,	  Vandvik	  PO.	  Lactose	  malabsorption	  in	  a	  population	  with	  irritable	  
bowel	  syndrome:	  Prevalence	  and	  symptoms.	  A	  case-­‐control	  study.	  Scand	  J	  Gastroenterol	  2004,	  
Jul;39(7):645-­‐9.	  
81.	  Turnbull	  GK.	  Lactose	  intolerance	  and	  irritable	  bowel	  syndrome.	  Nutrition	  2000;16(7-­‐8):665-­‐6.	  
82.	  Sciarretta	  G,	  Giacobazzi	  G,	  Verri	  A,	  Zanirato	  P,	  Garuti	  G,	  Malaguti	  P.	  Hydrogen	  breath	  test	  
quantification	  and	  clinical	  correlation	  of	  lactose	  malabsorption	  in	  adult	  irritable	  bowel	  syndrome	  and	  
ulcerative	  colitis.	  Dig	  Dis	  Sci	  1984,	  Dec;29(12):1098-­‐104.	  
83.	  Parker	  TJ,	  Woolner	  JT,	  Prevost	  AT,	  Tuffnell	  Q,	  Shorthouse	  M,	  Hunter	  JO.	  Irritable	  bowel	  
syndrome:	  Is	  the	  search	  for	  lactose	  intolerance	  justified?	  Eur	  J	  Gastroenterol	  Hepatol	  2001,	  
Mar;13(3):219-­‐25.	  
84.	  CHAUDHARY	  NA,	  TRUELOVE	  SC.	  The	  irritable	  colon	  syndrome.	  A	  study	  of	  the	  clinical	  features,	  
predisposing	  causes,	  and	  prognosis	  in	  130	  cases.	  Q	  J	  Med	  1962,	  Jul;31:307-­‐22.	  
85.	  Isgar	  B,	  Harman	  M,	  Kaye	  MD,	  Whorwell	  PJ.	  Symptoms	  of	  irritable	  bowel	  syndrome	  in	  ulcerative	  






86.	  Minderhoud	  IM,	  Oldenburg	  B,	  Wismeijer	  JA,	  van	  Berge	  Henegouwen	  GP,	  Smout	  AJ.	  Ibs-­‐Like	  
symptoms	  in	  patients	  with	  inflammatory	  bowel	  disease	  in	  remission;	  relationships	  with	  quality	  of	  life	  
and	  coping	  behavior.	  Dig	  Dis	  Sci	  2004,	  Mar;49(3):469-­‐74.	  
87.	  Simrén	  M,	  Axelsson	  J,	  Gillberg	  R,	  Abrahamsson	  H,	  Svedlund	  J,	  Björnsson	  ES.	  Quality	  of	  life	  in	  
inflammatory	  bowel	  disease	  in	  remission:	  The	  impact	  of	  ibs-­‐like	  symptoms	  and	  associated	  
psychological	  factors.	  Am	  J	  Gastroenterol	  2002,	  Feb;97(2):389-­‐96.	  
88.	  Collins	  SM,	  Piche	  T,	  Rampal	  P.	  The	  putative	  role	  of	  inflammation	  in	  the	  irritable	  bowel	  syndrome.	  
Gut	  2001,	  Dec;49(6):743-­‐5.	  
89.	  Loening-­‐Baucke	  V,	  Metcalf	  AM,	  Shirazi	  S.	  Rectosigmoid	  motility	  in	  patients	  with	  quiescent	  and	  
active	  ulcerative	  colitis.	  Am	  J	  Gastroenterol	  1989,	  Jan;84(1):34-­‐9.	  
90.	  Thaysen	  EH,	  Pedersen	  L.	  Idiopathic	  bile	  acid	  catharsis.	  Gut	  1976,	  Dec;17(12):965-­‐70.	  
91.	  Smith	  MJ,	  Cherian	  P,	  Raju	  GS,	  Dawson	  BF,	  Mahon	  S,	  Bardhan	  KD.	  Bile	  acid	  malabsorption	  in	  
persistent	  diarrhoea.	  J	  R	  Coll	  Physicians	  Lond	  2000;34(5):448-­‐51.	  
92.	  Merrick	  MV,	  Eastwood	  MA,	  Ford	  MJ.	  Is	  bile	  acid	  malabsorption	  underdiagnosed?	  An	  evaluation	  
of	  accuracy	  of	  diagnosis	  by	  measurement	  of	  sehcat	  retention.	  Br	  Med	  J	  (Clin	  Res	  Ed)	  1985,	  Mar	  
2;290(6469):665-­‐8.	  
93.	  Sinha	  L,	  Liston	  R,	  Testa	  HJ,	  Moriarty	  KJ.	  Idiopathic	  bile	  acid	  malabsorption:	  Qualitative	  and	  
quantitative	  clinical	  features	  and	  response	  to	  cholestyramine.	  Aliment	  Pharmacol	  Ther	  1998,	  
Sep;12(9):839-­‐44.	  
94.	  Cash	  BD,	  Schoenfeld	  P,	  Chey	  WD.	  The	  utility	  of	  diagnostic	  tests	  in	  irritable	  bowel	  syndrome	  
patients:	  A	  systematic	  review.	  Am	  J	  Gastroenterol	  2002,	  Nov;97(11):2812-­‐9.	  
95.	  NSC	  NCC.	  Irritable	  bowel	  syndrome:	  NICE	  guideline.	  .	  
96.	  Longstreth	  GF,	  Drossman	  DA.	  Severe	  irritable	  bowel	  and	  functional	  abdominal	  pain	  syndromes:	  
Managing	  the	  patient	  and	  health	  care	  costs.	  Clin	  Gastroenterol	  Hepatol	  2005,	  Apr;3(4):397-­‐400.	  
97.	  O'Sullivan	  MA,	  Mahmud	  N,	  Kelleher	  DP,	  Lovett	  E,	  O'Morain	  CA.	  Patient	  knowledge	  and	  






98.	  Owens	  DM,	  Nelson	  DK,	  Talley	  NJ.	  The	  irritable	  bowel	  syndrome:	  Long-­‐Term	  prognosis	  and	  the	  
physician-­‐patient	  interaction.	  Ann	  Intern	  Med	  1995,	  Jan	  15;122(2):107-­‐12.	  
99.	  Whitehead	  WE,	  Levy	  RL,	  Von	  Korff	  M,	  Feld	  AD,	  Palsson	  OS,	  Turner	  M,	  Drossman	  DA.	  The	  usual	  
medical	  care	  for	  irritable	  bowel	  syndrome.	  Aliment	  Pharmacol	  Ther	  2004,	  Dec;20(11-­‐12):1305-­‐15.	  
100.	  Thompson	  WG,	  Heaton	  KW,	  Smyth	  GT,	  Smyth	  C.	  Irritable	  bowel	  syndrome	  in	  general	  practice:	  
Prevalence,	  characteristics,	  and	  referral.	  Gut	  2000,	  Jan;46(1):78-­‐82.	  
101.	  Heitkemper	  MM,	  Jarrett	  ME,	  Levy	  RL,	  Cain	  KC,	  Burr	  RL,	  Feld	  A,	  et	  al.	  Self-­‐Management	  for	  
women	  with	  irritable	  bowel	  syndrome.	  Clin	  Gastroenterol	  Hepatol	  2004,	  Jul;2(7):585-­‐96.	  
102.	  Saito	  YA,	  Prather	  CM,	  Van	  Dyke	  CT,	  Fett	  S,	  Zinsmeister	  AR,	  Locke	  GR.	  Effects	  of	  multidisciplinary	  
education	  on	  outcomes	  in	  patients	  with	  irritable	  bowel	  syndrome.	  Clin	  Gastroenterol	  Hepatol	  2004,	  
Jul;2(7):576-­‐84.	  
103.	  Harvey	  RF,	  Pomare	  EW,	  Heaton	  KW.	  Effects	  of	  increased	  dietary	  fibre	  on	  intestinal	  transit.	  
Lancet	  1973,	  Jun	  9;1(7815):1278-­‐80.	  
104.	  Francis	  CY,	  Whorwell	  PJ.	  Bran	  and	  irritable	  bowel	  syndrome:	  Time	  for	  reappraisal.	  Lancet	  1994,	  
Jul	  2;344(8914):39-­‐40.	  
105.	  Lewis	  MJ,	  Whorwell	  PJ.	  Bran:	  May	  irritate	  irritable	  bowel.	  Nutrition	  1998,	  May;14(5):470-­‐1.	  
106.	  Suarez	  FL,	  Savaiano	  DA,	  Levitt	  MD.	  A	  comparison	  of	  symptoms	  after	  the	  consumption	  of	  milk	  or	  
lactose-­‐hydrolyzed	  milk	  by	  people	  with	  self-­‐reported	  severe	  lactose	  intolerance.	  N	  Engl	  J	  Med	  1995,	  
Jul	  6;333(1):1-­‐4.	  
107.	  Attar	  A,	  Lémann	  M,	  Ferguson	  A,	  Halphen	  M,	  Boutron	  MC,	  Flourié	  B,	  et	  al.	  Comparison	  of	  a	  low	  
dose	  polyethylene	  glycol	  electrolyte	  solution	  with	  lactulose	  for	  treatment	  of	  chronic	  constipation.	  
Gut	  1999,	  Feb;44(2):226-­‐30.	  
108.	  Davis	  K,	  Philpott	  S,	  Kumar	  D,	  Mendall	  M.	  Randomised	  double-­‐blind	  placebo-­‐controlled	  trial	  of	  






109.	  van	  Tilburg	  MA,	  Palsson	  OS,	  Levy	  RL,	  Feld	  AD,	  Turner	  MJ,	  Drossman	  DA,	  Whitehead	  WE.	  
Complementary	  and	  alternative	  medicine	  use	  and	  cost	  in	  functional	  bowel	  disorders:	  A	  six	  month	  
prospective	  study	  in	  a	  large	  HMO.	  BMC	  Complement	  Altern	  Med	  2008,	  Jul	  24;8(1):46.	  
110.	  Schneider	  A,	  Enck	  P,	  Streitberger	  K,	  Weiland	  C,	  Bagheri	  S,	  Witte	  S,	  et	  al.	  Acupuncture	  treatment	  
in	  irritable	  bowel	  syndrome.	  Gut	  2006,	  May;55(5):649-­‐54.	  
111.	  Tovey	  P.	  A	  single-­‐blind	  trial	  of	  reflexology	  for	  irritable	  bowel	  syndrome.	  Br	  J	  Gen	  Pract	  2002,	  
Jan;52(474):19-­‐23.	  
112.	  Amery	  W,	  Duyck	  F,	  Polak	  J,	  van	  den	  Bouwhuysen	  G.	  A	  multicentre	  double-­‐blind	  study	  in	  acute	  
diarrhoea	  comparing	  loperamide	  (R	  18553)	  with	  two	  common	  antidiarrhoeal	  agents	  and	  a	  placebo.	  
Curr	  Ther	  Res	  Clin	  Exp	  1975,	  Mar;17(3):263-­‐70.	  
113.	  Harford	  WV,	  Krejs	  GJ,	  Santa	  Ana	  CA,	  Fordtran	  JS.	  Acute	  effect	  of	  diphenoxylate	  with	  atropine	  
(lomotil)	  in	  patients	  with	  chronic	  diarrhea	  and	  fecal	  incontinence.	  Gastroenterology	  1980,	  
Mar;78(3):440-­‐3.	  
114.	  Lustman	  F,	  Walters	  EG,	  Shroff	  NE,	  Akbar	  FA.	  Diphenoxylate	  hydrochloride	  (lomotil)	  in	  the	  
treatment	  of	  acute	  diarrhoea.	  Br	  J	  Clin	  Pract	  1987,	  Mar;41(3):648-­‐51.	  
115.	  Quartero	  AO,	  Meineche-­‐Schmidt	  V,	  Muris	  J,	  Rubin	  G,	  de	  Wit	  N.	  Bulking	  agents,	  antispasmodic	  
and	  antidepressant	  medication	  for	  the	  treatment	  of	  irritable	  bowel	  syndrome.	  Cochrane	  Database	  
Syst	  Rev	  2005(2):CD003460.	  
116.	  Poynard	  T,	  Naveau	  S,	  Mory	  B,	  Chaput	  JC.	  Meta-­‐Analysis	  of	  smooth	  muscle	  relaxants	  in	  the	  
treatment	  of	  irritable	  bowel	  syndrome.	  Aliment	  Pharmacol	  Ther	  1994,	  Oct;8(5):499-­‐510.	  
117.	  Klein	  KB.	  Controlled	  treatment	  trials	  in	  the	  irritable	  bowel	  syndrome:	  A	  critique.	  
Gastroenterology	  1988,	  Jul;95(1):232-­‐41.	  
118.	  Jailwala	  J,	  Imperiale	  TF,	  Kroenke	  K.	  Pharmacologic	  treatment	  of	  the	  irritable	  bowel	  syndrome:	  A	  
systematic	  review	  of	  randomized,	  controlled	  trials.	  Ann	  Intern	  Med	  2000,	  Jul	  18;133(2):136-­‐47.	  
119.	  Poynard	  T,	  Regimbeau	  C,	  Benhamou	  Y.	  Meta-­‐Analysis	  of	  smooth	  muscle	  relaxants	  in	  the	  






120.	  Drossman	  DA,	  Toner	  BB,	  Whitehead	  WE,	  Diamant	  NE,	  Dalton	  CB,	  Duncan	  S,	  et	  al.	  Cognitive-­‐
Behavioral	  therapy	  versus	  education	  and	  desipramine	  versus	  placebo	  for	  moderate	  to	  severe	  
functional	  bowel	  disorders.	  Gastroenterology	  2003,	  Jul;125(1):19-­‐31.	  
121.	  Fioramonti	  J,	  Bueno	  L.	  Centrally	  acting	  agents	  and	  visceral	  sensitivity.	  Gut	  2002,	  Jul;51	  Suppl	  
1:i91-­‐5.	  
122.	  Drossman	  DA,	  Camilleri	  M,	  Mayer	  EA,	  Whitehead	  WE.	  AGA	  technical	  review	  on	  irritable	  bowel	  
syndrome.	  Gastroenterology	  2002,	  Dec;123(6):2108-­‐31.	  
123.	  Jackson	  JL,	  O'Malley	  PG,	  Tomkins	  G,	  Balden	  E,	  Santoro	  J,	  Kroenke	  K.	  Treatment	  of	  functional	  
gastrointestinal	  disorders	  with	  antidepressant	  medications:	  A	  meta-­‐analysis.	  Am	  J	  Med	  2000,	  
Jan;108(1):65-­‐72.	  
124.	  Creed	  F,	  Fernandes	  L,	  Guthrie	  E,	  Palmer	  S,	  Ratcliffe	  J,	  Read	  N,	  et	  al.	  The	  cost-­‐effectiveness	  of	  
psychotherapy	  and	  paroxetine	  for	  severe	  irritable	  bowel	  syndrome.	  Gastroenterology	  2003,	  
Feb;124(2):303-­‐17.	  
125.	  Kuiken	  SD,	  Tytgat	  GN,	  Boeckxstaens	  GE.	  The	  selective	  serotonin	  reuptake	  inhibitor	  fluoxetine	  
does	  not	  change	  rectal	  sensitivity	  and	  symptoms	  in	  patients	  with	  irritable	  bowel	  syndrome:	  A	  double	  
blind,	  randomized,	  placebo-­‐controlled	  study.	  Clin	  Gastroenterol	  Hepatol	  2003,	  May;1(3):219-­‐28.	  
126.	  Tabas	  G,	  Beaves	  M,	  Wang	  J,	  Friday	  P,	  Mardini	  H,	  Arnold	  G.	  Paroxetine	  to	  treat	  irritable	  bowel	  
syndrome	  not	  responding	  to	  high-­‐fiber	  diet:	  A	  double-­‐blind,	  placebo-­‐controlled	  trial.	  Am	  J	  
Gastroenterol	  2004,	  May;99(5):914-­‐20.	  
127.	  Tack	  J,	  Broekaert	  D,	  Fischler	  B,	  Van	  Oudenhove	  L,	  Gevers	  AM,	  Janssens	  J.	  A	  controlled	  crossover	  
study	  of	  the	  selective	  serotonin	  reuptake	  inhibitor	  citalopram	  in	  irritable	  bowel	  syndrome.	  Gut	  2006,	  
Aug;55(8):1095-­‐103.	  
128.	  Robinson	  A,	  Lee	  V,	  Kennedy	  A,	  Middleton	  L,	  Rogers	  A,	  Thompson	  DG,	  Reeves	  D.	  A	  randomised	  
controlled	  trial	  of	  self-­‐help	  interventions	  in	  patients	  with	  a	  primary	  care	  diagnosis	  of	  irritable	  bowel	  






129.	  Lacy	  BE,	  Weiser	  K,	  Noddin	  L,	  Robertson	  DJ,	  Crowell	  MD,	  Parratt-­‐Engstrom	  C,	  Grau	  MV.	  Irritable	  
bowel	  syndrome:	  Patients'	  attitudes,	  concerns	  and	  level	  of	  knowledge.	  Aliment	  Pharmacol	  Ther	  
2007,	  Jun	  1;25(11):1329-­‐41.	  
130.	  Kennedy	  A,	  Robinson	  A,	  Rogers	  A.	  Incorporating	  patients'	  views	  and	  experiences	  of	  life	  with	  IBS	  
in	  the	  development	  of	  an	  evidence	  based	  self-­‐help	  guidebook.	  Patient	  Educ	  Couns	  2003,	  
Jul;50(3):303-­‐10.	  
131.	  Kennedy	  A,	  Rogers	  A,	  Bower	  P.	  Support	  for	  self	  care	  for	  patients	  with	  chronic	  disease.	  BMJ	  
2007,	  Nov	  10;335(7627):968-­‐70.	  
132.	  Forbes	  A,	  MacAuley	  S,	  Chiotakakou-­‐Faliakou	  E.	  Hypnotherapy	  and	  therapeutic	  audiotape:	  
Effective	  in	  previously	  unsuccessfully	  treated	  irritable	  bowel	  syndrome?	  Int	  J	  Colorectal	  Dis	  2000,	  
Nov;15(5-­‐6):328-­‐34.	  
133.	  Tan	  G,	  Hammond	  DC,	  Joseph	  G.	  Hypnosis	  and	  irritable	  bowel	  syndrome:	  A	  review	  of	  efficacy	  
and	  mechanism	  of	  action.	  Am	  J	  Clin	  Hypn	  2005,	  Jan;47(3):161-­‐78.	  
134.	  Palsson	  OS,	  Whitehead	  WE.	  The	  growing	  case	  for	  hypnosis	  as	  adjunctive	  therapy	  for	  functional	  
gastrointestinal	  disorders.	  Gastroenterology	  2002,	  Dec;123(6):2132-­‐5.	  
135.	  Palsson	  OS,	  Turner	  MJ,	  Whitehead	  WE.	  Hypnosis	  home	  treatment	  for	  irritable	  bowel	  syndrome:	  
A	  pilot	  study.	  Int	  J	  Clin	  Exp	  Hypn	  2006,	  Jan;54(1):85-­‐99.	  
136.	  Gonsalkorale	  WM,	  Miller	  V,	  Afzal	  A,	  Whorwell	  PJ.	  Long	  term	  benefits	  of	  hypnotherapy	  for	  
irritable	  bowel	  syndrome.	  Gut	  2003,	  Nov;52(11):1623-­‐9.	  
137.	  Prior	  A,	  Colgan	  SM,	  Whorwell	  PJ.	  Changes	  in	  rectal	  sensitivity	  after	  hypnotherapy	  in	  patients	  
with	  irritable	  bowel	  syndrome.	  Gut	  1990,	  Aug;31(8):896-­‐8.	  
138.	  Lea	  R,	  Houghton	  LA,	  Calvert	  EL,	  Larder	  S,	  Gonsalkorale	  WM,	  Whelan	  V,	  et	  al.	  Gut-­‐Focused	  
hypnotherapy	  normalizes	  disordered	  rectal	  sensitivity	  in	  patients	  with	  irritable	  bowel	  syndrome.	  
Aliment	  Pharmacol	  Ther	  2003,	  Mar	  1;17(5):635-­‐42.	  
139.	  Gonsalkorale	  WM,	  Toner	  BB,	  Whorwell	  PJ.	  Cognitive	  change	  in	  patients	  undergoing	  






140.	  Gonsalkorale	  WM,	  Houghton	  LA,	  Whorwell	  PJ.	  Hypnotherapy	  in	  irritable	  bowel	  syndrome:	  A	  
large-­‐scale	  audit	  of	  a	  clinical	  service	  with	  examination	  of	  factors	  influencing	  responsiveness.	  Am	  J	  
Gastroenterol	  2002,	  Apr;97(4):954-­‐61.	  
141.	  Toner	  BB,	  Segal	  ZV,	  Emmott	  S,	  Myran	  D,	  Ali	  A,	  DiGasbarro	  I,	  Stuckless	  N.	  Cognitive-­‐Behavioral	  
group	  therapy	  for	  patients	  with	  irritable	  bowel	  syndrome.	  Int	  J	  Group	  Psychother	  1998,	  
Apr;48(2):215-­‐43.	  
142.	  Levy	  RL,	  Olden	  KW,	  Naliboff	  BD,	  Bradley	  LA,	  Francisconi	  C,	  Drossman	  DA,	  Creed	  F.	  Psychosocial	  
aspects	  of	  the	  functional	  gastrointestinal	  disorders.	  Gastroenterology	  2006,	  Apr;130(5):1447-­‐58.	  
143.	  Bennett	  P,	  Wilkinson	  S.	  A	  comparison	  of	  psychological	  and	  medical	  treatment	  of	  the	  irritable	  
bowel	  syndrome.	  Br	  J	  Clin	  Psychol	  1985,	  Sep;24	  (	  Pt	  3):215-­‐6.	  
144.	  Greene	  B,	  Blanchard	  EB.	  Cognitive	  therapy	  for	  irritable	  bowel	  syndrome.	  J	  Consult	  Clin	  Psychol	  
1994,	  Jun;62(3):576-­‐82.	  
145.	  Payne	  A,	  Blanchard	  EB.	  A	  controlled	  comparison	  of	  cognitive	  therapy	  and	  self-­‐help	  support	  
groups	  in	  the	  treatment	  of	  irritable	  bowel	  syndrome.	  J	  Consult	  Clin	  Psychol	  1995,	  Oct;63(5):779-­‐86.	  
146.	  Svedlund	  J,	  Sjödin	  I,	  Ottosson	  JO,	  Dotevall	  G.	  Controlled	  study	  of	  psychotherapy	  in	  irritable	  
bowel	  syndrome.	  Lancet	  1983,	  Sep	  10;2(8350):589-­‐92.	  
147.	  Guthrie	  E,	  Creed	  F,	  Dawson	  D,	  Tomenson	  B.	  A	  controlled	  trial	  of	  psychological	  treatment	  for	  the	  
irritable	  bowel	  syndrome.	  Gastroenterology	  1991,	  Feb;100(2):450-­‐7.	  
148.	  Guthrie	  E,	  Barlow	  J,	  Fernandes	  L,	  Ratcliffe	  J,	  Read	  N,	  Thompson	  DG,	  et	  al.	  Changes	  in	  tolerance	  
to	  rectal	  distension	  correlate	  with	  changes	  in	  psychological	  state	  in	  patients	  with	  severe	  irritable	  
bowel	  syndrome.	  Psychosom	  Med	  2004;66(4):578-­‐82.	  
149.	  Creed	  F,	  Guthrie	  E,	  Ratcliffe	  J,	  Fernandes	  L,	  Rigby	  C,	  Tomenson	  B,	  et	  al.	  Reported	  sexual	  abuse	  
predicts	  impaired	  functioning	  but	  a	  good	  response	  to	  psychological	  treatments	  in	  patients	  with	  
severe	  irritable	  bowel	  syndrome.	  Psychosom	  Med	  2005;67(3):490-­‐9.	  
150.	  Pilowsky	  I.	  Abnormal	  illness	  behaviour.	  Br	  J	  Med	  Psychol	  1969,	  Dec;42(4):347-­‐51.	  






152.	  MECHANIC	  D.	  The	  concept	  of	  illness	  behavior.	  J	  Chronic	  Dis	  1962,	  Feb;15:189-­‐94.	  
153.	  PARSONS	  T.	  Illness	  and	  the	  role	  of	  the	  physician:	  A	  sociological	  perspective.	  Am	  J	  
Orthopsychiatry	  1951,	  Jul;21(3):452-­‐60.	  
154.	  Levy	  RL,	  Whitehead	  WE,	  Von	  Korff	  MR,	  Feld	  AD.	  Intergenerational	  transmission	  of	  
gastrointestinal	  illness	  behavior.	  Am	  J	  Gastroenterol	  2000,	  Feb;95(2):451-­‐6.	  
155.	  Lowman	  BC,	  Drossman	  DA,	  Cramer	  EM,	  McKee	  DC.	  Recollection	  of	  childhood	  events	  in	  adults	  
with	  irritable	  bowel	  syndrome.	  J	  Clin	  Gastroenterol	  1987,	  Jun;9(3):324-­‐30.	  
156.	  Whitehead	  WE,	  Winget	  C,	  Fedoravicius	  AS,	  Wooley	  S,	  Blackwell	  B.	  Learned	  illness	  behavior	  in	  
patients	  with	  irritable	  bowel	  syndrome	  and	  peptic	  ulcer.	  Dig	  Dis	  Sci	  1982;27(3):202-­‐8.	  
157.	  Whitehead	  WE,	  Crowell	  MD,	  Heller	  BR,	  Robinson	  JC,	  Schuster	  MM,	  Horn	  S.	  Modeling	  and	  
reinforcement	  of	  the	  sick	  role	  during	  childhood	  predicts	  adult	  illness	  behavior.	  Psychosom	  Med	  
1994;56(6):541-­‐50.	  
158.	  Hill	  OW,	  Blendis	  L.	  Physical	  and	  psychological	  evaluation	  of	  'non-­‐organic'	  abdominal	  pain.	  Gut	  
1967,	  Jun;8(3):221-­‐9.	  
159.	  Schuster	  MM,	  Whitehead	  WE.	  Physiologic	  insights	  into	  irritable	  bowel	  syndrome.	  Clin	  
Gastroenterol	  1986,	  Oct;15(4):839-­‐53.	  
160.	  Koloski	  NA,	  Boyce	  PM,	  Talley	  NJ.	  Is	  health	  care	  seeking	  for	  irritable	  bowel	  syndrome	  and	  
functional	  dyspepsia	  a	  socially	  learned	  response	  to	  illness?	  Dig	  Dis	  Sci	  2005;50(1):153-­‐62.	  
161.	  Talley	  NJ,	  Boyce	  PM,	  Jones	  M.	  Predictors	  of	  health	  care	  seeking	  for	  irritable	  bowel	  syndrome:	  A	  
population	  based	  study.	  Gut	  1997,	  Sep;41(3):394-­‐8.	  
162.	  Howell	  S,	  Poulton	  R,	  Talley	  NJ.	  The	  natural	  history	  of	  childhood	  abdominal	  pain	  and	  its	  
association	  with	  adult	  irritable	  bowel	  syndrome:	  Birth-­‐Cohort	  study.	  Am	  J	  Gastroenterol	  2005,	  
Sep;100(9):2071-­‐8.	  
163.	  Gick	  ML,	  Thompson	  WG.	  Negative	  affect	  and	  the	  seeking	  of	  medical	  care	  in	  university	  students	  






164.	  Howell	  S,	  Talley	  NJ.	  Does	  fear	  of	  serious	  disease	  predict	  consulting	  behaviour	  amongst	  patients	  
with	  dyspepsia	  in	  general	  practice?	  Eur	  J	  Gastroenterol	  Hepatol	  1999,	  Aug;11(8):881-­‐6.	  
165.	  Engel	  GL.	  The	  need	  for	  a	  new	  medical	  model:	  A	  challenge	  for	  biomedicine.	  Science	  1977,	  Apr	  
8;196(4286):129-­‐36.	  
166.	  Longstreth	  GF,	  Hawkey	  CJ,	  Mayer	  EA,	  Jones	  RH,	  Naesdal	  J,	  Wilson	  IK,	  et	  al.	  Characteristics	  of	  
patients	  with	  irritable	  bowel	  syndrome	  recruited	  from	  three	  sources:	  Implications	  for	  clinical	  trials.	  
Aliment	  Pharmacol	  Ther	  2001,	  Jul;15(7):959-­‐64.	  
167.	  Rodríguez	  LA,	  Ruigómez	  A.	  Increased	  risk	  of	  irritable	  bowel	  syndrome	  after	  bacterial	  
gastroenteritis:	  Cohort	  study.	  BMJ	  1999,	  Feb	  27;318(7183):565-­‐6.	  
168.	  Spiller	  RC.	  Postinfectious	  irritable	  bowel	  syndrome.	  Gastroenterology	  2003,	  May;124(6):1662-­‐
71.	  
169.	  Thabane	  M,	  Kottachchi	  DT,	  Marshall	  JK.	  Systematic	  review	  and	  meta-­‐analysis:	  The	  incidence	  
and	  prognosis	  of	  post-­‐infectious	  irritable	  bowel	  syndrome.	  Aliment	  Pharmacol	  Ther	  2007,	  Aug	  
15;26(4):535-­‐44.	  
170.	  STEWART	  GT.	  Post-­‐Dysenteric	  colitis.	  Br	  Med	  J	  1950,	  Feb	  18;1(4650):405-­‐9.	  
171.	  Okhuysen	  PC,	  Jiang	  ZD,	  Carlin	  L,	  Forbes	  C,	  DuPont	  HL.	  Post-­‐Diarrhea	  chronic	  intestinal	  
symptoms	  and	  irritable	  bowel	  syndrome	  in	  north	  american	  travelers	  to	  mexico.	  Am	  J	  Gastroenterol	  
2004,	  Sep;99(9):1774-­‐8.	  
172.	  Parry	  SD,	  Stansfield	  R,	  Jelley	  D,	  Gregory	  W,	  Phillips	  E,	  Barton	  JR,	  Welfare	  MR.	  Does	  bacterial	  
gastroenteritis	  predispose	  people	  to	  functional	  gastrointestinal	  disorders?	  A	  prospective,	  
community-­‐based,	  case-­‐control	  study.	  Am	  J	  Gastroenterol	  2003,	  Sep;98(9):1970-­‐5.	  
173.	  McKendrick	  MW,	  Read	  NW.	  Irritable	  bowel	  syndrome-­‐-­‐post	  salmonella	  infection.	  J	  Infect	  1994,	  
Jul;29(1):1-­‐3.	  
174.	  Mearin	  F,	  Pérez-­‐Oliveras	  M,	  Perelló	  A,	  Vinyet	  J,	  Ibañez	  A,	  Coderch	  J,	  Perona	  M.	  Dyspepsia	  and	  
irritable	  bowel	  syndrome	  after	  a	  salmonella	  gastroenteritis	  outbreak:	  One-­‐Year	  follow-­‐up	  cohort	  






175.	  Ji	  S,	  Park	  H,	  Lee	  D,	  Song	  YK,	  Choi	  JP,	  Lee	  SI.	  Post-­‐Infectious	  irritable	  bowel	  syndrome	  in	  patients	  
with	  shigella	  infection.	  J	  Gastroenterol	  Hepatol	  2005,	  Mar;20(3):381-­‐6.	  
176.	  Kim	  HS,	  Kim	  MS,	  Ji	  SW,	  Park	  H.	  [The	  development	  of	  irritable	  bowel	  syndrome	  after	  shigella	  
infection:	  3	  year	  follow-­‐up	  study].	  Korean	  J	  Gastroenterol	  2006,	  Apr;47(4):300-­‐5.	  
177.	  Soyturk	  M,	  Akpinar	  H,	  Gurler	  O,	  Pozio	  E,	  Sari	  I,	  Akar	  S,	  et	  al.	  Irritable	  bowel	  syndrome	  in	  persons	  
who	  acquired	  trichinellosis.	  Am	  J	  Gastroenterol	  2007,	  May;102(5):1064-­‐9.	  
178.	  Marshall	  JK,	  Thabane	  M,	  Garg	  AX,	  Clark	  WF,	  Salvadori	  M,	  Collins	  SM,	  Walkerton	  Health	  Study	  
Investigators.	  Incidence	  and	  epidemiology	  of	  irritable	  bowel	  syndrome	  after	  a	  large	  waterborne	  
outbreak	  of	  bacterial	  dysentery.	  Gastroenterology	  2006,	  Aug;131(2):445-­‐50;	  quiz	  660.	  
179.	  Marshall	  JK,	  Thabane	  M,	  Borgaonkar	  MR,	  James	  C.	  Postinfectious	  irritable	  bowel	  syndrome	  
after	  a	  food-­‐borne	  outbreak	  of	  acute	  gastroenteritis	  attributed	  to	  a	  viral	  pathogen.	  Clin	  
Gastroenterol	  Hepatol	  2007,	  Apr;5(4):457-­‐60.	  
180.	  Halvorson	  HA,	  Schlett	  CD,	  Riddle	  MS.	  Postinfectious	  irritable	  bowel	  syndrome-­‐-­‐a	  meta-­‐analysis.	  
Am	  J	  Gastroenterol	  2006,	  Aug;101(8):1894-­‐9;	  quiz	  1942.	  
181.	  Spence	  MJ,	  Moss-­‐Morris	  R.	  The	  cognitive	  behavioural	  model	  of	  irritable	  bowel	  syndrome:	  A	  
prospective	  investigation	  of	  patients	  with	  gastroenteritis.	  Gut	  2007,	  Aug;56(8):1066-­‐71.	  
182.	  Dunlop	  SP,	  Jenkins	  D,	  Neal	  KR,	  Spiller	  RC.	  Relative	  importance	  of	  enterochromaffin	  cell	  
hyperplasia,	  anxiety,	  and	  depression	  in	  postinfectious	  IBS.	  Gastroenterology	  2003,	  Dec;125(6):1651-­‐
9.	  
183.	  Kristjánsson	  G,	  Venge	  P,	  Wanders	  A,	  Lööf	  L,	  Hällgren	  R.	  Clinical	  and	  subclinical	  intestinal	  
inflammation	  assessed	  by	  the	  mucosal	  patch	  technique:	  Studies	  of	  mucosal	  neutrophil	  and	  
eosinophil	  activation	  in	  inflammatory	  bowel	  diseases	  and	  irritable	  bowel	  syndrome.	  Gut	  2004,	  
Dec;53(12):1806-­‐12.	  
184.	  Schoepfer	  AM,	  Trummler	  M,	  Seeholzer	  P,	  Seibold-­‐Schmid	  B,	  Seibold	  F.	  Discriminating	  IBD	  from	  
IBS:	  Comparison	  of	  the	  test	  performance	  of	  fecal	  markers,	  blood	  leukocytes,	  CRP,	  and	  IBD	  






185.	  Wheatcroft	  J,	  Wakelin	  D,	  Smith	  A,	  Mahoney	  CR,	  Mawe	  G,	  Spiller	  R.	  Enterochromaffin	  cell	  
hyperplasia	  and	  decreased	  serotonin	  transporter	  in	  a	  mouse	  model	  of	  postinfectious	  bowel	  
dysfunction.	  Neurogastroenterol	  Motil	  2005,	  Dec;17(6):863-­‐70.	  
186.	  Wang	  LH,	  Fang	  XC,	  Pan	  GZ.	  Bacillary	  dysentery	  as	  a	  causative	  factor	  of	  irritable	  bowel	  syndrome	  
and	  its	  pathogenesis.	  Gut	  2004,	  Aug;53(8):1096-­‐101.	  
187.	  Gwee	  KA,	  Collins	  SM,	  Read	  NW,	  Rajnakova	  A,	  Deng	  Y,	  Graham	  JC,	  et	  al.	  Increased	  rectal	  mucosal	  
expression	  of	  interleukin	  1beta	  in	  recently	  acquired	  post-­‐infectious	  irritable	  bowel	  syndrome.	  Gut	  
2003,	  Apr;52(4):523-­‐6.	  
188.	  Chadwick	  VS,	  Chen	  W,	  Shu	  D,	  Paulus	  B,	  Bethwaite	  P,	  Tie	  A,	  Wilson	  I.	  Activation	  of	  the	  mucosal	  
immune	  system	  in	  irritable	  bowel	  syndrome.	  Gastroenterology	  2002,	  Jun;122(7):1778-­‐83.	  
189.	  Gonsalkorale	  WM,	  Perrey	  C,	  Pravica	  V,	  Whorwell	  PJ,	  Hutchinson	  IV.	  Interleukin	  10	  genotypes	  in	  
irritable	  bowel	  syndrome:	  Evidence	  for	  an	  inflammatory	  component?	  Gut	  2003,	  Jan;52(1):91-­‐3.	  
190.	  Spiller	  RC,	  Jenkins	  D,	  Thornley	  JP,	  Hebden	  JM,	  Wright	  T,	  Skinner	  M,	  Neal	  KR.	  Increased	  rectal	  
mucosal	  enteroendocrine	  cells,	  T	  lymphocytes,	  and	  increased	  gut	  permeability	  following	  acute	  
campylobacter	  enteritis	  and	  in	  post-­‐dysenteric	  irritable	  bowel	  syndrome.	  Gut	  2000,	  Dec;47(6):804-­‐
11.	  
191.	  Söderholm	  JD,	  Yates	  DA,	  Gareau	  MG,	  Yang	  PC,	  MacQueen	  G,	  Perdue	  MH.	  Neonatal	  maternal	  
separation	  predisposes	  adult	  rats	  to	  colonic	  barrier	  dysfunction	  in	  response	  to	  mild	  stress.	  Am	  J	  
Physiol	  Gastrointest	  Liver	  Physiol	  2002,	  Dec;283(6):G1257-­‐63.	  
192.	  Zareie	  M,	  Johnson-­‐Henry	  K,	  Jury	  J,	  Yang	  PC,	  Ngan	  BY,	  McKay	  DM,	  et	  al.	  Probiotics	  prevent	  
bacterial	  translocation	  and	  improve	  intestinal	  barrier	  function	  in	  rats	  following	  chronic	  psychological	  
stress.	  Gut	  2006,	  Nov;55(11):1553-­‐60.	  
193.	  Yang	  PC,	  Jury	  J,	  Söderholm	  JD,	  Sherman	  PM,	  McKay	  DM,	  Perdue	  MH.	  Chronic	  psychological	  
stress	  in	  rats	  induces	  intestinal	  sensitization	  to	  luminal	  antigens.	  Am	  J	  Pathol	  2006,	  Jan;168(1):104-­‐






194.	  Barbara	  G,	  Stanghellini	  V,	  De	  Giorgio	  R,	  Cremon	  C,	  Cottrell	  GS,	  Santini	  D,	  et	  al.	  Activated	  mast	  
cells	  in	  proximity	  to	  colonic	  nerves	  correlate	  with	  abdominal	  pain	  in	  irritable	  bowel	  syndrome.	  
Gastroenterology	  2004,	  Mar;126(3):693-­‐702.	  
195.	  Farthing	  MJ,	  Lennard-­‐jones	  JE.	  Sensibility	  of	  the	  rectum	  to	  distension	  and	  the	  anorectal	  
distension	  reflex	  in	  ulcerative	  colitis.	  Gut	  1978,	  Jan;19(1):64-­‐9.	  
196.	  Rao	  SS,	  Read	  NW,	  Davison	  PA,	  Bannister	  JJ,	  Holdsworth	  CD.	  Anorectal	  sensitivity	  and	  responses	  
to	  rectal	  distention	  in	  patients	  with	  ulcerative	  colitis.	  Gastroenterology	  1987,	  Dec;93(6):1270-­‐5.	  
197.	  Chang	  L,	  Munakata	  J,	  Mayer	  EA,	  Schmulson	  MJ,	  Johnson	  TD,	  Bernstein	  CN,	  et	  al.	  Perceptual	  
responses	  in	  patients	  with	  inflammatory	  and	  functional	  bowel	  disease.	  Gut	  2000,	  Oct;47(4):497-­‐505.	  
198.	  Meddings	  JB.	  Review	  article:	  Intestinal	  permeability	  in	  crohn's	  disease.	  Aliment	  Pharmacol	  Ther	  
1997,	  Dec;11	  Suppl	  3:47-­‐53;	  discussion	  53-­‐6.	  
199.	  Marshall	  JK,	  Thabane	  M,	  Garg	  AX,	  Clark	  W,	  Meddings	  J,	  Collins	  SM,	  WEL	  Investigators.	  Intestinal	  
permeability	  in	  patients	  with	  irritable	  bowel	  syndrome	  after	  a	  waterborne	  outbreak	  of	  acute	  
gastroenteritis	  in	  walkerton,	  ontario.	  Aliment	  Pharmacol	  Ther	  2004,	  Dec;20(11-­‐12):1317-­‐22.	  
200.	  Dunlop	  SP,	  Hebden	  J,	  Campbell	  E,	  Naesdal	  J,	  Olbe	  L,	  Perkins	  AC,	  Spiller	  RC.	  Abnormal	  intestinal	  
permeability	  in	  subgroups	  of	  diarrhea-­‐predominant	  irritable	  bowel	  syndromes.	  Am	  J	  Gastroenterol	  
2006,	  Jun;101(6):1288-­‐94.	  
201.	  Berkes	  J,	  Viswanathan	  VK,	  Savkovic	  SD,	  Hecht	  G.	  Intestinal	  epithelial	  responses	  to	  enteric	  
pathogens:	  Effects	  on	  the	  tight	  junction	  barrier,	  ion	  transport,	  and	  inflammation.	  Gut	  2003,	  
Mar;52(3):439-­‐51.	  
202.	  D'Incà	  R,	  Di	  Leo	  V,	  Corrao	  G,	  Martines	  D,	  D'Odorico	  A,	  Mestriner	  C,	  et	  al.	  Intestinal	  permeability	  
test	  as	  a	  predictor	  of	  clinical	  course	  in	  crohn's	  disease.	  Am	  J	  Gastroenterol	  1999,	  Oct;94(10):2956-­‐60.	  
203.	  Hollander	  D,	  Vadheim	  CM,	  Brettholz	  E,	  Petersen	  GM,	  Delahunty	  T,	  Rotter	  JI.	  Increased	  intestinal	  
permeability	  in	  patients	  with	  crohn's	  disease	  and	  their	  relatives.	  A	  possible	  etiologic	  factor.	  Ann	  
Intern	  Med	  1986,	  Dec;105(6):883-­‐5.	  
204.	  Bjarnason	  I,	  Marsh	  MN,	  Price	  A,	  Levi	  AJ,	  Peters	  TJ.	  Intestinal	  permeability	  in	  patients	  with	  






205.	  Clayburgh	  DR,	  Barrett	  TA,	  Tang	  Y,	  Meddings	  JB,	  Van	  Eldik	  LJ,	  Watterson	  DM,	  et	  al.	  Epithelial	  
myosin	  light	  chain	  kinase-­‐dependent	  barrier	  dysfunction	  mediates	  T	  cell	  activation-­‐induced	  diarrhea	  
in	  vivo.	  J	  Clin	  Invest	  2005,	  Oct;115(10):2702-­‐15.	  
206.	  Blair	  SA,	  Kane	  SV,	  Clayburgh	  DR,	  Turner	  JR.	  Epithelial	  myosin	  light	  chain	  kinase	  expression	  and	  
activity	  are	  upregulated	  in	  inflammatory	  bowel	  disease.	  Lab	  Invest	  2006,	  Feb;86(2):191-­‐201.	  
207.	  Zolotarevsky	  Y,	  Hecht	  G,	  Koutsouris	  A,	  Gonzalez	  DE,	  Quan	  C,	  Tom	  J,	  et	  al.	  A	  membrane-­‐
permeant	  peptide	  that	  inhibits	  MLC	  kinase	  restores	  barrier	  function	  in	  in	  vitro	  models	  of	  intestinal	  
disease.	  Gastroenterology	  2002,	  Jul;123(1):163-­‐72.	  
208.	  Whitehead	  WE,	  Holtkotter	  B,	  Enck	  P,	  Hoelzl	  R,	  Holmes	  KD,	  Anthony	  J,	  et	  al.	  Tolerance	  for	  
rectosigmoid	  distention	  in	  irritable	  bowel	  syndrome.	  Gastroenterology	  1990,	  May;98(5	  Pt	  1):1187-­‐
92.	  
209.	  Hobson	  AR,	  Furlong	  PL,	  Sarkar	  S,	  Matthews	  PJ,	  Willert	  RP,	  Worthen	  SF,	  et	  al.	  Neurophysiologic	  
assessment	  of	  esophageal	  sensory	  processing	  in	  noncardiac	  chest	  pain.	  Gastroenterology	  2006,	  
Jan;130(1):80-­‐8.	  
210.	  Harris	  ML,	  Hobson	  AR,	  Hamdy	  S,	  Thompson	  DG,	  Akkermans	  LM,	  Aziz	  Q.	  Neurophysiological	  
evaluation	  of	  healthy	  human	  anorectal	  sensation.	  Am	  J	  Physiol	  Gastrointest	  Liver	  Physiol	  2006,	  
Nov;291(5):G950-­‐8.	  
211.	  Murray	  CD,	  Flynn	  J,	  Ratcliffe	  L,	  Jacyna	  MR,	  Kamm	  MA,	  Emmanuel	  AV.	  Effect	  of	  acute	  physical	  
and	  psychological	  stress	  on	  gut	  autonomic	  innervation	  in	  irritable	  bowel	  syndrome.	  
Gastroenterology	  2004,	  Dec;127(6):1695-­‐703.	  
212.	  Francis	  CY,	  Morris	  J,	  Whorwell	  PJ.	  The	  irritable	  bowel	  severity	  scoring	  system:	  A	  simple	  method	  
of	  monitoring	  irritable	  bowel	  syndrome	  and	  its	  progress.	  Aliment	  Pharmacol	  Ther	  1997,	  
Apr;11(2):395-­‐402.	  
213.	  Drossman	  DA,	  Li	  Z,	  Toner	  BB,	  Diamant	  NE,	  Creed	  FH,	  Thompson	  D,	  et	  al.	  Functional	  bowel	  
disorders.	  A	  multicenter	  comparison	  of	  health	  status	  and	  development	  of	  illness	  severity	  index.	  Dig	  






214.	  Gracely	  RH,	  McGrath	  P,	  Dubner	  R.	  Validity	  and	  sensitivity	  of	  ratio	  scales	  of	  sensory	  and	  affective	  
verbal	  pain	  descriptors:	  Manipulation	  of	  affect	  by	  diazepam.	  Pain	  1978,	  Jun;5(1):19-­‐29.	  
215.	  Huskisson	  EC.	  Measurement	  of	  pain.	  J	  Rheumatol	  1982;9(5):768-­‐9.	  
216.	  Guyatt	  GH,	  Townsend	  M,	  Berman	  LB,	  Keller	  JL.	  A	  comparison	  of	  likert	  and	  visual	  analogue	  scales	  
for	  measuring	  change	  in	  function.	  J	  Chronic	  Dis	  1987;40(12):1129-­‐33.	  
217.	  Likert	  R.	  A	  technique	  for	  the	  measurement	  of	  attitudes.	  1932.	  
218.	  Huskisson	  EC.	  Measurement	  of	  pain.	  Lancet	  1974,	  Nov	  9;2(7889):1127-­‐31.	  
219.	  Sriwatanakul	  K,	  Kelvie	  W,	  Lasagna	  L,	  Calimlim	  JF,	  Weis	  OF,	  Mehta	  G.	  Studies	  with	  different	  types	  
of	  visual	  analog	  scales	  for	  measurement	  of	  pain.	  Clin	  Pharmacol	  Ther	  1983,	  Aug;34(2):234-­‐9.	  
220.	  Naliboff	  BD,	  Fullerton	  S,	  Mayer	  EA.	  Measurement	  of	  symptoms	  in	  irritable	  bowel	  syndrome	  
clinical	  trials.	  Am	  J	  Med	  1999,	  Nov	  8;107(5A):81S-­‐4S.	  
221.	  McDowell	  I.	  Measuring	  health:	  A	  guide	  to	  rating	  scales	  and	  questionnaires.	   	   Oxford	  University	  
Press.	  
222.	  Houghton	  LA,	  Heyman	  DJ,	  Whorwell	  PJ.	  Symptomatology,	  quality	  of	  life	  and	  economic	  features	  
of	  irritable	  bowel	  syndrome-­‐-­‐the	  effect	  of	  hypnotherapy.	  Aliment	  Pharmacol	  Ther	  1996,	  
Feb;10(1):91-­‐5.	  
223.	  Farup	  PG,	  Hovdenak	  N,	  Wetterhus	  S,	  Lange	  OJ,	  Hovde	  O,	  Trondstad	  R.	  The	  symptomatic	  effect	  
of	  cisapride	  in	  patients	  with	  irritable	  bowel	  syndrome	  and	  constipation.	  Scand	  J	  Gastroenterol	  1998,	  
Feb;33(2):128-­‐31.	  
224.	  Zigmond	  AS,	  Snaith	  RP.	  The	  hospital	  anxiety	  and	  depression	  scale.	  Acta	  Psychiatr	  Scand	  1983,	  
Jun;67(6):361-­‐70.	  
225.	  Toner	  BB,	  Garfinkel	  PE,	  Jeejeebhoy	  KN.	  Psychological	  factors	  in	  irritable	  bowel	  syndrome.	  Can	  J	  
Psychiatry	  1990,	  Mar;35(2):158-­‐61.	  
226.	  Dinan	  TG,	  O'Keane	  V,	  O'Boyle	  C,	  Chua	  A,	  Keeling	  PW.	  A	  comparison	  of	  the	  mental	  status,	  
personality	  profiles	  and	  life	  events	  of	  patients	  with	  irritable	  bowel	  syndrome	  and	  peptic	  ulcer	  






227.	  Fock	  KM,	  Chew	  CN,	  Tay	  LK,	  Peh	  LH,	  Chan	  S,	  Pang	  EP.	  Psychiatric	  illness,	  personality	  traits	  and	  
the	  irritable	  bowel	  syndrome.	  Ann	  Acad	  Med	  Singapore	  2001,	  Nov;30(6):611-­‐4.	  
228.	  Talley	  NJ,	  Boyce	  P,	  Owen	  BK.	  Psychological	  distress	  and	  seasonal	  symptom	  changes	  in	  irritable	  
bowel	  syndrome.	  Am	  J	  Gastroenterol	  1995,	  Dec;90(12):2115-­‐9.	  
229.	  Talley	  NJ,	  Boyce	  PM,	  Jones	  M.	  Predictors	  of	  health	  care	  seeking	  for	  irritable	  bowel	  syndrome:	  A	  
population	  based	  study.	  Gut	  1997,	  Sep;41(3):394-­‐8.	  
230.	  Pilowsky	  I.	  Dimensions	  of	  hypochondriasis.	  Br	  J	  Psychiatry	  1967,	  Jan;113(494):89-­‐93.	  
231.	  Spitzer	  RL,	  Kroenke	  K,	  Williams	  JB.	  Validation	  and	  utility	  of	  a	  self-­‐report	  version	  of	  PRIME-­‐MD:	  
The	  PHQ	  primary	  care	  study.	  Primary	  care	  evaluation	  of	  mental	  disorders.	  Patient	  health	  
questionnaire.	  JAMA	  1999,	  Nov	  10;282(18):1737-­‐44.	  
232.	  Spitzer	  RL,	  Williams	  JB,	  Kroenke	  K,	  Linzer	  M,	  deGruy	  FV,	  Hahn	  SR,	  et	  al.	  Utility	  of	  a	  new	  
procedure	  for	  diagnosing	  mental	  disorders	  in	  primary	  care.	  The	  PRIME-­‐MD	  1000	  study.	  JAMA	  1994,	  
Dec	  14;272(22):1749-­‐56.	  
233.	  Kroenke	  K,	  Spitzer	  RL,	  Williams	  JB.	  The	  PHQ-­‐15:	  Validity	  of	  a	  new	  measure	  for	  evaluating	  the	  
severity	  of	  somatic	  symptoms.	  Psychosom	  Med	  2002;64(2):258-­‐66.	  
234.	  Mayer	  EA,	  Naliboff	  BD,	  Chang	  L,	  Coutinho	  SV.	  V.	  Stress	  and	  irritable	  bowel	  syndrome.	  Am	  J	  
Physiol	  Gastrointest	  Liver	  Physiol	  2001,	  Apr;280(4):G519-­‐24.	  
235.	  Reiss	  S.	  Trait	  anxiety:	  It's	  not	  what	  you	  think	  it	  is.	  J	  Anxiety	  Disord	  1997;11(2):201-­‐14.	  
236.	   	   Spielberger	  CD.	  Anxiety:	  State-­‐Trait	  process..	  In:	  Stress	  and	  anxiety.	  Washington,	  DC:	  
Hemisphere.	  ;	  1975.	  
237.	  Mayer	  EA,	  Craske	  M,	  Naliboff	  BD.	  Depression,	  anxiety,	  and	  the	  gastrointestinal	  system.	  J	  Clin	  
Psychiatry	  2001;62	  Suppl	  8:28-­‐36;	  discussion	  37.	  
238.	  Cattell	  RB,	  Scheier	  IH.	  The	  meaning	  and	  measurement	  of	  neuroticism	  and	  anxiety.	   	   Ronald;	  
1961.	  






240.	  Spielberger	  CD,	  Gorsuch	  RL.	  STAI	  manual	  for	  the	  state-­‐trait	  anxiety	  inventory	  ("	  self-­‐evaluation	  
questionnaire").	   	   Consulting	  Psychologists	  Press;	  1970.	  
241.	  Spielberger	  CD,	  Gorsuch	  RL,	  Lushene	  R,	  Vagg	  PR,	  Jacobs	  GA.	  State-­‐Trait	  anxiety	  inventory	  for	  
adults.	   	   Consulting	  Psychologists	  Press	  Palo	  Alto,	  CA;	  1983.	  
242.	  Barnes	  LLB,	  Harp	  D,	  Jung	  WS.	  Reliability	  generalization	  of	  scores	  on	  the	  spielberger	  state-­‐trait	  
anxiety	  inventory.	  Educational	  and	  Psychological	  Measurement	  2002;62(4):603.	  
243.	  Longstreth	  GF,	  Bolus	  R,	  Naliboff	  B,	  Chang	  L,	  Kulich	  KR,	  Carlsson	  J,	  et	  al.	  Impact	  of	  irritable	  bowel	  
syndrome	  on	  patients'	  lives:	  Development	  and	  psychometric	  documentation	  of	  a	  disease-­‐specific	  
measure	  for	  use	  in	  clinical	  trials.	  Eur	  J	  Gastroenterol	  Hepatol	  2005,	  Apr;17(4):411-­‐20.	  
244.	  Patrick	  DL,	  Drossman	  DA,	  Frederick	  IO,	  DiCesare	  J,	  Puder	  KL.	  Quality	  of	  life	  in	  persons	  with	  
irritable	  bowel	  syndrome:	  Development	  and	  validation	  of	  a	  new	  measure.	  Dig	  Dis	  Sci	  1998,	  
Feb;43(2):400-­‐11.	  
245.	  Chassany	  O,	  Marquis	  P,	  Scherrer	  B,	  Read	  NW,	  Finger	  T,	  Bergmann	  JF,	  et	  al.	  Validation	  of	  a	  
specific	  quality	  of	  life	  questionnaire	  for	  functional	  digestive	  disorders.	  Gut	  1999,	  Apr;44(4):527-­‐33.	  
246.	  Wong	  E,	  Guyatt	  GH,	  Cook	  DJ,	  Griffith	  LE,	  Irvine	  EJ.	  Development	  of	  a	  questionnaire	  to	  measure	  
quality	  of	  life	  in	  patients	  with	  irritable	  bowel	  syndrome.	  Eur	  J	  Surg	  Suppl	  1998(583):50-­‐6.	  
247.	  Hahn	  BA,	  Kirchdoerfer	  LJ,	  Fullerton	  S,	  Mayer	  E.	  Evaluation	  of	  a	  new	  quality	  of	  life	  questionnaire	  
for	  patients	  with	  irritable	  bowel	  syndrome.	  Aliment	  Pharmacol	  Ther	  1997,	  Jun;11(3):547-­‐52.	  
248.	  Ghani	  AC,	  Donnelly	  CA,	  Garnett	  GP.	  Sampling	  biases	  and	  missing	  data	  in	  explorations	  of	  sexual	  
partner	  networks	  for	  the	  spread	  of	  sexually	  transmitted	  diseases.	  Stat	  Med	  1998,	  Sep	  
30;17(18):2079-­‐97.	  
249.	  Wyrwich	  KW,	  Tardino	  VM.	  A	  blueprint	  for	  symptom	  scales	  and	  responses:	  Measurement	  and	  
reporting.	  Gut	  2004,	  May;53	  Suppl	  4:iv45-­‐8.	  
250.	  Meunier	  P,	  Collet	  L,	  Duclaux	  R,	  Chery-­‐Croze	  S.	  Endorectal	  cerebral	  evoked	  potentials	  in	  human.	  






251.	  Collet	  L,	  Meunier	  P,	  Duclaux	  R,	  Chery-­‐Croze	  S,	  Falipou	  P.	  Cerebral	  evoked	  potentials	  after	  
endorectal	  mechanical	  stimulation	  in	  humans.	  Am	  J	  Physiol	  1988,	  Apr;254(4	  Pt	  1):G477-­‐82.	  
252.	  Frieling	  T,	  Enck	  P,	  Wienbeck	  M.	  Cerebral	  responses	  evoked	  by	  electrical	  stimulation	  of	  
rectosigmoid	  in	  normal	  subjects.	  Dig	  Dis	  Sci	  1989,	  Feb;34(2):202-­‐5.	  
253.	  Loening-­‐Baucke	  V,	  Read	  NW,	  Yamada	  T.	  Cerebral	  evoked	  potentials	  after	  rectal	  stimulation.	  
Electroencephalogr	  Clin	  Neurophysiol	  1991;80(6):490-­‐5.	  
254.	  Hollerbach	  S,	  Fitzpatrick	  D,	  Shine	  G,	  Kamath	  MV,	  Upton	  AR,	  Tougas	  G.	  Cognitive	  evoked	  
potentials	  to	  anticipated	  oesophageal	  stimulus	  in	  humans:	  Quantitative	  assessment	  of	  the	  cognitive	  
aspects	  of	  visceral	  perception.	  Neurogastroenterol	  Motil	  1999,	  Feb;11(1):37-­‐46.	  
255.	  Hobday	  DI,	  Hobson	  AR,	  Sarkar	  S,	  Furlong	  PL,	  Thompson	  DG,	  Aziz	  Q.	  Cortical	  processing	  of	  
human	  gut	  sensation:	  An	  evoked	  potential	  study.	  Am	  J	  Physiol	  Gastrointest	  Liver	  Physiol	  2002,	  
Aug;283(2):G335-­‐9.	  
256.	  Engel	  GL.	  The	  need	  for	  a	  new	  medical	  model:	  A	  challenge	  for	  biomedicine.	  Science	  1977,	  Apr	  
8;196(4286):129-­‐36.	  
257.	  Drossman	  DA,	  Creed	  FH,	  Olden	  KW,	  Svedlund	  J,	  Toner	  BB,	  Whitehead	  WE.	  Psychosocial	  aspects	  
of	  the	  functional	  gastrointestinal	  disorders.	  Gut	  1999,	  Sep;45	  Suppl	  2:II25-­‐30.	  
258.	  MacDonald	  AJ,	  Bouchier	  IA.	  Non-­‐Organic	  gastrointestinal	  illness:	  A	  medical	  and	  psychiatric	  
study.	  Br	  J	  Psychiatry	  1980,	  Mar;136:276-­‐83.	  
259.	  Colgan	  S,	  Creed	  F,	  Klass	  H.	  Symptom	  complaints,	  psychiatric	  disorder	  and	  abnormal	  illness	  
behaviour	  in	  patients	  with	  upper	  abdominal	  pain.	  Psychol	  Med	  1988,	  Nov;18(4):887-­‐92.	  
260.	  Corney	  RH,	  Stanton	  R.	  Physical	  symptom	  severity,	  psychological	  and	  social	  dysfunction	  in	  a	  
series	  of	  outpatients	  with	  irritable	  bowel	  syndrome.	  J	  Psychosom	  Res	  1990;34(5):483-­‐91.	  
261.	  Craig	  TK,	  Brown	  GW.	  Goal	  frustration	  and	  life	  events	  in	  the	  aetiology	  of	  painful	  gastrointestinal	  
disorder.	  J	  Psychosom	  Res	  1984;28(5):411-­‐21.	  
262.	  Ford	  MJ,	  Miller	  PM,	  Eastwood	  J,	  Eastwood	  MA.	  Life	  events,	  psychiatric	  illness	  and	  the	  irritable	  






263.	  Toner	  BB,	  Garfinkel	  PE,	  Jeejeebhoy	  KN.	  Psychological	  factors	  in	  irritable	  bowel	  syndrome.	  Can	  J	  
Psychiatry	  1990,	  Mar;35(2):158-­‐61.	  
264.	  Lydiard	  RB.	  Irritable	  bowel	  syndrome,	  anxiety,	  and	  depression:	  What	  are	  the	  links?	  J	  Clin	  
Psychiatry	  2001;62	  Suppl	  8:38-­‐45;	  discussion	  46-­‐7.	  
265.	  Lydiard	  RB,	  Falsetti	  SA.	  Experience	  with	  anxiety	  and	  depression	  treatment	  studies:	  Implications	  
for	  designing	  irritable	  bowel	  syndrome	  clinical	  trials.	  Am	  J	  Med	  1999,	  Nov	  8;107(5A):65S-­‐73S.	  
266.	  van	  Hemert	  AM,	  Hengeveld	  MW,	  Bolk	  JH,	  Rooijmans	  HG,	  Vandenbroucke	  JP.	  Psychiatric	  
disorders	  in	  relation	  to	  medical	  illness	  among	  patients	  of	  a	  general	  medical	  out-­‐patient	  clinic.	  
Psychol	  Med	  1993,	  Feb;23(1):167-­‐73.	  
267.	  Ansseau	  M,	  Dierick	  M,	  Buntinkx	  F,	  Cnockaert	  P,	  De	  Smedt	  J,	  Van	  Den	  Haute	  M,	  Vander	  
Mijnsbrugge	  D.	  High	  prevalence	  of	  mental	  disorders	  in	  primary	  care.	  J	  Affect	  Disord	  2004,	  
Jan;78(1):49-­‐55.	  
268.	  Blanchard	  EB,	  Lackner	  JM,	  Jaccard	  J,	  Rowell	  D,	  Carosella	  AM,	  Powell	  C,	  et	  al.	  The	  role	  of	  stress	  in	  
symptom	  exacerbation	  among	  IBS	  patients.	  J	  Psychosom	  Res	  2008,	  Feb;64(2):119-­‐28.	  
269.	  Sterling	  P,	  Eyer	  J.	  Allostasis:	  A	  new	  paradigm	  to	  explain	  arousal	  pathology.	  Handbook	  of	  Life	  
Stress,	  Cognition	  and	  Health	  1988.	  
270.	  McEwen	  BS,	  Stellar	  E.	  Stress	  and	  the	  individual.	  Mechanisms	  leading	  to	  disease.	  Arch	  Intern	  
Med	  1993,	  Sep	  27;153(18):2093-­‐101.	  
271.	  McEwen	  BS.	  Stress,	  adaptation,	  and	  disease.	  Allostasis	  and	  allostatic	  load.	  Ann	  N	  Y	  Acad	  Sci	  
1998,	  May	  1;840:33-­‐44.	  
272.	  Felitti	  VJ,	  Anda	  RF,	  Nordenberg	  D,	  Williamson	  DF,	  Spitz	  AM,	  Edwards	  V,	  et	  al.	  Relationship	  of	  
childhood	  abuse	  and	  household	  dysfunction	  to	  many	  of	  the	  leading	  causes	  of	  death	  in	  adults.	  The	  
adverse	  childhood	  experiences	  (ACE)	  study.	  Am	  J	  Prev	  Med	  1998,	  May;14(4):245-­‐58.	  
273.	  Spertus	  IL,	  Yehuda	  R,	  Wong	  CM,	  Halligan	  S,	  Seremetis	  SV.	  Childhood	  emotional	  abuse	  and	  
neglect	  as	  predictors	  of	  psychological	  and	  physical	  symptoms	  in	  women	  presenting	  to	  a	  primary	  care	  






274.	  Dube	  SR,	  Anda	  RF,	  Felitti	  VJ,	  Chapman	  DP,	  Williamson	  DF,	  Giles	  WH.	  Childhood	  abuse,	  
household	  dysfunction,	  and	  the	  risk	  of	  attempted	  suicide	  throughout	  the	  life	  span:	  Findings	  from	  the	  
adverse	  childhood	  experiences	  study.	  JAMA	  2001,	  Dec	  26;286(24):3089-­‐96.	  
275.	  Danese	  A,	  Moffitt	  TE,	  Harrington	  H,	  Milne	  BJ,	  Polanczyk	  G,	  Pariante	  CM,	  et	  al.	  Adverse	  
childhood	  experiences	  and	  adult	  risk	  factors	  for	  age-­‐related	  disease:	  Depression,	  inflammation,	  and	  
clustering	  of	  metabolic	  risk	  markers.	  Arch	  Pediatr	  Adolesc	  Med	  2009,	  Dec;163(12):1135-­‐43.	  
276.	  Anda	  RF,	  Felitti	  VJ,	  Bremner	  JD,	  Walker	  JD,	  Whitfield	  C,	  Perry	  BD,	  et	  al.	  The	  enduring	  effects	  of	  
abuse	  and	  related	  adverse	  experiences	  in	  childhood.	  A	  convergence	  of	  evidence	  from	  neurobiology	  
and	  epidemiology.	  Eur	  Arch	  Psychiatry	  Clin	  Neurosci	  2006,	  Apr;256(3):174-­‐86.	  
277.	  Chapman	  DP,	  Whitfield	  CL,	  Felitti	  VJ,	  Dube	  SR,	  Edwards	  VJ,	  Anda	  RF.	  Adverse	  childhood	  
experiences	  and	  the	  risk	  of	  depressive	  disorders	  in	  adulthood.	  J	  Affect	  Disord	  2004,	  Oct	  
15;82(2):217-­‐25.	  
278.	  Drossman	  DA.	  Sexual	  and	  physical	  abuse	  and	  gastrointestinal	  illness.	  Scand	  J	  Gastroenterol	  
Suppl	  1995;208:90-­‐6.	  
279.	  Chitkara	  DK,	  van	  Tilburg	  MA,	  Blois-­‐Martin	  N,	  Whitehead	  WE.	  Early	  life	  risk	  factors	  that	  
contribute	  to	  irritable	  bowel	  syndrome	  in	  adults:	  A	  systematic	  review.	  Am	  J	  Gastroenterol	  2008,	  
Mar;103(3):765-­‐74;	  quiz	  775.	  
280.	  Bennett	  EJ,	  Tennant	  CC,	  Piesse	  C,	  Badcock	  CA,	  Kellow	  JE.	  Level	  of	  chronic	  life	  stress	  predicts	  
clinical	  outcome	  in	  irritable	  bowel	  syndrome.	  British	  Medical	  Journal	  1998;43(2):256-­‐61.	  
281.	  Gwee	  KA,	  Leong	  YL,	  Graham	  C,	  McKendrick	  MW,	  Collins	  SM,	  Walters	  SJ,	  et	  al.	  The	  role	  of	  
psychological	  and	  biological	  factors	  in	  postinfective	  gut	  dysfunction.	  British	  Medical	  Journal	  
1999;44(3):400-­‐6.	  
282.	  Jarrett	  M,	  Heitkemper	  M,	  Cain	  KC,	  Tuftin	  M,	  Walker	  EA,	  Bond	  EF,	  Levy	  RL.	  The	  relationship	  
between	  psychological	  distress	  and	  gastrointestinal	  symptoms	  in	  women	  with	  irritable	  bowel	  






283.	  Levy	  RL,	  Cain	  KC,	  Jarrett	  M,	  Heitkemper	  MM.	  The	  relationship	  between	  daily	  life	  stress	  and	  
gastrointestinal	  symptoms	  in	  women	  with	  irritable	  bowel	  syndrome.	  J	  Behav	  Med	  1997,	  
Apr;20(2):177-­‐93.	  
284.	  Hertig	  VL,	  Cain	  KC,	  Jarrett	  ME,	  Burr	  RL,	  Heitkemper	  MM.	  Daily	  stress	  and	  gastrointestinal	  
symptoms	  in	  women	  with	  irritable	  bowel	  syndrome.	  Nurs	  Res	  2007;56(6):399-­‐406.	  
285.	  Suarez	  K,	  Mayer	  C,	  Ehlert	  U,	  Nater	  UM.	  Psychological	  stress	  and	  self-­‐reported	  functional	  
gastrointestinal	  disorders.	  J	  Nerv	  Ment	  Dis	  2010,	  Mar;198(3):226-­‐9.	  
286.	  Shaw	  G,	  Srivastava	  ED,	  Sadlier	  M,	  Swann	  P,	  James	  JY,	  Rhodes	  J.	  Stress	  management	  for	  irritable	  
bowel	  syndrome:	  A	  controlled	  trial.	  Digestion	  1991;50(1):36-­‐42.	  
287.	  Jarrett	  ME,	  Cain	  KC,	  Burr	  RL,	  Hertig	  VL,	  Rosen	  SN,	  Heitkemper	  MM.	  Comprehensive	  self-­‐
management	  for	  irritable	  bowel	  syndrome:	  Randomized	  trial	  of	  in-­‐person	  vs.	  Combined	  in-­‐person	  
and	  telephone	  sessions.	  Am	  J	  Gastroenterol	  2009,	  Dec;104(12):3004-­‐14.	  
288.	  Guthrie	  E,	  Creed	  F,	  Dawson	  D,	  Tomenson	  B.	  A	  controlled	  trial	  of	  psychological	  treatment	  for	  the	  
irritable	  bowel	  syndrome.	  1991,	  Feb;100(2):450-­‐7.	  
289.	  Chang	  L,	  Sundaresh	  S,	  Elliott	  J,	  Anton	  PA,	  Baldi	  P,	  Licudine	  A,	  et	  al.	  Dysregulation	  of	  the	  
hypothalamic-­‐pituitary-­‐adrenal	  (HPA)	  axis	  in	  irritable	  bowel	  syndrome.	  Neurogastroenterol	  Motil	  
2008.	  
290.	  Dinan	  TG,	  Quigley	  EM,	  Ahmed	  SM,	  Scully	  P,	  O'Brien	  S,	  O'Mahony	  L,	  et	  al.	  Hypothalamic-­‐
Pituitary-­‐Gut	  axis	  dysregulation	  in	  irritable	  bowel	  syndrome:	  Plasma	  cytokines	  as	  a	  potential	  
biomarker?	  Gastroenterology	  2006,	  Feb;130(2):304-­‐11.	  
291.	  Posserud	  I,	  Agerforz	  P,	  Ekman	  R,	  Björnsson	  ES,	  Abrahamsson	  H,	  Simrén	  M.	  Altered	  visceral	  
perceptual	  and	  neuroendocrine	  response	  in	  patients	  with	  irritable	  bowel	  syndrome	  during	  mental	  
stress.	  Gut	  2004,	  Aug;53(8):1102-­‐8.	  
292.	  Tillisch	  K,	  Mayer	  EA,	  Labus	  JS,	  Stains	  J,	  Chang	  L,	  Naliboff	  BD.	  Sex	  specific	  alterations	  in	  
autonomic	  function	  among	  patients	  with	  irritable	  bowel	  syndrome.	  Gut	  2005,	  Oct;54(10):1396-­‐401.	  
293.	  Chang	  L.	  The	  role	  of	  stress	  on	  physiologic	  responses	  and	  clinical	  symptoms	  in	  irritable	  bowel	  






294.	  Videlock	  EJ,	  Adeyemo	  M,	  Licudine	  A,	  Hirano	  M,	  Ohning	  G,	  Mayer	  M,	  et	  al.	  Childhood	  trauma	  is	  
associated	  with	  hypothalamic-­‐pituitary-­‐adrenal	  axis	  responsiveness	  in	  irritable	  bowel	  syndrome.	  
Gastroenterology	  2009;137(6):1954	  -­‐	  1962.	  
295.	  Meaney	  MJ.	  Maternal	  care,	  gene	  expression,	  and	  the	  transmission	  of	  individual	  differences	  in	  
stress	  reactivity	  across	  generations.	  Annu	  Rev	  Neurosci	  2001;24:1161-­‐92.	  
296.	  Gareau	  MG,	  Jury	  J,	  Yang	  PC,	  MacQueen	  G,	  Perdue	  MH.	  Neonatal	  maternal	  separation	  causes	  
colonic	  dysfunction	  in	  rat	  pups	  including	  impaired	  host	  resistance.	  Pediatr	  Res	  2006,	  Jan;59(1):83-­‐8.	  
297.	  Gareau	  MG,	  Jury	  J,	  Perdue	  MH.	  Neonatal	  maternal	  separation	  of	  rat	  pups	  results	  in	  abnormal	  
cholinergic	  regulation	  of	  epithelial	  permeability.	  Am	  J	  Physiol	  Gastrointest	  Liver	  Physiol	  2007,	  
Jul;293(1):G198-­‐203.	  
298.	  Francis	  D,	  Diorio	  J,	  Liu	  D,	  Meaney	  MJ.	  Nongenomic	  transmission	  across	  generations	  of	  maternal	  
behavior	  and	  stress	  responses	  in	  the	  rat.	  Science	  1999,	  Nov	  5;286(5442):1155-­‐8.	  
299.	  Bird	  A.	  Perceptions	  of	  epigenetics.	  Nature	  2007,	  May	  24;447(7143):396-­‐8.	  
300.	  Champagne	  F,	  Meaney	  MJ.	  Like	  mother,	  like	  daughter:	  Evidence	  for	  non-­‐genomic	  transmission	  
of	  parental	  behavior	  and	  stress	  responsivity.	  Prog	  Brain	  Res	  2001;133:287-­‐302.	  
301.	  Szyf	  M,	  Weaver	  I,	  Meaney	  M.	  Maternal	  care,	  the	  epigenome	  and	  phenotypic	  differences	  in	  
behavior.	  Reprod	  Toxicol	  2007,	  Jul;24(1):9-­‐19.	  
302.	  Szyf	  M,	  McGowan	  P,	  Meaney	  MJ.	  The	  social	  environment	  and	  the	  epigenome.	  Environ	  Mol	  
Mutagen	  2008,	  Jan;49(1):46-­‐60.	  
303.	  Grillon	  C.	  Startle	  reactivity	  and	  anxiety	  disorders:	  Aversive	  conditioning,	  context,	  and	  
neurobiology.	  Biol	  Psychiatry	  2002,	  Nov	  15;52(10):958-­‐75.	  
304.	  Naliboff	  BD,	  Waters	  AM,	  Labus	  JS,	  Kilpatrick	  L,	  Craske	  MG,	  Chang	  L,	  et	  al.	  Increased	  acoustic	  
startle	  responses	  in	  IBS	  patients	  during	  abdominal	  and	  nonabdominal	  threat.	  Psychosom	  Med	  2008,	  
Oct	  8;70(8):920-­‐7.	  







306.	  Davis	  M.	  The	  role	  of	  the	  amygdala	  in	  fear	  and	  anxiety.	  Annu	  Rev	  Neurosci	  1992;15:353-­‐75.	  
307.	  Davis	  M.	  Neurobiology	  of	  fear	  responses:	  The	  role	  of	  the	  amygdala.	  J	  Neuropsychiatry	  Clin	  
Neurosci	  1997;9(3):382-­‐402.	  
308.	  Neugebauer	  V,	  Li	  W,	  Bird	  GC,	  Han	  JS.	  The	  amygdala	  and	  persistent	  pain.	  Neuroscientist	  2004,	  
Jun;10(3):221-­‐34.	  
309.	  Bradley	  MM,	  Cuthbert	  BN,	  Lang	  PJ.	  Affect	  and	  the	  startle	  reflex.	  Startle	  Modification:	  
Implications	  for	  Neuroscience,	  Cognitive	  Science,	  and	  Clinical	  Science	  1999:157-­‐83.	  
310.	  Rhudy	  JL,	  Williams	  AE,	  McCabe	  KM,	  Nguyen	  MA,	  Rambo	  P.	  Affective	  modulation	  of	  nociception	  
at	  spinal	  and	  supraspinal	  levels.	  Psychophysiology	  2005,	  Sep;42(5):579-­‐87.	  
311.	  Choi	  JS,	  Kim	  JJ.	  Amygdala	  regulates	  risk	  of	  predation	  in	  rats	  foraging	  in	  a	  dynamic	  fear	  
environment.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  2010,	  Nov	  29.	  
312.	  De	  Martino	  B,	  Camerer	  CF,	  Adolphs	  R.	  Amygdala	  damage	  eliminates	  monetary	  loss	  aversion.	  
Proc	  Natl	  Acad	  Sci	  U	  S	  A	  2010,	  Feb	  23;107(8):3788-­‐92.	  
313.	  Liberzon	  I,	  Britton	  JC,	  Phan	  KL.	  Neural	  correlates	  of	  traumatic	  recall	  in	  posttraumatic	  stress	  
disorder.	  Stress	  2003,	  Sep;6(3):151-­‐6.	  
314.	  Shin	  LM,	  Orr	  SP,	  Carson	  MA,	  Rauch	  SL,	  Macklin	  ML,	  Lasko	  NB,	  et	  al.	  Regional	  cerebral	  blood	  flow	  
in	  the	  amygdala	  and	  medial	  prefrontal	  cortex	  during	  traumatic	  imagery	  in	  male	  and	  female	  vietnam	  
veterans	  with	  PTSD.	  Arch	  Gen	  Psychiatry	  2004,	  Feb;61(2):168-­‐76.	  
315.	  Naliboff	  BD,	  Derbyshire	  SW,	  Munakata	  J,	  Berman	  S,	  Mandelkern	  M,	  Chang	  L,	  Mayer	  EA.	  
Cerebral	  activation	  in	  patients	  with	  irritable	  bowel	  syndrome	  and	  control	  subjects	  during	  
rectosigmoid	  stimulation.	  Psychosom	  Med	  2001;63(3):365-­‐75.	  
316.	  Naliboff	  BD,	  Berman	  S,	  Suyenobu	  B,	  Labus	  JS,	  Chang	  L,	  Stains	  J,	  et	  al.	  Longitudinal	  change	  in	  
perceptual	  and	  brain	  activation	  response	  to	  visceral	  stimuli	  in	  irritable	  bowel	  syndrome	  patients.	  






317.	  Petrovic	  P,	  Dietrich	  T,	  Fransson	  P,	  Andersson	  J,	  Carlsson	  K,	  Ingvar	  M.	  Placebo	  in	  emotional	  
processing-­‐-­‐induced	  expectations	  of	  anxiety	  relief	  activate	  a	  generalized	  modulatory	  network.	  
Neuron	  2005,	  Jun	  16;46(6):957-­‐69.	  
318.	  Berman	  SM,	  Naliboff	  BD,	  Suyenobu	  B,	  Labus	  JS,	  Stains	  J,	  Ohning	  G,	  et	  al.	  Reduced	  brainstem	  
inhibition	  during	  anticipated	  pelvic	  visceral	  pain	  correlates	  with	  enhanced	  brain	  response	  to	  the	  
visceral	  stimulus	  in	  women	  with	  irritable	  bowel	  syndrome.	  J	  Neurosci	  2008,	  Jan	  9;28(2):349-­‐59.	  
319.	  Mayer	  EA,	  Naliboff	  BD,	  Craig	  AD.	  Neuroimaging	  of	  the	  brain-­‐gut	  axis:	  From	  basic	  understanding	  
to	  treatment	  of	  functional	  GI	  disorders.	  Gastroenterology	  2006,	  Dec;131(6):1925-­‐42.	  
320.	  Gue	  M,	  Junien	  JL,	  Bueno	  L.	  Conditioned	  emotional	  response	  in	  rats	  enhances	  colonic	  motility	  
through	  the	  central	  release	  of	  corticotropin-­‐releasing	  factor.	  Gastroenterology	  1991,	  
Apr;100(4):964-­‐70.	  
321.	  Young	  SJ,	  Alpers	  DH,	  Norland	  CC,	  Woodruff	  RA.	  Psychiatric	  illness	  and	  the	  irritable	  bowel	  
syndrome.	  Practical	  implications	  for	  the	  primary	  physician.	  Gastroenterology	  1976,	  Feb;70(2):162-­‐6.	  
322.	  Miller	  AR,	  North	  CS,	  Clouse	  RE,	  Wetzel	  RD,	  Spitznagel	  EL,	  Alpers	  DH.	  The	  association	  of	  irritable	  
bowel	  syndrome	  and	  somatization	  disorder.	  Ann	  Clin	  Psychiatry	  2001,	  Mar;13(1):25-­‐30.	  
323.	  North	  CS,	  Downs	  D,	  Clouse	  RE,	  Alrakawi	  A,	  Dokucu	  ME,	  Cox	  J,	  et	  al.	  The	  presentation	  of	  irritable	  
bowel	  syndrome	  in	  the	  context	  of	  somatization	  disorder.	  Clin	  Gastroenterol	  Hepatol	  2004,	  
Sep;2(9):787-­‐95.	  
324.	  Lydiard	  RB,	  Fossey	  MD,	  Marsh	  W,	  Ballenger	  JC.	  Prevalence	  of	  psychiatric	  disorders	  in	  patients	  
with	  irritable	  bowel	  syndrome.	  Psychosomatics	  1993;34(3):229-­‐34.	  
325.	  American	  Academy	  of	  Family	  Physicians	  APAAPAWGOD-­‐I,	  American	  Academy	  of	  Family	  
Physicians	  APAAPAWGOD-­‐I,	  American	  Academy	  of	  Family	  Physicians	  APAAPAWGOD-­‐I.	  Diagnostic	  
and	  statistical	  manual	  of	  mental	  disorders,	  fourth	  edition	  :	  Primary	  care	  version.	  Washington,	  DC:	  
American	  Psychiatric	  Association;	  1995.	  







327.	  Ketterer	  MW,	  Buckholtz	  CD.	  Somatization	  disorder.	  J	  Am	  Osteopath	  Assoc	  1989,	  Apr;89(4):489-­‐
90,	  495-­‐9.	  
328.	  Lenze	  EJ,	  Miller	  AR,	  Munir	  ZB,	  Pornnoppadol	  C,	  North	  CS.	  Psychiatric	  symptoms	  endorsed	  by	  
somatization	  disorder	  patients	  in	  a	  psychiatric	  clinic.	  Ann	  Clin	  Psychiatry	  1999,	  Jun;11(2):73-­‐9.	  
329.	  Munakata	  J,	  Naliboff	  B,	  Harraf	  F,	  Kodner	  A,	  Lembo	  T,	  Chang	  L,	  et	  al.	  Repetitive	  sigmoid	  
stimulation	  induces	  rectal	  hyperalgesia	  in	  patients	  with	  irritable	  bowel	  syndrome.	  Gastroenterology	  
1997,	  Jan;112(1):55-­‐63.	  
330.	  Tougas	  G,	  Hudoba	  P,	  Fitzpatrick	  D,	  Hunt	  RH,	  Upton	  AR.	  Cerebral-­‐Evoked	  potential	  responses	  
following	  direct	  vagal	  and	  esophageal	  electrical	  stimulation	  in	  humans.	  Am	  J	  Physiol	  1993,	  Mar;264(3	  
Pt	  1):G486-­‐91.	  
331.	  Bromm	  B,	  Treede	  RD.	  Human	  cerebral	  potentials	  evoked	  by	  CO2	  laser	  stimuli	  causing	  pain.	  Exp	  
Brain	  Res	  1987;67(1):153-­‐62.	  
332.	  Bromm	  B,	  Treede	  RD.	  Pain	  related	  cerebral	  potentials:	  Late	  and	  ultralate	  components.	  Int	  J	  
Neurosci	  1987,	  Mar;33(1-­‐2):15-­‐23.	  
333.	  Bromm	  B,	  Lorenz	  J.	  Neurophysiological	  evaluation	  of	  pain.	  Electroencephalogr	  Clin	  
Neurophysiol	  1998,	  Oct;107(4):227-­‐53.	  
334.	  Hobson	  AR,	  Furlong	  PL,	  Worthen	  SF,	  Hillebrand	  A,	  Barnes	  GR,	  Singh	  KD,	  Aziz	  Q.	  Real-­‐Time	  
imaging	  of	  human	  cortical	  activity	  evoked	  by	  painful	  esophageal	  stimulation.	  Gastroenterology	  2005,	  
Mar;128(3):610-­‐9.	  
335.	  Prior	  A,	  Serial	  E,	  Sun	  WM,	  Read	  NW.	  Irritable	  bowel	  syndrome:	  Differences	  between	  patients	  
who	  show	  rectal	  sensitivity	  and	  those	  who	  do	  not.	  Eur	  J	  Gastroenterol	  Hepatol	  1993;5(5):343.	  
336.	  Mertz	  H,	  Naliboff	  B,	  Munakata	  J,	  Niazi	  N,	  Mayer	  EA.	  Altered	  rectal	  perception	  is	  a	  biological	  
marker	  of	  patients	  with	  irritable	  bowel	  syndrome.	  Gastroenterology	  1995,	  Jul;109(1):40-­‐52.	  
337.	  Prior	  A,	  Maxton	  DG,	  Whorwell	  PJ.	  Anorectal	  manometry	  in	  irritable	  bowel	  syndrome:	  






338.	  Ritchie	  J.	  Pain	  from	  distension	  of	  the	  pelvic	  colon	  by	  inflating	  a	  balloon	  in	  the	  irritable	  colon	  
syndrome.	  Gut	  1973,	  Feb;14(2):125-­‐32.	  
339.	  Kellow	  JE,	  Delvaux	  M,	  Azpiroz	  F,	  Camilleri	  M,	  Quigley	  EM,	  Thompson	  DG.	  Principles	  of	  applied	  
neurogastroenterology:	  Physiology/motility-­‐sensation.	  Gut	  1999,	  Sep;45	  Suppl	  2:II17-­‐24.	  
340.	  Bouin	  M,	  Plourde	  V,	  Boivin	  M,	  Riberdy	  M,	  Lupien	  F,	  Lagani\vcre	  M,	  et	  al.	  Rectal	  distention	  
testing	  in	  patients	  with	  irritable	  bowel	  syndrome:	  Sensitivity,	  specificity,	  and	  predictive	  values	  of	  
pain	  sensory	  thresholds.	  Gastroenterology	  2002;122(7):1771-­‐7.	  
341.	  Whitehead	  WE,	  Palsson	  OS.	  Is	  rectal	  pain	  sensitivity	  a	  biological	  marker	  for	  irritable	  bowel	  
syndrome:	  Psychological	  influences	  on	  pain	  perception.	  Gastroenterology	  1998,	  Nov;115(5):1263-­‐71.	  
342.	  Gershon	  MD.	  Nerves,	  reflexes,	  and	  the	  enteric	  nervous	  system:	  Pathogenesis	  of	  the	  irritable	  
bowel	  syndrome.	  J	  Clin	  Gastroenterol	  2005;39(5	  Suppl	  3):S184-­‐93.	  
343.	  Cervero	  F.	  Sensory	  innervation	  of	  the	  viscera:	  Peripheral	  basis	  of	  visceral	  pain.	  Physiol	  Rev	  1994,	  
Jan;74(1):95-­‐138.	  
344.	  Cervero	  F,	  Laird	  JM.	  Understanding	  the	  signaling	  and	  transmission	  of	  visceral	  nociceptive	  
events.	  J	  Neurobiol	  2004,	  Oct;61(1):45-­‐54.	  
345.	  Longhurst	  JC,	  Dittman	  LE.	  Hypoxia,	  bradykinin,	  and	  prostaglandins	  stimulate	  ischemically	  
sensitive	  visceral	  afferents.	  Am	  J	  Physiol	  1987,	  Sep;253(3	  Pt	  2):H556-­‐67.	  
346.	  Häbler	  HJ,	  Jänig	  W,	  Koltzenburg	  M.	  Activation	  of	  unmyelinated	  afferent	  fibres	  by	  mechanical	  
stimuli	  and	  inflammation	  of	  the	  urinary	  bladder	  in	  the	  cat.	  J	  Physiol	  1990,	  Jun;425:545-­‐62.	  
347.	  Belmonte	  C,	  Cervero	  F.	  Neurobiology	  of	  nociceptors.	  illustrated	  ed.	  Oxford;	  New	  York:	  Oxford	  
University	  Press;	  1996.	  
348.	  Adelson	  DW,	  Wei	  JY,	  Kruger	  L.	  Warm-­‐Sensitive	  afferent	  splanchnic	  c-­‐fiber	  units	  in	  vitro.	  J	  
Neurophysiol	  1997,	  Jun;77(6):2989-­‐3002.	  
349.	  Bouin	  M,	  Delvaux	  M,	  Blanc	  C,	  Lagier	  E,	  Delisle	  MB,	  Fioramonti	  J,	  et	  al.	  Intrarectal	  injection	  of	  
glycerol	  induces	  hypersensitivity	  to	  rectal	  distension	  in	  healthy	  subjects	  without	  modifying	  rectal	  






350.	  Verne	  GN,	  Robinson	  ME,	  Vase	  L,	  Price	  DD.	  Reversal	  of	  visceral	  and	  cutaneous	  hyperalgesia	  by	  
local	  rectal	  anesthesia	  in	  irritable	  bowel	  syndrome	  (IBS)	  patients.	  Pain	  2003,	  Sep;105(1-­‐2):223-­‐30.	  
351.	  Accarino	  AM,	  Azpiroz	  F,	  Malagelada	  JR.	  Selective	  dysfunction	  of	  mechanosensitive	  intestinal	  
afferents	  in	  irritable	  bowel	  syndrome.	  Gastroenterology	  1995,	  Mar;108(3):636-­‐43.	  
352.	  Fukudo	  S,	  Kanazawa	  M,	  Kano	  M,	  Sagami	  Y,	  Endo	  Y,	  Utsumi	  A,	  et	  al.	  Exaggerated	  motility	  of	  the	  
descending	  colon	  with	  repetitive	  distention	  of	  the	  sigmoid	  colon	  in	  patients	  with	  irritable	  bowel	  
syndrome.	  J	  Gastroenterol	  2002,	  Nov;37	  Suppl	  14:145-­‐50.	  
353.	  Bielefeldt	  K,	  Christianson	  JA,	  Davis	  BM.	  Basic	  and	  clinical	  aspects	  of	  visceral	  sensation:	  
Transmission	  in	  the	  CNS.	  Neurogastroenterol	  Motil	  2005,	  Aug;17(4):488-­‐99.	  
354.	  Giamberardino	  MA.	  Recent	  and	  forgotten	  aspects	  of	  visceral	  pain.	  Eur	  J	  Pain	  1999,	  Jun;3(2):77-­‐
92.	  
355.	  Ruch	  TC.	  Howell's	  textbook	  of	  physiology.	  Fulton	  J,	  editors.	  ;	  1946.	  
356.	  Sato	  A,	  Schmidt	  RF.	  Somatosympathetic	  reflexes:	  Afferent	  fibers,	  central	  pathways,	  discharge	  
characteristics.	  Physiol	  Rev	  1973,	  Oct;53(4):916-­‐47.	  
357.	  Craig	  AD.	  How	  do	  you	  feel?	  Interoception:	  The	  sense	  of	  the	  physiological	  condition	  of	  the	  body.	  
Nat	  Rev	  Neurosci	  2002,	  Aug;3(8):655-­‐66.	  
358.	  Craig	  AD.	  Pain	  mechanisms:	  Labeled	  lines	  versus	  convergence	  in	  central	  processing.	  Annu	  Rev	  
Neurosci	  2003;26:1-­‐30.	  
359.	  Bernstein	  CN,	  Frankenstein	  UN,	  Rawsthorne	  P,	  Pitz	  M,	  Summers	  R,	  McIntyre	  MC.	  Cortical	  
mapping	  of	  visceral	  pain	  in	  patients	  with	  GI	  disorders	  using	  functional	  magnetic	  resonance	  imaging.	  
Am	  J	  Gastroenterol	  2002,	  Feb;97(2):319-­‐27.	  
360.	  Lawal	  A,	  Kern	  M,	  Sidhu	  H,	  Hofmann	  C,	  Shaker	  R.	  Novel	  evidence	  for	  hypersensitivity	  of	  visceral	  







361.	  Azpiroz	  F,	  Bouin	  M,	  Camilleri	  M,	  Mayer	  EA,	  Poitras	  P,	  Serra	  J,	  Spiller	  RC.	  Mechanisms	  of	  
hypersensitivity	  in	  IBS	  and	  functional	  disorders.	  Neurogastroenterology	  and	  Motility	  2007;19(s1):62-­‐
88.	  
362.	  Mayer	  EA,	  Berman	  S,	  Suyenobu	  B,	  Labus	  J,	  Mandelkern	  MA,	  Naliboff	  BD,	  Chang	  L.	  Differences	  in	  
brain	  responses	  to	  visceral	  pain	  between	  patients	  with	  irritable	  bowel	  syndrome	  and	  ulcerative	  
colitis.	  Pain	  2005,	  Jun;115(3):398-­‐409.	  
363.	  Orrison	  WW.	  Neuroimaging.	  illustrated	  ed.	  Philadelphia:	  W.B.	  Saunders;	  2000.	  
364.	  Dorn	  SD,	  Palsson	  OS,	  Thiwan	  SI,	  Kanazawa	  M,	  Clark	  WC,	  van	  Tilburg	  MA,	  et	  al.	  Increased	  colonic	  
pain	  sensitivity	  in	  irritable	  bowel	  syndrome	  is	  the	  result	  of	  an	  increased	  tendency	  to	  report	  pain	  
rather	  than	  increased	  neurosensory	  sensitivity.	  Gut	  2007,	  Sep;56(9):1202-­‐9.	  
365.	  Hobson	  AR,	  Sarkar	  S,	  Furlong	  PL,	  Thompson	  DG,	  Aziz	  Q.	  A	  cortical	  evoked	  potential	  study	  of	  
afferents	  mediating	  human	  esophageal	  sensation.	  Am	  J	  Physiol	  Gastrointest	  Liver	  Physiol	  2000,	  
Jul;279(1):G139-­‐47.	  
366.	  Spiller	  RC,	  Jenkins	  D,	  Thornley	  JP,	  Hebden	  JM,	  Wright	  T,	  Skinner	  M,	  Neal	  KR.	  Increased	  rectal	  
mucosal	  enteroendocrine	  cells,	  T	  lymphocytes,	  and	  increased	  gut	  permeability	  following	  acute	  
campylobacter	  enteritis	  and	  in	  post-­‐dysenteric	  irritable	  bowel	  syndrome.	  Gut	  2000,	  Dec;47(6):804-­‐
11.	  
367.	  Liebregts	  T,	  Adam	  B,	  Bredack	  C,	  Röth	  A,	  Heinzel	  S,	  Lester	  S,	  et	  al.	  Immune	  activation	  in	  patients	  
with	  irritable	  bowel	  syndrome.	  Gastroenterology	  2007,	  Mar;132(3):913-­‐20.	  
368.	  Guglielmo-­‐Viret	  V,	  Thullier	  P.	  Comparison	  of	  an	  electrochemiluminescence	  assay	  in	  plate	  format	  
over	  a	  colorimetric	  ELISA,	  for	  the	  detection	  of	  ricin	  B	  chain	  (RCA-­‐B).	  J	  Immunol	  Methods	  2007,	  Dec	  
1;328(1-­‐2):70-­‐8.	  
369.	  Blalock	  JE,	  Smith	  EM.	  Conceptual	  development	  of	  the	  immune	  system	  as	  a	  sixth	  sense.	  Brain	  
Behav	  Immun	  2007,	  Jan;21(1):23-­‐33.	  







371.	  Segerstrom	  SC,	  Miller	  GE.	  Psychological	  stress	  and	  the	  human	  immune	  system:	  A	  meta-­‐analytic	  
study	  of	  30	  years	  of	  inquiry.	  Psychological	  Bulletin	  2004;130(4):601-­‐30.	  
372.	  Avitsur	  R,	  Padgett	  DA,	  Sheridan	  JF.	  Social	  interactions,	  stress,	  and	  immunity.	  Neurol	  Clin	  2006,	  
Aug;24(3):483-­‐91.	  
373.	  Elliot,	  G.	  R,	  Eisdorfer,	  C..	  Stress	  and	  human	  health:	  Analysis	  and	  implications	  of	  research	  :	  A	  
study.	   	   Springer	  Pub.	  Co.;	  1982.	  
374.	  Kiecolt-­‐Glaser	  JK,	  Dura	  JR,	  Speicher	  CE,	  Trask	  OJ,	  Glaser	  R.	  Spousal	  caregivers	  of	  dementia	  
victims:	  Longitudinal	  changes	  in	  immunity	  and	  health.	  Psychosom	  Med	  1991;53(4):345-­‐62.	  
375.	  Herbert	  TB,	  Cohen	  S.	  Stress	  and	  immunity	  in	  humans:	  A	  meta-­‐analytic	  review.	  Psychosom	  Med	  
1993;55(4):364-­‐79.	  
376.	  Cohen	  S,	  Miller	  GE,	  Rabin	  BS.	  Psychological	  stress	  and	  antibody	  response	  to	  immunization:	  A	  
critical	  review	  of	  the	  human	  literature.	  Psychosom	  Med	  2001;63(1):7-­‐18.	  
377.	  Dopp	  JM,	  Miller	  GE,	  Myers	  HF,	  Fahey	  JL.	  Increased	  natural	  killer-­‐cell	  mobilization	  and	  
cytotoxicity	  during	  marital	  conflict.	  Brain	  Behav	  Immun	  2000,	  Mar;14(1):10-­‐26.	  
378.	  Sapolsky	  RM.	  Why	  zebras	  don't	  get	  ulcers.	  New	  York:	  Times	  Books;	  2004.	  
379.	  Marshall	  GD,	  Agarwal	  SK,	  Lloyd	  C,	  Cohen	  L,	  Henninger	  EM,	  Morris	  GJ.	  Cytokine	  dysregulation	  
associated	  with	  exam	  stress	  in	  healthy	  medical	  students.	  Brain	  Behav	  Immun	  1998,	  Dec;12(4):297-­‐
307.	  
380.	  Jones	  JF.	  An	  extended	  concept	  of	  altered	  self:	  Chronic	  fatigue	  and	  post-­‐infection	  syndromes.	  
Psychoneuroendocrinology	  2008,	  Feb;33(2):119-­‐29.	  
381.	  Hart	  BL.	  Biological	  basis	  of	  the	  behavior	  of	  sick	  animals.	  Neurosci	  Biobehav	  Rev	  1988;12(2):123-­‐
37.	  
382.	  Peters	  A,	  Schweiger	  U,	  Pellerin	  L,	  Hubold	  C,	  Oltmanns	  KM,	  Conrad	  M,	  et	  al.	  The	  selfish	  brain:	  






383.	  Taché	  Y,	  Brunnhuber	  S.	  From	  hans	  selye's	  discovery	  of	  biological	  stress	  to	  the	  identification	  of	  
corticotropin-­‐releasing	  factor	  signaling	  pathways:	  Implication	  in	  stress-­‐related	  functional	  bowel	  
diseases.	  Ann	  N	  Y	  Acad	  Sci	  2008,	  Dec;1148:29-­‐41.	  
384.	  Taché	  Y,	  Kiank	  C,	  Stengel	  A.	  A	  role	  for	  corticotropin-­‐releasing	  factor	  in	  functional	  
gastrointestinal	  disorders.	  Curr	  Gastroenterol	  Rep	  2009,	  Aug;11(4):270-­‐7.	  
385.	  Taché	  Y,	  Martinez	  V,	  Million	  M,	  Maillot	  C.	  Role	  of	  corticotropin	  releasing	  factor	  receptor	  
subtype	  1	  in	  stress-­‐related	  functional	  colonic	  alterations:	  Implications	  in	  irritable	  bowel	  syndrome.	  
Eur	  J	  Surg	  Suppl	  2002(587):16-­‐22.	  
386.	  Fukudo	  S,	  Nomura	  T,	  Hongo	  M.	  Impact	  of	  corticotropin-­‐releasing	  hormone	  on	  gastrointestinal	  
motility	  and	  adrenocorticotropic	  hormone	  in	  normal	  controls	  and	  patients	  with	  irritable	  bowel	  
syndrome.	  Gut	  1998,	  Jun;42(6):845-­‐9.	  
387.	  Sagami	  Y,	  Shimada	  Y,	  Tayama	  J,	  Nomura	  T,	  Satake	  M,	  Endo	  Y,	  et	  al.	  Effect	  of	  a	  corticotropin	  
releasing	  hormone	  receptor	  antagonist	  on	  colonic	  sensory	  and	  motor	  function	  in	  patients	  with	  
irritable	  bowel	  syndrome.	  Gut	  2004,	  Jul;53(7):958-­‐64.	  
388.	  Ströhle	  A,	  Holsboer	  F.	  Stress	  responsive	  neurohormones	  in	  depression	  and	  anxiety.	  
Pharmacopsychiatry	  2003,	  Nov;36	  Suppl	  3:S207-­‐14.	  
389.	  Bremner	  JD,	  Licinio	  J,	  Darnell	  A,	  Krystal	  JH,	  Owens	  MJ,	  Southwick	  SM,	  et	  al.	  Elevated	  CSF	  
corticotropin-­‐releasing	  factor	  concentrations	  in	  posttraumatic	  stress	  disorder.	  American	  Journal	  of	  
Psychiatry	  1997;154(5):624.	  
390.	  Southwick	  SM,	  Vythilingam	  M,	  Charney	  DS.	  The	  psychobiology	  of	  depression	  and	  resilience	  to	  
stress:	  Implications	  for	  prevention	  and	  treatment.	  Annu	  Rev	  Clin	  Psychol	  2005;1:255-­‐91.	  
391.	  Infante-­‐Duarte	  C,	  Horton	  HF,	  Byrne	  MC,	  Kamradt	  T.	  Microbial	  lipopeptides	  induce	  the	  
production	  of	  IL-­‐17	  in	  th	  cells.	  J	  Immunol	  2000,	  Dec	  1;165(11):6107-­‐15.	  
392.	  Liang	  SC,	  Tan	  XY,	  Luxenberg	  DP,	  Karim	  R,	  Dunussi-­‐Joannopoulos	  K,	  Collins	  M,	  Fouser	  LA.	  
Interleukin	  (IL)-­‐22	  and	  IL-­‐17	  are	  coexpressed	  by	  th17	  cells	  and	  cooperatively	  enhance	  expression	  of	  






393.	  Steinman	  L,	  Steinman	  L.	  A	  brief	  history	  of	  TH17,	  the	  first	  major	  revision	  in	  the	  TH1/TH2	  
hypothesis	  of	  T	  cell|[ndash]|mediated	  tissue	  damage.	  Nat	  Med	  2007,	  Feb	  2;13(2):139.	  
394.	  Domingues	  HS,	  Mues	  M,	  Lassmann	  H,	  Wekerle	  H,	  Krishnamoorthy	  G.	  Functional	  and	  pathogenic	  
differences	  of	  th1	  and	  th17	  cells	  in	  experimental	  autoimmune	  encephalomyelitis.	  Plos	  One	  
2010;5(11):e15531.	  
395.	  Wynn	  TA.	  T(H)-­‐17:	  A	  giant	  step	  from	  T(H)1	  and	  T(H)2.	  Nat	  Immunol	  2005,	  Nov;6(11):1069-­‐70.	  
396.	  Kolls	  JK,	  Lindén	  A.	  Interleukin-­‐17	  family	  members	  and	  inflammation.	  Immunity	  2004,	  
Oct;21(4):467-­‐76.	  
397.	  Reinhardt	  RL,	  Kang	  SJ,	  Liang	  HE,	  Locksley	  RM.	  T	  helper	  cell	  effector	  fates-­‐-­‐who,	  how	  and	  where?	  
Curr	  Opin	  Immunol	  2006,	  Jun;18(3):271-­‐7.	  
398.	  Park	  H,	  Li	  Z,	  Yang	  XO,	  Chang	  SH,	  Nurieva	  R,	  Wang	  YH,	  et	  al.	  A	  distinct	  lineage	  of	  CD4	  T	  cells	  
regulates	  tissue	  inflammation	  by	  producing	  interleukin	  17.	  Nat	  Immunol	  2005,	  Nov;6(11):1133-­‐41.	  
399.	  Andoh	  A,	  Ogawa	  A,	  Bamba	  S,	  Fujiyama	  Y.	  Interaction	  between	  interleukin-­‐17-­‐producing	  CD4+	  T	  
cells	  and	  colonic	  subepithelial	  myofibroblasts:	  What	  are	  they	  doing	  in	  mucosal	  inflammation?	  J	  
Gastroenterol	  2007,	  Jan;42	  Suppl	  17:29-­‐33.	  
	  
